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SUMMARY
Neurofibromatosis Type 1 (NF1) is an autosomal dominant disorder caused by 
constitutional inactivation of the NF1 gene. NF1 is associated with extreme phenotypic 
variability and results in an increased risk of developing benign and malignant 
peripheral nerve sheath tumours (MPNSTs). The molecular mechanisms that underlie 
NF1 tumorigenesis are poorly understood although inactivation of additional loci in 
conjunction with NF1 mutations is postulated to be involved. A combinative approach 
encompassing genetic, epigenetic and functional analysis was employed to dissect the 
molecular mechanisms responsible for tumorigenesis and progression to malignancy in 
NF1.
Genetic analysis of benign cutaneous neurofibromas from NF1 patients with a high 
tumour burden was undertaken involving PCR, sequencing, Loss of Heterozygosity 
(LOH) and Multiplex Ligation-dependent Probe Amplification (MLPA) at the NF1 locus. 
In addition, Microsatellite Instability (MSI) analysis and molecular analysis of the TP53, 
RB1, CDKN2A and MMR  genes was performed in a subset of these tumours. It was 
revealed that a small proportion of tumours from such patients harbour LOH of the TP53 
and RB1 genes, a novel finding which indicates that additional modifying loci may 
underlie the development of multiple cutaneous neurofibromas in patients with a high 
tumour burden. Furthermore, Schwann cell culture and Laser Capture Microdissection 
were used to enhance the somatic mutation detection rate in the NF1 gene.
Pyrosequencing methylation analysis was employed to determine whether NF1 gene 
methylation was associated with NF1 tumorigenesis. Promoter methylation of potential 
modifying genes; RASSF1A and MGMT  was also assessed. Results of this study 
demonstrate that methylation of the NF1 and MGMT genes is unlikely to contribute to 
NF1 tumorigenesis. RASSF1A promoter methylation was significantly higher in tumour 
samples in comparison to controls. RASSF1A promoter methylation was correlated with 
a reduction in RASSF1A gene expression, as evidenced by 5aza2dc treatment.
Non-synonymous missense mutations account for 15% of lesions in the NF1 germline 
and somatic mutational spectrum; although without a suitable functional test, their 
pathogenicity cannot be defined with certainty. Site directed mutagenesis, a Ras ELISA 
and bioinformatic analysis were utilised to develop a novel functional assay to assess 
the potential pathogenicity of NF1 gap related domain (GRD) missense variants. Of the 
16 mutations functionally analysed, 11 were found to be pathogenic.
A panel of 14 candidate genes were found to be aberrantly expressed in 14 tumours 
and 5 MPNST tumour-derived cell lines by relative quantification. A number of genes in 
the Rho-GTPase pathway including RAC1 and ROCK2 are over-expressed in these 
tumours, suggesting that these genes might be critical for survival of MPNST cells. 
ShRNA (short hairpin RNA) for RAC1 and ROCK2 were used in adhesion, migration, 
invasion and wound healing assays on control and MPNST derived cell lines. RAC1 and 
ROCK2 knockdown in MPNST cell lines resulted in a significant increase in cell 
adhesion and a reduction in wound healing, migratory and invasive activity. The cMET 
gene was also over-expressed in MPNSTs. Treatment of MPNST cell lines with cMET 
inhibitors also resulted in a reduction of cell growth and migration. This study has 
identified several novel therapeutic targets for NF1-associated malignancies.
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CHAPTER 1: General introduction
The neurofibromatoses are inherited autosomal dominant disorders which predispose to 
tumour formation, particularly of the nerve sheath, resulting in a profound impact on the 
nervous system. There are currently three recognised types of neurofibromatoses: 
Neurofibromatosis type 1 (NF1) (MIM_162200), Neurofibromatosis type 2 (NF2) 
(MIM_101000) and Schwannomatosis. In addition to tumour formation, NF1 has a major 
pigmentary component whereas the clinical manifestations of NF2 are primarily linked 
with the nervous systems, including the most distinctive NF2 lesion, schwannomas 
which are also the cardinal feature of Schwannomatosis. This thesis will only be 
concerned with genetic, epigenetic and functional analysis of tumorigenesis in 
neurofibromatosis type 1. The work of an international network of clinicians and 
researchers has led to significant advancements in the development of diagnostic 
criteria, management strategies, mouse models and importantly clinical trials for NF1.
1.1 Neurofibromatosis Type 1 (NF1)
Neurofibromatosis type 1, (NF1) (MIM 162200) has been classified by molecular 
genetics studies as a complex, inherited, autosomal dominant disorder affecting multiple 
cell types and body systems. Descriptions of individuals with NF1 features have been 
recorded throughout history (table 1.1) although NF1 became synonymous with von 
Recklinghausen’s disease after Friedrich Daniel Von Recklinghausen (1833-1911) gave 
a classic description of Neurofibromatosis in 1882 (Von Recklinghausen, 1882). The 
gene responsible for Neurofibromatosis Type 1, the NF1 gene was eventually mapped 
to chromosome 17q11.2 and cloned in 1990 (Cawthon et a/,1990; Wallace et al, 1990; 
Viskochil et al, 1990). The NF1 gene has a high mutation rate resulting in approximately 
one mutation occurring per 10,000 gametes per generation. Nearly half of all mutations 
arising in the NF1 gene occur as de novo events resulting in a birth incidence of 
approximately 1 in 3500 people and an overall prevalence in the worldwide population 
of about 1 in 5000 people (Huson et al, 1989; Evans et al, 2010).
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Table 1.1 Timeline of important events in the research and diagnosis of NF1.
Date Described By Description Reference
13th Century Heinricius - Cistercian monk
Drawing of a man with skin nodules 
suggested to be that of an NF1 patient
Zanca & Zanca, 1980; 
Morse, 1999
1592 Ulisse Aldrovandi - Italian Physician
Recorded a case that was later published 
posthumously in an atlas, Monstrorum 
Historia, in 1642
Zanca & Zanca, 1980; 
Morse, 1999
1768
Mark Akenside 
(1721-1770) - 
British Physician
Published the first description of NF in 
English
Akenside, 1768; 
Ober, 1978
1793 Ludwig and W. G. Tilesius
Description of a patient with multiple 
fibrous tumours of the skin under the title 
“Case History of Extraordinarily Unsightly 
Skin.” The patient was described as 
having countless growths on the skin, 
cafe' au lait spots, macrocephaly, and 
scoliosis
Zanca & Zanca, 1980; 
Morse, 1999
1863 Rudolf L. Virchow (1821-1902)
Describes clinical and neuropathological 
features of NF in a series of reports. 
Virchow's classification of neuromas and 
fibromas on a pathological basis laid the 
groundwork for von Recklinghausen’s 
landmark presentation
Zanca & Zanca, 1980; 
Morse, 1999
1807-1883 Robert William Smith
Presented 2 new cases and postulated, 
but was unable to prove that the tumours 
arose from fibrous connective tissue of 
small nerves
Smith, 1849
1882
Friedrich Daniel 
von
Recklinghausen
Report “On Multiple Cutaneous Fibromas 
and Their Relationship to Multiple 
Neuromas, in which he reviewed the 
existing literature and added 2 cases, 
with extensive description of the 
pathological characteristics including the 
cutaneous and neurologic manifestations, 
demonstrating its nervous origin.
Von Recklinghausen, 
1882
1978
National Neurofibromatosis Foundation is 
established; 
now known as the Children’s Tumor 
Foundation
1987
NIH establishes the nomenclature for 
NF1 as well as diagnostic criteria and 
treatment guidelines. Genetic markers for 
NF1 are identified on chromosome 17
NIH, 1988
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Date Described By Description Reference
1990 Identification of the NF1 gene
Cawthon et a/,1990; 
Wallace et al, 1990; 
Viskochil etal, 1990
1992 Description of the protein encoded by NF1 gene: neurofibromin
Gutmann and Collins 
1993; 
Viskochil et al, 1993
1994 Strains of Nf1-mutant mice generated Jacks et al, 1994; Bran nan et al, 1994
1995 Direct testing for NF1 is made available
1997
Dr. Andre 
Bernards 
(Massachusetts 
General Hospital 
Cancer Center 
and Harvard 
Medical School
Drosophila melanogaster model of NF1 is 
developed
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Figure 1.1 NF1 gene organisation. The NF1 gene spans 283kb of genomic DNA, contains 61 exons; of which 4 are alternatively spliced (9a, 10a, 23a, 48a), 
although neither of these forms interrupt the correct reading of the frame (Reviewed by: Upadhyaya, 2008). The NF1 gene is also transcribed into 12 kb 
mRNA, with an open reading frame of 8454 nucleotides (Viskochil, 1999) and also contains a well-defined isochore boundary (section 5.1). Three distinct 
genes: EV12A, EV12b and OMgp are situated within intron 27b (-61 kb) and each consist of 2 exons which are transcribed in the reverse orientation from the 
complementary strand of the NF1 gene (Viskochil et al, 1999). Additionally, an unprocessed pseudogene, Adenylate kinase 3 (AK3) has been identified in 
several loci throughout the genome including one located in intron 37 of the NF1 gene which is transcribed in the same orientation as the NF1 gene (Xu et al, 
1992). The protein products of these genes do not appear to interact, and deletions of the NF1 gene which also affect these embedded genes are not 
correlated with any specific phenotype (Viskochil et al, 1990). (Not drawn to scale). Arrows represent the direction of translation. Hexagon represents the stop 
codon.
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1.2. Molecular genetics of NF1
1.2.1 Identification of the NF1 gene
In 1987 the NF1 gene was assigned to chromosome 17 by gene linkage studies. More 
refined mapping located the gene to a region near to 17q11.2 by two independent 
groups (Barker et al, 1987; Seizinger et al, 1987). Subsequently, the gene was mapped 
to within 10-15 cM (Fain et al, 1987) and finally within 3cM of 17q11.2 corresponding to 
a region approximately 2-6x106 bp long (Barker et al, 1987; Seizinger et al, 1987; 
Goldgar et al, 1989). Two patients with a clinical diagnosis of NF1 both with balanced 
translocations, one involving chromosome 1 and 17 and the other 17 and 22 provided 
the key to a finer definition of the position of the NF1 gene. It was determined that the 
breakpoint in both individuals was in 17q11.2, most likely on the proximal long arm 
(Schmidt et al, 1987; Leadbetter et al, 1989; Menon et al, 1989; Collins et al, 1989)
Pulsed-field gel electrophoresis encompassing probes close to the breakpoint (17L1 
and IFIO), somatic cell hybrid technology and linking clones which were approximately 
60kb apart were used to determine that a gene within the 17q11.2 locus was the gene 
altered by these rearrangements (Fountain et al, 1989; O’Connell et al, 1990). Further 
weight was given to 17q11.2 following a number of studies on patients harbouring 
centromere recombinants using a series of DNA markers (proximal HHH202 and distal 
EW206) to provide physical landmarks (Reviewed by: Goldgar et al, 1989. Skolnick et 
al, 1987; Pericak-Vance et al, 1987; Upadhyaya et al, 1987; Diehl et al, 1989; Kittur et 
al, 1989; Fain et al, 1989a and 1989b; Seizenger et al, 1989; Mathew et al, 1989; 
Stephens et al, 1989; Vance et al, 1989; vanTuinen etal, 1987).
A number of other candidate genes which all map to this region were also identified 
including; EV12, NF1-c2 (NF1 candidate gene 2) the human oncogene homolog 
ERBA1, ERBB2, and NGFR, but neither were disrupted by the translocation or linked to 
the manifestations of NF1. This suggested that these genes are instead embedded 
within the NF1 gene (Seizenger et al, 1987; O’Connell et al, 1990 Fountain et al, 1989;
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Collins et al, 1989). The true NF1 gene, initially termed NF1LT (Wallace et al, 1990) 
was subsequently identified by positional cloning experiments in 1990 located at 
17q11.2 (Cawthon etal, 1990; Wallace etal, 1990; Viskochil et al, 1990) (figure 1.1).
1.2.2 NF1 promoter and 5 ’untranslated region
The 5’ end of the NF1 gene, in which the promoter is located, is highly conserved 
between humans and mice, consisting of several putative regulatory elements 
surrounding the transcription start site (TSS) (Hajra et al, 1994; Fishbein et al, 2005). 
The promoter is very GC rich and has no TATA or CCAAT boxes, a characteristic of 
promoters found in housekeeping genes (Hajra et al, 1994). The promoter also contains 
a 5’ untranslated region (5’UTR) upstream of the translation initiation codon and the 
major transcriptional start site is approximately 484bp upstream of the initiation codon 
(Hajra et al, 1994). There are also minor transcription start sites 11 nucleotides 
upstream and 1 nucleotide downstream of the major transcription start sites (Hajra et al, 
1994). Aberrant methylation at CpG sites in gene promoters has been implicated in a 
number of cancers (section 5.1). The presence of conserved transcription factor binding 
sites located in a -33 and +261 bp region in addition to a large CpG island at the 5’ end 
of the NF1 gene which encompasses the NF1 promoter, may provide possible targets 
for DNA methylation (Hajra et al, 1994).
There are a number of regulatory elements in the NF1 promoter region, conserved in 
both humans and mice including; a cyclic adenosine 3 \5 ’-monophosphate (cAMP) 
response element (CRE), -16bp from the translation initiation codon. Indeed, there is 
evidence that NF1 expression in Schwann cells increases in response to high doses of 
cAMP (Gutmann et al, 1993b). Other elements include; SP1, +416 to +460bp upstream 
of the ATG codon, which may have an important role in regulating NF1 transcription 
(Zou et al, 2004), several AP2 sites located at +72, +264, +306, +335 and +463, in 
addition to a serum response element (-14) (Hajra et al, 1994). Furthermore, a putative 
repressor region has been identified within the NF1 promoter region that consists of 
CCCTC-rich sequences and is located between the transcription and translation start
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sites and may be related to the AP2 sites (Zou et al, 2004). The evolutionary 
conservation of the NF1 promoter region indicates that these sequence features are 
likely to be significant to the functional regulation of the NF1 gene.
1.2.3 3’untranslated region
Polyadenylation motifs (AAUAAA) are important for cleavage and polyadenylation of 
mammalian pre-mRNAs (Bernards et al, 1993). In mammalian cells, the mRNA 
transcript is known to be cleaved within 30bp downstream of a polyadenylation signal 
and just upstream of a GU rich domain which has less sequence conservation (Jackson 
and Standart, 1990). The NF1 3’UTR is a large region of approximately 3.2kb in length, 
containing a stop codon located in exon 49 and a number of polyadenylation signals.
1.2.3.1 Role of the NF1 3’UTR
A definitive role for the 3’UTR has yet to be identified. Evidence derived from protein 
interactions indicates that the 3’UTR of various mRNAs may contain sequence motifs 
which have a role in mRNA stability, intracellular localisation and translation (Jackson 
and Standart, 1990; Bernards et al, 1993). At least five protein binding sites, termed 
NF1-protein binding regions 1-5  (NF1-PBR1- 5) have been identified in the NF1 3’UTR. 
The embryonic lethal abnormal visual (ELAV)-like protein HuR has been shown to 
interact with this region and is able to reduce the expression of a reporter gene 
(Haeussler et al, 2000). Additionally, the poly-A binding protein (PABP), common to 
most eukaryotes, is known to bind to 3’UTR’s and is thought to enhance translation 
initiation in addition to modulation of the termination phase (Jackson and Standart, 
1990; Hoshino et al, 1999). PABP interaction with the NF1 3’ UTR has not, however, 
been studied. As with the 5’UTR, the 3’UTR also exhibits significant sequence 
conservation and homology to other species including mice, suggesting that it may be a 
target of inactivating mutations. In rare instances, this has proven to be the case as rare 
variants and polymorphisms have been identified in the 3’UTR, perhaps evidence of the 
functional significance of this region (Upadhyaya etal, 1995; Cowley et al, 1998).
7
1.2.4 Alternative splicing
Alternative splicing is an important mechanism by which diversity in the proteosome is 
generated. It is also important for regulating gene expression at different developmental 
stages and in different tissue types. Alternative splicing events are classified into five 
different splicing patterns: cassette exons, mutually exclusive cassette exons, 
alternative 5’ splice site (SS), alternative 3’SS and retained introns. Deregulation of 
alternative splicing has been identified in tumorigenesis and alternative splicing has 
been investigated as a possible mechanism of genotype-phenotype correlations in NF1 
patients (Eisenbarth et al, 1995). Switches in the ratio of transcripts have not, however, 
been linked with specific NF1-related manifestations (Eisenbarth et al, 1995). 
Alternatively used exons have been identified in the NF1 gene sequence (Cawthon et 
al, 1990a; Gutmann et al, 1995).
1.2.4.1 Type 1 neurofibromin
Type 1 neurofibromin lacks both 23a and 48a exon protein sequences and is known to 
have superior affinity for Ras (Xu et al, 1990).
1.2.4.2 Type 2 neurofibromin
This protein transcript involves the insertion of 21 amino acids into exon 23a in the GAP 
(GTPase activating protein) related domain (GRD) of neurofibromin. This isoform has 
been detected in the majority of human and rodent tissues and is expressed in 
astrocytes but not central nervous system (CNS) neurons (Andersen et al, 1993; 
Gutmann et al, 1999). Induction of type 2 neurofibromin has also been demonstrated in 
neuroblasts and Schwann cells which have differentiated in vitro, potentially altering its 
functional properties (Nishi et al, 1991; Andersen et al, 1993; Gutmann et al, 1993c; 
Gutmann et al, 1995b,). This isoform is less efficient in Ras downregulation as the GAP 
function is disrupted (Andersen et al, 1993; Skuse et al, 1996).
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1.2.4.3 Third neurofibromin isoform
This NF1 transcript consists of an insertion of 18 amino acids into exon 48a in the 
carboxyl terminus. This transcript is expressed in the heart and skeletal muscle, 
correlating with cardiac and skeletal muscle abnormalities in Nf1'/+ mice, although this is 
an usual finding due to the paucity of muscle related NF1 manifestations (Gutmann et 
al, 1995a).
1.2.4.4 Other neurofibromin isoforms
Other splice products of neurofibromin have been identified including an N-terminus 
isoform which contains both the 23a and 48a protein isoforms and a new exon, termed 
10a-2 (Kauffman et al, 2002). The overall expression of the 10a-2 transcript is very low 
in comparison to the expression of the wild-type mRNA. Analysis of the amino acid 
sequence for this transcript revealed that this new splice product contains a 
transmembrane segment not found in wild-type neurofibromin. It is postulated that due 
to the overall expression of this isoform that it may have a housekeeping function on an 
intracellular membrane such as the endoplasmic reticulum (Kauffman et al, 2002).
The 9br transcript encodes 10 amino acids which are inserted into the amino terminal of 
neurofibromin after residue 1,260 (Danglot et al, 1995; Gutmann et al, 1999). The 9br 
isoform is exclusively expressed in the CNS with little or no expression in the 
cerebellum, brainstem, or spinal cord. It is suggested that as this isoform is identified in 
the neurons of the forebrain during the early stages of postnatal development it may 
have a conserved role in nervous system development and differentiation (Gutmann et 
al, 1999).
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1.2.5 Embedded genes
Introns 1 and 27b are significantly larger than the rest of the introns in the NF1 gene. 
Three distinct genes: EV12A, EV12b and OMgp are situated within intron 27b (~61kb) 
(figure 1.1)
1.2.5.1 EV12A and EV12B
EV12A and EV12B are human homologues of mouse genes: Evi-2A and Evi-2B. They 
have been implicated in retrovirus induced murine myeloid tumours suggesting that they 
may also act as oncogenes (O’Connell et al, 1990; Vourc'h and Andres, 2004). EV12A 
and EV12B encode transmembrane proteins for which the main functions are relatively 
unknown (Vourc'h and Andres, 2004). EV12A encodes a 232 amino acid polypeptide 
that is expressed in the brain, peripheral blood and bone marrow (Cawthon et al, 
1990b). EVI2B is a protein consisting of 448 amino acids expressed in peripheral blood, 
bone marrow and fibroblasts (Cawthon et al, 1991).
1.2.5.2 OMG
OMG is a developmental^ regulated gene primarily expressed in oligodendrocytes of 
the CNS (Viskochil et al, 1990b; Habib et al, 1998). OMG encodes oligodendrocyte 
myelin glycoprotein (OMgp) an extracellular adhesion protein (Mikol and Stephansson, 
1988). The neuronal function of OMgp is not well known but murine models have 
demonstrated that OMgp can act as a tumour suppressor (Habib et al, 1998). Three 
alterations in OMG have also been identified in patients with non-syndromic mental 
retardation (Venturin et al, 2006; Vedrine et al, 2011) suggesting that OMG may also act 
as an inhibitor of neural stem cell proliferation and neurite outgrowth (Viskochil et al, 
1991; Vourc'h and Andres, 2004). Furthermore, overexpression of OMG in NIH3T3 
fibroblasts has growth suppressive effects and loss of OMG through deletions at the 
NF1 locus could act as a possible mediator of the neurological defects associated with 
NF1 microdeletions (Habib et al, 1998; Martina et al, 2009).
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1.2.6 Pseudogene-like sequences
Pseudogenes are thought to arise by multiple duplications and intra-chromosomal 
transposition events (Luijten et al, 2001). They are non-functional sequences containing 
degenerative features such as premature stop codons and frameshift mutations which 
prevent expression of these sequences (Balakirev and Ayala, 2003). There are more 
than 30 known pseudogenes for the NF1 gene with about 95% sequence homology, 
identified by analysis of the published sequence and through fluorescence in situ 
hybridisation (FISH) of NF1 cDNA (Luijten et al, 2001). These occur on chromosomes 
2q21.1, 14q 11.1, 14q11.2, 15q11.2, 18p11.21, 21q11.2-q21.1, and 22q11.1 (NCBI 
Entrez Gene), (Marchuk et al, 1992; Legius et al, 1992; Suzuki et al, 1994; Purandare et 
al, 1995; Cummings et al, 1996; Hulsebos et al, 1996; Kehrer-Sawatzki et al, 1997; 
Regnier et al, 1997; Luijten et al, 2000b). Such pseudogenes are expressed in specific 
cell types further complicating the analysis of neurofibromin distribution (Section 1.2.6). 
Comparison of exon composition indicates that 24 exons of the NF1 gene (7-9, 10b, 
11-23-1 and 24-27b) have homologous counterparts in pseudogenes, which are 
generally disrupted by indels, the only exception being NF1-ch21 in which the reading 
frame was uninterrupted for the first two exons (Yu et al, 2005). Expression from NF1 
pseudogenes on chromosomes 2, 15 and 21 is thought to be possible, further 
complicating NF1 molecular analysis (Yu et al, 2005). Very few characterised NF1 
mutations appear to have an equivalent on a pseudogene. Whether NF1 pseudogenes 
represent junk sequences or have functional consequences is therefore still unclear. 
Indeed, even NF1 pseudogenes which do not encode functional domains have been 
suggested to contribute to increased mutation rates, serving as a mutational reservoir 
(Marchuk etal, 1992; Balakirev and Ayala, 2003).
1.2.7 mRNA editing
mRNA editing is one of several mechanisms of posttranscriptional regulation by which 
the repertoire of sequence diversity can be increased, resulting in species and tissue 
specific modulation of gene expression (Maas and Rich, 2000). mRNA splicing
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alterations occur in about 50% of NF1 patients indicating that mRNA processing may be 
an important consideration for assessing NF1 phenotypic variability (Park and Pivnick, 
1998).
1.2.7.1 O U  editing of RNA
O U  editing of RNA has been postulated to be a possible mechanism for NF1 
inactivation, through a mechanism equivalent to biallelic NF1 gene inactivation (Skuse 
et al, 1996; Skuse and Cappione 1997). A C>U variant can be generated at c.3916 
which results in NF1 gene inactivation, generating a UGA premature stop codon in the 
GRD of the edited version of the NF1 mRNA resulting in truncation of the NF1 mRNA 
(Skuse et al, 1996; Ashkenas 1997; Cappione et al, 1997; Skuse and Cappione 1997). 
Furthermore, there is a trend towards higher levels of C>U editing in malignant tumours 
with overall levels determined to be 4%-17% in comparison to non-tumour tissues 
(Skuse et al, 1996; Skuse and Cappione 1997). Such tumours have a number of 
distinguishing features including inclusion of the alternatively spliced exon 23a in the 
edited transcript and the presence of apobec-1 mRNA which mediates site specific 
deamination of single cytidine residues in apolipoprotein B (apoB) mRNA (Hadjiagapiou 
et al, 1994; Skuse et al, 1996; Mukhopadhyay et al, 2002). Inappropriate expression of 
such auxiliary editing factors may therefore contribute to variations in neurofibromin 
inactivation, potentially underlying the level of sporadic NF1 cases and supporting the 
role of modifying genes.
1.3 Neurofibromin
1.3.1 NF1 gene expression
1.3.1.1 cDNA sequence of the NF1 gene
The NF1 cDNA sequence was first described by Gutmann and Collins (1993), and 
Viskochil et al (1993). The NF1 protein product is neurofibromin, a large ~220-250kDa
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(2818 amino acid) protein which is ubiquitously expressed correlating with the varied 
tissue distribution of NF1 clinical manifestations (DeClue et al, 1991; Gutmann et al, 
1991; Daston etal, 1992).
1.3.1.2 Neurofibromin tissue distribution
NF1 mRNA can be identified at low concentrations in most adult tissues including; skin 
fibroblasts, spleen, lung, muscle and immortalised lymphoblastoid cell lines, with mRNA 
and protein levels varying between cell and tissue types (Wallace et al, 1990). The 
highest expression of neurofibromin is seen in neurons in the adult brain, CNS and 
peripheral nervous system (PNS), confirmed by GAP activity (Golubic et al, 1992), 
western blotting and immunostaining (DeClue etal, 1991; Daston etal, 1992; Norlund et 
al, 1993). Additionally, earlier studies demonstrated that neurofibromin levels are high 
during rat embryonic development with a role for neurofibromin in axonal path finding or 
target recognition, diminishing in non-neural tissues during postnatal development 
(Daston et al, 1992; Daston and Ratner, 1992). Importantly, neurofibromin is also 
expressed in non-myelinating but not myelin forming Schwann cells, concordant with 
evidence of NF1 somatic mutations occurring in Schwann cells derived from 
neurofibromas (Daston et al, 1992; Maertens et al, 2006). The variation in neurofibromin 
tissue distribution in neural and non neural tissues is likely to underlie the differences in 
the function of neurofibromin, indicating that NF1 mutations can generate a wide variety 
of pathologies based on the diverse expression of neurofibromin both within and outside 
of the CNS.
1.3.2 Intracellular distribution of neurofibromin
In cell signalling pathways such as the RasMAPK (Ras mitogen activated protein 
kinase) pathway, specific biological responses are generated dependent on the 
localisation of proteins in the cell, neurofibromin has been reported to localise to many 
subcellular compartments including the cytosol and within both the actin and tubulin
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cytoskeleton structures (section 1.3.6) (Gregory et al, 1993; Li et al, 2001; 
Vandenbroucke et al, 2004; Leondartis et al, 2009).
1.3.2.1 Neurofibromin C-tail phosphorylation
Ser2808 is a primary target of PKC at the C-tail of neurofibromin and phosphorylation at 
this residue is correlated with the subcellular shuttling of the protein. Under basal 
conditions, nuclear neurofibromin is C-tail Ser2808 dephosphorylated whereas the 
cytosolic pool of the protein is substantially C-tail Ser2808 phosphorylated (Leondartis 
et al, 2009). Furthermore, activation of the RasMAPK pathway with a phorbol ester: 
tetradecanoyl phorbol acetate (TPA), a diacylglycerol analogue, resulted in C-tail 
phosphorylation and cytosolic localisation of neurofibromin, indicating that this may 
mediate or regulate nucleocytoplasmic shuttling of neurofibromin, a common feature to 
other tumour suppressor proteins (Fabbro and Henderson 2003; Leondartis et al, 2009). 
Furthermore, this phosphorylation event may involve the stabilisation and modulation of 
functional properties of the protein, through interactions with other cellular proteins and 
components including; Ras, cytosolic proteins such as microtubules (Gregory et al, 
1993), the actin cytoskeleton (section 1.3.6) (Mangoura et al, 2006b), mitochondria 
(Roudebush et al, 1997) and even scaffold proteins such as 14-3-3. Indeed, cAMP 
dependent phosphorylation of serine and threonine residues in the C-terminal domain 
by PKA results in the interaction of neurofibromin with 14-3-3 which may result in 
modulation of biochemical and biological functions of neurofibromin (Feng et al, 2004). 
It is suggested therefore that prolonged C-tail phosphorylation is needed for regulation 
of the RasMAPK pathway through recruitment of neurofibromin from the nucleus to the 
cytosol, further evidence for potential non-GAP functions for neurofibromin within the 
nucleus which remain to be determined.
1.3.2.2 Protection against NF1 phenotypes
The localisation of neurofibromin has additionally thought to be associated with 
protection against some NF1 phenotypes, evidenced by the inability of an NF1 mutant,
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NF1-DE43 to undergo nuclear localisation (Vandenbroucke et al, 2002). Similarly, the 
microtubule-binding Ras effector, RASSFIc, is usually associated with the nucleus but 
following DNA damage experiments, RASSFIc becomes localised in the cytosol and is 
associated with components of microtubules where it is thought to activate the 
RasMAPK pathway and JNK 1 and 2 (Kitagawa et al, 2006).
1.3.3 Neurofibromin RasGAP function
There is very high conservation of the NF1 gene between species, with -98%  homology 
between mouse and human and 60% between Drosophila and humans particularly in 
the GRD (Bernards et al, 1993; The et al, 1997). Neurofibromin has extensive 
sequence homology to two mammalian RAS-GTPases (Guanosine triphosphatase) 
including the first mammalian GAP to be identified: p120GAP (Trahey and McCormick 
et al, 1987), the Drosophila Gap1 protein and the IRA proteins (Ira1p/lra2p), two 
inhibitory regulators of the Ras-cyclic AMP pathway found in the yeast Saccharomyces 
cerevisiae (Xu et al, 1990; Andersen et al, 1993; Weinberg, 2007). There are at least 
160 genes which are now predicted to encode proteins that resemble GAPs (McTaggart 
et al, 2006). The catalytic domains of such proteins are crucial for binding to Ras 
proteins and stimulating the low intrinsic GTPase activity of Ras proteins to convert from 
the guanosine triphosphate (GTP) bound activated Ras to guanosine diphosphate 
(GDP) bound inactivated Ras (Ballester et al, 1990; Xu et al, 1990; DeClue et al, 1991) 
(figure 1.2).
Mutants of IRA1/IRA2 demonstrate sensitivity to heat shock and nutrient starvation, 
phenotypes which are similar to those found in yeast cells expressing RAS2va1'19, a 
mutation equivalent to mammalian rasval~12 (Tanaka et al, 1989; Xu et al, 1990). 
Furthermore, neurofibromin demonstrates functional homology with the previously 
identified Ras-GTPases harbouring the ability to stimulate the intrinsic GTPase activity 
of both yeast RAS2 and mammalian HRAS, although neurofibromin does have distinct 
physiological requirements for interactions (Xu et al, 1990). The main functional role of 
neurofibromin is therefore that of a highly conserved RAS-GAP with the gap related
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domain encoded by exons 20 to 27a of neurofibromin. Under normal circumstances, 
neurofibromin is a major regulator of Ras signalling, accelerating the slow process of 
hydrolysis of GTP to GDP through its association with Ras (Ballester et al, 1990; Xu et 
al, 1990; McTaggart etal, 2006).
1.3.4 Neurofibromin Non-GAP function
Determining the in vivo interactions of neurofibromin is an important aspect of the 
design of therapeutic targets for the clinical manifestations of NF1, particularly NF1- 
associated benign and malignant tumour types (section 1.5.1). Studies on neurofibromin 
have largely focused on its RasGAP function and tumorigenesis although there is 
mounting evidence which indicates that neurofibromin has a number of other functional 
non-GAP roles. Indeed, mutations have been identified outside of the GRD; Ras 
inhibitors have only been found to rescue some phenotypes in NF1 deficient cell lines 
and neurofibromin has also been found to co-localise and bind with other proteins. 
Furthermore, the GRD only accounts for about 10% of the protein as neurofibromin 
contains a number of other additional regions including: an N-terminus cysteine/serine- 
rich domain (CSRD) (section 1.3.4.1), a leucine-repeat domain upstream of the extreme 
carboxyl terminus domain (Martin et al, 1990), and a C-terminal helical domain 
containing a functional nuclear localization sequence (NLS-CTD) (Li et al, 2001; 
Vandenbroucke et al, 2004).
1.3.4.1 Neurofibromin cysteine serine rich domain (CSRD)
A region upstream of the GRD, located in exons 11-17 may represent a further 
functional domain (Izawa et al, 1996; Fahsold et al, 2000). This domain, termed the 
cysteine serine rich domain (CSRD) is located in the N-terminal of neurofibromin at 
amino acid residues 543-909 and contains three cysteine pairs (residues 622/632, 
673/680, and 714/721). There are a number of potential functions for this domain based 
on its structural properties. The cysteine residues, for example, exhibit similarities to the 
ATP binding domain in the BCR protein (Maru and Witte, 1991) and there is additional
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homology to MAP-2 and tau proteins, known to associate with microtubules (Gregory et 
al, 1993). Moreover, there are a number of cAMP dependent protein kinase A (PKA) 
recognition sites located at residues 583 and 815-834, potential evidence for 
neurofibromin mediation of cAMP signalling (Marchuk et al, 1991; Guo et al, 1997; The 
et al, 1997) (sectionl.3.4.2). Some of the most compelling evidence for the functional 
role of the CSRD in neurofibromin is the possible allosteric regulation of the GRD by the 
CSRD (Mangoura et al, 2006). Indeed, co-overexpression of CSRD+GRD results in a 
30% downregulation of EGF stimulated Ras activation indicating that together the 
CSRD and GRD confer greater regulation on Ras (Mangoura et al, 2006). Moreover, 
chronic inhibition of PKC with TPA, results in a reduction in Ras-GAP activity of the 
CSRD-GRD and a significant increase in Ras activation following EGF stimulation, 
indicating that neurofibromin Ras-GAP activity may be regulated by PKC-dependent 
phosphorylation of the N-terminal CSRD (Mangoura et al, 2006; Griner and Kazanietz, 
2007; Leondaritis et al, 2009).
1.3.4.2 Neurofibromin and cAMP signalling
The different domains of neurofibromin have been found to regulate immediate versus 
long term memory. The C terminal domain is thought to be responsible for learning and 
the regulation of immediate memory. Conversely, the GRD is thought to control long 
term memory formation and is additionally important for synaptic plasticity (Brambilla et 
al, 1997; Atkins et al, 1998). These two regions have, however, been found to contribute 
to different signal transduction pathways, underlying the association with distinct phases 
of memory (Ho et al, 2007). Whilst the GRD signals through the RasMAPK pathway 
(section 1.4.1), the C-terminal region is required for G-protein-dependent adenylyl 
cyclase activation, regulating intracellular cAMP (Guo et al, 1997, 2000; The et al, 1997; 
Tong et al, 2002; Dasgupta et al, 2003; Hannan et al, 2006).
Studies in both mice and drosophila have shown that cAMP regulation is stimulated by 
neurotransmitters such as serotonin and histamine (Hannan et al, 2006). In Drosophila 
NF1 null mutants (NF1P1 and NF1P2), neurofibromin was essential for the cellular
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response to neuropeptides, specifically: PACAP38 (pituitary adenylyl cyclase-activating 
polypeptide) at the neuromuscular junction (The et al, 1997). In conjunction with an 
effect on body size, this induced a 100-fold enhancement of potassium currents, 
activating the RasMAPK and cAMP pathways (The et al, 1997). This activity is 
eliminated in the mutants and rescued in a Ras independent manner, by exposure of 
cells to increased concentrations of cAMP (The et al, 1997). In Drosophila, 
neurofibromin consequently acts not only as a Ras-GAP but also as a regulator of the 
cAMP pathway that involves the rutabaga (ru/)-encoded adenylyl cyclase (Guo et al, 
1997; Guo et al, 2000).
Given the sequence homology between Drosophila and human neurofibromin, it is 
expected that similar mechanisms would be observed in humans indicating that 
signalling from both the GRD and C-terminal region may underlie the cognitive defects 
seen in individuals with NF1. Indeed, neurofibromin also regulates G-protein stimulated 
adenylyl cyclase activity in mammalian neurons (Tong et al, 2002) and Nf1-deficient 
astrocytes have impaired cAMP responses to PACAP, which is associated with 
decreased calcium influx, further evidence that mammalian neurofibromin functions at 
the level of adenylyl cyclase activation (Dasgupta et al, 2003).
1.3.4.3 Neurofibromin Sec14 PH domain
A novel bipartite element, distinct from the GRD has also been identified in 
neurofibromin. This region is located at the immediate C-terminus of the GRD and 
contains an N-terminal, lipid binding Sec14- homologous domain (Aravind et al, 1999) 
and a neighbouring C-terminal pleckstrin homology (PH)-like region (Bonneau et al, 
2004; DAngelo et al, 2006). Sec14-like domains have been previously identified in 
yeast where it acts as a phosphatidylinositol transfer protein (PITP) with a role in 
exchanging (3-sn-phosphatidyl)choline (PtdCho) and 1-(3-snphosphatidyl)-D-myo- 
inositol (Ptdlns) between membrane compartments (Bonneau et al, 2004; Phillips et al,
2006). The PH domain is likely to regulate ligand binding in the Sec14 domain 
(DAngelo et al, 2006; Welti et al, 2007).
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A number of mutations have been identified in the Sec14-PH domain (Human Gene 
Mutation Database, HGMD). Mutations including p.K1750del and p.11584V have also 
been created by site directed mutagenesis in the Sec14-PH domain and expressed in 
cultured cells of patients (Welti et al, 2011). No major change was observed in the 
composition of bound lipids in the non-truncating mutant proteins compared to the wild 
type and those carrying truncating mutations (p.K1750del) (Welti et al, 2011). PH 
domains are known to represent a family of typical protein interaction modules 
suggesting that this domain may control protein-protein interactions although the lipid 
binding activity of this domain may not represent the only functional role of the Sec14- 
PH domain (Blomberg et al, 1999). The natural ligand for this domain is yet to be 
identified but such ligand binding partners are thought to include phosphoproteins such 
as PtdlnsPs or a similar species with strong local negative charge (D’Angelo et al, 2006; 
Welti et al, 2011). Two-hybrid screens or pull-down assays may reveal further 
interaction partners and insight into neurofibromin function.
1.3.5 Neurofibromin and ubiquitin mediated proteolysis
Ubiquitin-mediated proteolysis is involved in the regulation of a number of key cellular 
processes including cell cycle control, differentiation, and immune responses 
(Ciechanover et al, 2000). Ubiquitination via the ubiquitin-proteosome pathway involves 
the covalent attachment of ubiquitin molecules to lysine residues on the target protein, 
followed by its rapid degradation by the 26S proteosome (Ciechanover et al, 2000). It 
has been indicated in a number of cell lines including primary human lung embryonic 
fibroblasts (IMR90 cells) and a rat Schwannoma cell line that in response to serum 
stimulation, neurofibromin is degraded completely. This suggests that the duration and 
amplitude of Ras signalling may be regulated by the action of the ubiquitin-proteosome 
pathway on amino acids which lie upstream of the GRD in neurofibromin (Cichowski et 
al, 2003). The identification of this pathway as a crucial mediator of neurofibromin 
activity may have important implications in terms of therapeutic interventions which 
could be aimed at blocking NF1 inactivation or by up-regulating the NF1 protein.
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1.3.6 Neurofibromin-cytoskeleton association
Neurofibromin is localised in both the cytosol and is also associated with the membrane. 
No membrane spanning region has been identified in the sequence of neurofibromin, 
however, suggesting that it may not be an integral membrane protein (Marchuk et al, 
1991; De Clue et al, 1991). Indeed, precipitation of neurofibromin with bovine brain 
Triton-insoluble fractions indicates that neurofibromin resides mainly in the particulate 
fraction and so may be associated with the cytoskeleton (Hattori et al, 1992). This 
indicates that cytoskeietal proteins may serve to regulate the activity and potentially the 
localisation of neurofibromin. Components of microtubule function which are important 
in cell division may therefore represent key therapeutic targets for chemotherapeutic 
agents such as colchicine (Myrdal and Auersperg, 1985; Bar-Sagi and Feramisco, 
1986).
1.3.6.1 Tubulin and neurofibromin association
Neurofibromin isoform 1 (section 1.2.4.1) co-localises with cytoplasmic microtubules 
such as tubulin in fibroblasts and Schwann cells, suggesting that this complex could be 
important in the regulation of Ras activity (Gutmann and Collins, 1991; Bollag et al, 
1993; Gregory et al, 1993; Gutmann et al, 1995a). The GAP activity of such tubulin- 
neurofibromin complexes is reduced, indicating that the GAP function of neurofibromin 
is partially inhibited by its association with tubulin and possibly other phospholipids. This 
interaction may therefore represent an important mechanism for rapidly generating high 
levels of activated Ras in the cell through downregulation of neurofibromin GAP function 
(Bollag et al, 1993; Gregory et al, 1993; Gutmann et al, 1995a). Furthermore, 
immunohistochemical and western blot analysis of neurofibromin has shown a potential 
interaction with mitochondria although the reason for this association is not clear and 
may relate to sequestration of neurofibromin so that it is unable to bind to Ras 
(Roudebush et al, 1997).
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1.3.6.2 Embryonic development and cytoskeletal interaction
During embryonic development, interaction of neurofibromin with cytoskeletal 
components (intermediate filament cytoskeleton (cytokeratin 14), desmoplakin and |34 
integrin) is a key event in the formation of desmosomes and hemidesmosomes 
(Koivunen et al, 2000). This suggests that during an early period of cellular development 
when NF1 expression is high, neurofibromin is associated with bundles of intermediate 
filaments of the basal keratinocytes. This interaction may therefore be important for the 
polarisation of basal cells and the maturation of intercellular junctions (Malminen et al, 
2002). Moreover, neurofibromin also localises with F-actin and the microtubule 
cytoskeleton during differentiation of telencephalic neurons (Li et al, 2001).
1.3.6.3 Syndecan association with neurofibromin
Syndecans are transmembrane proteoglycans which are involved in the organisation of 
cytoskeleton and/or actin microfilaments and can function as cell surface receptors 
during cell-cell and/or cell-matrix interactions. Syndecan association with neurofibromin 
has also been studied and it is indicated that they form a bipartite interaction with 
neurofibromin (Hsueh et al, 2001).
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1.4 NF1 associated pathways
1.4.1 The RasMAPK pathway
1.4.1.1 G proteins
The role of the RasMAPK pathway is to integrate extracellular input from ligands 
including growth factors, and to transduce the signal to the intracellular environment 
(figure 1.2). Signal transduction through this pathway occurs with the use of an intricate 
system of membrane-bound as well as cellular molecules. GTP binding proteins (G 
proteins) are well characterised cytoplasmic proteins which belong to this pathway are 
involved in the regulation of many cellular processes including cell proliferation, 
differentiation and migration (Woods et al, 2002; Denayer et al, 2008). Aberrant G 
protein regulation consequently results in cellular transformation. The G protein family is 
divided into two distinct types: small guanosine nucleotide bound G proteins, including 
Rho, Rab, Ran and importantly Ras, which is disrupted in about 20% of all human 
cancers (Bos e ta !, 1989; Mitin et al, 2005), and heterotrimeric G proteins.
1.4.1.2 The Ras family
Ras exists as a multi-gene family consisting of HRAS, KRAS and NRAS, (Parada et al, 
1982) all of which are activated by binding and stimulation of receptor tyrosine kinases 
(RTK) such as epidermal growth factor receptors (EGFR), G protein-coupled receptors, 
cytokine receptors and extracellular matrix receptors by growth factors (Tidyman and 
Rauen 2009). Ras functions as a biochemical switch mechanism, existing in two forms: 
the GTP-bound activated form and GDP-bound inactivated form, dependent upon the 
intracellular protein partner with which it is associated. These include GAPs (p120GAP 
and neurofibromin) or GEFs (guanine nucleotide exchange factors) including SOS, 
RasGRF and RasGRP (Mitin et al, 2005; McTaggart et al, 2006). The exchange of GDP 
and GTP and the state of Ras activity within a cell is therefore dependent on the levels 
of these proteins. As outlined in figure 1.2 and figure 1.3, upon activation of Ras through
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GTP charging, there are a number of downstream intracellular targets for Ras which 
can be subsequently activated. In normal resting cells, upon growth factor binding the 
receptor interacts with the Src homology 2 domain (SH2) domain on the GRB2 adaptor 
protein (Mitin et al, 2005; Tidyman and Rauen, 2009). SOS is bound to GRB2 by the 
Src homology 3 domain (SH3) (Mitin, 2005). Upon receptor activation, GRB2 and 
consequently SOS are recruited to the plasma membrane where they are brought into 
direct proximity of Ras where the GEF activity of SOS increases the levels of activated 
Ras in the cell by catalysing the exchange of GDP for GTP (Tidyman and Rauen 2009). 
SHC acts as an anchor for GRB2 through tyrosine phosphorylation (figure 1.2 and 1.3).
1.4.2 Ras associated pathways
1.4.2.1 Ras-PI3K-PTEN-AKT-mTOR pathway
Ras can directly interact with the catalytic subunit of type 1 phosphatidylinositol 3- 
kinases (PI3Ks), which catalyses the formation of secondary messenger lipids: 
phosphatidylinositol 3,4,5triphosphate [PI(3,4,5)P3] and phosphatidylinositol 
3,4bisphosphate [PI(3,4)P2] from phosphatidylinositol-4,5-bisphosphate (Ptdlns(4,5)P2> 
which bind to and augment the translocation of phosphoinositide-dependent protein 
kinases (PDK1) [3-phosphoinositide-dependent protein kinase-1] and AKT (PKB). 
(Rodriguez-Viciana etal, 1994; Pacold etal, 2000; Martelli etal, 2010) (figure 1.3).
1.4.2.1.1 PTEN
Negative regulation of the PI3K pathway is achieved through the tumour suppressor 
protein phosphatase and tensin homologue deleted on chromosome ten (PTEN). 
Ptdlns(3,4,5)P3 is the main substrate for PTEN although other substrates include focal 
adhesion kinase (FAK), SHC exchange protein, transcriptional regulators ETS-2 and 
Sp1, and platelet-derived growth factor receptor (PDGFR) (Mahimainathan et al, 2004). 
PTEN point mutations, loss of heterozygosity and promoter methylation are often 
described in association with cancer. Moreover, PTEN is frequently mutated in NF1- 
associated malignant tumours (Gregorian, 2009; Mawrin et al, 2010).
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1.4.2.2 PI3K and the cytoskeleton
Aspects of cytoskeletal regulation are also controlled by PI3K pathway activation, 
leading to stimulation of RAC, a RHO family protein involved in the regulation of both 
the actin cytoskeleton and a number of transcription-factor pathways including activating 
nuclear factor-xB (NF-kB) (section 6.1). A role for RAC in PI3K-dependent and 
independent mechanisms has also been defined in RAS-induced transformation 
(Lambert et al, 2002). Further evidence for Ras-independent NF1 involvement in 
cytoskeletal rearrangements is demonstrated by the ability of NF1 overexpression to 
induce the expression of focal adhesion kinase (FAK) in addition to the modulation of 
MAPKs (Corral et al, 2003).
1.4.2.3 Ras-RALGDS pathway
Another family of effectors for Ras is the RAS-related (RAL) proteins involving three 
members: RAL guanine nucleotide dissociation stimulator (RALGDS), RALGDS-like 
gene (RGL/RSB2) and RGL2/RLF which are able to interact with Ras-GTP through their 
Ras association (RA) domains, (figure 1.3)
1.4.2.4 Ras-phospholipase Ce pathway
The connection between Ras and Phospholipase Ce as an effector has been reported 
only recently. Phospholipase Ce is known to have Ras association domains in addition 
to a Ras-GEF domain and a phospholipase C domain (figure 1.3).
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Figure 1.2. RasMAPK signalling pathway and the Ras opathies’. The tyrosine kinase Raf, is the primary Ras effector. Raf is activated by recruitment to the 
plasma membrane and phosphorylation by ‘scaffold’ proteins. The MAPK pathway consists of a highly conserved cascade of three structurally related protein 
kinases, each activating the next kinase in the pathway by phosphorylation. MEK1 and MEK2 (MKK -  MAP kinase kinase), dual specificity kinases are 
activated by phosphorylation at either threonine or tyrosine residues. ERK1 and ERK2 (MK -  Map kinase/ extracellular signal-regulated kinases 1 and 2) are 
the final kinases in the pathway and are activated following serine/threonine phosphorylation. Cytosolic and nuclear substrates for ERK include regulators of 
the expression of mediators of the cell cycle including FOS, c-JUN and D-cyclins which are involved in the G1 phase cell cycle progression. Adapted from 
Downward et al (2002)
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Figure 1.3. Signalling Downstream of Ras. Once in its activated GTP-bound state, Ras can activate numerous downstream effectors: (i) The RasMAPK 
pathway (figure 1.2) (ii) P13K pathway. PDK1 activates a number of kinases in the AGC family, including AKT, PKCs, p70S6K and RSK. Furthermore 
RacGEFs are activated by PI3K which able to activate RhoGTPases. (iii) Activation of the RAL GDS pathway results in stimulation of phospholipase D1 
(PLD1) and activation of CDC42/RAC-GAP-RAL binding protein 1 (RALBP1) (Boettner et al, 2002; Feig et al, 2003). Downstream of the RALGDS pathway, 
these proteins, in concert with AKT are capable of inhibiting the FoxO family which are FORKHEAD transcription factors thought to be involved in induction of 
cyclin-dependent kinase inhibitor KIP1 (p27) which promotes arrest of the cell cycle through BIM and FAS LIGAND expression subsequently promoting 
apoptosis (De Ruiter et al, 2001). (iv) Phospholipase Ce is thought to function in the activation of PKC by Ras following the hydrolysis of Ptdlns(4,5)P2 to 
diacylglycerol and inositol-1,4 ,5-trisphosphate (lns(1,4,5)P3). Furthermore there is evidence that Ras could be linked to calcium mobilisation through this 
mechanism (Kelley et al, 2001) Adapted from Downward et al (2002).
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1.5. NF1 diagnostic and clinical features
NF1 is characterised by highly variable symptoms and inconsistent severity, even 
between family members sharing the same mutation. The spectrum of clinical features 
associated with NF1 patients, indicates that NF1 mutations must occur in a number of 
different cell types. The extreme variability of NF1 clinical manifestations has resulted in 
difficulties in establishing definitive clinical diagnostic criteria. In 1988, the National 
Institute of Health (NIH) issued a ‘Consensus Statement’ with the aim of defining 
standard diagnostic criteria for NF1 to help characterise NF1 and distinguish it from 
other related disorders (NIH, 1988). These features are highly specific in adults but in 
children with no family history of NF1, diagnosis can often be difficult as the majority of 
NF1 characteristics manifest with age. In children with a clear family history of NF1, the 
diagnosis is much simpler, with only one feature needed; usually the presence of a 
pigmentary anomaly such as Cafe au lait (CAL) macules. CAL macules normally occur 
in children of 2 years of age and frequently increase in numbers throughout childhood 
but can diminish over time. Two or more of the NIH diagnostic criteria (listed below) 
signify the presence of NF1.
1. Six or more CAL macules: (0.5 cm at largest diameter in pre-pubertal individuals 
or 1.5 cm in individuals past puberty)
2. Axillary freckling or freckling in inguinal regions due folding of the skin
3. Two or more neurofibromas of any type or 1 plexiform neurofibroma
4. Two or more Lisch nodules (iris hamartomas)
5. A distinctive osseous lesion
6. A first-degree relative with NF1 diagnosed by using the above-listed criteria
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1.5.1 NF1-associated tumours
Patients with NF1 have an increased risk of developing a number of different benign 
and malignant tumour types as outlined below. The overall risk of cancer has been 
found to be 2.7 times higher in NF1 patients than in the general population, with a 20% 
cumulative risk of a malignancy by age 50 (Walker et al, 2006).
1.5.1.1 Cutaneous neurofibromas
Neurofibromas are benign tumours which originate from the peripheral nerve sheath. 
Cutaneous neurofibromas are confined to a single area and comprise of Schwann cells, 
fibroblasts, perineural cells, mast cells and axons (Kimura et al, 1974; Le and parade,
2007). Cutaneous neurofibromas are one of the hallmarks of NF1, occurring in the 
majority of patients during adolescence and the initial years of adulthood, increasing in 
size and number during both puberty and pregnancy (table 1.2). Despite no response to 
hormonal contraceptives, the timing of neurofibroma development indicates that there 
may be a role for hormonal factors in their formation (Mclaughlin et al, 2003). 
Neurofibromas have not been reported to undergo malignant transformation. There is 
currently no definitive treatment for neurofibromas as they are only removed for 
cosmetic reasons or if they are causing the patient pain or discomfort due to excessive 
size or location. Surgical excision is the standard treatment for cutaneous 
neurofibromas; however, this can involve the additional risk of producing thickened 
scarring and recurrence of neurofibromas post-surgery. More recently, laser treatment 
has also been found to be helpful for small lesions.
1.5.1.2 Subcutaneous neurofibromas
Subcutaneous neurofibromas are a cause of pain and neurological deficit. These 
tumours occur below the skin and are defined as superficially situated tumours in which 
the skin moves freely over the lesion (Tucker et al, 2005). Due to their subcutaneous 
location, these tumours can be mistaken for glomus tumours (section 1.5.1.9). As an
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association of NF1 with breast cancer has been reported (section 1.6.3), it is important 
that women with subcutaneous breast lumps are referred to an NF1 specialist to 
distinguish neurofibromas from breast carcinomas (Sharif etal, 2007) (table 1.2).
1.5.1.3 Plexiform neurofibromas
Plexiform neurofibromas exhibit a similar composition to benign neurofibromas being 
comprised of an irregular mix of Schwann cells, local elements of supporting nerve 
fibres including perineural cells, neurons, fibroblasts, and blood vessels in addition to 
infiltrating mast cells (Ferner et al, 2007; Le et al, 2011). Plexiform neurofibromas are 
generally larger in size than cutaneous neurofibromas, implicate multiple nerve fascicles 
and are capable of infiltrating surrounding tissue and blood vessels (Reviewed by 
Upadhyaya, 2008a). Plexiform neurofibromas arise in ~60% of NF1 patients and are 
thought to be congenital due to their propensity for growth, usually growing during 
childhood and adolescence. Very large plexiform neurofibromas can cause extensive 
disfigurement and neurological deficit. Due to their infiltrative nature, they can be difficult 
to remove surgically and additionally, about 15% of plexiform neurofibromas undergo 
malignant transformation to become MPNSTs and so it is crucial the they are closely 
monitored (Ferner et al, 2007) (table 1.2). Plexiform neurofibromas are generally more 
problematic and equally as difficult to treat due to their size, location and involvement of 
multiple nerves. There have been a number of previous studies into the use of 
chemotherapeutic agents in the treatment of plexiform neurofibromas but the success of 
such studies has been relatively limited (supplementary table 1).
1.5.1.4 Malignant peripheral nerve sheath tumours (MPNSTs)
Individuals with NF1 have a 15 year decrease in life expectancy with mortality related to 
NF1-associated malignancies (Zoller et al, 1995; Rasmussen et al, 2001). MPNSTs are 
an extremely rare, aggressive malignancy, accounting for approximately 3-10% of soft 
tissue sarcomas (Grobmyer et al, 2008). These tumours can occur sporadically, later in 
life in the general population but up to 50% of MPNSTs are associated with NF1,
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occurring in 10-15% of individuals (Evans et al, 2002). Commonly originating in the 
nerve roots, extremities and pelvis but also occurring at other sites, MPNSTs usually 
present as enlarged masses causing disability, pain and neurological deficit due to 
pressure on surrounding tissues. A pre-existing plexiform neurofibroma can undergo 
malignant transformation evident from a rapid change in size or development of pain. 
Indeed individuals with a subcutaneous neurofibroma are 20 times more likely to 
develop an MPNST indicating that close follow up of patients with such tumours is 
warranted to rapidly identify any malignant changes (Tucker eta l, 2005) (table 1.2).
In terms of treatment options for MPNSTs, these are very limited and so consequently 
contribute to the low survival rates of such patients. The main treatment option for such 
patients is generally complete surgical resection with clear margins (Ferner and 
Gutmann, 2002). Chemotherapy has been used in numerous preclinical studies on 
MPNSTs and also in clinical trials for the treatment of MPNSTs but its efficacy is still 
debated (Supplementary table 1). Radiation therapy has also been employed in the 
adjuvant setting with some success (Ducatman et al, 1986) but is mostly avoided due to 
previous observations that radiotherapy is often associated with the occurrence of other 
malignant symptoms (Sharif et al, 2006).
The major focus of drug discovery for MPNSTs in addition to other NF1-associated 
malignancies such as optic gliomas (supplementary table 1) has involved targeting of 
specific aspects of Ras signalling. This includes Ras localisation and attachment to the 
inner membrane which mainly involves interference with post translational prenylation of 
Ras with the Statin family of drugs to inhibit Ras prenylation (FTI family (Farnesyl 
protein transferase inhibitor)). Geranylgeranyl transferase could also act as a secondary 
mechanism if prenylation is inhibited, indicating that a combinative approach of FTI and 
geranylgeranyl transferase inhibitors would be required. Other targets other than the 
RasMAPK pathway have been investigated in MPNSTs including mTOR, AKT, PI3K, 
EGFR, VEGFA/EGFR and PDGFR (supplementary table 1).
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1.5.1.5 Spinal nerve root neurofibromas
Spinal nerve root neurofibromas occur in about 40% of individuals with NF1, but only 
about 2% are symptomatic, causing compressions of the spinal root or spinal cord, 
often appearing worse upon neuroimaging (MRI) than the resulting neurological deficit. 
(Thakkar et at, 1999; Ferner et al, 2007). Due to the pathology and risks associated with 
NF1 surgery, patients with such spinal tumours require strict observation (table 1.2).
1.5.1.6 Brain and optic pathway tumours
Gliomas have been detected in most parts of the CNS although they generally occur in 
the optic pathways, cerebellum and brainstem (Listernick et al, 2007). Astrocytomas are 
slow growing high grade gliomas representing 4-5% of all cancer related deaths each 
year (Woods et al, 2002). These tumours rarely metastasise but have an infiltrative and 
invasive nature, making surgical removal a major challenge. Pilocytic astrocytomas 
usually occur in adulthood but are occasionally diagnosed in children. Grade IV 
astrocytomas (glioblastoma multiforme) are the most malignant of all astrocytomas with 
a very aggressive nature and are typified by extensive vascularisation and areas of 
necrosis. Individuals with glioblastoma multiforme have an estimated 5 year survival of 
2.7% with a mean survival time of less than a year (Sant et al, 2011). Approximately 
15% of children with NF1 are found to have optic pathway gliomas which are rare in 
adults and are usually present by the age of 6. These gliomas are rarely symptomatic, 
but 5% result in visual impairment (Listernick et al, 2007). Diagnosis is difficult in 
children as they are unlikely to complain of defects in vision (table 1.2).
1.5.1.7 Phaeochromocytomas (PHEO)
Phaeochromocytomas (PHEO) are catecholamine-secreting tumours of the chromaffin 
cells of the adrenal medulla. Extra-adrenal tumours have also been identified and are 
known as paragangliomas (Mannelli et al, 2007). Germline mutations in NF1, VHL, 
SDHD, SDHC SDHB and RET are found in 25% of patients indicating an association
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with several disorders including multiple endocrine neoplasia type 2 A or B, von Hippel- 
Lindau disease and NF1 (Mannelli et al, 2007). Recently, mutations in TMEM127 were 
also identified in hereditary PHEO (Neumann et al, 2011). There are many reports of 
NF1 patients with PHEO in the literature and the incidence is estimated to be 5-10% 
although the underlying pathogenesis of PHEO and paragangliomas is unclear (Kramer 
et al, 2007; Erem et al, 2007; Mannelli et al, 2007; Babinska et al, 2008; Kobayashi et 
al, 2009). Urinary or plasma analysis of catecholamine or metanephrine in addition to 
MRI or CT scan of the abdomen or pelvis is required to determine the presence of 
PHEO. Correct diagnosis is important to prevent associated problems including 
cardiovascular complications (Babihska et al, 2008) (table 1.2).
1.5.1.8 Gastrointestinal stromal tumours (GIST)
Gastrointestinal stromal tumours (GIST) are rare mesenchymal soft tissue sarcomas 
which arise in the gastrointestinal tract and usually present with abdominal pain, bowel 
obstruction with and without perforation and gastrointestinal bleeding (Giuly et al, 2003). 
GISTs can occur sporadically or in a familial setting. In the latter case, GISTs are 
related to underlying mutations in the interstitial cells of Cajal (ICC) or their precursors 
(Yantiss et al, 2005). NF1 patients are known to be at an increased risk of developing 
GISTs with an estimated incidence of 3.9%-25% (Kramer et al, 2007; Hegyi et al, 2009). 
The occurrence of multiple GISTs in an NF1 patient may suggest that a subset of these 
patients have a germline c-kit mutation instead of NF1 mutations (Yantiss et al, 2005). 
Indeed, germline mutations in c-kit results in a cutaneous hyperpigmented phenotype 
and c-kit somatic mutations are identified in GISTs (Yantiss et al, 2005). The underlying 
molecular mechanisms responsible for GIST development in the context of NF1 is yet to 
be fully established (table 1.2). Mutations in c-kit and PDGFA are rare and are likely to 
be late events in the development of these tumours indicating that NF1-associated 
GIST development is likely to be distinct from that of sporadic GISTs (Yantiss et al, 
2005; Kang et al, 2007). An association of gastric carcinoid tumours with NF1 was also 
identified by Stewart et al (2007) in the absence of other predisposing factors such as 
pernicious anaemia.
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1.5.1.9 Glomus tumours
Glomus tumours are rare benign tumours of the glomus body, a thermoregulatory shunt 
located in the digits which generate severe pain in response to alteration of temperature 
or pressure. The association of glomus tumours in the fingers and toes with NF1 has 
only recently been recognised (Ferner et al, 2007; Brems et al, 2009) (table 1.2).
1.5.1.10 Haematological malignancy
Juvenile myelomonocytic leukaemia (JMML) (MIM 607785) is a rare myeloproliferative 
disorder (MPD), clinically and cytogenetically distinct from adult chronic myeloid 
leukaemia with a highly variable disease course. 11% of individuals with JMML harbour 
germline NF1 mutations indicating that NF1 patients have a 200-fold elevated risk of 
developing JMML (Stiller et al, 1994; Niemeyer and Locatelli, 2006) (table 1.2)
1.5.2 Nonverbal and verbal learning disabilities
Nonverbal and verbal learning disabilities have been identified in 30% to 65% of 
children with NF1. Deficits in IQ and motor function are well documented and suggest 
that abnormal expression of NF1 or other genes commonly found to be deleted 
alongside the NF1 gene may be implicated in non-syndromic mental retardation (North, 
etal, 1997; Rosser and Packer, 2003; Vedrine, 2011).
1.5.3 Non-nervous system NF1 symptoms
Other common manifestations of NF1 not associated with the nervous system defined 
by the consensus conference include osseous abnormalities including bone dysplasia 
such as sphenoid wing dysplasia and scoliosis in addition to short stature and 
macrocephaly (NIH, 1988).
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Table 1.2 Somatic mutational events in NF1-associated benign and malignant tumours.
Tumour Type Benign or Malignant
Underlying Somatic 
Mutations Reference
Cutaneous
neurofibromas Benign NF1 Chapter 3
Cutaneous 
neurofibromas from 
patients with high 
tumour burden
Benign NF1, TP53, RB1 Chapter 3
Plexiform
neurofibromas
Benign/Malignant
Potential NF1, TP53, RB1, CDKN2A Chapter 3
Spinal neurofibromas Benign NF1 Upadhyaya et al, 2009
MPNSTs Malignant See chapter 6 for details Chapter 6
Grade IV 
astrocytomas 
(glioblastoma 
multiforme)
Malignant- High 
Grade 50% EGFR activation Yamazaki et al, 
1988.Malignant- Low 
Grade PTEN
Paragangliomas and 
Phaeochromocytomas Malignant
NF1
Mannelli et al, 2007; 
Neumann et al, 
2011
Tyrosine-kinases mutation
induction of hypoxia-inducible 
factor (HIF)
TMEM127
Gastrointestinal 
Stromal Tumours Malignant
NF1 haploinsufficiency in ICC 
cells Takazawa et al, 
2005; 
Stewart et al, 2007
5% PDGFRA
90-95% activating mutations in 
c-kit
Glomus Tumours Benign NF1 Brems et al, 2009
Gastric Carcinoid 
Tumours Malignant NF1, CTNNB1
Stewart et al, 2007; 
Fujimori et al, 2001
JMML HaematologicalMalignancy See Table 1.5
Stiller etal, 1994; 
Niemeyer and 
Locatelli, 2006
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1.6 NF1 associated syndromes
1.6.1 NF1 variant forms
There are two known NF1 variant forms including familial spinal neurofibromatosis 
(FSNF) (MIM 162210) and segmental NF1 (SNF1). Additionally, there are a number of 
syndromes with similar features to NF1 including Neurofibromatosis type 2 (NF2) (MIM 
101000), familial Schwannomatosis (MIM 162091) and Watson syndrome (MIM 
193520). These disorders are summarised in table 1.3.
1.6.2 The ‘Ras-opathies’
The NF1 gene is an integral part of the RasMAPK molecular signalling pathway, 
involved in cellular regulation and development. In addition to NF1, a number of 
seemingly unrelated developmental disorders have been characterised with underlying 
mutations in genes associated with the RasMAPK pathway (Denayer et al, 2008; 
Reviewed by Bennett et al, 2009) (table 1.3, table 1.4 and figure 1.2). General clinical 
features associated with these disorders suggest that the evolutionary conserved 
RasMAPK pathway is not only important in oncogenesis but also has key roles in 
growth, development, cognition, the immune system and vascular development 
(Denayer et al, 2008). Diagnosis of these ‘Ras-opathies’ or Neuro-cardio-facio- 
cutaneous syndromes is complicated due to complex interactions between genes in the 
RasMAPK pathway which results in a high level of clinical overlap. Diagnosis cannot be 
based solely on clinical features and molecular characterisation is equally as difficult.
1.6.2.1 Noonan syndrome
Noonan syndrome (NS); (MIM 163950) is a clinically heterogeneous autosomal 
dominant disorder, although de novo mutations have been reported (Noonan et al, 
1963). NS is characterised by pleomorphic features as outlined in table 1.3 and has an 
estimated prevalence of 1/1000-1/2500 (Noonan, 1968; Allanson, 1987). NS is often
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difficult to distinguish from NF1, Leopard syndrome, cardio-facio-cutaneous syndrome 
and Costello syndrome. A distinctive facial phenotype as well as typical cardiac 
malformations is often a reliable clinical feature to aid in diagnosis, but can vary 
between family members and between patients with the same molecular aberration 
(Jorge, 2009). The underlying genetic causes of NS are outlined in table 1.3 
Approximately 75% of individuals harbour mutations in PTPN11, SOS1, KRAS, NRAS, 
RAF1, BRAF or MEK1, indicating that this disorder is multifactorial with a very complex 
genetic basis and suggesting that additional genes responsible for this disorder remain 
to be identified. Additionally, mutations in SHOC2 have recently been identified in 
Noonan-like syndrome with loose anagen hair (NS/LAH) (Cordeddu et al, 2009). The 
highest proportion of mutations are in the PTPN11 gene (50%) (table 1.4), 90% of which 
are a small subset of missense mutations located in exons 3 and 8, which encode the 
N-SH2 and PTP domains. (Tartaglia et al 2001; Digilio, 2002; Legius, 2002). 
Furthermore, SHP-2 is expressed at high levels in hematopoietic cells and is required 
for correct haematological development, explaining the incidence of haematological 
abnormalities in NS including JMML, which has also been associated with NF1 (Choong 
et al, 1999; Loh et al, 2004; Qu et al, 1998).
1.6.2.2 LEOPARD syndrome
LEOPARD syndrome (LS) (MIM 151100) is a less prevalent autosomal dominant 
disorder labelled by Gorlin et al (1971) as an acronym of its principal features (table1.3). 
LS in children closely resembles NS and is especially difficult to diagnose as a hallmark 
feature; lentigines, do not appear until later in childhood. The underlying genetic basis of 
LS (table 1.3 and table 1.4) is similar to that of NS and the associated multiple giant cell 
lesion syndrome (MIM 163955) (Bertola et al, 2001) due to underlying PTPN11 
alterations, indicating that mutations in PTPN11 give a broad spectrum of phenotypes. 
PTPN11 mutations in LS are, however, associated with amino acids in the catalytic 
domain resulting in a reduction in SHP2 activity (Digilio et al, 2002; Legius et al, 2002; 
Kontaridis et al, 2006). Residual catalytic activity in the mutant SHP2 protein in LS may 
be sufficient to cause the overlapping clinical features of LS and NS (Oishi et al, 2009).
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Table 1.3 NF1 variants, associated syndromes and disorders mapping to the RasMAPK pathway
Disorder Phenotype Causative Gene Reference
Familial Spinal 
Neurofibromatosis 
(FSNF)
Few of the cardinal clinical features of NF1. Instead FSNF patients 
harbour multiple bilateral spinal tumours (section 1.5.1.5). Some 
patients have MPNSTs. Major spinal component of FSNF may be 
explained by differential impairment of neurofibromin in different 
progenitor cell types
Specific spectrum of NF1 
mutations: missense or splice 
site alterations
Kauffman et al, 2001; 
Wimmer et al, 2002; 
Kluwe et al, 2003; 
Messiaen et al, 2007;
Fauth et al, 2009; 
Upadhyaya et al, 2009; 
Leeta l, 2009
Segmental NF1 
(SNF)
Estimated prevalence of -0.0006%  to 0.0018%, often presenting in 
one quarter or even half of the patients body.
Postzygotic NF1 mutation 
occurring during 
embryogenesis, the timing of 
which triggers the resulting 
phenotype. NF1 mutations are 
rarely identified in patients with 
SNF1; only five mutations 
reported to date, three of 
which encompassed atypical 
NF1 deletions (section 
1.9.1.1.4).
Wolkenstein etal, 1995; 
Ingordo etal, 1995; 
Tinschert et al, 2000; 
Gottlieb etal, 2001; 
Youssoufian & Pyeritz, 
2002; Redlick and Shaw, 
2004; Consoli et al, 2005;
Maertens et al, 2007; 
Kehrer-Sawatzki & Cooper, 
2008;
Erickson, 2010; 
Messiaen etal, 2011;
Neurofibromatosis 
Type 2 (NF2)
Affecting about 1 in 25,000. Hallmark feature of NF2 is 
Schwannomas, generally benign, encapsulated tumours which 
consist of Schwann cells alone and occur on or around the vestibular 
branches of both auditory nerves and even in the dermis
NF2 gene (110 kb) which 
encodes Merlin 
(Schwannomin) 
tumour suppressor gene 
sporadic NF2 mutations do 
occur
Trofatter etal, 1993; 
Rouleau etal, 1993; 
Huson and Hughes, 1994; 
Kluwe et al, 1996; 
Gutmann etal, 1997; 
Friedman etal, 1999; 
Korf & Rubenstein, 2005
Schwannomatosis
Difficult to distinguish from NF2. Incidence of approximately 1 in 
30,000. Development of Schwannomas which do not occur on the
vestibular nerve
Tumour suppressor gene 
INI1/SMARCB1, Somatic NF2 
have also been identified
MacCollin et al, 2003; 
Korf and Rubenstein, 2005; 
MacCollin et al, 2005; 
Hulsebos et al, 2007
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Disorder Phenotype Causative Gene Reference
Watson Syndrome
Clinical features reminiscent of both NF1 and Noonan syndrome. 
Lower frequency of CALs, Lisch nodules and neurofibromas, short 
stature, cognitive impairment and pulmonary stenosis with a distinct 
lack of other NF1 complications
Linkage between Watson 
syndrome and NF1 flanking 
markers and an 80-kb NF1 
deletion have been reported
Watson, 1967; 
Allanson etal, 1991; 
Upadhyaya etal, 1992; 
Tassabehji et al, 1993; 
Ruggieri and Huson, 1999;
Noonan Syndrome Congenital heart disease, facial dysmorphism, short stature, skeletal defects, cognitive deficits and haematological abnormalities.
PTPN11, SOS1, RAF1, MEK1, 
KRAS, NRAS, BRAF
Noonan, 1968; 
Allanson, 1987;
Tartaglia et al 2001; 
Schubbert et al, 2006; 
Roberts et al, 2007; 
Razzaque etal, 2007; 
Pandit etal, 2007
Noonan-like 
syndrome (NS/LAH) Loose anagen hair
SHOC2 Mazzanti et al, 2003; Cordeddu et al, 2009
LEOPARD Syndrome
Lentigines, electrocardiographic abnormalities, ocular hypertelorism, 
pulmonary valve stenosis, abnormal genitalia, retardation of growth
and deafness.
PTPN11, RAF1
Digilio et al, 2002; 
Legius et al, 2002; 
Kontaridis et al, 2006
Legius Syndrome NF1-Like Syndrome: cafe au lait macules, axillary freckling, mild neurocognitive impairment and macrocephaly SPRED1
Brems et al, 2007, 
Pasmant et al, 2009, 
Spurlock et al, 2009
Costello Syndrome
Macrocephaly, cutis laxa, nasal and perioral papillomata, deep 
palmar and plantar creases, diffuse skin hyperpigmentation and nail 
dysmorphology. Increased risk of malignancy: rhabdomyosarcoma, 
transitional-cell carcinoma and neuroblastoma.
HRAS (c.34G>A; pG12S and 
p.G12A), KRAS, BRAF, MEK1
Costello, 1971; 
Costello, 1977;
Gripp, 2005;
Nava, 2007
Cardio-facio- 
cutaneous Syndrome
Craniofacial dysmorphology, ectodermal anomalies and cardiac 
defects. Coarse face, congenital heart defects, ectodermal anomalies 
(follicular and palmar hyperkeratosis), short stature, mental 
retardation (moderate to severe). Facial features reminiscent of NS 
and Costello syndrome.
KRAS, BRAF, MEK1, MEK2, 
SOS1
Rodriguez-Viciana et al, 
2006;
Schubbert, 2006; 
Schubbert et al, 2007; 
Niihori et al, 2006;
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Table 1.4 Ras pathway related genes and their function
Gene Gene Function Location Related Disorders
PTEN
Acts as a dual specificity protein phosphatase (Tumour suppressor) 
Negatively regulates AKT/PKB signalling pathway
10q23.3 Leopard Syndrome
PTPN11
Protein Tyrosine Phosphatase, encodes SHP-2, a Src homology-2 (SH2)- 
containing protein tyrosine phosphatase (PTP)
Regulates cellular processes: cell growth, differentiation, mitotic cycle, and 
oncogenic transformation.
12q24 Noonan Syndrome, Acute Myeloid Leukaemia and Leopard Syndrome
S0S1
Guanine nucleotide exchange factor for RAS (GEF)
Regulates Ras by facilitating the exchange of GTP for GDP.
2p22-p21
Gingivival fibromatosis type 1 and 
Noonan syndrome
BRAF
Serine/threonine protein kinase.
Regulates MAP kinase/ERK signalling pathway: affects cell division, differentiation, 
secretion.
7q34
Cardio-facio-cutaneous syndrome 
and Costello Syndrome.
RAF1/CRAF
MAP kinase kinase kinase (MAP3K)
functions downstream of the Ras family of membrane associated GTPases to 
which it binds directly
Role in the control of gene expression, involved in cell division, apoptosis, cell 
differentiation and cell migration
3p25
Noonan Syndrome and Leopard 
Syndrome
HRAS
Protein member of the GTPase superfamily.
Intrinsic GTPase activity.
Functions in signal transduction pathways by binding to GTP and GDP.
11 p15.5 Costello Syndrome
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Gene Gene Function Location Related Disorders
KRAS
Protein member of the GTPase superfamily.
Intrinsic GTPase activity.
Functions in signal transduction pathways by binding to GTP and GDP.
12p12.1
Leopard Syndrome, Noonan 
Syndrome, Cardio-facio-cutaneous 
Syndrome and Costello Syndrome
MAP2K1 /  
MEK1
Dual specificity mitogen activated protein kinase.
Involved in cellular processes: proliferation, differentiation, transcription regulation 
and development.
15q22.1-q22.33
Cardio-facio-cutaneous syndrome, 
Noonan Syndrome and Costello 
Syndrome.
MAP2K2/  
MEK2
Dual specificity mitogen activated protein kinase 2
Critical role in mitogen growth factor signal transduction.
19p13.3 Cardio-facio-cutaneous syndrome
SMARCB1
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily b, member 1. (tumour suppressor)
Relieves repressive chromatin structures, allowing the transcriptional machinery to 
access its targets more effectively.
22q11 Malignant Rhabdoid Tumours
PI3Ky
pi3/pi4-kinase family of proteins.
Modulator of extracellular signals: elicited by E-cadherin-mediated cell-cell 
adhesion.
Role in maintenance of the structural and functional integrity of epithelia and 
promoting assembly of adherens junctions.
7q22.3 Myeloid Leukaemia
SPRED1
SPROUTY/SPRED family of proteins.
Tyrosine kinase substrates.
Functions in the RasMAPK pathway between Ras and Raf, as a negative regulator 
of Ras
15q14 Legius Syndrome
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1.6.2.3 Legius syndrome (Neurofibromatosis Type 1 like syndrome)
Patients with a clinical diagnosis of NF1 have been reported who exhibit a pigmentary 
phenotype and who do not develop any tumour related complications, usually clinically 
classified as ‘autosomal dominant, cafe au lait spots only’. This phenotype is 
reminiscent of individuals harbouring c.2970-2972 delAAT p.990delM mutation in exon 
17 of the NF1 gene in which all patients exhibit the same pigmentary phenotype 
(Upadhyaya et al, 2007). Recently, however, mutations in the SPRED1 gene have been 
identified in patients with this same phenotype and this disorder has been newly 
designated as Legius syndrome (MIM 611431) (figure 1.2 and table 1.3, table 1.4), an 
autosomal dominant disorder with many phenotypic characteristics in common with 
individuals with NF1 but no occurrence of Lisch nodules of the iris or tumours of the 
peripheral nervous system such as neurofibromas (Brems et al, 2007, Pasmant et al, 
2009, Spurlock et al, 2009; Messiaen et al, 2009). Some individuals have even been 
described as having facial features reminiscent of individuals with NS demonstrating 
that especially in younger children, Legius syndrome is difficult to distinguish from NF1 
and other disorders of the RasMAPK pathway (Brems et al, 2007). It is still currently 
unclear whether individuals with mutations in SPRED1 are at an increased risk of 
developing cancer as is observed in patients with NF1.
1.6.2.4 Costello syndrome
The cardinal clinical features of Costello syndrome (MIM 218040) are outlined in Table 
1.3. (Costello, 1971, 1977; Nava, 2007). Clinically overlapping phenotypic features in 
patients with Costello syndrome make it difficult to distinguish from that of NS and CFC, 
especially in new-borns. As the individual matures, the features become more 
pronounced and distinctive. Individuals with Costello syndrome are also at an increased 
risk of developing tumours (Gripp, 2005). 80% of identified mutations in Costello 
syndrome are heterogeneous HRAS germline mutations, which are not present in CFC 
syndrome (Estep et al, 2006; van Steensel et al, 2006; van der Burgt et al, 2007; 
Zampino et al, 2007; Gripp et al, 2008; Lo et al, 2008; Schulz et al, 2008) (table 1.4).
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1.6.2.5 Cardio-facio-cutaneous syndrome (CFC)
Individuals with cardio-facio-cutaneous syndrome (CFC) (MIM 115150) Blumberg et al 
(1979) have many features which overlap with those of both NS and Costello 
syndromes, although a distinguishing feature of CFC is the occurrence of neurological 
abnormalities which are not present in individuals with NS (Yoon et al, 2007) (table 1.3). 
Unlike with NS and Costello syndromes, it is not clear whether individuals with CFC are 
at an increased risk of developing benign and malignant tumours. There have been 
instances recorded in the literature of individuals with CFC with BRAF and MEK1 
mutations and acute lymphoblastic leukaemia and a hepatoblastoma (Van den Burg et 
al, 1999; Gripp et al, 2005; Makita et al, 2007; Al-Rahawan et al, 2007). Mutations in at 
least four genes (KRAS, BRAF, MEK1, MEK2) have been characterised in CFC (table 
1.4) (Upadhyaya et al, 2010). More recently SOS1 has also been recognised as having 
a potential role in CFC (Bennett et al, 2009).
1.6.3 Association of NF1 with other syndromes
A number of syndromes have been identified which may have an association with NF1, 
although in many cases the co-occurrence may be purely coincidental and in other 
disorders there is a proven association. Furthermore there are a few disorders in which 
the underlying causes are in genes associated with the RasMAPK pathway. These 
disorders are detailed in table 1.5.
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Table 1.5. Reported potential association between NF1 and other disorders
Disorder Phenotype Causative Gene Reference
Tuberous
Sclerosis
Hamartomas in multiple body systems, most commonly; the brain, 
kidneys, skin, heart and lungs. Neurological abnormalities, renal 
angiomyolipomas (AMLs) and pulmonary LAM 
(lymphangioleiomyomatosis).
TSC1 MIM 191100, TSC2 MIM 613254 Carsillo et al, 2000
MoyaMoya 
Disease (MIM 
252350)
Chronic occlusive cerebrovascular disorder. Steno-occlusive 
changes in the circle of Willis. In children; transient ischaemic 
attacks and cerebral infarction. In adults; intracerebral, 
intraventricular or subarachnoid haemorrhages. Headaches and 
seizures occur in both adults and children.
17q25 Ohaegbulam, 2001; Tonsgard, 2006
HNPCC (Lynch 
Syndrome) (MIM 
120435)
Early onset development of multiple tumours of the colon. Extra 
colonic cancer including endometrial, ovarian and urinary tract
cancers.
MLH1, MSH2, MSH6, PMS2.
Lynch & de la 
Chapelle, 2003;
Lynch et al, 2008;
Boland et al, 2008
Juvenile 
myelomonocytic 
leukaemia JMML 
(MIM 607785)
Haematological Malignancy. Hypersensitivity to granulocyte- 
macrophage colony-stimulating factor (GM-CSF).
NF1, NRAS, KRAS, PTPN11, BCR- 
ABL1 fusion gene (36%)
Kalra etal, 1994; 
Bader-Meunier et 
al, 1997; 
Niemeyer et al, 
1997;
Flotho etal, 1999; 
Flotho etal, 2007
Retinoblastoma 
(MIM 180200) Unilateral/bilateral retinoblastomas RB1
Friend etal, 1986; 
Nicholas et al, 
2005; 
Broaddus et al, 
2009
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Disorder Phenotype Causative Gene Reference
CMT
Weakness and atrophy of the distal muscle groups of the limbs, 
gait disturbance, impaired sensation in the hands and feet, 
decreased and/or absent deep tendon reflexes, and skeletal 
deformities including pes cavus and hammer toes.
CMT1A: PMP-22; CMT1B: myelin 
protein zero gene (MPZ) on 
chromosome 1.
Lupski etal, 1993; 
Pareyson et al, 
1999; 
Berciano et al, 
2003; 
Lancaster et al, 
2010
Hereditary gingival 
fibromatosis 
(HGF) (MIM 
135300)
Slow but progressive benign overgrowth of the keratinized
gingiva. SOS1
Hart etal, 1998; 
Hart et al, 2002
Capillary 
malformation- 
arteriovenous 
malformation 
(CM-AVM) 
(MIM 608354)
Arteriovenous malformations and fistulas. AVMs in skin, muscle, 
bone, heart and the brain. RASA1
Eerola et al, 2003; 
Boon et al, 2005; 
Revencu et al, 
2008
Autoimmune 
lymphoproliferative 
syndrome (ALPS) 
(MIM 601859)
Defective lymphocyte apoptosis, accumulation of non-malignant 
lymphocytes and increased risk of developing haematological 
malignancies.
CD95 pathway, NRAS (p.G13D), Loss 
of BCL-2-interacting mediator of cell 
death (BIN).
Oliveira et al, 2004; 
Bidere et al, 2006;
Oliveira et al, 2007
Carney Complex 
(MIM 160980).
Neoplasias involving the heart, central nervous system and 
endocrine organs including schwannomas, cardiac myxomas, 
psammomatous melanotic schwannoma (PMS), acromegaly, 
large cell calcifying sertoli cell tumour (LCCSCT), thyroid 
carcinoma or nodule & breast adenoma. Cutaneous pigmentation 
abnormalities and mucosal lesions.
PRKARIa, p16
Carney etal, 1986; 
Stratakis et al, 
2001; 
Sandrini et al, 2003
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1.7 NF1 tumour suppressor function
1.7.1 NF1 and tumour development
The idea of tumour suppressor genes was derived from both investigations of the 
familial incidence of retinoblastoma and cell-fusion experiments. Whilst many have 
contributed to the identification of mechanisms by which heritable tumours develop, the 
seminal two hit hypothesis for tumour suppressor genes (Knudson, 1971), eloquently 
explains the occurrence of the primary pathologies associated with NF1 tumours. 
Following loss of function of the NF1 tumour suppressor gene, there is an associated 
increase in signalling through the RasMAPK pathway and its related signalling 
cascades (section 1.4). Individuals with NF1 are born with an NF1 germline mutation 
resulting in loss of function of one NF1 allele, leaving only one wild type copy of the NF1 
gene. The second hit hypothesis (Knudson, 1971), when applied to NF1 implies that 
NF1-associated pathologies arise as a result of a second mutational event causing 
somatic cell inactivation of the remaining wild type allele of the NF1 gene and resulting 
in complete loss of NF1 tumour suppressor function. Indeed, molecular analysis of 
tumour derived Schwann cells; the main cell constituent of neurofibromas demonstrates 
biallelic inactivation of the NF1 gene resulting in tumorigenesis through aberrant 
Schwann cell proliferation (Serra et al 2001).
The nature of the cell type and the germ layers from which the cells are derived 
contribute to the different NF1 pathologies. Different benign and malignant NF1- 
associated tumours, for example, arise from cells of the neural crest including: NF1 
inactivation in Schwann cells which gives rise to the formation of neurofibromas, 
pheochromocytomas are a result of a second hit in chromaffin cells and pigmentary 
abnormalities including cafe-au-lait macules are caused by NF1 loss in melanocytes 
(Zhu et al, 2002; Le and Parada, 2007). Furthermore the cells of the germ layer such as 
the skin-derived precursors (SKPs) (section 1.7.5) give rise to cutaneous 
neurofibromas, myelomonocytic leukaemia develops in myeloid cells and astrocytomas 
develop as a result of NF1 inactivation in glial cells (Largaespada et al, 1996; Bajenaru
45
et al, 2003; Le and Parada, 2007; Yang et al, 2008; Le et al, 2009). Many questions 
remain unanswered, however, including the exact underlying mechanisms involved in 
the development of NF1 associated tumours, and whether other genetic modifiers are 
implicated in malignant progression.
1.7.2 Schwann cells and the peripheral nervous system (PNS)
The development of peripheral nerves requires co-operation from three distinct cell 
types; peripheral neurons, Schwann cells and fibroblasts. Schwann cells are the 
principle glial cells of the PNS, of which there are two well characterised types; 
myelinating and non-myelinating Schwann cells. A further class of non-myelinating 
Schwann cell, the terminal Schwann cell (TSC), also exists at the neuromuscular 
junction. Myelinating Schwann cells form part of the lipid rich myelin sheath which wraps 
around long segments of axons with a multilayered sheath of extended membrane. This 
forms a complex seal with the axon surface thereby defining the nodes of Ranvier at the 
junctions between adjacent Schwann cells. Myelination is important for a reduction in 
energy consumption and most importantly, an increase in the velocity of axonal 
conduction (Salzer, 1997). Non-myelinating Schwann cells (Remak cells), form Remak 
bundles by engulfing small-calibre C fibre axons which are involved in relaying pain 
signals and have the potential to myelinate, if given the appropriate signals (Griffin and 
Thompson, 2008). In normal nerves, these non-myelinating cells vastly outnumber the 
myelinating Schwann cells. The development of the Schwann cell lineage involves 
transition from migrating neural crest cells to Schwann cell precursors (SCPs) (glial 
restricted progenitor cells) and finally to the myelinating and non-myelinating mature 
Schwann cells (figure 1.4) (Jessen and Mirsky, 2005). Schwann cells, Remak cells and 
their respective precursors rely on neuregulin-1 type III, an axonal growth factor for their 
survival, proliferation and terminal differentiation (Nave and Salzer, 2006).
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1.7.3 Schwann cells and NF1 tumorigenesis
The vast majority of tumours which arise in the PNS are derived from Schwann cells or 
their precursors (Urich and Tien, 1998). In the case of individuals with NF1, or the rarer 
disorders; NF2, Schwannomatosis or Carney Complex syndrome (section 1.6.3), such 
patients are at an increased risk of developing peripheral nerve sheath tumours in 
comparison to the general population. NF1-associated peripheral nerve sheath tumours 
are composed of a highly heterogeneous mixture of cellular subtypes (figure 1.5). These 
include: Schwann cell-like elements (“Schwann cells”) which are p75 and S100b 
immunoreactive, mast cells, fibroblasts, vascular elements, perineurial-like cells which 
are characterised by long thin cytoplasmic processes, several pinocytotic vesicles, and 
a discontinuous basal lamina but lack the normal immunoreactivity of perineurial cells. 
Furthermore, there are also CD34-immunoreactive dendritic cells which were postulated 
to represent a novel nerve sheath cell type or may instead be macrophages (Weiss and 
Nickoloff, 1993; Cohen et al, 1993). It is now clear, however, that only Schwann cells 
harbour the NF1 inactivating second hit in NF1-associated peripheral nerve sheath 
tumours (section 3.1).
1.7.4 NF1 Schwann cell culture
It is clear that the heterogeneity of cell types in neurofibromas extends to that of the 
Schwann cells as both NF1+I' and NF1~A Schwann cells are present in neurofibromas. 
Recently a culture technique was developed which is capable of distinguishing between 
the two populations (section 2.1.3) (Serra et al, 2000; Rosenbaum et al, 2000; Maertens 
et al, 2006).
1.7.5 Skin-derived precursors (SKPs)
The precise cell type within the Schwann cell lineage that is responsible for 
neurofibroma formation has been a major subject of debate. Schwann cell precursors, 
immature Schwann cells, or mature Schwann cells have all been touted as the cell type
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which may have the potential to give rise to neurofibromas. It is thought that there is a 
dual origin for the development of plexiform neurofibromas and cutaneous 
neurofibromas due to the way in which they are separated both temporally and spatially 
(Lu et al, 2009). Evidence for two distinct origins for such tumours comes from mouse 
models in which plexiform neurofibromas develop but the models fail to give rise to 
dermal tumours (Cichowski et al, 1999; Joseph et al, 2008; Vogel et al, 1999; Wu et al, 
2008; Zheng et al, 2008; Zhu et al, 2002) (section 1.8). Following the identification of 
adult tissue stem cells, it was postulated that such cells may be the source of 
neurofibroma formation. Skin-derived precursors (SKPs) represented an attractive 
prospect for the origin of neurofibromas. SKPs are neural crest-like pluripotent stem 
cells, located in both the human and mouse dermis, which are capable of differentiating 
in both the neuronal and glial cell lines (Toma et al, 2001; Toma et al, 2005; Miller et al, 
2005; Fernandes et al, 2006; McKenzie et al, 2006; Lu et al, 2009). The suggestion that 
somatic stem cells or their progenitors are the cells of origin of neurofibromas is 
important. This stem cell model of tumorigenesis has important implications for 
understanding early cellular events that dictate neurofibromagenesis, in addition to 
other tumour types. Furthermore, viewing NF1 as a disease of stem and progenitor cells 
has important implications for the development of NF1 associated therapy (Le et al, 
2011).
1.7.7 NF1 haploinsufficiency and the tumour micro-environment
Whilst Schwann cells derived from peripheral nerve sheath tumours have been 
determined to harbour complete loss of NF1, the other constituents of these tumours 
such as the fibroblasts and mast cells retain one functional copy of the NF1 gene. The 
consequence of this haploinsufficiency has been well studied in recent years and it has 
been concluded that tumour formation also requires NF1 haploinsufficiency of the 
tumour microenvironment (Caroll and Ratner, 2008). Indeed, in the conditional knockout 
murine model of NF1, mice did not develop any neurofibromas and loss of Nf1 in SKPs 
was demonstrated to be required but not sufficient to induce tumours (Zhu et al, 2001; 
Zhu et al, 2002) (section 1.8.4.2). This suggested that tumour formation was subject to
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haploinsufficiency in the surrounding tumour microenvironment (Lu et al, 2009). Mast 
cells and other inflammatory cells are capable of infiltrating neurofibromas in large 
numbers indicating that inflammatory cells may be involved in the pathogenesis of NF1 
tumours (Greggio, 1911). Schwann cells secrete high levels of stem cell factor (SCF), a 
ligand for the c-kit receptor tyrosine kinase on mast cells which is required to promote 
maturation, activation, survival and migration of mast cells (Demitsu et al, 1998; Hirota 
et al, 1993; Ryan et al, 1994).
Loss of neurofibromin enhances SCF secretion as Nf1'A Schwann cells have been found 
to secrete up to 6-fold more SCF than both wild type and Nf1'/+ Schwann cells (Yang et 
al, 2003). Activation of the c-KIT receptor is thought to result in the activation of the 
RasMAPK and downstream effector pathways including P13K, generating VEGF, 
TGFp, NGF and MMPs which aid in propagation of mast cell proliferation, growth and 
survival (Hirota et al, 1993; Ingram et al, 2000, 2001; Yang et al, 2008). Furthermore, 
Nf1+/~ mast cells which have been stimulated by SCF can alter the activity of Nf1+/~ 
fibroblasts, another major cellular component of neurofibromas. Higher levels of TGF-p 
are secreted by the Nf1+/~ mast cells and in response to this, fibroblasts are promoted to 
migrate, proliferate and synthesise collagen (Yang et al, 2006). This suggests that NF1 
haploinsufficiency modulates the fate of inflammatory cells such as mast cells in the 
tumour microenvironment and that haploinsufficiency, in conjunction with NF1~A 
Schwann cells is required for the initial stages of NF1-associated neurofibroma 
formation. This hypothesis would, however, not apply to sporadic neurofibromas (Caroll 
and Ratner). Furthermore, a recent proposed model for development of cutaneous 
neurofibromas suggests that they are associated with hair and subcutaneous fat. 
Multipotent NFTA cells in these tissues may be a major source of neurofibroma-derived 
progenitors which can give rise to the different cell types found in cutaneous 
neurofibromas (Jouhilahti et al, 2011)
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Figure 1.4. Schematic illustration of the main cell types and developmental transitions involved in Schwann cell development The embryonic phase of 
Schwann cell development involves three transient cell populations, (i) Migrating neural crest cells, (ii) Schwann cell precursors (SCPs) which express 
differentiation markers that are not found in migrating neural crest cells (brain fatty acid-binding protein (BFABP), protein zero (PO) and desert hedgehog 
(DHH)) and (iii) immature Schwann cells. The fate of these immature Schwann cells is considered to be the same. Their developmental potential is therefore 
determined by the axons with which they associate. Adapted from Jessen and Mirsky (2005).
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Figure 1.5 Schematic illustration of the composition of peripheral nerves and the tumours derived from 
them. Each nerve fascicle in the peripheral nerve contains (i) the endoneurium; axons, Schwann cells, 
fibroblasts, mast cells, and collagen, and (ii) the perineurium, a layer of perineurial cells, which forms the 
blood-nerve barrier. Biallelic NF1 inactivation in Schwann cells results in the formation of neurofibromas 
which contain all of the cells typically present in peripheral nerves in addition to abnormal Schwann cells 
which have become dissociated from axons during tumour formation to generate a heterogeneous mass 
of cells. Malignant progression of a neurofibroma to MPNST results in further disruption to the 
architecture of the nerve. AdaDted from Mclauahlin and Jacks (2003^
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1.8 Mouse models
Animal models are of great importance to the study of genetic diseases such as NF1, 
providing the ability to study the natural history of a disease and the function of genes 
during embryogenesis and fetal development due to the relatively short lifespan of 
animals used. Animal models also generate new insight into the mechanisms of tumour 
formation, cellular regulation, and the relationship between mutations. Genotype- 
phenotype correlations and interacting pathways which underlie molecular mechanisms 
responsible for malignancy can also be studied. Importantly animal models provide a 
subject in which to study the in vivo effects of potential therapies for NF1 
manifestations. There are, however, some disadvantages of animal models such as the 
size of smaller mammals which precludes the use of some surgical techniques and the 
cost, time and space needed to maintain the colonies of animals. These disadvantages 
are, however, far outweighed by the benefits and possibilities offered by animal models. 
In addition to Drosophila models of cognitive defects in NF1 and a number of naturally 
occurring NF1 animal tumour models, various different strategies have been developed 
to generate complex murine models of NF1:
1.8.1 Naturally occurring
Phenotypic characteristics of NF1 have been found to naturally occur in a wide variety 
of vertebrates including bicolour damselfish (Pomacentrus partitus), dogs, chickens and 
Holstein cattle (Goedegeburre, 1975; Schmale et al, 1983; Sartin et al, 1994 Reviewed 
by Riccardi et al, 1994). In such vertebrates, there is the development of isolated 
symptoms such as individual neurofibromas, gliomas, schwannomas and what appear 
to be Lisch nodules. All these features have similar histology to those observed in 
humans.
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1.8.2 Chemically induced
Mutagenic and oncogenic agents have been successfully used to recapitulate tumour 
disorders in small mammals such as rats and mice. Using transplacental prenatal 
exposure to agents such as nitrosourea (ethyinitrosourea), neoplasms which are 
associated with NF1 can be generated (Cardesa et al, 1978; Nakamura et al, 1989). 
Prenatal exposure therefore may be capable of generating both germline and somatic 
mutations resulting in tumour formation (Riccardi et al, 1988). Genotoxic therapy 
induced tumours are a complication of cancer treatment in humans and this has also 
been investigated in mouse models of NF1. Mutagen exposed (radiation and 
cyclophosphamide) Nf1+/' mice develop secondary cancers that also occur in humans 
(Chao et al, 2005).
1.8.3 Targeted disruption
1.8.3.1 The Nf1 heterozygote
The first Nf1 knockout mouse was generated by Jacks et al (1994) and Brannan et al 
(1994). This mouse harboured a targeted disruption of exon 31 of the Nf1 gene 
(Nf1+/n31) which resulted in NF1 protein instability. Crucially, it was seen that compared 
to mice carrying the wild type NF1 gene, heterozygous mice were predisposed to 
forming numerous cancers following their first year. This resulted in a shorter life 
expectancy and development of NF1 -associated pathologies found in humans including 
pheochromocytomas and myeloid leukaemia which arose following LOH of the 
remaining wild type Nf1 allele (Jacks et al 1994; Brannan et al 1994). The remaining 
hallmarks of NF1 identified in NF1 patients such as neurofibromas, Lisch nodules, or 
CAL macules, never arose in such mice. This suggested that the genetic background of 
these mice led to a decrease in the likelihood of a second-hit occurring especially as 
NF1 patients who only carry one functional copy of the NF1 gene usually develop 
relatively ubiquitous symptoms. Although the Nf1+/~ mouse model does not generate any 
additional information for those wishing to study neurofibroma development, the model
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is not a complete failure as many studies have used it to investigate other pathologies 
associated with Nf1+/' cell lineages such as Schwann cells, fibroblasts, vascular cells, 
and hematopoietic cells.
Unfortunately, developing mice with a deletion of the Nf1 gene resulting in mice which 
are homozygous for the Nf1 gene (Nf1'A) is extremely difficult as such mice die at 
embryonic day 13.5, part way through the 19-20 day embryogenesis of a mouse. It has 
been found that these mice die as a result of defects in cardiac development resulting in 
the generation of a double outlet right ventricle due to the requirement for Nf1 in the 
endothelial cells during the development of the endocardial cushion. This indicates that 
Nf1 is required for normal embryonic development as has been found in the majority of 
other studied tumour suppressor genes (Brannan et al, 1994; Jacks et al, 1994).
1.8.3.2 The Nf1 chimera
Cichowski et al (1999) developed a murine model to determine the tumour suppressor 
function of Nf1 and to identify whether LOH precedes tumour formation. Nf1'A chimeric 
mice were produced by injecting Nf1'A embryonic stem (ES) cells into wild-type 
blastocysts. Only about 60% of the mice generated had the appropriate level of 
chimerism required to elicit survival and the desired phenotypic effect. The remaining 
mice developed myelodysplasia, neuromotor defects and importantly neurofibroma 
formation along multiple nerves with features reminiscent of the human tumours 
(Cichowski et al, 1999). It was indicated that tumour formation in these mice required 
Nf1 nullizygosity based on the relatively uniform expression of a (3-galactosidase 
transgene in these tumours (Cichowski et al, 1999). Advantages to this model included 
important evidence for Nf1 tumour suppressor function and an indication that 
neurofibromas are derived from Schwann cells. It was still unclear; however what was 
the precise nature of the cell of origin for neurofibromas and what genetic and cellular 
conditions are required for tumour formation.
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1.8.3.3 Genetic cooperativity
The close proximity of NF1 and p53 on both human and mouse chromosomes indicates 
that dual loss of two such tumour suppressor genes may cooperate to accelerate 
tumorigenesis. Nf1 deficient mutant mice have therefore been generated which have 
been crossed with mice harbouring p53 deficiencies in both the linked (c/s) and unlinked 
(trans) configuration of mutant alleles (Cichowski et al, 1999; Vogel et al, 1999; Reilly et 
al, 2000). It was observed that the c/'s configuration in which both of the tumour 
suppressor mutations were in linkage with each other, resulted in a significantly more 
severe tumour phenotype. This included the development of aggressive MPNSTs and 
malignant astrocytomas between 6 and 12 months of age, most likely due to the loss of 
the majority of chromosome 11 which carries both p53 and Nf1. Mice with the c/'s 
configuration had a more severe phenotype than mice harbouring mutations in trans or 
with only a single gene mutated (Cichowski et al, 1999; Vogel et al, 1999; Reilly et al, 
2000). Interestingly, the genetic background of the mice affected the penetrance of 
NF1 -associated pathologies indicating that variable expression of NF1 is related to 
additional genetic modifications (Reilly et al, 2000, Reilly et al, 2004; Reilly et al, 2006).
1.8.3.4 Mouse models of myeloid malignancies associated with NF1.
Children with NF1 show a 200-500 fold increased likelihood of developing myeloid 
malignancies, namely JMML (section 1.6.3) (Bader-Meunier et al, 1999). A subset of 
children with NF1 who have undergone therapy involving alkylating agents in the 
treatment of anaplastic astrocytoma, glioblastoma, Wilms’ tumour, or acute 
lymphoblastic leukaemia have developed AML (Maris et al, 1997). Mahgoub et al (1999) 
therefore tried to recapitulate this form of disease progression by treating Nf1+I' mice 
with alkylating agents. It was found that in the Nf1+I' mice, cyclophosphamide but not the 
topoisomerase II inhibitor etoposide is capable of inducing a myeloproliferative disorder 
(MPD) (Mahgoub et al, 1999). This mouse model could therefore help in further study of 
how alkylating agents induce leukaemia.
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1.8.3.5 Mouse models of astrocytoma and optic glioma formation
Individuals with NF1 are at a higher risk of developing pilocytic astrocytomas, frequently 
associated with the optic nerve (section 1.5.1.6) and Nf1+I~ mice have been found to 
have a 1.6-fold increase in astrocyte proliferation (Gutmann et al, 1999). Nf1+I' mice 
demonstrate that Nf1+,~ astrocytes display a cell-autonomous increase in cellular 
proliferation and also demonstrate other genetic events including loss of p53 and RB1. 
These mice are susceptible to cancer but don’t develop gliomas. Mice with an Nf1 
conditional knockout in astrocytes were therefore developed using Cre/LoxP technology 
on embryonic day 14 (Bajenaru et al, 2002). These mice have increased numbers of 
astrocytes but still do not develop gliomas indicating that additional genetic inactivation 
or cellular components are required in the formation of these tumours. Therefore, Nf1+/~ 
mice were generated which a conditional Nf1 inactivation in astrocytes and these 
models successfully develop low-grade optic nerve and chiasm astrocytomas and so 
may represent a preclinical model (Bajenaru et al, 2003; Bajenaru et al, 2005).
1.8.3.6 Models of learning and memory deficits associated with NF1
Silva et al (1997) studied Nf1+/' mice (Jacks et al, 1994) using the Morris water maze 
which is specifically designed to test regions of the hippocampus in which NF1 is highly 
expressed (Nordlund et al, 1995). Nf1+/~ mice were found to exhibit defects in spatial 
learning and memory, traits which are also identified in NF1 patients (Silva et al, 1997). 
Repetition of trials improved mouse learning deficits indicating that this may be an 
important strategy for the treatment of learning abnormalities in NF1 patients (Silva et 
al, 1997). Furthermore, in Nf1(*A) mice which were heterozygous for Nmdarl (Nmdar1+/~) 
targeted disruption of Nmdarl had no affect by itself. In combination with heterozygous 
Nf1, it served to exacerbate the spatial learning and memory deficits of the Nf1+/~ mice 
(Silva et al, 1997). In Nf1+/~ mice crossed with mice heterozygous for a null mutation in 
the K-ras gene (K-ras+/~, 129T2/SvEmsJ), the K-ras+/~ mutation can rescue learning 
deficits due to elevated levels of Ras. Nf1+/~ mice can also be rescued with 
pharmacological intervention (Johnson etal, 1997 Costa etal, 2002).
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1.8.4 Transgenic
1.8.4.1 Conditional Nf1 knockout
Following earlier failed attempts to generate conditional Nf1'A using homologous 
recombination, Cre-recombinase mediated gene deletion was utilised with loxP sites 
flanking exon 31 and 32 of Nf1 (Nf1flox/flox) to create a conditional knockout murine 
model of NF1 (Zhu et al, 2001; Zhu et al, 2002). The Nf1flox/flox mice were then 
crossed with mice expressing Cre protein under control of the Krox20 promoter 
(Krox20cre) which specifically promotes transcription in 5-10% of Schwann cells 
removing the problem of embryonic lethality in an Nf1'A mouse. The Nf1flox/flox\ 
Krox20cre mouse, did not, however, develop any neurofibromas providing pivotal 
evidence for an important role for not only loss of Nf1 in Schwann cells but additionally 
microenvironment haploinsufficiency (Zhu et al, 2001; Zhu et al, 2002).
To produce a haploinsufficient microenvironment with Nf1 'A Schwann cells, Nf1flox/flox; 
Krox20cre mice were intercrossed with an Nf1+I~ mouse resulting in Nflflox/-; Krox20cre 
mice (Zhu et al, 2002). In this mouse, normal development is seen until 10 to 12 months 
of age, when tumours with similarities to human plexiform neurofibromas develop which 
consist of Schwann cells, pervasive collagen bundles, fibroblasts and infiltrating mast 
cells. Such masses do not occur in Nf1flox/flox;Krox20cre mice which have Nf1'A 
Schwann cells on a wild-type background (Zhu et al, 2002). This mouse therefore 
provides evidence for the hypothesis that haploinsufficiency of the microenvironment is 
required and provides a reliable model to study neurofibromagenesis.
1.8.4.2 Nf1*A mast cells
Following studies by Zhu et al (2002), implicating the haploinsufficient microenvironment 
in the development of NF1-associated neurofibromas, Yang et al (2003) determined the 
role of mast cells in neurofibromagenesis using transplanted bone marrow from Nf1+/~ 
mice which was introduced into lethally irradiated Nf1flox/flox\ Krox20cre mice (Zhu et
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al, 2002). To ensure that the donor engrafted haematopoietic cells had successfully 
reconstituted the hosts’ bone marrow, a GFP reporter gene was carried by the donor 
cells (Yang et al, 2003). The resulting mice had Nf1 haploinsufficient bone marrow cells, 
approximately 10% of Schwann cells were Nf1 nullizygous and all other cells were 
functionally wild-type. These mice developed neuromotor defects, weight loss, dorsal 
root ganglia thickening, and an increased mortality rate within 6 months in comparison 
to the Nf1 flox/-,Krox20cre mice (Zhu et al, 2002; Yang et al, 2003). Validation of these 
mice was completed by transplanting wild type bone marrow into the Nflflox/- 
;Krox20cre mouse which consequently resulted in a lack of tumour development in this 
usually reliable tumorigenic model. These studies together suggested that 
haploinsufficiency in the bone marrow microenvironment is required for neurofibroma 
formation.
Additional experiments by Yang et al (2003) were undertaken with the focus of 
investigating whether mast cells which are stimulated by SCF are the primary effectors 
of the tumour microenvironment. N fi+/~ bone marrow cells carrying kinase inhibiting c-kit 
gene mutations were transplanted into Nf1flox/flox\ Krox20cre mice. In these mice, 
there was no evidence for neuromotor defects, dorsal root ganglia enlargement, and 
mast cell infiltration indicating that this model of tumour development is dependent on 
loss of Nf1 in Schwann cells in addition to c-kit-dependent Nf1 haploinsufficiency in the 
bone marrow Yang et al (2003).
A model explaining the occurrence of sporadic plexiform neurofibromas has been 
generated in which Dhh-Cre N f 1 deletion in glial cells at a specific stage of murine 
development (E12.5) allows the development of neurofibromas which demonstrate loss 
of axon Schwann cell interaction, mast cell accumulation, and fibrosis. This indicates 
that these tumours are characteristic of plexiform neurofibromas which develop even on 
a wild type genetic background (Wu et al, 2008). The mTOR inhibitor analog RAD001 
and Sorafenib, a multi-targeted kinase inhibitor have been tested on this model. It was 
found that RAD001 has no effect on neurofibroma growth where as Sorafenib may be of 
significant therapeutic benefit to neurofibromas based on this model.
58
1.9 The NF1 gene mutational spectrum
The large size of the NF1 gene, high mutation rate, lack of mutational hotspots, 
presence of pseudogenes and cellular heterogeneity within both benign and malignant 
NF1 associated tumours has hampered the search for both somatic and germline NF1 
mutations. Approximately 90% of germline NF1 mutations are identified using the most 
current mutational detection methods in patients with a clinical diagnosis of NF1 
(Messiaen et al, 2000; Ars et al, 2000). Somatic NF1 mutation detection rates in NF1- 
associated tumours is, however, much lower with between 12% and 64% of somatic 
mutations identified in cutaneous neurofibromas (John et al, 2000; Serra et al, 2001b; 
Upadhyaya et al 2004; Spurlock et al, 2007), with an increase to 75% in cases in which 
DNA for mutational analysis is derived from Schwann cell cultures (Maertens et al,
2006). Only a few investigations have assessed the full spectrum of germline and 
somatic mutational events, across all tumour types, using a wide range of molecular 
techniques. Knowledge of the mutational type, nature and frequency of NF1 somatic 
mutations in addition to the role of modifying loci are crucial to understanding possible 
genotype-phenotype relationships in NF1 and the underlying variability in clinical 
presentation seen in NF1 patients.
1.9.1 NF1 germline mutations
To date over 1273 NF1 germline mutations have been identified through large whole 
gene studies (HGMD; Fahsold et al, 2000; Messiaen et al, 2000; Han et al, 2001; Ars et 
al, 2003) In general, the NF1 germline mutational spectrum is highly varied. Truncating 
mutations represent about 80% of identified NF1 germline mutations (Fahsold et al, 
2000; Ars et al, 2003), which is similar to the mutational spectrum of other tumour- 
suppressor genes including APC, TSC1, BRCA1, ATM and RB1 (Suzuki et al, 1998; 
Jones et al, 1999; Lohmann et al, 1996; 1997; Miki et al, 1994; Sandoval et al, 1999). 
The remaining 10-20% of NF1 mutations; are either unidentified due to the above 
outlined features of the NF1 gene or are characterised as missense variants of 
unknown pathogenicity (Ars etal, 2003).
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1.9.1.1 Microdeletions
Deletions of the entire NF1 gene locus and flanking regions occur in 5-10% of 
individuals with NF1 (Kluwe et al, 2004). These deletions are generally recurrent 
deletions which result from non allelic homologous recombination (NAHR) between the 
NF1 proximal and distal low-copy repeats which flank the NF1 gene (NF1-REP-a and -  
c) (Dorschner et al, 2000; Jenne et al, 2001; Lopez-Correa et al, 2001; De-Raedt et al, 
2006; Kehrer-Sawatzki et al, 2008).
1.9.1.1.1 Type I microdeletion (1.4Mb)
This deletion is identified in 80% of patients with microdeletions, occurring between two 
recombination hotspots, termed paralogous recombination sites 1 and 2 (PRS1 and 
PRS2) (De-Raedt et al, 2006; Kehrer-Sawatzki et al, 2008; Pasmant et al, 2010; 
Messiaen et al, 2011).
1.9.1.1.2 Type 2 microdeletion (1.2 Mb)
This a smaller deletion with breakpoints located in the SUZ12 gene (suppressor of zeste 
12 homolog; NM_015355) and its pseudogene SUZ12P. These deletions are commonly 
mediated by NAHR (Kehrer-Sawatzki et al, 2004; Steinmann et al, 2007; Roehl et al, 
2010).
1.9.1.1.3 Type 3 microdeletion (1.0Mb)
These recently identified recurrent deletions are also mediated by NAHR and 
encompass breakpoints in NF1 REP B and NF1 REP C (Bengesser et al, 2010; 
Pasmant et al, 2010).
1.9.1.1.4 ‘Atypical’ micodeletions
‘Atypical’ deletions encompass breakpoints which are not recurrent and not homology 
mediated (Venturin et al, 2004). These deletions therefore vary widely in the number 
and types of genes which are deleted (Pasmant et al, 2008, 2010).
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1.9.1.1.5 Non Allelic Homologous Recombination (NAHR)
The mechanisms underlying (NAHR) are not fully understood but are thought to be 
similar to those of allelic homologous recombination (AHR) but with the use of a 
nonallelic template to repair the initiating double strand break (Roehl et al, 2010). The 
occurrence of low copy repeats (LCRs) close to the breakpoints suggests that the 
unusual DNA structure surrounding the LCRs may confuse the DNA replication 
machinery resulting in breakpoints caused by replication errors (Roehl etal, 2010).
1.9.1.1.6 Mosaicism and microdeletions
Importantly, a number of patients who exhibit mosaicism possess large germline 
deletions of the NF1 gene (section 1.9.1.1). Mosaicism in NF1 can cause both a mild 
phenotype, generalised across all limbs and body segments or alternatively regionally 
limited distribution of NF1 manifestations, (segmental mosaicism), associated with 
segmental NF1 (SNF1) (section 1.6.1) (Ruggieri and Huson, 2001). The excess of 
identified microdeletions in patients with mosaicism may be attributed to the ease in 
which large mosaic deletions can be identified at the single cell level by FISH analysis in 
comparison to nucleotide substitutions (Maertens et al, 2007).
The majority of deletions identified in mosaic patients so far have been type 2 or 
atypical deletions, with only one type 1 deletion identified to date which was only 
confirmed by MLPA and so the true breakpoints are unknown and it may be larger than 
1.4Mb (De Luca et al, 2007; reviewed in Kehrer-Sawatzki and Cooper, 2008). A more 
recent study confirmed the presence of two mosaic type 1 deletions with breakpoint 
scanning PCR and SNP analysis. This indicates that at least 2% of type 1 deletions may 
exhibit mosaicism suggesting that de novo NAHR is not confined to the germline and 
maternal meiosis and may also occur postzygotically by mitosis (Messiaen et al, 2011). 
Interestingly, previous studies have also reported that there is a prevalence of females 
in mosaic founder patients and sporadic patients with type-2 NF1 deletions (Steinmann 
et al, 2007; Messiaen et al, 2011). It has been suggested that FISH analysis should be 
used as an additional analysis technique on other cell types (e.g. buccal smears) in 
cases of potential mosaicism (Messiaen et al, 2011).
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1.9.1.2 Gross rearrangements
In addition to NF1 microdeletions, deletions of several hundred kb of the NF1 gene as 
well as deletion of individual and multiple exons have also been reported and these 
mutations encompass ~7% of the current NF1 mutational spectrum (Fang et al, 2001; 
Wimmer et al, 2006; De Luca et al, 2007; Upadhyaya et al, 2006; Bausch et al, 2007). 
Similarly, gross insertions of between 350bp and 10kb have been reported (Wallace et 
al, 1991; Upadhyaya et al, 1992; Fahsold et al, 2000; Wimmer et al, 2007) and 
duplications of single and multiple exons have also been detected, although these are a 
rare occurrence, with only 6 reported gross duplications and 4 gross insertions in the 
literature to date (HGMD) (De Luca et al, 2004; Tassabehji et al, 1993; Bausch et al, 
2007; Wimmer et al, 2006)
1.9.1.3 Small insertions and deletions
Micro-Insertions and deletions in the NF1 gene are commonly found to cause 
frameshifts where the correct reading of the frame is disrupted by insertion or deletion of 
bases. This disrupts single or multiple codons and results in a premature stop codon. In 
frame deletions are, however, also found to occur (Shen et al, 1993; Serra et al, 2001; 
Mattocks et al, 2004) and include the 3bp deletion in exon 17 which is associated with a 
milder phenotype (Upadhyaya et al, 2007) (section 1.10.5). Micro-insertions and 
deletions account for approximately 40% of all identified NF1 mutations. Micro-deletions 
(27%) are more common than Micro-insertions (13%) (HGMD). Micro-insertions 
commonly involve between 1 and 2bp (Ars et al, 2003) although a few larger insertions 
of between 7bp and 11 bp have been identified (Maynard et al, 1997; Ars et al, 2000; 
Bahuau et al, 2000; Serra et al, 2001). Four larger insertions have also been reported 
(350bp) (Wimmer etal, 2007; Upadhyaya et al, 1992; Fahsold et al, 2000) in addition to 
insertion of the Alu repetitive sequence into an intron resulting in the deletion of a 
downstream exon during splicing (Wallace et al, 1991). Micro deletions between 1bp 
and 4bps are common although microdeletions of 13-20bps have been reported (Ars et 
al, 2000; Kluwe et al, 2003; Baralie et al, 2005; Lee et al, 2006) and even deletions of
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105bp (Heim et al, 1995). Whilst small insertions and deletions are individually relatively 
common in the NF1 gene, a combination of both mutations occurring coincidentally is a 
relatively uncommon mutational mechanism, representing less than 2% of all published 
NF1 germline mutations (HGMD).
1.9.1.4 Base-pair substitutions
These lesions include missense variants where one amino acid is substituted for that of 
another, nonsense mutations in which a premature stop codon is introduced and 
additionally splice site alterations. Altogether, these base substitutions account for 
nearly 50% of all identified mutations, approximately 20% of which constitute splice site 
alterations and about 30% are nonsense and missense mutations. Of this 30%, 57% 
represent nonsense mutations with the remainder representing missense mutations 
(HGMD). The pathogenicity of many missense mutations is uncertain and would require 
familial, biochemical and functional analysis to determine whether they are neutral or 
disease causing (chapter 4).
1.9.1.4.1 Transitions and transversions
Transitions which involve the substitution of two-ring purines (A>G) or one-ring 
pyrimidines (C>T) are generally more frequent than transversions which involve 
changes of purine for pyrimidine bases (e.g. A>C). 60% of NF1 point mutations are 
found to be associated with transitions whilst the remaining 40% representing 
transversions (HGMD).
1.9.1.4.2 CpG dinucleotides
Methylation of CpG dinucleotides is a common transition in mammalian DNA and 
involves the deamination of methylated cytosine in CpG dinucleotides, most commonly 
resulting in a C>T transition (Cooper and Krawczak, 1993). Methylation and CpG 
dinucleotides are further discussed in section 5.1.
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1.9.1.4.3 Splicing alterations 
Splice site alterations account for a large proportion of NF1 mutations (Ars et al, 2000; 
Messiaen et al, 2000) and evaluating the effect of splice site (SS) alterations could be 
an important tool for determining novel regulatory mechanisms. Splicing is a complex 
process by which introns are removed from pre-mRNA and successive exons are joined 
to produce a mature mRNA molecule. Canonical splice sites (SSs) are present at the 5’ 
and 3’ ends of exons in addition to the polypyrimidine tract and the branch point which 
are present upstream of the 3’SS (Hastings and Krainer, 2003). These sequence- 
specific SS’s are recognized by the ‘spliceosome’, sequence specific splicing machinery 
which consists of a complex of small nuclear ribonucleoproteins (snRNPs) and 
associated proteins which assemble on the pre-mRNA (Mardon et al, 1987). U1 snRNP 
interaction with the 5’SS is considered to be one of the most important stages in the 
definition of SS’s through an RNA-RNA interaction, although there are contradictory 
views for this idea (Seraphin et al, 1987; Eperon et al, 1993). Furthermore, non-splice 
site c/s-acting sequence elements; enhancer and silencer elements are capable of 
enhancing the fidelity of a splicing reaction by increasing or decreasing exon and intron 
recognition. These include exon splicing enhancers (ESEs) and exon splicing silencers 
(ESS) in addition to intron splicing enhancers (ISEs) and intron splicing silencers (ISS). 
These additional elements are important for determination of correct splice sites from 
numerous cryptic splice sites which are also present (Kralovicova and Vorechovsky,
2007).
Disruptions affecting U1 snRNA binding and ESE’s have been reported (Baralle et al, 
2003; Hutter et al, 2004; Raponi et al, 2009). Furthermore, other factors including the 
genomic context including polypyrimidine tracts (Raponi et al, 2009) and external 
environmental stimuli in vitro such as pH, temperature and cellular stress can affect 
exon inclusion and induce splicing defects (Blaustein et al, 2007). Splicing mutations 
can generate several outcomes on the mature mRNA. These include: exon skipping 
from classical splice site mutations and single nucleotide substitutions within introns 
which create de novo splice sites resulting in cryptic exon inclusion. Single-nucleotide 
substitutions within exons can also cause the creation of de novo splice sites which
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results in the loss of sections of an exon if these de novo SS’s are used. Additionally 
mutations which disrupt the use of SS’s can cause activation of cryptic intronic/exonic 
SS’s and finally sequence aberrations in the exon can also cause exon skipping 
(Wimmer et al, 2007). The later consequence has been previously shown in the NF1 
gene to primarily disrupt ESE’s which compromises exon recognition (Zatkova et al, 
2004).
Recent evidence also suggests that nucleotide substitutions which occur in deeper 
intronic sequences can also affect splicing and have been demonstrated to be 
pathogenic (Pagani et al, 2000; Raponi et al, 2006). Analysis of NF1 splicing mutations 
at exon 29 has demonstrated that positions +4 and +5 of the SS are less tolerant of 
base changes which differ from the wild type sequence (Raponi et al, 2009). 
Additionally, analysis of the same +5G>C splicing mutation at IVS3, IVS1 and IVS7 
SS’s, the mutation was only pathogenic at the IVS3 SS where it had an adverse impact 
on exon inclusion levels (Raponi et al, 2009). Such findings are important from a clinical 
point of view and indicate that splicing disruption is a key NF1 pathogenic mechanism.
1.9.1.5 Chromosomal rearrangements
Rearrangements involving chromosome 17 such as t(1;17) (Schmidt et al, 1987) and 
t(17;22) (Ledbetter et al, 1989), importantly provided the key to the identification of the 
NF1 gene and its associated locus. Deletions of chromosome 17 have therefore been 
previously reported as germline mutations (Andersen et al, 1990; Upadhyaya et al, 
1996; Riva et al, 1996) in addition to inversions and transversions involving 
chromosome 17 (Schmidt et al, 1987; Ledbetter et al, 1989; Asamoah et al, 1995; 
Fahsold et al, 1995; Kehrer-Sawatzki et al, 1997). There are additionally a number of 
reports of complex rearrangements involving the deletion, insertion and rearrangements 
of multiple non-consecutive NF1 exons (Wimmer et al, 2006; Mantripragada et al, 
2006). Moreover, gross chromosomal alterations are a key feature of malignant NF1- 
associated tumours, likely contributing to the process of malignant transformation of 
such tumours (section 6.1).
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1.9.2 Recurrent mutations
Approximately 50% of NF1 germline and somatic mutations represent novel alterations 
indicating that about 50% are recurrent mutations as seen in recent large germline and 
somatic mutational studies (Fahsold et al, 2000; Ars et al, 2003; Mattocks et al, 2004; 
De Luca et al, 2004). Recurrent NF1 mutations are found in both the germline and 
soma. A few studies have determined the recurrent nature of a large panel of germline 
mutations (Ars et al, 2003; Fahsold et al, 2000). Of the 1,273 germline mutations which 
have been described so far (HGMD), there are a number of commonly identified 
mutations (table 1.6). Approximately 215 somatic point mutations have been 
characterised so far to date, of these mutations, there are a number of recurrent point 
mutations which have been found in numerous NF1-associated benign and malignant 
tumour types including: c.2446T>C; p.R816X in both plexiform neurofibromas and 
MPNSTs (John et al, 2000; Bottillo et al, 2009) (table 1.7). Similarly, some recurrent 
mutations have been identified multiple times in both the germline and soma, including 
one of the most common germline mutations; c.910C>T p.R304X (table 1.7).
Additionally, there are no known mutational hotspots in the NF1 gene as mutations 
appear to be relatively evenly distributed along the coding sequence (DeLuca et al, 
2004). There are, however, some potential ‘warm spots’ in which NF1 gene mutations 
occur more frequently than in the rest of the gene although they are not associated with 
any of the known functional domains of NF1. These include exons 4b and 37, which 
have a mutation rate 4- to 5-fold higher than average (Messiaen et al, 2000; Fahsold et 
al, 2000; Ars et al, 2003; DeLuca et al, 2004). Exon 7 also demonstrates a higher 
frequency of mutations than the rest of the gene which may be due to its propensity to 
undergo splicing errors due to weakly defined exon-intron boundaries (Fahsold et al, 
2000; Ars et al, 2003; Bottillo et al, 2007). Analysis of the distribution of NF1 mutations 
could be skewed due to previous bias in the exons which were analysed. Most analysis 
has, however, been weighted to account for this possibility (Fahsold et al, 2000). Of 
interest is the observation that there is no major clustering of mutations in any of the 
known NF1 functional domains including the GRD, CSRD (section 1.3) and there is also
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a significant lack of mutations identified towards the 3’ end of the gene in exons 48 and 
49 (HGMD) (Fahsold et al, 2000; Ars et al, 2003; DeLuca et al, 2004). Analysis of the 
type and distribution of NF1 mutations is clearly of importance for determining not only 
gene regions most likely to harbour mutations to increase the efficiency of mutation 
screening but also for determining potential genotype phenotype correlations.
1.9.3 NF1 somatic mutations
Thus far, neurofibromas whether from the same or different patients appear to exhibit 
distinct somatic mutations demonstrating that each neurofibroma is the consequence of 
discrete mutational incidents. Investigation of somatic mutations in a variety of benign 
and malignant NF1 related tumours may aid in the establishment of genotype- 
phenotype correlations and determination of inter-individual neurofibroma number and 
mutation rates. The somatic mutational spectrum is very similar to that of the germline 
with about 80% representing truncating mutations and 10-20% are missense mutations 
(Thomas et al, 2010). Additionally loss of heterozygosity (LOH) is an additional somatic 
mutational mechanism found in both benign and malignant tumours.
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Table 1.6 Recurrent germline NF1 mutations and the number of citations for each
mutation.
Mutation Affect on protein Function
Number
of
Citations
References
c. 6792C>A 
p.Y2264X Exon 37 skipping 16
Robinson et al, 1995 (2); 
Messiaen etal, 1997 (1); 
Hoffmeyer et al, 1998 (2); 
Fahsold et al, 2000 (2);
Ars et al, 2003 (6); 
Mattocks et al, 2004 (2); 
De Luca et al, 2004 (1)
c.5839C>T
P.R1947X Occurs at a CpG dinucleotide 16
Estivill etal, 1991 (1); 
Ainsworth etal, 1993 (1); 
Horiuchi et al, 1994 (2); 
Valero et al, 1994 (1); 
Lazaro etal, 1995 (2); 
Fahsold et al, 2000 (2); 
Messiaen et al, 2000 (1);
Ars etal, 2003 (4); 
DeLuca et al, 2004 (2);
c.910C>T p.R304X Exon 7 skipping 13
Hoffmeyer et al, 1998 (1); 
Fahsold et al, 2000 (1); 
Messiaen etal, 2000 (1);
Ars et al, 2003 (7); 
Colapietro et al, 2003 (1); 
DeLuca et al, 2004 (1); 
Bottillo et al, 2007 (1);
c.4537C>T
P.R1513X Nonsense 12
Fahsold et al, 2000 (7); 
Messiaen et al, 2000 (1);
Ars et al, 2003 (1); 
Mattocks et al, 2004 (2); 
DeLuca et al, 2004 (1)
c.499delTGTT 10
Fahsold et al, 2000 (6);
Ars et al, 2003 (3); 
Mattocks et al, 2004 (1)
c. 1885G>A 
P.G629R
Inactivation of the 3' consensus splice 
site and use of cryptic 3' splice site. 
Deletion of 41 nucleotides of exon 12b
9
Gasparini etal, 1996 (1);
Ars et al, 2003 (5); 
Mattocks et al, 2004 (2); 
DeLuca et al, 2004(1)
6789delTTAC 9
Robinson et al, 1995 (1); 
Hoffmeyer et al, 1998 (2); 
Fahsold et al, 2000 (5); 
Deluca et al, 2004 (1)
c.5546G>A
P.R1849Q
Inactivation of the 5' splice site. 
Exon 29 skipping 8
Fahsold et al, 2000 (2); 
Messiaen et al, 2000 (1); 
Arsef al, 2003 (5)
c.1318C>T 
p. R440X 6
Fahsold et al, 2000 (3); 
Mattocks et al, 2004 (3)
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Table 1.7 Recurrent somatic NF1 mutations and the tumours in which they have been
identified
Recurrent Mutation Germline or Somatic Tumour Type References
C.4084OT; p.R1362X Somatic
Cutaneous
neurofibroma
JMML
Eisenbarth et al, 2000; 
Thomas et al, 2010; 
Steinemann et al, 2009
c. 1260+1 G>A Somatic
Germline
Cutaneous
neurofibroma Serra et al, 2001
c.910C>T; p.R304X Somatic
Germline
Cutaneous 
neurofibroma 
Plexiform neurofibroma
Upadhyaya et al, 2004;
Upadhyaya et al, 2008; 
Upadhyaya et al, 2008
c.2088delG; p.W696X Somatic Cutaneousneurofibroma
Upadhyaya et al, 2004; 
Thomas et al, 2010
c.4083insT; p.L1361fsX13 Somatic
Cutaneous 
neurofibroma 
Plexiform neurofibroma
Upadhyaya et al, 2004; 
Upadhyaya et al, 2008
c.4537C>T; p.R1513X Somatic Cutaneousneurofibroma
Maertens et al, 2006; 
Spurlock et al, 2007
c.2041C>T; p.R681X Somatic
Germline
Cutaneous
neurofibroma Thomas et al, 2010; 
Serra et al, 2001
c.2446T>C; p.R816X
Somatic
Germline
Plexiform neurofibroma 
MPNST
John et al, 2000; 
Bottillo et al, 2009; 
Bottillo et al, 2009
c.1246C>T; p.R315X
Somatic
Germline
Plexiform neurofibroma Upadhyaya et al, 2008; 
Maertens et al, 2006
c.5242C>T; p.R1748X
Somatic
Germline
GIST Maertens et al, 2006; 
Steinemann et al, 2009
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1.9.3.1 Loss of Heterozygosity (LOH)
LOH (Loss of Heterozygosity) of the NF1 gene is a relatively common somatic event in 
NF1 associated benign and malignant tumours. LOH results in the loss of the remaining 
wild type copy of the NF1 gene and is known to occur through a variety of mechanisms 
including: mitotic recombination (copy neutral LOH), deletion, chromosomal loss due to 
non-disjunction and chromosomal loss followed by reduplication (Serra et al, 2001). 
Distinguishing between these mechanisms is not possible with LOH analysis alone, but 
it is possible to rule out the latter two mechanisms with additional analysis techniques 
including MLPA or FISH. In cases where no deletion is found in samples which harbour 
LOH, it is likely that mitotic recombination is the cause of LOH. LOH is found in both 
benign and malignant tumour but occurs at different rates. LOH occurs in approximately 
25% of neurofibromas (Upadhyaya et al, 2004; Serra et al, 2007; De Raedt et al, 2006) 
and at significantly higher levels of up to 50-85% in plexiform neurofibromas and 
MPNSTs (Upadhyaya etal, 2008, 2009; Laycock-VanSpyk etal, 2011).
1.9.3.2 Aberrant methylation of the NF1 gene
Loss of function of tumour suppressor genes is classically associated with DNA 
mutations including base substitutions, splicing alterations and gene deletions. DNA 
methylation is, however, becoming increasingly recognised as an important mechanism 
of gene inactivation especially in relation to tumour suppressor genes due to the inverse 
relationship between the level of gene methylation and transcriptional activity 
(Rodenhiser et al, 1993). The low level of NF1 somatic mutational detection, the 
spontaneity of new mutations and the proportion of mutations involving CpG 
dinucleotides (~20%) suggests that methylation of the NF1 gene and perhaps other 
genetic loci such as MGMT, p16 (CDKN2A), TP53, RB1, MLH1, MSH2 and RASSF1A 
(table 1.8) may be involved in NF1 tumorigenesis. Analysis of aberrant methylation of 
the NF1 gene and additional genetic loci is discussed in more detail in section 5.1.
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Table 1.8 Frequently methylated genes and the cancers with which they are commonly associated. Adapted from Cheung 
et al (2009) with data from www.mit.lifescience. ntu.edu.tw
Gene Function Cancer Association References To Date Reference
p16 (CDKN2A)
Protein product (ARF) functions as a stabilizer 
of the tumour suppressor protein p53 as it can 
interact with, and sequester, MDM1, a protein 
responsible for the degradation of p53
Lung Cancer 
Colorectal cancer 
Breast Cancer
Hepatocellular Carcinoma
>450
Nakata et al, 2006; 
Nosho et al, 2007; 
Oue et al, 2003
Ras association 
domain family 1 
isoform (RASSF1A)
RASSF1A is thought to interact with KRAS 
through a Ras association domain and is 
known to have several key cellular effects 
including promotion of apoptosis, cell cycle 
arrest, and maintenance of genomic stability 
Inhibits proliferation through negatively 
regulating cell cycle progression at G1/S 
phase transition by inhibiting accumulation of 
cyclin D1
Lung cancer
Colorectal Carcinomas
Breast Cancer 
Prostate Cancer 
Ovarian cancer 
Liver Cancer 
Renal Cancer 
Cervical 
Hepatocellular Carcinoma
>270
Hesson et al, 2004;
Kim et al, 2003; 
Teodoridis et al, 2005
O-6-methylguanine-
DNA
methyltransferase
(MGMT)
Cellular defence against the biological effects 
of 06-methylguanine in DNA; involved in DNA 
repair and drug resistance. MGMT expression 
protects against G:C to A:T DNA transitions
Colorectal Cancer 
Glioblastoma 
Glioma 
Lung Cancer 
Brain Cancer 
Lymphoma
Small Cell Lung cancer 
Melanoma
>210
Hanabata et al, 2004; 
Ogino et al, 2007; 
Yu etal, 2004
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Gene Function Cancer Association References To Date Reference
MLH1 Responsible for DNA mismatch repair; also implicated in DNA damage signalling
Colorectal Cancer
Endometrial Cancer 
Ovarian cancer
>140
Nan et al, 2005; 
Ogino et al, 2007; 
To et at, 2002
APC
Tumour suppressor which acts as an 
antagonist of the Wnt signalling pathway; also 
involved in cell migration and adhesion, 
transcriptional activation, and apoptosis
Colorectal 
Lung Cancer 
Gastric 
Prostate Cancer 
Breast Cancer
>130
Arnold et al, 2004; 
Sarbia et al, 2004; 
Suzuki et al, 2006
RARB Receptor for retinoic acid; limits growth of many cell types by regulating gene expression
Lung Cancer 
Prostate Cancer 
Kidney Cancer
>100
Dulaimi et al, 2004; 
Florl etal, 2004; 
Maruyama et al, 2004
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1.9.5 Modifying loci
There are numerous modifying loci including biallelic defects in mismatch repair genes 
(MMR) and TP53, CDKN2A and RB1 alterations which are thought to modulate NF1 
phenotypic expression and NF1-associated tumour development. These are discussed 
in detail in section 3.1.
1.10 Mutation detection techniques
Our current knowledge of the molecular mechanisms that underlie NF1 tumorigenesis is 
still relatively limited. The characterisation of germline and somatic mutations present in 
a large series of tumours from unrelated patients will provide data on the mutational 
type, nature and frequency of NF1 somatic mutations. This is a crucial step towards 
understanding the complex genotype-phenotype relationships in NF1 and in the 
identification of relevant biological pathways affected in NF1 associated tumours. The 
following is an overview of the most commonly used analysis methods for NF1 somatic 
and germline mutational analysis in addition to new techniques with important future 
applications.
1.10.1 Identification of microlesions and gross chromosomal rearrangements
1.10.1.1 Fluorescence In Situ Hybridisation (FISH)
The detection and characterisation of microdeletions has been historically very difficult 
and laborious. Whilst not available in all labs, FISH has been widely used in conjunction 
with other approaches encompassing YAC (yeast artificial chromosome) clones of an 
NF1 gene region followed by locus specific cloned PCR product clones as part of a high 
resolution FISH technique. FISH is a reliable technique for determining how many 
copies of a specific chromosome are present without having to produce a full karyotype. 
FISH is also a rapid technique as cells for analysis by FISH do not have to be cultured. 
However FISH is, unable to give as much information as a full karyotype including
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changes at other chromosomes or details on the structure of chromosomes which are 
identified through this analysis. Furthermore, the patient to be analysed has to present 
with fairly typical clinical symptoms for use of the correct probes for a specific disorder.
Fluorescent dye probes which are specific to the chromosome of interest including RP5- 
1002G3 (detected by red fluorescent signals) which is located in the telomeric region of 
the NF1 gene and RP5-926B9 (green) which covers the centromeric part of the NF1 
gene have been used to label samples through hybridisation for NF1 analysis (de Raedt 
et al, 2004). Slides with hybridised probes and chromosomes are subsequently 
analysed using fluorescence microscopes and the number of signals seen from these 
probes determines the number of chromosomes present. Using this method it has been 
possible to not only identify NF1 gene deletions but also to distinguish between type 1 
and type 2 microdeletions (Wimmer et al, 2006; Griffiths et al, 2007; Messiaen et al, 
2011.) Furthermore, FISH analysis has been successfully used for NF1 pre-implantation 
genetic diagnosis (PGD) on single blastomeres (Vanneste etal, 2009).
1.10.1.2 Multiplex Ligation-dependent Probe Amplification (MLPA)
MLPA is an important molecular tool which allows the identification and characterisation 
of aberrant copy number changes in many genomic DNA sequences through the use of 
one simple PCR based reaction. MLPA is an alternative method of detection of single 
and multiple exonic deletions and duplications. MLPA assays for the NF1 gene have 
been developed (MRC, Holland) including the SALSA P081/082 and SALSA P122 
assays. The SALSA P081/082 NF1 MLPA assay (v. 04) consists of 81 probes but only 
tests 51 of the 60 NF1 exons. The SALSA P122 (v.01) has 5 probes in the NF1 gene 
and 7 probes in the regions flanking the NF1 gene. These kits are able to define both 
germline and somatic single and multiple exon deletions (De Luca et al, 2007; 
Upadhyaya et al, 2008b) but are also able to distinguish between different types of 
microdeletions with the use of only two probes (Wimmer et al, 2006; Messiaen et al, 
2011; Valero et al, 2011).
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The basic MLPA technique as outlined by MRC Holland, has 5 main stages: 
denaturation, hybridisation of the probes to the target sequences, ligation of the probes 
through a thermostable ligase, amplification using a universal primer pair to amplify all 
ligated probes and quantification, which for the purposes of this study involved the use 
of a 3100 Genetic Analyser (ABI Biosystems). Each peak seen when the data is 
generated represents the amplification product of a specific probe. Samples tested are 
compared to one positive and five negative controls allowing a difference in relative 
peak height to be observed. These differences indicate copy number variation of the 
target sequence of a particular probe.
There are several key advantages of MLPA. These include the ability to perform the 
technique using small quantities of DNA (20ng) which can even be partially degraded 
such as from paraffin, formalin treated tissues and free fetal DNA from maternal plasma. 
Variability in temperature also has very little effect on the efficiency and effectiveness of 
this technique and it is able to discriminate between sequences which differ in only a 
single nucleotide. Furthermore, MLPA is a rapid and relatively inexpensive initial 
method of screening for NF1 microdeletions which is complementary to a high- 
resolution technique such as array CGH and can be used in conjunction with LOH 
analysis to help determine the mechanism of LOH. Additionally, it is also possible to 
apply this technique to look at epigenetics including hypermethylation of p53 in tumours 
and imprinting defects in Prader-Willi or Angelman syndromes.
There are also a number of disadvantages to the use of MLPA for detection of 
microdeletions and the reciprocal duplications. It has been reported that MLPA 
occasionally produces false positive results which can occur due to the presence of 
SNPs and point mutations either within or close to the sites at which the MLPA probes 
ligate to the DNA (Pasmant et al, 2010). MLPA is also unable to determine the 
breakpoints of atypical deletions, a substantial concern given that atypical deletions are 
present in -10%  of patients with large NF1 deletions (Pasmant et al, 2010; Messiaen et 
al, 2011). It is thought that larger atypical deletions may in fact consist of deletions of 
genes such as GOSR1, TBC1D29, RHOT1, RHBDL3 and C17orf75 in addition to the 14
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genes present within the type-1 deletions. It is hoped that our current knowledge of 
atypical deletions should allow improvements in the positioning of probes in future 
MLPA kits. Furthermore, there have been reports of false positives due to underlying 
levels of mosaicism, indicating that it is important to use other methods such as FISH to 
confirm the analysis (Messiaen et al, 2010)
1.10.1.3 CGH arrays
Microarrays have been recently developed specifically for detection of deletions and 
duplications of the NF1 gene which are both cost effective and efficient, thereby 
overcoming previous issues of lack of FISH facilities in some labs and the problem of 
heterogeneity in MLPA analysis. Previous studies have employed two types of 
microarray for CGH analysis of the NF1 gene derived from pooled PCR products of the 
NF1 locus. Firstly, Mantripragada et al (2006) developed an array containing 183 
probes covering a 2.24 Mb of region 17q11.2, with an average resolution of 12 kb. Shen 
et al (2007) developed a second array with an average resolution of 4.5 kb and 493 
pooled probes measuring 200 to 998 bp. Neither of these two array CGH platforms 
were capable of producing exon level resolution, could not differentiate between type 1 
and type 2 microdeletions or determine some atypical breakpoints and did not cover all 
the exons of the NF1 gene. However, they were able to identify molecular 
rearrangements within the NF1 gene sequence. More recently, a higher resolution 
oligonucleotide array CGH was developed by Pasmant et al (2009). This array was able 
to detect large NF1 rearrangements, distinguish between type 1 and type 2 
microdeletions, covers a higher density of the NF1 gene and provides enough 
information to allow for sequencing of the breakpoint regions. Moreover, this technique 
was found to be accurate for NF1 microdeletion characterisation, rapid (analysing 8 
patients simultaneously on 15K slides), efficient (€100 per patient) and sensitive.
Arrays have also been recently employed to screen for genes which are upregulated or 
downregulated in MPNSTs by comparing the molecular profiles of malignant NF1 
tumours with those of normal tissue or benign tumours. This has allowed genes which
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are involved in MPNST development to be determined. Identification of aberrations in 
numerous genes affecting multiple pathways in MPNSTs demonstrates that MPNST 
development is a complicated, multistep process requiring the inactivation of many 
genes. These genes clearly provide new targets for future therapy of MPNSTs (section 
6 .1).
Major advantages of CGH array analysis over other methods include the ability to 
analyse the equivalent of hundreds of FISH or MLPA analyses on all 46 chromosomes 
in only one test. Array CGH also has more sensitivity and resolution than karyotyping, 
FISH or MLPA to detect chromosomal abnormalities. The ability of array CGH to detect 
and evaluate low-level mosaicism is unclear. It is suggested that array CGH will not 
detect mosaicism below 20% although it has been reported in some array CGH 
analyses of routine diagnostic samples (Ballif et al, 2006). Furthermore array CGH can 
be performed on very small amounts of starting material and there is no requirement for 
dividing cells so it can be performed on frozen stored samples and post-mortem 
samples. Array CGH is also amenable to automation suggesting that costs can be 
reduced due to less input from technical staff. There are, however, a few disadvantages 
of CGH analysis including the inability to detect balanced inversions and translocations, 
especially rare ones, and currently costs are higher than with G banded karyotyping.
1.10.1.4 LOH analysis
The analysis of LOH in the NF1 gene is typically carried out by performing a comparison 
between normal cells and tumour cells or blood, utilising a panel of molecular markers 
distributed throughout the length of the gene. The disadvantage of LOH studies is that 
they are complicated in NF1 patients due to the large gene size and the problem of 
mixed populations of cells. Despite this, however, microsatellite markers as well as 
RFLP’s can be utilised in LOH detection to identify not only the presence of LOH but 
also to characterise it in terms of the size of deletion and the position of specific areas of 
LOH within the NF1 gene. For example, neurofibromas which are positive for LOH at all 
markers used including flanking 3’ and 5’ regions and intragenic markers, suggests that
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there is LOH throughout the whole gene. In this way therefore, this technique is useful 
for not only detecting the form of NF1 somatic inactivation but also for complete 
characterisation of the 17p and 17q gene regions. The results produced from LOH are 
analysed with simple formulas to calculate the ratio of peak heights of each allele. 
Calculation of LOH in tumour uses the formula (Tb/Ta)/(Bb/Ba), where T is the tumour 
peak ratio between alleles a and b and B is the blood peak ratio between alleles a and b 
(Neves et al, 2002). The percentage difference between the peak heights of the two 
alleles is scored and LOH noted in alleles with less than the cut off point of around 50%. 
Allelic loss is therefore scored if the area under one allelic peak in the tumour was 
reduced by 50% or more relative to the other allele, after correcting for the relative peak 
areas by using normal DNA (Dasgupta et al, 2003).
1.10.2 Identification of point mutations
1.10.2.1 Direct sequencing
The advent of sequencing technology and consequent improvements to such methods 
has been critical to the identification of microlesions (Maxam and Gilbert, 1977; Sanger 
et al, 1977). Sanger and Coulson (1975) first introduced the plus minus method for DNA 
sequencing which was based on a comparison of the “plus” and “minus” DNA 
sequences but used polyacrylamide gels to separate the products and was only able to 
determine the sequence of single stranded DNA (ssDNA). The Maxam and Gilbert 
(1977) method was very similar to that of Sanger and Coulson (1975) in that it was 
based on resolving fragments in a polyacrylamide gel but these bands were based on 
termination of a double-stranded DNA restriction fragment which was radio-labelled with 
32P. The bands on the gel represented cleavage of the fragment by base specific 
chemical reactions resulting in the production of a band for every sequence position 
which was not possible with the plus minus method.
The ‘dideoxy’ method introduced by Sanger (1977) is widely regarded as a superior 
method for DNA sequencing, which solved the problems of the plus minus method. It is
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based on the use of chain-terminating nucleotide analogues which were used instead of 
the four natural dNTPs to induce termination at specific bases during four reactions, 
each consisting of one analogue. When the analogues are incorporated into the growing 
strand, the E. coli Pol I enzyme is unable to extend the DNA strand any further initiating 
chain termination. Refinements of these sequencing methods have allowed the use of 
both DNA and cDNA to not only identify but also characterise a wide variety of point 
mutations such as nonsense, missense and splice site mutations as well as small 
insertions, deletions and SNPs. Sequencing has been widely used in NF1 analysis to 
identify germline and somatic mutations with mutation detection rates with sequencing 
alone up to 79% using DNA from purified Schwann cell cultures (Maertens et al, 2006b).
The main advantages to sequencing are the ability to automate many of the processes 
involved allowing determination of the complete genetic information in an individual or 
organism with minimal input from technical staff. Additionally, genome organisation and 
evolution can be studied using sequencing. Most importantly, sequencing has opened 
up avenues for functional genomics and a better understanding of molecular 
interactions and the basis of disease manifestation. Furthermore, genetic components 
such as SNPs have become more prominent and the underlying mechanisms for 
individual responses to drugs can be determined (pharmacogenetics). Conversely, 
disadvantages of sequencing include the relatively short read length produced, reliance 
on PCR to generate the products for sequencing, both especially problematic in large 
genes such as NF1. Furthermore, there is the occasional occurrence of artefacts due to 
contamination, indicating that whilst sequencing is mostly accurate and reliable, 
repetition of the reaction and subsequent confirmation is required.
1.10.2.2 Single Stranded Conformation Polymorphism (SSCP)
SSCP is a simple and inexpensive technique for the detection of point mutations. It is 
based on the electrophoretic separation of single-stranded DNA (SS DNA) due to 
changes in the sequence, often as subtle as a single base pair change (Orita et al, 
1989). The major disadvantage of SSCP is that the tertiary structure of SS DNA
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changes under changing physiological conditions including temperature and the ionic 
environment, indicating that these variables may affect the outcome of the analysis if 
not kept constant. Under optimal conditions SSCP is capable of detecting a high 
proportion of base changes and has been successfully used in NF1 mutational analysis 
(Origone et al, 2002; Pros et al, 2006).
1.10.2.3 Heteroduplex analysis
Heteroduplexes are formed following mixing of wild type and mutant DNA which is 
subsequently denatured by heating and re-annealed upon cooling. Heteroduplex 
analysis is based on the distinct electrophoretic mobility of homoduplexes and 
heteroduplexes in non-denaturing polyacrylamide gels. Heteroduplex DNA contains 
mismatched DNA which generates molecules with an unusual structure which can be 
easily distinguished from homoduplex DNA by gel analysis (Keen et al, 1991). 
Heteroduplex analysis is a precursor to DHPLC and is a simple method which is 
capable of producing a high mutation detection rate. It can be applied to large numbers 
of samples, particularly PCR products with no need to manipulate the PCR product and 
with the added capability of detection of allele specific mutations. Additionally, there are 
a number of other methods for detecting heteroduplex DNA formation including: 
chemical cleavage of mismatch (CCM) (Cotton et al, 1988), enzymatic cleavage 
analysis (Shenk etal, 1975; Myers etal, 1985; Lu and Hsu, 1992; Youil etal, 1995).
1.10.2.4 Denaturing High Performance Liquid Chromatography (DHPLC)
DHPLC (Oefner and Underhill, 1995; Underhill et al, 1997) is a sensitive method for 
detection of heteroduplex DNA, capable of detecting single base substitutions. It is 
based on the analysis of heteroduplexes generated by DNA mismatches through 
denaturation and reverse-phase chromatography. Advantages of DHPLC include its 
relatively low cost, the ability to semi-automate the process allowing a reduction of 
personal interaction and its sensitivity and specificity, especially as there is no 
requirement for DNA pre-treatment or for primers containing modifications or labels.
8 0
DHPLC has been widely used in NF1 mutation analysis (Upadhyaya et al, 2004) and 
can detect up to 73% of mutations (De Luca et al, 2003; DeLuca et al, 2004), although 
in a recent study, DHPLC was used in a sensitive strategy involving MLPA which 
detected germline mutations in 95% of individuals (Valero et al, 2011).
1.10.2.5 Comparative Sequence Analysis (CSA)
CSA is a low cost, simple and rapid sequence analysis method for identifying and 
characterising point mutations (Mattocks et al, 2000). CSA is completed on raw 
sequence data and is the comparative analysis of normalised peak heights in a sample 
trace compared to a reference trace. CSA has been used to analyse the NF1 gene and 
has produced high mutation detection rates (89%) (Mattocks et al, 2004). Furthermore, 
Baralle et al, (2003b), identified NF1 mutations in patients with Neurofibromatosis- 
Noonan Syndrome (NFNS) using this technique.
1.10.2.6 Protein Truncation Test (PTT)
Approximately 80% of NF1 germline and somatic mutations have been found to result in 
protein truncation (Shen et al, 1996, Ars et al, 2000; Fahsold et al, 2000; Ars et al, 
2003). PTT was first described by (Roest et al, 1993) and has been routinely used in 
previous analysis of the NF1 gene as an alternative to SSCP and heteroduplex analysis 
(Klose et al, 1999; Osborn and Upadhyaya, 1999; Ars et al, 2000; Origone et al, 2002; 
Upadhyaya et al, 2003; DeLuca et al, 2004). This method can screen large fragments 
up to 2kb in size which is a clear advantage when analysing a gene as large as the NF1 
gene. The mutation detection rate is, however, fairly low (39%-53%) (Osborn and 
Upadhyaya, 1999; DeLuca et al, 2004) which may reflect the inability to detect 
mutations which are not truncating and which account for approximately 10-20% of 
mutations in the NF1 gene.
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1.10.3 Splice site alterations and the hybrid minigene splicing assay
As with other point mutations, detection of splice site mutations is usually through direct 
sequencing. Whilst splice site mutations can be detected in DNA, cDNA sequencing 
uncovers splicing defects which may not be detectable in genomic DNA. There are 
many underlying reasons for this including the possibility that the mutation lies outside 
of the sequence which is analysed such as deep intronic mutations. These mutations 
can result in the inclusion of a cryptic exon as these mutations may create novel splice 
sites (Perrin et al, 1996). Furthermore, the mutation may be detected in genomic DNA 
but based on this sequence it cannot be classified as a pathogenic alteration. cDNA 
analysis can give further insight into the disruption of splicing caused by the mutation 
(Messiaen and Wimmer, 2005).
To unequivocally determine the effect of splice site mutations, functional assays such as 
the minigene assay (Raponi et al, 2006; Bottillo et al, 2007; Raponi et al, 2009) and 
bioinformatic analysis tools have been employed. The hybrid minigene assay is based 
on the generation of constructs of human genomic DNA which is amplified from normal 
and mutated exons to produce DNA fragments which contain the exon, in addition to 
flanking intronic regions (Raponi et al, 2006; Raponi et al, 2009). Oligonucleotides for 
specific exons harbour a restriction site for the enzyme Nde1 at the 5’ end. These are 
used to clone the product into the alpha-globin-fibronectin EDB minigene which has 
been modified to remove the alternatively-spliced EDB exon generating a site for the 
insertion of the exons of interest (Pagani et al, 2000; Raponi et al, 2006; Raponi et al, 
2009). Transfection of wild type NF1 constructs and the minigene intronic mutation 
constructs into HeLa cells followed by RT-PCR analysis determines the percentage of 
transcripts which are analogous to those identified in the normal control samples. 
Aberrant transcripts can be sequenced to determine the pathogenic effect of the 
mutation on the NF1 gene (Raponi et al, 2006; Raponi et al, 2009.
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1.10.4 Next generation technologies
With the advent and increasing application of array and more importantly next 
generation technology, it may be possible to identify the whole spectrum of somatic and 
germline mutations and much more, using one standardised platform. Such technology 
is still very much in its infancy but is rapidly evolving to allow for more cost effective 
solutions with very little technical input due to the increasing application of robotics. 
Whole genome sequencing has seen a huge advancement in technology since the first 
whole genomes were sequenced (Venter et al, 2001; Lander et al, 2001).
Refinements to the basic ‘dideoxy’ sequencing method (Sanger, 1977) have now made 
it possible, through the use of 2nd generation sequencing technologies including Roche 
454; based on pyrosequencing technology, the lllumina Genome Analyser (GAI) and 
ABI Supported Oligonucleotide Ligation and Detection system (SOLID) to sequence an 
entire genome in only 2 weeks, producing 30-fold coverage for only £2000-3000. 3rd 
Generation Technologies are also becoming available (Pacific Biosciences) although 
they currently represent a major leap in technology from that of capillary sequencing.
The actual methods used in the sequencing phase does differ substantially between the 
sequencers. All of these technologies are ‘massively parallel’ meaning that the number 
of sequence reads is far greater than with the original 96 which can be obtained with 
capillary sequencing. It is clear that next generation sequencing technologies offer an 
advantage over existing technologies including arrays and capillary sequencing. There 
are, however, numerous technical challenges associated with such technology, the 
most prevalent of which is the handling, storage and analysis of such large quantities of 
data. Additionally, the alignment of Indels, determination of important changes from the 
sheer number of SNPs which are generated in addition to the presence of gross 
chromosomal rearrangements are also significant challenges.
2nd and 3rd Generation technologies do not represent a replacement of capillary 
sequencing but instead offer a number of new and far reaching applications. These 
include: re-sequencing such as genome-wide exome sequencing in which the
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identification of non-synonymous SNPs is possible, transcriptome sequencing, gene 
expression analysis (SAGE) mutation analysis, methylation detection and miRNA 
discovery. De Novo sequencing is another important application of next generation 
sequencing technologies which is especially important in metagenomics and the 
technology can also be applied to CHiPseq. Importantly, it would also be possible to 
apply such technologies to the analysis of degraded tissue such as paraffin embedded 
tissue.
Next generation sequencing technologies have been utilised in numerous recent studies 
for the identification of variants involved in several cancers (Reviewed by: Meyerson et 
al, 2010). Additionally, Chou et al (2010) recently used NF1 as a model for next 
generation sequence analysis to evaluate a microarray-based sample-enrichment 
process and the efficiency of the Roche/454 GS FLX system for re-sequencing 
purposes. It is clear that this technology could provide important insight into the 
underlying molecular mechanisms responsible for tumorigenesis and malignancy in NF1 
associated tumours and may represent the future of NF1 somatic analysis.
1.10.5 Genotype-phenotype correlations
NF1 is characterised by highly variable clinical features and a distinct lack of general 
genotype-phenotype correlations. There are, however, two recognised genotype- 
phenotype correlations which occur in a small percentage of patients. The 
‘microdeletion syndrome’ occurs in about 10% of individuals (section 1.9.1.1) and 
generally results in a more severe phenotype. Microdeletion patients exhibit larger 
numbers of neurofibromas and an earlier age of onset of benign neurofibromas, 
developmental delay and learning disabilities, dysmorphic features and importantly, a 
possible higher incidence of MPNSTs (Upadhyaya et al, 1998; Riva et al, 2000; De 
Raedt et al, 2003; Venturin et al, 2004; Pasmant et al, 2010). This is a likely genotype- 
phenotype correlation but should be treated with caution based on the phenotypic 
variability which still exists within such patients, the lack of microdeletions which have 
been extensively studied (~150), imprecise definition of boundaries and lack of
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appropriate controls (Pasmant et al, 2010). Patients with the delAAT mutation in exon 
17 have a much milder phenotype with patients only exhibiting minor pigmentary 
abnormalities with no known reports of neurofibromas or malignancies (Upadhyaya et 
al, 2007). This lack of genotype phenotype correlations means that predicting the 
clinical course of patients without either of these two mutations is not possible. Larger 
studies of germline and somatic data are clearly warranted to aid in the detection of 
genotype-phenotype correlations.
1.10.6 Evolution to malignancy
The development of cutaneous neurofibromas is the hallmark feature of NF1, and these 
benign growths, when located on the face, neck and arms of patients, often present 
distressful cosmetic problems. These tumours are known to harbour a primary hit in one 
NF1 allele and a secondary somatic hit in the wild type NF1 allele resulting in a loss of 
neurofibromin function. Cutaneous neurofibromas are known to be benign and have not 
been exclusively shown to progress to malignancy. The loss of neurofibromin is 
therefore clearly necessary for tumour formation but is not sufficient for progression of 
the tumour to malignancy. A myriad of genetic changes have been identified in MPNSTs 
including gross chromosomal rearrangements, copy number changes and aberrant 
gene expression in multiple genes and genetic pathways including the commonly 
identified; TP53, CDKN2A, RB1, EGFR genes, (Mantripragada et al, 2008; Kourea etal, 
1999a; Kourea et al, 1999b; Nielsen et al, 1999; Mawrin et al, 2002), in addition to less 
frequently associated changes in genes such as CDK2, CDK4, HGF, MET, PDGFRA, 
ITGB4, MMP1 HMMR (Mantripragada et al, 2008; Perrone et al, 2009) (section 6.1). 
Such changes and the genes and mechanisms by which they elicit malignant 
transformation are, however, not fully understood and a molecular profile which 
distinguishes sporadic MPNSTs from NF1-associated MPNSTs has not been 
determined (Watson et al, 2004). The underlying mechanisms of NF1-associated 
tumorigenesis and malignancy are discussed further in section 6.1.
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1.11 Aims of thesis
NF1 is associated with extreme phenotypic variability and commonly results in an 
increased risk of developing benign and malignant peripheral nerve sheath tumours 
(MPNSTs). Identification of somatic mutations in NF1-associated tumours remains 
notoriously challenging and the molecular mechanisms that underlie NF1 tumorigenesis 
are still poorly understood. It is postulated that in addition to NF1 germline and somatic 
mutations, somatic lesions in other genes may be involved in NF1 tumorigenesis. A 
combinative approach encompassing genetic, epigenetic and functional analysis is 
therefore required to dissect the molecular mechanisms responsible for tumorigenesis 
in NF1. The primary aims of this thesis are:
1. Identification of underlying molecular mechanisms responsible for development 
of different NF1 associated tumours
2. Development of a novel strategy for functionally characterising variants of 
unknown pathogenicity locafted in the GRD of neurofibromin.
3. Elucidating the role of aberrant methylation in NF1 -associated tumour 
development.
4. To investigate potential therapeutic options for NF1 -associated malignant 
peripheral nerve sheath tumours (MPNSTs).
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CHAPTER 2: General methods and materials
2.1 Materials
2.1.1 General buffers, solutions, reagents and chemicals
Phosphate-Buffered Saline (PBS) (1X). liquid
10mM sodium phosphate, 138mM NaCI, 2.7mM KCI, pH7.4 (Invitrogen, cat no: 
20012-019)
Tris-HCL
Stock solutions of 1M Tris-HCI were prepared at pH7.4 and pH8.0, (Sigma, cat 
no:T3253)
Ethvlenediaminetetraacetic acid (EDTA)
0.5M EDTA adjusted to pH8.0 with NaOH pellets. (Sigma, cat no: ED2SS)
Boric Acid (Sigma, cat no: B7901)
Tris-Borate-EDTA (TBE) buffer (5X)
0.445M Tris-HCL, 0.445M boric acid, 0.01 M EDTA
Diluted to 1X for use in gel electrophoresis with dH20: 0.089M Tris, 0.089M boric 
acid and 0.002M EDTA
Tris-EDTA (TE) Buffer fix )
10mM Tris-HCL pH8.0, 1mM EDTA pH8.0
10x TBS-T p H 7.6
Tris 24.2g, NaCI 80g (Fisher Scientific, cat no: S/3160/60), 0.1% (w/v) Tween 20 
(Sigma, cat no: 274348)
Bovine Serum Albumin (BSA) (Promega, cat no: R396E)
Ethanol (Fisher Scientific, cat no: E/0600/DF17)
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Propan-2-ol (Isopropanol) (Fisher Scientific, cat no: P/7490/17)
Methanol (Fisher Scientific, cat no: M/3900/17)
Acetone (VWR, cat no: 20063.296)
Glycerol (Sigma, cat no: G5516)
Sodium Acetate (Sigma, cat no: S2889)
DNA extraction buffer
Tris 20mM, EDTA 25Mm and NaCI 0.1M
Sodium Dodecvl Sulfate (SDS1 (Sigma, cat no: L4390)
DMSO (Sigma, cat no: D2650)
TRIzol (Invitrogen, cat no: 15596-026)
AauaPhenol (Q-BIOgene, cat no: AQUAPH01)
Chloroform:lsoamvl alcohol 24:1 (Sigma, cat no: C0549)
Ammonium Acetate (Sigma, cat no: A1542)
Powdered Milk (Merck, cat no: 1.15363.0500)
‘Blenis’ Ivsis buffer
10 mM K2P04 (pH 7.4), 1 mM EDTA pH 7.05, 5 mM EGTA, 10 mM MgCI2, 50 mM 
p-glycerol phosphate, 1 mM N a3V04 (Added fresh before use), 2 mM DTT (Added 
fresh before use.) Protease inhibitors: complete, Mini Protease Inhibitor Cocktail 
tablets. (Roche, cat no: 04693124001). Each tablet is sufficient for a volume of 10 ml 
extraction solution.
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1x running buffer for SDS PAGE
20ml of 20X NuPAGE® MES SDS Running Buffer (for Bis-Tris Gels only) 
(Invitrogen, cat no: NP0002) or 20X NuPAGE® Tris-Acetate SDS Running Buffer 
(Invitrogen, cat no: LA0041) in 400ml dH20
Western blot transfer buffer (500ml)
50ml 20X NUPAGE transfer buffer (Invitrogen, cat no: NP00061), 425ml of dH20 , 
25ml 100% methanol
ECL Prime western blotting detection reagent (GE Healthcare, cat no: RPN2232)
1M PTT (Invitrogen, cat no: P2325)
Hi-Di™ Formamide (Applied Biosystems, cat no: 4311320)
2.1.2 Bacterial culture
2.1.2.1 Bacterial strains
One Shot®OmniMAX 2T 1 R T1 phage resistant chemically competent cell line. For 
all cloning applications. (Invitrogen, cat no:C8540-03)
2.1.2.2 Bacterial culture reagents 
Luria Bertani (LB) culture medium
10g Tryptone, 5g Yeast extract, (Becton, Dickinson cat no:211705 and 212750) 10g 
NaCI in 1L dH20
LB-Aaar medium
15g Bacterial agar (Becton, Dickinson cat no:214010), 10g Tryptone, 5g Yeast 
extract, 5g NaCI in 1L dH20
SOC medium (Invitrogen, cat no: 15544-034)
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Formulation per 1 litre: 2% Tryptone, 0.5% Yeast extract, 10mM Sodium chloride, 
2.5mM Potassium chloride, 10mM Magnesium chloride, 10mM Magnesium sulphate, 
20mM Glucose
Ampicillin stock solution
50mg/ml ampicillin sodium salt (Melford Laboratories LTD, cat no: A0104) in dH20 , 
filter sterilised and stored at -20°C. Final concentration of 100ug/ml.
Kanamvcin stock Solution
50mg/ml kanamycin disulfate salt (Sigma, cat no: K1876) in dH20 , filter sterilised 
and stored at -20°C. Final concentration of 100ug/ml.
Qiaqen plasmid extraction kits
QIAprep miniprep plasmid kits (Qiagen, cat no: 27104) and QIAprep maxi kits 
(Qiagen, cat no: 12263).
2.1.3 Cell culture
2.1.3.1 Cell lines
Tumour derived cell lines were either directly cultured from primary tissue 
(neurofibroma derived Schwann cell lines) or obtained from our collaborators in the 
department of Maxillofacial Surgery, University Medical Centre Hamburg Eppendorf, 
Martinistrasse 52, 20246, Hamburg, Germany or the Brain Tumour Research Centre 
The Hospital for Sick Children Rl, 101 College Street Toronto Medical Discovery 
Tower, East Tower, 11-401E Toronto, ON, Canada. The cell lines used were:
Patient derived MPNST cell lines: SNF96.2, SNF94.3, ST8814, T530 and T532 
Kindly donated by Abhijit Guha (University of Toronto, Canada)
Patient derived MPNST cell lines: T566, T567 and T568
Kindly donated by Victor Mautner (University Medical Centre, Hamburg)
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Neurofibroma derived Schwann cell lines: T534, T535A, T535B, T536A, T536B, 
T539, T541.1, T541.2, T541.3, T543.1, T543.2 and T543.3. Tissue kindly donated by 
our NF1 patients.
Patient derived fibroblast cell lines: T issue kindly donated by our NF1 patients and 
relatives.
Human embryonic kidney cells (HEK293): ATCC, cat no: CRL-1573 (Kindly donated 
by Dr Andrew Tee, Cardiff University, Cardiff)
2.1.3.2 Cell culture reagents
Dulbecco’s Modified Eagle Medium (DMEM)
L-glutamine, 4500 mg/L D-glucose, 110mg/L sodium pyruvate (Gibco, Invitrogen, cat 
no: 41966-029)
Fetal Bovine Serum (FBS) (Gibco. Invitrogen, cat no: 10106 169) 
Penicillin/Streptomycin (Pen/Strep)
10 000 units of penicillin (base) and 10 000 units of streptomycin (base)/ml utilising 
penicillin G (sodium salt) and streptomycin sulphate in 0.85% saline (Invitrogen, cat 
no: 15140-122)
Qpti-MEM® I reduced serum medium 1x
Contains: HEPES buffer, 2,400mg/L sodium bicarbonate, hypoxanthine, thymidine, 
Sodium Pyruvate, L-glutamine, No phenol red. (Invitrogen, cat no:11058-021)
Trvosin-EDTA solution (Invitrogen, cat no: R-001-100)
Cell freezing medium
10% DMSO, DMEM, 10%FBS
Lipofectamine 2000 transfection reagent (Invitrogen, cat no: 11668-019).
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3-lsobutvl-1-methvlxanthine (IBMX1
Powder dissolved in 50% Ethanol and used at 0.5M (Sigma cat no: 15879)
Insulin
1 mg/ml stock in PBS plus 5pl of 1M HCL (Sigma, cat no: 16634-50MG)
Forskolin
2pM stock in 96% ETOH. (Sigma, cat no: F-6886)
B-Hereaulin (rhNRG-1-B1/HRG-B1)
0.2mM stock: 50pg in 31.25pl PBS and 1%BSA (R&D Systems, cat no: 396-HB) 
Collaqenase (278U/mg)
2780U/ml stock: 10mg/1ml in DMEM and 10% FBS (Sigma, cat no: C0130-100MG) 
Disease I (6U/mg)
30U/ml: 5mg/1ml in dH20  (Roche, cat no: 04942086001)
N2 supplement (Gibco, cat no: 17502-018)
Poteinase K
1 mg/ml stock in dH20  (Sigma, cat no: P2308-500MG)
Polv-L-Lvsine
0.1 mg/ml stock (Sigma, cat no: P4707)
Natural mouse laminin
1 mg/ml Stock. 4pg/ml working concentration. (Invitrogen, cat no: 23017-015)
2.1.4 M olecular biology solutions and reagents 
Ethidium bromide (Sigma, cat no: E1510)
DNA loading solution
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0.03g Bromophenol Blue (Sigma, cat no: B8026), 0.03g Xylene Cyanol (Sigma, cat 
no:X4126), 7.5g Ficoll 400 (Sigma, cat no: F9378) and 0.558g EDTA in 50ml dhfeO
NuPAGE® LDS sample buffer (4X) (10 mh (Invitrogen, cat no: NP0007)
Novex® Sharp pre-stained protein standard (Invitrogen, cat no:LC5800)
1Kb plus ladder (250|jg)
Suitable for sizing linear double stranded DNA fragments from 100 to 12kb. The 
ladder consists of 12 bands ranging in size from 1000bp to 12000bp in exact 1000bp 
increments as well as 7 bands from 100bp to 850bp (Invitrogen cat no: 10787-018).
Primers
All primers for use in PCR and sequencing were unless otherwise stated designed 
using Primer3 V. 0.4.0 (Rozen and Skaletsky, 2000) and synthesised by Eurogentec 
using standard purification and 10nm synthesis scale. All primers containing a HEX, 
FAM or TET fluorescent label were synthesised on a 40nm scale. All primers were 
put through BLAT software (Kent, 2002) to ensure specificity.
Deoxvnucleotide triphosphates (4x 25pm)
100mM stock. dNTP set consisting of dATP, dCTP, dGTP, dTTP for PCR and cDNA 
synthesis (Invitrogen, cat no: 10297-018)
Agarose (multipurpose) (Roche, cat no: 11388991001)
Bioresolve aaarose. hi-strenath. low melting point (Bioaene. cat no: 300-750)
NuPAGE® polyacrylamide gel
NuPAGE® Novex 4-12% Bis-Tris Gel 1.0 mm (Invitrogen, cat no: NP0322) 
NuPAGE® Novex 3-8% Tris-Acetate Gel 1.0 mm (Invitrogen, cat no: EA03752)
Whatmann chromatography paper (Sigma, Cat no: Z270903).
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Immobilon- P membrane PVDF (Millipore. cat no: IPVH 000 10)
X-rav film (Fujifilm, cat no: 4741008389)
2.1.5 M olecular biology enzymes
AmpliTaq Gold® DNA polymerase with gold buffer and Mod? solution (2U/jjI) 
(Applied Biosystems, cat no: 4311818)
Big Dye terminator v1 cycle sequencing kit (Applied Biosystems, cat no: 4337450) 
Power SYBR® Green PCR master mix (Applied Biosystems, cat no: 4367659) 
Superscript II reverse transcriptase (Invitrogen, cat no: 18064-014)
RNAsin ribonuclease inhibitor (Promega cat no: N2111)
Shrimp Alkaline Phosphatase (SAP) (GE Healthcare, cat no: E70092Z)
2.1.5.1 Restriction enzymes
Enzyme Buffer Company Catalogue Number
Msp 10x Buffer Cambio REZ-MSP-2K
Rsa1 10x R E act Buffer Invitrogen 515424-013
Hind\\\ 10x Buffer E Promega R604A and R005A
EcoR\ SuRE/Cut Buffer H Roche 11175084001
Dpnl 10x NE Buffer 4 New England Biolabs R0176S and B7004S)
Exol New England Biolabs M0293
2.1.6 Immunohistochemistry reagents
Citrate buffer (pH6)
2.1g Citric Acid Monohydrate (Sigma, Cat no: 33114), 1 Litre dH20
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Hydrogen Peroxide
300ml dH20  and 3ml H20 2 (Sigma: Cat no: H1009)
VECTASTAIN ABC kit (rabbit laGI (Vector labs, cat no: PK-4001)
Block buffer: 500|jl TBS and 7.5|jl goat serum
Secondary antibody: 500pl TBS, 7.5pl goat serum, 2.5pl goat Biotinylated secondary 
antibody anti rabbit
ABC peroxidase: 10pl buffer A, 10|jl buffer B, 500|jl TBS
VECTASTAIN ABC kit (mouse laG) (Vector labs, cat no: PK-4002)
Block buffer: 500pl TBS and 7.5|jl horse serum
Secondary antibody: 500|j| TBS, 7.5|jl horse serum, 2.5|jl goat Biotinylated 
secondary antibody anti mouse
ABC peroxidase: 10pl buffer A, 10|jI buffer B, 500|jI TBS 
Peroxidase substrate kit DAB
2.5ml dH20 , 1 drop buffer, 2 drops DAB, 1 drop H20 2 peroxidase (Vector Labs, Cat 
no: SK-4100)
DPX (VWR, cat no: 360294H)
Gills Haematoxvlin (Sigma, cat no: GHS132-1L)
Polv-L-Lvsine (Sigma, cat no: P8920)
Diluted 1:10 with dH20
2.1.7 Antibodies
2.1.7.1 Primary antibodies (TBS-T + 2% BSA)
• Mouse monoclonal Rac1: 1:500 (Abeam, ab33186)
•  Mouse monoclonal ROCK2: 1:1000 (Abeam: ab56661)
• Mouse monoclonal V5 (1:5000) (Abeam: ab27671)
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•  Rabbit polyclonal IgG, c-Met HRP (1:10,000) (Santa Cruz Bio, Cat no:C-28)
• Mouse monoclonal p53 pre-diluted antibody (Biogenex, cat no: MU239-UC)
• Rabbit polyclonal anti-S100 (1:100) (Dako, cat no: Z0311)
2.1.7.2 Secondary antibodies
• Anti-mouse IgG, HRP-linked Antibody (1:1000) (NEB: 7076S): Rac1 and 
ROCK2:
• Rabbit polyclonal secondary antibody to mouse IgG HRP conjugated 
(1:10,000) (Abeam: ab6728): V5 and p-cMET:
2.1.8 Laser capture microdissection
LCM PALM 1.0 PEN membrane slides (Carl Zeiss, cat no: 415190-9041-001)
Leica RM 2235 microtome (Leica)
Axiovert S100 inverted phase contrast and fluorescence microscope (Zeiss)
2.1.9 Equipment and instruments
Thermocyclers for PCR reactions and incubations included a Primus 96+ (MWG- 
Biotech), GS1 (G-STORM) and Gene Amp PCR System 2700 (Applied Biosystems). 
Horizontal gel tank apparatus were supplied by Biorad. Centrifugations were 
performed in a bench-top microcentrifuge, Eppendorf 5415C (Eppendorf) as well as 
a Universal 320 (Hettich Zentrifugen). Purified sequencing reactions were analysed 
using an ABI Prism 3730 Genetic Analyser and all LOH, MSI and MLPA reactions 
were run on an ABI Prism 3100 (Applied Biosystems). Relative quantification was 
completed on an ABI 7500 (Applied Biosystems). The transfer system for SDS 
PAGE was from Hoefer and the Minigel Western blot electrophoresis module was 
from Novex, supplied by Invitrogen. Following nucleic acid extraction, the resulting 
concentration was determined using 2pl of the DNA or RNA on a Nannodrop 8000 
spectrophotometer (Thermo Scientific).
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2.2 Methods
2.2.1 Bacterial culture
2.2.1.1 General growth of bacteria
All bacterial culture was completed under sterile conditions. All solutions and 
glassware were autoclaved prior to use and sterile plastic ware was used. Universals 
were used for all small scale culture and large scale culture was contained in 
glassware.
2.2.1.2 Preparation of LB culture medium
All bacteria were cultured in LB medium. This was prepared as described in section
2.1.2.2 and adjusted to pH7. The lid was screwed loosely onto the bottle and held in 
place with a strip of autoclave tape and autoclaved using the liquid cycle.
2.2.1.3 Preparation of LB-agar plates
LB plates (section 2.1.2.2) were prepared in the same manner as the LB culture 
medium but with the addition of bacterial agar. Following autoclaving on the liquid 
cycle, the LB-agar was cooled to 55°C and the appropriate antibiotic at the 
appropriate concentration was added. A thin layer of agar (approx 20ml) was poured 
into each 80mm sterile petri dish and allowed to set. Plates were stored in a plastic 
bag at 4°C.
2.2.1.4 Transformation of bacterial cells
The E.coli strain one Shot®OmniMAX 2T1R were chosen as they are a chemically 
competent cell line suitable for all cloning applications including gateway technology. 
One Shot®OmniMAX 2T1R chemically competent bacteria were thawed on ice and 
25pl of bacteria were transferred to a pre-chilled 1.5ml eppendorf tube. 2.5pl of the 
plasmid DNA was added to the bacterial cells, mixed gently and incubated on ice for 
30 minutes. A control transformation was also carried out by adding 5pl of pUC19
97
high copy number control plasmid to a separate aliquot of 25pl of cells and incubated 
as above. Cells were heat shocked at 42°C for 30 seconds and incubated on ice for 
2 minutes. 250pl of SOC media was added to the cells and the cells were then 
shaken horizontally for an hour at 37°C in an orbital shaker at 220rpm (Innova 4000, 
New Brunswick Scientific). During this growth period, selective antibiotics were 
omitted to allow the cells to express antibiotic resistance genes prior to exposure. At 
the same time agar plates containing the appropriate antibiotic were placed in the 
incubator (Prime series, Gallenkamp) at 37°C to warm up.
Following the hour incubation, the pUC19 control transformations were diluted 1:50 
in LB medium and 100pl was spread onto LB-agar plates containing the appropriate 
antibiotic. Unless otherwise stated, experimental transformation reactions were 
centrifuged at 6500rpm using a microcentrifuge for 2 minutes to concentrate the 
cells. The resulting pellets were re-suspended in 150pl of LB medium and spread 
onto LB agar plates. The plates were allowed to dry for 10 minutes and incubated at 
37°C for approximately 14-16 hours, after which colonies were counted and the 
transformation efficiency calculated according to the number of colonies on the 
control transformation plate. Plates were stored at 4°C.
2.2.1.5 Starter cultures
Sterile pipette tips were used to isolate single colonies from freshly streaked 
selective LB-agar plates and used to inoculate 5ml of LB medium containing the 
appropriate selective antibiotic. This was incubated for 14 hours at 37°C in an orbital 
shaker at 220rpm and the cells were either harvested by centrifugation for 2 minutes 
at 13,000 rpm in a microcentrifuge, added to glycerol for long term storage (section 
2.2.1.6) or diluted 1/5 with LB and transferred to 250ml large scale cultures (section 
2 .2 .1.8).
2.2.1.6 Long term storage of transformed bacteria
50% Glycerol was made by adding 250ml 100% glycerol to 250ml distilled water. 
The bottle was capped but not tightened and autoclaved on a liquid cycle. After 
cooling the lid was tightened and the 50% stock was stored at room temperature. For
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long term storage, glycerol stocks were prepared by adding 500pl of overnight 
culture to 500pl of 50% glycerol in a 2ml screw top tube, vortexed to mix and stored 
at -80°C. Bacterial transformants were recovered from glycerol stocks by streaking a 
sterile transfer loop of the glycerol stock onto an LB-agar plate containing the 
appropriate antibiotic and incubating overnight at 37°C.
2.2.1.7 Small scale plasmid purification
Small scale purification of plasmid DNA was completed using a QIAprep spin 
miniprep kit for purification of 1-5ml of plasmid DNA using a microcentrifuge and 
using the manufacturers protocol (Qiagen). The protocol is based on the alkaline 
lysis method by Birnboim and Doly (1979). Briefly, bacterial cells were harvested by 
centrifugation (as above) then resuspended in 250pl of buffer P1, containing 
RNaseA (100pg/ml) and transferred to a microcentrifuge tube. 250pl of buffer P2 
(lysis buffer) was added to the tube and inverted 4-6 times to mix and cause lysis of 
the bacterial cells. 350pl of buffer N3 (neutralisation buffer) was then added to the 
tube and again inverted 4-6 times to mix and neutralise the reaction. The reaction 
was then centrifuged for 10 minutes at 13,000rpm. A solid white pellet formed and 
the supernatant was transferred to a spin column and centrifuged for a further minute 
after which the flow through was discarded. The QIAprep spin column silica 
membrane was then washed by adding 750pl of buffer PE and centrifuged for 1 
minute to remove salts. The flow through was discarded and the column centrifuged 
for an additional minute to remove residual wash buffer. Finally, the QIAprep column 
was put into a clean 1.5ml microcentrifuge tube and 50pl buffer EB (10mM TrisHCI, 
pH 8.5) or dH20  was applied to the centre of each QIAprep column to elute the DNA. 
This was left to incubate at room temperature for 1 minute and then centrifuged for 1 
minute at 13,000rpm.
2.2.1.8 Large scale plasmid purification
The HiSpeed Plasmid maxiprep kit (Qiagen) was used for purification of low copy 
plasmid DNA using the manufacturers’ protocol. Briefly, bacterial cells were 
harvested by centrifugation at 6000 x g for 15 min at 4°C and then resuspended in 
10ml of buffer P1. 10ml buffer P2 was added to the tube and inverted 4-6 times to
99
mix and cause lysis of bacterial cells; this was incubated for 5 minutes. 10ml pre­
chilled buffer P3 was added to the mixture and this was immediately poured into the 
barrel of a QIAfilter Cartridge and incubated at room temperature for 10 minutes. 
During this incubation, a HiSpeed Maxi Tip was equilibrated by applying 10 ml Buffer 
QBT and this was allowed to flow through the column by gravity flow. The cap from 
the QIAfilter outlet nozzle was removed and the plunger was inserted into the 
QIAfilter Maxi Cartridge and the cell lysate filtered into the previously equilibrated 
HiSpeed Tip. The cleared lysate was allowed to enter the resin by gravity flow. The 
HiSpeed Maxi Tip was then washed with 60ml Buffer QC and the DNA was eluted 
with 15ml Buffer QF. The DNA was precipitated by adding 10.5ml (0.7 volumes) 
room temperature isopropanol and mixed and incubated at room temperature for 5 
minutes. During the incubation the plunger was removed from a 30 ml syringe and 
attached to the QIAprecipitator Maxi Module outlet nozzle. The QIAprecipitator was 
placed over a waste bottle and the eluate/isopropanol mixture was transferred into 
the 30ml syringe, the plunger inserted, and the eluate/isopropanol mixture was 
filtered through the QIAprecipitator using constant pressure. 2ml 70% ethanol was 
then added to the syringe and the DNA was washed by inserting the plunger and 
pressing the ethanol through the QIAprecipitator using constant pressure. The 
membrane was dried twice by pressing air through the QIAprecipitator quickly and 
forcefully and the outlet nozzle of the QIAprecipitator was dried with absorbent paper 
to prevent ethanol carryover. Finally the DNA was eluted by holding the outlet of the 
QIAprecipitator over a 1.5ml collection tube and 1ml of Buffer TE was added to a 5ml 
syringe and filtered using constant pressure.
2.2.2 Cell culture
2.2.2.1 Growth and maintenance of cell lines
All patient derived MPNST cell lines (SNF 96.2, SNF94.3, ST8814, T530, T532, 
T566, T567, T568) and HEK293 cells were grown in T75 flasks (Helena Biosciences, 
cat no:90076) in 10ml of DMEM, 10% FCS and 1% pen/strep. Neurofibroma derived 
Schwann cell lines were grown as described in section 2.2.2.5 and passaged using 
the same method described below.
1 0 0
2.2.2.2 Splitting cells
All adherent cell lines were passaged using the same method. The cells were first 
washed with 5ml of PBS and then detached with 2ml of Trypsin-EDTA and incubated 
at 37°C for a few minutes (cells rounded up when inspected under a microscope). 
The trypsinised cells were then transferred into two separate falcon tubes and the 
medium was made up to 10ml with DMEM and 10% FBS. The tubes were 
centrifuged at 1200rpm for 7-10 minutes to produce a cell pellet at the bottom of the 
tube. The medium was removed from the falcon tube (leaving the pellet at the 
bottom) and the pellet was resuspended in the appropriate volume of medium. The 
cells were then mixed into this medium using a pipette to distribute the cells and the 
medium was divided evenly between the appropriate number of flasks (coated in the 
case of neurofibroma derived Schwann cells, section 2.2.2.5.3). Flasks were 
incubated at 37°C with CO2 and either split, cryopreserved (section 2.2.2.4), or the 
medium was changed when appropriate.
2.2.2.3 Determination of cell density
Accurate numbers in a cell suspension were calculated by counting the cells in a 
Neubauer improved bright line haemocytometer (Marienfield, cat no: 0630030). Cells 
were trypsinised as previously described and resuspended in 1ml DMEM and 10% 
FBS. Cells were thoroughly dispersed and 30pl of the cell suspension was mixed 
with 30pl 0.1% w/v trypan blue in PBS solution (BioWhittaker, cat no: 17-942E); non- 
viable cells were stained blue. This was immediately mixed well and a sufficient 
volume to fill a side of the haemocytometer chamber was aspirated. Viable cells in 
each of the four corner squares bordered by triple lines were counted, omitting cells 
lying on these lines. The mean count of the total viable cells per four corner squares 
was calculated using the following formula:
C 1 = t x tb x 1/4 x 104 
t = total viable cell count of four corner squares 
tb = correction for the trypan blue dilution (counting dilution was 1/tb)
1/4 = correction to give mean cells per corner square 
104 = conversion factor for counting chamber 
C 1 = initial cell concentration per ml
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The working concentration was then obtained by mixing 1 volume of the original cell 
suspension with the appropriate volume of growth medium. Cells were dispensed in 
growth medium and seeded into the appropriate vessel and incubated as per the 
standard protocol as previously described. The dilution factor (d) was calculated to 
obtain the working cell concentration per ml (C2) using the following formula:
d = C2 (working cell concentration) / C 1 (initial cell concentration)
2.2.2.4 Cryopreservation
The medium was removed and cells were washed with 5ml PBS and 2ml of Trypsin 
as previously described. The entire contents of the flask was transferred into one 
falcon tube and centrifuged at 12000rpm for 7-10minutes to produce a pellet. 
Following centrifugation, the medium was removed and the cell pellet was 
resuspended in 0.5ml of the freeze mix: DMEM and 10% FBS and 10% DMSO. The 
mixture was transferred to a cryogenic vial and frozen to -80°C using a freezing 
container; Mr Frosty (Nalgene®) filled with isopropanol. This creates a temperature 
gradient, freezing the cells by 1°C per minute to prevent the formation of ice crystals 
within the cells which could rupture the membrane. Cells were transferred to liquid 
nitrogen for long term storage. Cells were defrosted rapidly at 37°C and quickly 
transferred to the appropriate flask containing the correct pre-warmed medium.
2.2.2.5 Schwann cell culture
Culture conditions for neurofibroma derived Schwann cells have been reported by 
Rosenbaum et al, (2000) and Serra et al, (2000) and are described in detail below. 
The presence of forskolin in the medium promotes the proliferation of Schwann cells. 
This occurs through elevation of intracellular cAMP and suppression of fibroblast 
growth. Replacement of proliferation medium by serum-free N2 medium (Bottenstein 
and Sato, 1979) followed by medium without forskolin, promotes schwann cell 
differentiation. N2 medium is a serum-free synthetic medium supplemented with 
insulin, transferrin, progesterone, selenium, and putrescine. Cells respond to the 
removal of serum through extensive process formation and retention of other 
differentiated properties. Growth of neuronal cells is stimulated with the N2 medium
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and non-neuronal growth is suppressed. Cells were passaged when cultures were 
confluent and harvested not earlier than at passage eight.
2.2.2.5.1 Preincubation
3ml of preincubation medium (DMEM +10% FBS, 1% Pen/strep Forskolin [2pM]) 
filtered once through Millex syringe driven 0.22pM filters (Millipore, cat 
no:SLGS033SS) was added to each well on a 6 well plate (Nunclon, cat no: 
140675). The tumours were dissected in DMEM + 10% FBS and a small piece from 
the centre of the tumour was dissected out and put into the pre-incubation medium in 
the 6 well plate. The tumour sections were then left to incubate for 10-14 days with 
the medium changed every 3 days without changing the plate or washing with PBS.
2.2.2.5.2 Incubation
Following the 10-14 day incubation in the preincubation medium, the tissue was 
transferred to a new 6 well plate and dissected into smaller pieces using a scalpel. 
Samples were then incubated for 24 hours in 3ml of DMEM + 10% FBS, 1% 
PenStrep, Collagenase [160U/ml] and Dispase I [0.8U/ml] filtered once with the 
Millex 0.22pM filter.
2.2.2.5.3 Coating flasks and plates
A T25 flask (Nunclon, cat no: 136196) was coated with 1.2ml of sterile Poly-L-Lysine 
solution. This was left for 1 hour at room temperature and was then washed with 
sterile PBS. 1.2ml of 4pg/ml laminin was then filtered and added to each flask. This 
was incubated for 1 hour at 37°C, excess removed and then the flask was washed 
with PBS. The tissue in the 6 well plate was broken up using a pipette, transferred to 
a falcon tube and centrifuged for 10 minutes at 1200rpm. The supernatant was 
discarded and the pellet was resuspended in 5ml of DMEM + 10% FBS, 1% 
Pen/Strep, IBMX, [0.5mM], p-Heregulin [10nM], Forskolin [2pM] and Insulin 
[2.5pg/ml] and incubated for 24 hours. The medium was removed the following day 
and the N2 medium was prepared (10ml DMEM F12, 100pl/10ml N2 Supplement 
and 1% Pen/Strep) filtered as before, added to the 6 well plate and incubated for 24 
hours. The following day the N2 medium was removed and replaced with 5ml of 
medium without Forskolin: DMEM +10% FBS, 1% Pen/Strep, IBMX [0.5mM], p-
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Heregulin [10nM] and lnsulin[2.5pg/ml] and incubated for 6 days under standard 
conditions, with the medium replaced after 3 days. After 6 days the cells were 
confluent and so were transferred to a larger T75 flask, coated with laminin and poly- 
l-lysine as previously described. The cultures were then harvested following the 8th- 
12th passage, the Schwann cell content of each culture being established by S100 
immunohistochemistry (Serra et al., 2000). S100 is a calcium binding protein 
specifically found in Schwann cells of the peripheral nerve (Mirsky and Jessen, 
1996). Immunohistochemical analysis of Schwann cell lines used in all experiments 
was carried out to ensure that the population of cells that had been cultured was 
pure. Due to the method of fixation used for these cultures, while differential S100 
staining could be identified, the morphology of the cells was often disrupted.
2.2.2.6 Plasmid DNA transfection
Transfection using lipofectamine (lipofection) was used to introduce plasmid DNA 
into cell lines. Synthetic cationic lipids including lipofectamine, interact spontaneously 
with DNA to form lipid-DNA complexes. These complexes can then fuse with the 
plasma membrane of cells in culture resulting in uptake of DNA and consequently 
expression of the DNA (Feigner et al, 1987). Lipofection is effective for both transient 
and stable expression of transfected DNA and can have greater transfection 
efficiency than calcium phosphate and electroporation.
2.2.2.6.1 Forward Transfection 
One day prior to transfection, cells were seeded at the appropriate concentration 
(6x105 for HEK293) in 2ml of growth medium (DMEM and 10% FCS) in 6 well plates 
(Jencons, cat no: 734-0948) without antibiotics. Cells were seeded at a high density 
to ensure high transfection efficiency, high expression levels and to minimise 
cytotoxicity. For each transfection sample 3 complexes were prepared: (i) 4.0pg of 
plasmid DNA was diluted in 250pl of opti-MEM I reduced serum medium and gently 
mixed, (ii) Lipofectamine 2000 was gently mixed prior to use and then 10pl diluted in 
250pl of opti-MEM I Reduced Serum Medium and incubated for 5 minutes at room 
temperature, (iii) After 5 minutes, complexes 1 and 2 were combined and gently 
mixed and incubated for 20 minutes at room temperature. The entire 500pl volume 
containing the two complexes was added to each well containing the cells and
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medium. The plates were mixed by rocking the plate gently. Cells were incubated at 
37°C with C02for 48 hours. The medium was replaced after 6 hours.
2.2.2.6.2 Reverse Transfection for shRNA
On the day of transfection, 200ul of optimem and 2ml pen/strep free media per plate 
was pre-warmed to 37°C for an hour along with trypsin and enough pen/strep free 
media for resuspension of cells following trypsinisation. For each transfection sample 
the following complexes were prepared: (i) 2.5ug shRNA vector was added to an 
eppendorf along with 100ul of pre-warmed opti-MEM I Reduced serum medium and 
gently mixed, (ii) Lipofectamine 2000 was gently mixed prior to use and then 6.25pl 
diluted in 100pl of opti-MEM I Reduced Serum Medium (1:2.5 ratio of shRNA 
(ug):Lipofectamine 2000 (ul)) and incubated for 5 minutes at room temperature, (iii) 
After 5 minutes, complexes 1 and 2 were combined and gently mixed and incubated 
for 25 minutes at room temperature. After 25 minutes, the transfection mixture was 
added to a 35mm plate (Helena Biosciences, cat no: 93040). Cells were trypsinised 
as described above and during this period, 2ml pen/strep free media was added to 
the 35mm plate and mixed with the transfection mixture. Cells were seeded at the 
appropriate concentration, mixed and then incubated at 37°C with C 02 for 4-6 hours 
before changing the media to DMEM, 10% FCS and 1% Pen/strep. Cells were 
cultured for an additional 48 hours, and the media was changed if necessary.
2.2.2.6.3 Creating a stable knockdown
shRNA vectors used in this study contained a puromycin resistance cassette 
ensuring that cells successfully transfected with these vectors can survive even in 
the presence of the puromycin antibiotic. MPNST derived cell lines were treated with 
2.5pg/ml puromycin every two days for 2 weeks (if significant cell death was seen, 
media was changed). After two weeks colonies formed which were individually 
trypsinised by pipetting 100pl of trypsin onto the colony, mixing in the pipette and 
then seeded separately in to new plates to continue growing.
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2.2.3 Molecular biology
2.2.3.1 NF1 patient DNA and tissue samples
Tumours and DNA samples from patients fulfilling the NF1 NIH diagnostic criteria 
were provided by genetic centres in the UK (Cardiff, Institute of Medical Genetics, 
Cardiff University), Germany (Hamburg, Laboratory for Tumor Biology and 
Developmental Disorders, University Hospital Eppendorf.) and Canada (The Brain 
Tumour Research Centre The Hospital for Sick Children Rl, 101 College Street 
Toronto Medical Discovery Tower, East Tower, 11-401E Toronto). Samples were 
obtained from patients with informed consent and all studies gained ethical approval 
from all the relevant institutional research boards. All tissue was kept at -80°C until 
required in order to ensure preservation of DNA and labile RNA.
2 .2.3.1.1 DNA extraction from tissue samples 
Once removed from the freezer, a scalpel was used to excise tumour tissue from 
surrounding tissue. Excised tissue for DNA extraction was finely chopped up using a 
scalpel and transferred to a 1.5ml microcentrifuge tube containing: 500pl extraction 
buffer, 50pl proteinase K and 12.5pl 20% SDS. The tube was incubated in a water 
bath at 65°C for 2 hours (alternatively 37°C overnight) and vortexed briefly every half 
hour. Once dissolved, 500pl Phenol was added to each tube and centrifuged at 
13,000 rpm for 15 minutes using a microcentrifuge. The supernatant was 
subsequently transferred to a 15ml tube (Sarstedt) and 25pl of 7.5M Ammonium 
Acetate and 1.5ml of 100% Ethanol were added to the tube. The tube was slowly 
inverted until the DNA had spooled into a ball. The DNA was then transferred to a 
clean microcentrifuge tube containing 70% ethanol, inverted a few times and left for 
a minute to remove any salt in the solution which could interfere with PCR and 
digestions. The alcohol was then removed and the DNA pellet left to air dry for 10 
minutes. 1x TE at a volume appropriate to the amount of DNA present (typically 200- 
400pl) was added and the tube put on a rotating wheel to dissolve overnight.
1 0 6
2.2.3.1.2 RNA extraction from tissue samples 
All RNA work was carried out using sterile RNase-free plastic ware and reagents 
designed to reduce the risk of RNase contamination and RNA degradation. The 
frozen sample was removed from the freezer just prior to extraction when it was 
powdered by grinding with liquid Nitrogen with a pestle and motar. To prevent 
thawing in the mortar, it was previously chilled in a -80°C freezer for 10 minutes. By 
grinding the tissue in this manner, cellular disruption is more complete allowing for a 
high yield of RNA. The powdered tissue was transferred using a spatula to a 
universal tube containing 1ml TRIZOL. TRIzol contains guanidinium isothiocyanate, 
a powerful protein denaturant used to inactivate RNases. The tube was then 
incubated at 30°C for 10 minutes and 200pl of chloroform was added. Chloroform 
allows for the partitioning of RNA into aqueous supernatant for separation. Low pH is 
crucial since at neutral pH DNA not RNA partitions into the aqueous phase. The 
aqueous phase contains RNA; the interphase holds the DNA and the proteins and 
lipids are found in the organic phase.
The tube was vortexed for 15 seconds and incubated at 30°C for 3 minutes. The 
tube was then centrifuged at 14,000 rpm for 10 minutes at 4°C. The upper layer was 
transferred to a clean microfuge tube and 500pl of isopropyl alcohol was added and 
the tube was incubated on ice for 10 minutes. Isopropyl alcohol is better than alcohol 
precipitation for smaller amounts of RNA as there is less risk of losing very small 
nucleic acid pellets and it also reduces the risk of organic solvent contamination. 
After the incubation, the tube was centrifuged again under the same conditions as 
before. After centrifuging, the supernatant was removed without dislodging the RNA 
pellet, and 1ml of 75% ethanol was added and the tube centrifuged at 7,500 rpm for 
5 minutes at 4°C. In the final stage, the ethanol was removed and the pellet was 
allowed to air dry for 10 minutes before 50pl RNA free water was added in addition 
to 0.5pl RNAsin. 2pl of RNA was run on a 1% LMT agarose (low melting temp) gel 
with 5pl of loading dye to ensure the RNA had not degraded.
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2.2.3.1.3 Extraction of DNA from peripheral blood
All DNA extractions from peripheral blood were carried out by the NHS molecular 
genetics department, Cardiff, using the Gentra Nucleic Acid Purification System 
(Autopure)
2.2.3.1.4 DNA and RNA extraction from cultured cells
Cells were pelleted at 12,000rpm for 10 minutes in a centrifuge. Excess medium was 
removed and the pellets were washed with PBS to remove any inhibitory 
compounds. DNA and RNA was extracted using the protocols detailed in sections
2.2.3.1.1 and 2.2.3.1.2
2.2.3.1.5 Purification of DNA from agarose gels
The MinElute gel extraction kit protocol (Qiagen, cat no:28604) was used to purify 
PCR products from 1.5% agarose gels following the protocol supplied by the 
manufacturer. Briefly, DNA fragments were excised from the gel with a clean, sharp 
scalpel and extra agarose was removed. The gel slices were weighed and 3 volumes 
of Buffer QG was added to 1 volume of gel (100mg/100pl). The tube was incubated 
at 50°C for 10 minutes (or until the gel slice has dissolved). The tube was vortexed 
every 2-3 minutes to help the gel to dissolve. One volume of isopropanol was added 
to the sample and the content of the tube was mixed by inverting the tube several 
times. The entire sample was applied to the membrane of a MinElute column and 
centrifuged for 1 minute at 12,000rpm. The flow through was discarded and 500pl of 
Buffer QG was applied to the membrane and the column centrifuged again for 1 
minute at 12,000rpm. The flow through was removed and 750pl of wash buffer PE 
was added to the column and centrifuged under the same conditions. Again the flow 
through was removed and the column was centrifuged to remove any residual 
ethanol containing buffer to ensure there is no interference with downstream 
applications. The tube was placed in a clean 1.5ml microcentrifuge tube and 10pl of 
elution buffer/dH20  was applied to the membrane and left to stand for 1 minute. 
Finally the tube was centrifuged at 12,000rpm for 1 minute to elute the DNA.
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2.2.3.1.6 DNA extraction from FFPE tissues 
DNA extraction was completed using the QIAamp DNA micro kit (Qiagen, cat no: 
56304) following the manufacturers protocol. Briefly, this involved the addition of 15pl 
of Buffer ATL to the laser-microdissected sample. 10pl of proteinase K was then also 
added and this was mixed by pulse-vortexing for 15 seconds. The sample was 
placed in a thermomixer and incubated at 56°C for 3hours with occasional agitation. 
Following this incubation, 25pl of buffer ATL was added in addition to 50pl of buffer 
AL and this was again mixed by pulse-vortexing for 15 seconds. 50pl 100% ethanol 
was also added and this was again mixed thoroughly by pulse-vortexing for 15 
seconds and incubated for 5 min at room temperature (15-25°C) followed by brief 
centrifugation to remove drops from inside the lid. The entire lysate was transferred 
to the QIAamp MinElute column (in a 2 ml collection tube) and this was centrifuged 
at 8000rpm for 1 minute. The QIAamp MinElute column was placed in a clean 2 ml 
collection tube, and the previous collection tube containing the flow-through was 
discarded. 500pl buffer AW1 was added to the column and centrifuged 8000rpm for 
1 min. Again the collection tube was changed and 500pl buffer AW2 was added to 
the column and centrifuged at 8000rpm for 1 min. The collection tube was changed 
again and the column was centrifuged at 14,000 rpm for 3 min to dry the membrane 
completely. Finally, the QIAamp MinElute column was placed into a clean 1.5ml 
microcentrifuge tube and 50pl buffer AE was added to the centre of the membrane 
and incubated at room temperature for 1 minute. The column was then centrifuged at 
14,000rpm for 1 minute to elute the DNA. Extracted DNA was stored at -80°C until 
used for NF1 gene analysis (section 3.3.3).
2.2.3.2 Polymerase chain reaction (PCR)
Direct sequencing allows the myriad of changes such as deletions, insertions and 
single base pair substitutions to be detected. For optimal product purification and 
recovery of small PCR products (<300bp) of the NF1 gene, a 25pl PCR reaction was 
set up using DNA at a concentration of 6ng/pl and carried out on a thermal cycler at 
an annealing temperature of 60°C using the primers in supplementary table 2 and 
the following reagents and conditions:
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Reaaent Volume 25pl Cvcle Conditions x35 Cycles
DNA [6ng/pl] 5pl
Buffer 2.5pl 95°C 10 Minutes
Mg [50mM] 1 |jl
dNTP’s [10pM] 2pl 94° C 1 Minute
Sense Primer [1pm/pl] 1 pi 60°C 1 Minute
Antisense Primer [1pm/pl] 1pl 72°C 1 Minute
Taq 0.1pl
H20 12.4pl 72°C 10 Minute
2.2.3.2.1 Agarose gel electrophoresis 
1.5% agarose gels were made by combining 1.5g multipurpose agarose with 100ml 
of 1X TBE and heated in a microwave for 2 minutes to melt the agarose. 100ml of 
1.5% agarose gel was stained with 4pl of Ethidium Bromide, poured into the gel 
moulds and left to set prior to loading of PCR product. Unless otherwise stated, 4pl 
of PCR product was combined with 5pl of DNA loading dye and loaded onto the 
1.5% multipurpose agarose gels. Gel tank equipment (Biorad) was set to 100Volts 
(0.4Amps) and run for 30 minutes. After running the gel, bands were visualised 
under UV with a GelDoc Imaging Station and Quantity One Software (Biorad)
2.2.3.3 DNA sequencing
2.2.3.3.1 ExoSAP PCR purification 
This method of purification involves the enzymatic removal of excess nucleotides 
and primers from the PCR reactions. 1pl of SAP and Exol was added to the PCR 
product to be purified in a 2:1 ratio. The PCR product was then incubated for 1 hour 
at 37°C to activate the Exol and then 80°C for 15minutes to deactivate the Exol.
2.2.3.3.2 Big Dye terminator reaction 
The BigDye terminator mix was prepared using the following reagents and cycle 
conditions:
1 1 0
Reaaent Volume 10 pi Cvcle Conditions x30 Cycles
DNA (PCR product) 1.5pl 96°C 5 minutes
BigDye 0.25pl
Buffer 2pl 96° C 30seconds
Primer[10pM] 0.16pl 50°C 15 seconds
H20 6.09pl
60°C 4 minutes
2.2.3.3.3 Isopropanol sequencing purification 
This method removes unincorporated dyes by isopropanol precipitation. 40pl of 75%  
isopropanol was added to each well and mixed gently. The reaction was incubated at 
room temperature for 30 minutes followed by centrifugation at 4000rpm for 45 
minutes. After centrifugation, the plate was inverted on to absorbent paper to remove 
the isopropanol and then placed inverted into the rotor bucket and centrifuged at 
500rpm for 30 seconds. The plate was left to air dry in a dark box for 10 minutes and 
DNA was finally resuspended in 10pl of Hi-Di™ Formamide and analysed on an ABI 
3730 analyser (Applied Biosystems).
2.2.3.4 RNA analysis
2.2.3.4.1 RNA first strand synthesis and reverse transcription 
Following RNA extraction, first strand synthesis was carried out in a 12pl reaction 
volume with random primers (200ng/pl), dNTP mix (10mM) and RNA (2.5ng/pl). The 
reaction mixture was heated to 65°C for 5 minutes to disrupt any template secondary 
structures and then was briefly chilled on ice to prevent re-formation of secondary 
structures. 1pl of Superscript II Reverse Transcriptase (200U/pl) was added to each 
reaction and heated for 2 minutes at 25°C. 4pl 5x First Strand buffer, 2pl 0.1 M DTT 
and 1pl RNAsin was then added to each reaction and reactions were heated at 25°C 
for 10 minutes, 42°C for 50 minutes and finally 70°C for 15 minutes.
111
2.2.3.4.2 cDNA PCR
A 25|jl cDNA PCR was set up using the following reagents, cycle conditions, and the 
primers in supplementary table 3 at an annealing temperature of 58°C. Gel analysis, 
PCR purification, sequencing and sequence purification were also completed as 
previously described
Reaction Volume 25pl Cvcle Conditions x35 Cycles
cDNA 1pl
Buffer 2.5pl 94° C 1 Minute
Mg [50mM] 0.27pl 56°C 1 Minute
dNTP’s [10pM] 0.5pl 72°C 1 Minute
Sense Primer [10pm/pl] 0.5pl
Antisense Primer [10pm/pl] 0.5pl 72°C 10 Minutes
Taq 0.2pl
H20 19.05pl
2.2.3.5 Characterisation of Sequence Alterations
All sequence alterations were fully characterized by direct sequencing using an ABI 
3730 analyser (Applied Biosystems). The resulting sequence was analysed using 
Sequencher software (Gene Codes, USA)
2.2.4 Immunohistochemistry (\HC)
2.2.4.1 Preparation of slides for IHC
For all IHC except laser capture microdissection, Superfrost microscopy slides 
(VWR, cat no: 8037/1) were pre-treated with UV for 30 minutes, immersed in poly-l- 
lysine for 5 minutes and then incubated at 40°C in an incubator overnight to dry. 5pm 
thick sections were cut from pre-chilled formalin fixed paraffin embedded (FFPE) 
blocks using a microtome and mounted onto the slides using a water bath at 40°C. 
The slides were then incubated at 40°C in an incubator overnight.
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2.2.4.2 Preparation of LCM PALM membrane slides
LCM PALM membrane 1.0 PEN slides were pre-treated with UV light for 30 minutes 
and then with Poly-L-Lysine for 5 minutes. The slides were then incubated at 40°C 
overnight to dry. Blocks of paraffin embedded tissues were cut into 10pm thick 
sections using a Microtome. Dependent on the size of the tumour, up to 3 sections 
were cut for H&E staining and mounted onto the central membrane area of the LCM 
slides using a water bath at 40°C. An adjacent section was also cut for S100 staining 
and mounted onto normal pre-treated microscopy slides. The LCM slides were then 
incubated at 60°C overnight (40°C for S100 slides) to melt the wax and fix the 
samples to the slides.
2.2.4.3 IHC on FFPE tissues
Deparaffinisation was completed using sequencial wash steps. Two xylene washes 
for 5 minutes each, two 100% ethanol washes (5 minutes each), a 70% ethanol 
wash (5 minutes), 50% ethanol wash (5 minutes) and finally a dH20  wash for 2 
minutes. Slides were then put into Citrate Buffer to aid in antigen recovery and 
heated on high power in a microwave to start the buffer boiling and then for 10 
minutes on medium power to maintain boiling of the buffer. The slides were rinsed in 
running tap water for 5 minutes and put into 3% H2 O2 to block endogenous peroxide 
for 20 minutes. After another 5 minute wash in running tap water and then a 5 minute 
TBS wash, slides were put into a tray and the sample was circled with a wax pen. 
The block buffer was prepared (section 2.1.6) and 100pl added to each slide and 
incubated at room temperature for 20 minutes.
Following the incubation, the buffer was tapped off and the primary antibody was 
prepared at the recommended dilution (section 2.1.7.1) and 100pl was added per 
slide and incubated at 4°C overnight. Following this incubation, the slides were 
washed twice with TBS for 5 minutes each. During these wash steps, the ABC 
peroxidase and secondary antibodies were prepared (section 2.1.7.2). The slides 
were then incubated with 100pl of secondary antibody at room temperature for 30 
minutes. The slides were washed twice more with TBS for 5 minutes each and then
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each slide was incubated with 10OpI ABC peroxidase at room temperature for 30 
minutes. The slides were washed twice more with TBS for 5 minutes each and 
during the second incubation; the DAB was prepared (section 2.1.6). 200pl DAB was 
added to each slide and the colour was allowed to develop and then immediately the 
DAB was tapped off and slides were washed in TBS for 2 minutes and dhfeO for 2 
minutes. If a counterstain was required (e.g. Gills Haematoxylin), slides were 
immersed in the counterstain for 1 minute and then rinsed in running water for 5 
minutes. The slides were finally dehydrated using sequencial washes: 50% ethanol 
(5 minutes), 70% ethanol (5 minutes), two 100% ethanol washes for 5 minutes each 
and two xylene washes for 5 minutes each. Slides were finally mounted using DPX.
2.2.4.4 Modified Haematoxylin and Eosin staining for FFPE tissues for LCM
A modified H&E stain was applied to each of the slides using an automated Varistain 
Gemini (Thermo Scientific). Slides were initially dewaxed and hydrated using 
sequencial washes of xylene (5 minutes) followed by a fresh xylene wash (2 
minutes), 100% ethanol wash (1 minute), 95% ethanol (1 minute), 70% ethanol (1 
minute) and a running water wash (1 minute). The sections were then stained with 
Harris Haematoxylin (2 minutes) followed by two running water washes for 1 minute 
each. Slides were immersed in bluing reagent for 1 minute and Eosin for 10 seconds 
followed by two running water washes for 1 minute each. Finally slides were 
dehydrated with 70% ethanol (1 minute), 95% ethanol (1 minute) and 100% ethanol 
for 1 minute. Following staining, H&E stained slides were stored at -80°C until used 
in LCM.
2.2.4.5 mmunocytochemistry (ICC)
Cells were grown as previously described. Once confluent, cells were split and 2x105 
cells were resuspended in DMEM, 10% FBS and 1% Pen/strep and plated onto 
small 22x26mm coverslips placed into each well on a six well plate. Cells were left to 
adhere to the coverslip for 4 hours before the wells were filled with 2ml of the same 
medium and incubated at 37°C overnight. Leaving the cells for longer than this led to 
detachment from the plate due to the cells becoming over confluent.
The following day, the medium was removed and the wells were washed twice with 
PBS for 1 minute. 1ml of methanol and acetone in a 1:1 ratio was added to each well
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and incubated at -20°C for 20 minutes to fix the cells. The methanol and acetone 
was then removed and 1ml of PBS was added to the wells to wash the cells. The 
cells on the coverslips were stained as described in section 2.2.4.5 with the omission 
of the deparaffinisation, antigen recovery and hydrogen peroxide steps which were 
not required.
2.2.5 Relative quantification (qPCR)
Relative quantification PCR (qPCR) is a method by which changes in expression of a 
nucleic acid sequence (the target) in a test sample can be determined relative to the 
same sequence in a calibrator sample such as an untreated control or a sample at 
time point zero in a time course study (Livak and Schmittgen, 2001). Without 
needing to determine the exact copy number of the template, relative quantification 
can give an accurate comparison between the initial levels of template in each 
sample. Relative quantification was used to determine a relative increase or 
decrease in expression of the genes of interest as determined by the delta delta ct 
method [AAct] (comparative ct) given by the equation: t=0=2-AAct. The ct values of 
the samples of interest are compared with that of a control (calibrator sample - RNA 
from normal tissue). The ct values of both the calibrator and the samples of interest 
are then normalized to an appropriate endogenous housekeeping gene (B2M) 
(Ponchel et al, 2003). Relative quantification was completed with the use of real-time 
PCR in which it is possible to observe the progress of a PCR reaction as it takes 
place with data collected throughout the reaction not just at the end point. The 
reaction is typified by the point during the cycle at which the target to be amplified is 
first detected instead of the amount of target which is accumulated by the end of the 
reaction. Primers for use in real time PCR were designed using Primer Express 
(Applied Biosystems). Relative quantification was carried out using the following 
reagents and cycle conditions:
Reagent Volume 12.5pl SYBR® Green 6.5pl
DNA (5ng/pl) 1 pi Sense Primer [2pM] 1 pi
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Antisense Primer [2pM] 1 |jl 95°C 10 minutes
h 2o 3(jI
Cycle Conditions x40 Cycles
95°C
60°C
15seconds 
1 minute
50°C 2minutes
Three replicates were used per experiment and Beta-2-Macroglobulin (B2M) served 
as an endogenous control. Control reactions were used to eliminate the presence of 
contaminants in the DNA samples and specificity of PCRs were determined by gel 
analysis and the addition of a dissociation step, producing a single peak upon 
analysis representing a specific reaction. All data was analysed with the ABI 7500 
SDS System software (Applied Biosystems). All reactions were assessed for PCR 
efficiency by producing standard curves. The ct values were plotted against the log 
concentration of the template and a linear trend line was applied. The qPCR 
standard curve slope to efficiency calculator (Stratagene) was used to assess the 
efficiency based on the equation: Efficiency = -1+10(-1/slope). A slope of -3 .32  
represents optimal efficiency (100%), assays with amplification efficiencies of 
between 90 and 100% considered acceptable with an r2 close to 1 and a Y-intercept 
similar for all assays. All qPCR assays in this study were >97% efficient.
2.2.6 Immunoprecipitation (IP)
Immunoprecipitation uses the antigen-antibody reaction principle to identify a specific 
protein of interest. A protein can therefore be purified from a mixture of proteins to 
assess its quantity or physical characteristics. Cells were lysed in 1ml of lysis buffer 
(see above). Samples were put through several freeze thaw cycles to aid in cell lysis 
and finally sonicated in a 2ml tube surrounded by ice for 10 seconds or homogenised 
for 20seconds per sample to break up cells (the homogeniser was washed with 
dH20  in between each sample). The cells were then centrifuged at 13,000rpm for 8 
minutes at 4°C to pellet cell debris and remove air bubbles. A 1.5ml eppendorf tube 
corresponding to each sample was pre-chilled on ice and the cMET  rabbit polyclonal 
antibody was added to the tube at a concentration of 1pg/ml (5pl). 600pl of cell 
lysate was added to each tube containing the antibody and incubated at 4°C 
overnight with agitation. The 20% ethanol in which G-coupled Sepharose beads are 
stored was removed by inverting and briefly centrifuging at 3000rpm for 2 minutes at
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4°C. G-coupled Sepharose beads were resuspended in 1ml lysis buffer containing 
protease inhibitors and the beads were washed by centrifuging them at 3000rpm for 
3 minutes, followed by removal of the lysis buffer and addition of an equal volume of 
fresh lysis buffer to the volume of compacted beads. Pipette tips with 5mm cut from 
the end were used to prevent damage to the beads. This was repeated twice more. 
The final bead slurry was mixed well to ensure a homogenous suspension of beads 
before 30pl of beads was added to the 600pl of each cell lysate and antibody. The 
lysate-bead mixture was incubated at 4°C under rotary agitation for 30 minutes. 
Following incubation, the tubes were centrifuged at 3000rpm for 3 minutes to remove 
the supernatant. 500ul of fresh lysis buffer was added to each tube and the process 
was repeated 3 more times for a total of 4 washes. Following the final wash step, all 
of the supernatant was removed and 30pl of each cell lysate (~50jag) was added to 
8pl of NuPAGE loading dye and 2pl of DTT. The samples were then either frozen at 
-80°C or run on SDS-PAGE.
2.2.7 Western blot
Prior to completion of downstream assays, gene expression was determined by 
western blot. Cells were washed twice with ice cold PBS and then lysed in 200pl of 
the appropriate buffer. ‘Blenis’ lysis buffer was used for all cell lysis except for cells 
used in the Ras ELISA assay (Section 4.3.6) in which the buffer provided with the kit 
was used. Cells were scraped from the plate and incubated on ice in a 
microcentrifuge tube for 15 minutes. Total proteins in the cell lysates were then 
vortexed or sonicated for 10 seconds and centrifuged at 14,000rpm for 10 minutes at 
4°C. The supernatant was then either run with SDS-PAGE or stored at -80°C. DTT 
and 4x NUPAGE loading dye were combined in a 1:4 ratio and 10pl of this mix was 
added to 30pl of cell lysate for each sample (~50pg). The tube was gently flicked to 
mix and incubated at 70°C for 10minutes on a heat block. The samples were briefly 
centrifuged to collect the sample and 20pl of each sample was loaded into each well 
of the gel followed by 4pl of pre-stained ladder. Sample extracts were resolved on 
NuPAGE Novex 4-12% Bis-Tris gel or NuPAGE Novex 3-8% Tris-Acetate gels 
depending on the size of the protein. The combs were removed; the gels were rinsed
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with dhfeO to remove any un-polymerised gel and slotted into the gel apparatus. The 
tank was filled with 1x running buffer and the gel was then run at 150v for an hour.
The membrane was briefly pre-treated with 100% methanol and then washed off in 
1x transfer buffer for 5 minutes. Following SDS-PAGE, the total proteins were 
transferred to Immobilon PVDF membrane (Millipore) and the transfer apparatus was 
constructed (Hoefer) with sponges and a piece of whatmann paper below the 
membrane and the same above. All components were pre-rinsed in 1x transfer 
buffer to prevent the membrane from drying out. Bubbles were removed by rolling a 
stripette over the surface of the whatmann paper. The blotting apparatus was then 
run at 25v for 2 hours.
The membrane was blocked with 5% (w/v) powdered milk in TBS-T. The membrane 
was washed briefly with H2O to remove methanol before the membrane was 
incubated for 30minutes with the milk with gentle agitation. The milk was washed 
once with dh^O and then incubated in 10ml of primary antibody overnight at 4°C on 
an orbital shaker. Following the overnight incubation, the antibody was removed and 
kept for future use. The membrane was then washed once in 1x TBS-T. 10ml of the 
appropriate secondary antibody was added to the membrane and it was incubated at 
room temperature on an orbital shaker for 30 minutes. The membrane was then 
washed 3-4 times with TBS-T.
1ml of the ECL mix in a 1:1 ratio was put on a pre-cleaned glass plate. The 
membrane was blotted on to a piece of paper towel and then put in the ECL mix. The 
mix was washed over the surface and incubated for 2 minutes. The membrane was 
removed from the mix and placed face down on to a piece of Clingfilm. The excess 
Clingfilm and creases were removed and then the membrane in the Clingfilm was 
taped into a cassette and developed by exposing it on x-ray film.
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CHAPTER 3: Analysis of somatic mutations in cutaneous neurofibromas
3.1 Introduction
This chapter focuses on two main aspects of NF1 somatic mutation detection; firstly the 
validation of methods of somatic mutation enrichment in heterogeneous tumours and 
secondly implementation of such methods for somatic NF1 mutation detection in benign 
cutaneous neurofibromas derived from patients with high tumour burden. These 
patients represent the extreme end of the spectrum of NF1 manifestations. In this study 
they are defined as patients with >500 benign cutaneous neurofibromas, harbouring 
more tumours than patients of a comparable age.
Cutaneous neurofibromas are considered to be the hallmark feature of NF1. Within 
these neurofibromas, Schwann cells which harbour the somatic NF1 mutations are the 
predominant cell type, although they only comprise between 40% and 80% of cells 
(Peltonen et al, 1988; Wallace et al, 2000). A number of heterozygous fibroblasts, mast 
cells and perineural cells make up the remainder of the total cell content. (Kimura et al, 
1974; Le and parade, 2007). There are several lines of evidence responsible for the 
conclusion that Schwann cells bear somatic NF1 mutations. Although wild-type and 
neurofibroma derived NF1',~ Schwann cells have the same proliferative activities 
(anchorage dependent growth and normal axon interaction), they have distinct invasive 
and angiogenic capabilities (Sheela et al, 1990; Muir, 1995). Additionally, LOH of the 
NF1 gene can only be identified in Schwann cells but not fibroblasts which were both 
isolated from within the same tumour (Kluwe et al, 1999; Rutkowski et al, 2000). 
Furthermore, in a pivotal study by Zhu et al (2002), mice with a deletion of the NF1 gene 
in the Schwann cell lineage were found to develop neurofibromas (section 1.8). 
Although the cell of origin of neurofibromas has been a major subject of debate, recent 
studies have confirmed that skin-derived precursor cells are the cell type from which 
neurofibromas are derived (Le et al, 2009; Le et al, 2011). Biallelic inactivation of NF1 in 
Schwann cells is, however, not sufficient to promote tumorigenesis and thus a role for 
the tumour microenvironment has been postulated and indeed demonstrated in mouse 
models (Zhu etal, 2002;Yang etal, 2003; Le etal, 2009) (section 1.9.4.1).
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Cutaneous neurofibromas therefore represent heterogeneous entities with high 
biological heterogeneity relating to the cellular composition of these tumours and also 
genetic heterogeneity due to the presence of both NF1 hemizygous and homozygous 
cell populations. The somatic mutation detection rate in DNA derived from whole 
cutaneous neurofibromas in previous studies varies between 12% and 64% (John et al, 
2000; Serra et al, 2001b; Upadhyaya et al 2004; Spurlock et al, 2007). This paucity of 
identified mutations is partly related to the size and complexity of the NF1 gene but is 
more likely a problem of the cellular and molecular heterogeneity of these tumours. It is 
clear that to be able to accurately and efficiently assess the mechanisms of 
tumorigenesis in neurofibromas, improvements to somatic mutation detection methods 
need to be sought.
Mutation detection methods are continually evolving to ensure that mutation detection is 
both efficient and cost effective. The type of mutation detection methods employed in 
genotyping studies are dependent on the types of mutation which are most commonly 
associated with the gene of interest. The application of a set of complementary 
techniques that allow the detection of the different mutation types is therefore important. 
However, this in itself is a challenge as the use of multiple methods results in increased 
costs, labour and analysis time. The most common methods of mutation detection 
employed to identify and characterise the range of NF1 germline and somatic mutations 
detected in NF1 patients are outlined in section 1.10. These techniques include; FISH, 
MLPA, LOH analysis and the use of microarrays for identification of microdeletions and 
microinsertions. Point mutations are detected through direct sequencing of DNA or 
cDNA, SSCP, heteroduplex analysis and the protein truncation test (PTT). There is, 
however, no standardised, routine platform for the analysis of the whole spectrum of 
NF1 mutations and no consistently used method to resolve the issue of cellular 
heterogeneity in NF1-associated tumours.
Serra et al (2000) have established an improved culture technique for Schwann cells 
which is capable of purifying populations of NF1 heterozygous (NF1+/~) as well as 
homozygous (NF1'A) Schwann cells from primary peripheral nerve sheath tumours 
(Rosenbaum et al, 2000; Serra et al, 2000). This technique has been successfully used 
to enhance the mutation detection rate in small cohorts of neurofibromas, although the
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challenges associated with this technique need to be addressed (Maertens et al, 2006). 
Furthermore, laser capture microdissection (LCM) has been utilised to isolate specific 
alterations in distinct cell types from a heterogeneous cellular background. LCM has 
been employed in the analysis of many tumour samples including breast carcinomas 
and is readily applicable to targeting Schwann cells from within heterogeneous NF1- 
associated tumours (Edward, 2007; Zanni and Chan, 2011). This method has not 
previously been applied to NF1 somatic mutation detection; however, indicating that 
determination of the efficacy of LCM in routine NF1 somatic mutation analysis is 
warranted.
There is considerable variation in the number and distribution of neurofibromas even 
between family members and individuals with the same NF1 germline mutation. This 
indicates that other genetic loci including TP53, CDKN2A, RB1 and mismatch repair 
(MMR) genes may be modifying the phenotypic expression of NF1, particularly in 
patients with a high tumour burden. In predisposition cancer syndromes, multiple 
genetic abnormalities frequently occur in pre-malignant lesions which are not present in 
the normal tissue. Malignant neoplasms usually arise due to the accumulation of genetic 
alterations typically involving loss of function of regulatory elements of the cell cycle 
machinery including TP53, CDKN2A and RB1 which can mediate abnormal cell cycle 
arrest through DNA damage and aberrant apoptosis. Such genes are frequently found 
to be mutated in MPNSTs (Kourea et al, 1999; Nielsen et al, 1999; Mawrin et al, 2002; 
Mantripragada et al, 2008) although only two previous studies (Upadhyaya et al, 2008; 
Stewart et al, 2008) have identified TP53 LOH in plexiform neurofibromas and there is 
no previous indication of the involvement of these genes in the development of benign 
cutaneous neurofibromas (Carroll and Ratner, 2008; Le et al, 2009; Parrinello and 
Lloyd, 2009; Upadhyaya et al, 2004).
TP53 is a prime candidate for loss of function in malignant tumours and has been widely 
investigated in the case of both sporadic and NF1-associated MPNSTs. TP53 is a key 
tumour suppressor gene involved in regulation of the cell cycle, with a major role in cell 
survival. Loss of TP53 function is seen in about half of all human cancers where p53 
protein expression is frequently lost or apoptosis fails to be initiated due to accumulation
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of non-functioning proteins in the nucleus (Menon et al, 1990; Legius et al, 1994; 
Kindblom et al, 1995; Schneider-Stock et al, 1997; Birindelli et al, 2001; Mawrin et al,
2002). Mice carrying cis-linked Nf1 and TP53 mutations develop MPNSTs, indicating 
that accumulation of mutations at various oncogenic loci is important in malignancy. 
(Cichowski et al, 1999; Vogel et al, 1999; Reilly et al, 2000). TP53 and other cell cycle 
related genes; CDKN2A and RB1 may therefore represent important modifying genes in 
neurofibroma development.
CDKN2A/p16INK4a which encodes p16INK4A and p14ARF has also been investigated in 
NF1 malignancies due to its prominent role in the cell cycle and its involvement in the 
development of other tumour types. Several studies have described deletions in 
CDKN2A, in MPNSTs in addition to inactivation of the CDKN1B gene which encodes 
the cell cycle regulator p27 (KIP1) (Kourea et al, 1999a Kourea et al, 1999b; Nielsen et 
al, 1999; Perry et al, 2002; Holtkamp et al, 2008). Additionally, the RB1 gene 
responsible for the development of retinoblastoma has been found to be mutated in a 
number of sarcomas including MPNSTs (Birindelli et al, 2001). RB1 is a tumour 
suppressor gene, which regulates G1/S transition (Weinberg, 1995), causing cell cycle 
arrest in G1 through suppression of E2F transcription factors and by E2F independent 
mechanisms (Riley et al, 1994; Cobrinik, 2005). RB1 therefore controls cellular 
differentiation during embryogenesis and in adult tissues, as well as regulation of 
apoptotic cell death, maintenance of permanent cell cycle arrest and preservation of 
chromosomal stability (Dannenberg et al, 2006). Loss of RB1 consequently results in 
increased proliferation due to induction of cell-cycle regulators such as cyclin D1 and 
suppression of cell cycle inhibitors including KIP1. (Downward et al, 2002).
Bi-allelic defects in mismatch repair genes (MMR) can cause instability of microsatellite 
repeats and are known to be associated with an “NF1-like phenotype”. Heterozygous 
mutations in MLH1 (Wang et al, 1999), homozygous MSH6 mutations (Menko et al, 
2004), homozygous PMS2 (Kruger et al, 2008) and most recently homozygous MSH2 
mutations (Toledano et al, 2009) have all been linked to this “NF1-like phenotype” 
including the presence of multiple cafe au lait macules. It is therefore indicated that NF1 
inactivation may be an important step in malignant progression in mismatch repair
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deficient cells (Wimmer and Etzler, 2008; Wang et al, 2003). Indeed, bi-allelic defects in 
mismatch repair genes (MMR) are often associated with colonic and extra-colonic 
tumours, especially in HNPCC, an autosomal dominant disorder in which the underlying 
mutational mechanisms involve germline mutations in a mismatch repair gene (MMR) 
including: MLH1, MSH2, MSH6 or PMS2 (Lynch et al, 2008). The MMR proteins 
function in the process of detection and repair of DNA replication errors, specifically 
short insertions and deletions which form loops in addition to single basepair 
mismatches (Boland et al, 2008). Somatic mutation of one of these genes in the 
remaining wild type copy in patients with a constitutional mismatch repair deficiency 
therefore results in cells with defective MMR. This primarily affects repeat sequences 
which cause microsatellite instability (MSI) and consequently lead to tumour 
development suggesting that defective MMR may also act as a modifier for 
neurofibroma development.
Animal models which harbour deficiencies in one or all of the major MMR genes have 
also been developed which recapitulate to an extent, NF1 in humans (de Wind et al, 
1995; Reitmair et al, 1995; Reitmair et al, 1996; Sohn et al, 2003; Gutmann et al, 2003; 
Chen et al, 2005; Feitsma et al, 2008). While zebrafish mutants develop MPNSTs and 
neurofibromas at low frequencies (Feitsma et al, 2008), some MMR knockout animal 
models including the mouse MMR models do not develop the full spectrum of NF1 
features (Reitmair et al, 1996; Chen et al, 2005). It has, however, been found that in the 
MLH1 knockout mouse model, MLH1 deficiency exacerbates the consequences of an 
NF1+/' mutation, acting to accelerate myeloid leukaemia in such models (Gutmann et al,
2003). In previous studies, MSI has been detected in around 25% of neurofibromas 
(Ottini et al, 1995; DeRaedt et al, 2006; Thomas et al, 2010) and upwards of 50% in 
MPNSTs (Serra et al, 1997; Spurlock et al, 2007), further evidence for a possible 
association of MMR deficiencies with NF1 tumorigenesis.
Our understanding of the molecular mechanisms that underlie NF1 tumorigenesis is still 
relatively limited. Identification of the precise genetic pathways altered during 
neurofibroma formation and more importantly the factors responsible for malignant 
transformation are crucial for complete comprehension of NF1 tumorigenesis. It is
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important to determine why some types of neurofibroma develop only during 
adolescence whilst others are present from birth in addition to the underlying initiating 
events in neurofibroma growth and the mechanism responsible for variability in the 
number and distribution of neurofibromas. To date, more than 1,273 different germline 
NF1 mutations have been reported (HGMD) but only about 215 different characterised 
somatic NF1 mutations have been reported in cutaneous neurofibromas. This 
demonstrates a clear need to expand the NF1 somatic mutational database. 
Improvements to somatic mutational detection methods and enrichment strategies will 
facilitate the identification of common mutations and mechanisms for somatic NF1 
inactivation. Knowledge of the nature, type and frequency of somatic mutations in the 
NF1 gene, in addition to the identification of other modifying loci are all key steps for 
elucidating the mechanisms controlling neurofibromagenesis.
This study was undertaken in two parts; (i) validation of Schwann cell culture and laser 
capture microdissection as a strategy for improving somatic mutation detection, (ii) 
Utilisation of such techniques in the analysis of 89 benign cutaneous neurofibromas 
derived from NF1 patients with very high tumour burden in which some neurofibromas 
studied were also present adjacent to each other. Such high burden of tumours may 
indicate that alterations of additional modifying loci are underlying the development of 
tumours in these severely affected patients. The three basic aims of this chapter are:
1) To develop and assess the efficacy of Schwann cell culture and LCM for 
improving NF1 somatic mutation detection
2) Application of LCM to the analysis of cutaneous neurofibromas derived from NF1 
patients with high tumour burden.
3) To determine whether somatic mutations in other ‘modifying’ genes, including the 
TP53, CDKN2A, RB1 and MMR  genes, are also involved in the growth of 
neurofibromas in patients with high burden of cutaneous neurofibromas.
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3.2 Methods
3.2.1 Patients
3.2.1.1 Clinical presentation
Upon clinical examination, all 31 unrelated NF1 patients from whom neurofibromas 
were derived exhibited the NIH diagnostic criteria for NF1 (section 1.5). Additional 
complications for patients with multiple neurofibromas are summarised in table 3.1.
3.2.1.2 Tissue samples
Schwann cell culture and LCM were employed in an enrichment strategy with the aim of 
increasing the somatic mutational detection rate by enriching the Schwann cell 
population. All 13 fresh cutaneous neurofibroma samples for Schwann cell culture were 
surgically removed from 3 unrelated patients and stored at 4°C in McCoys medium until 
cultured as described in section 2.2.2.5. DNA and RNA from Schwann cell cultures was 
extracted as described in sections 2.2.3.1.1 and 2.2.3.1.2. Tumour DNA for LCM was 
derived from 35 formalin fixed paraffin embedded (FFPE) samples; 30 benign 
cutaneous neurofibromas, 4 plexiform neurofibromas and 1 MPNST derived from 25 
individuals, in which DNA from all fresh tumour samples had been previously analysed 
but no somatic NF1 mutations had been identified.
Following validation of the effectiveness of Schwann cell culture and LCM using the 
above samples, 89 neurofibromas derived from patients with multiple benign cutaneous 
neurofibromas were analysed for somatic NF1 mutations. Three unrelated NF1 patients,
2 females, aged 44 and 46 (patients 1 and 2 respectively) and 1 male aged 60 (patient
3) all with a high burden of cutaneous neurofibromas (>550) were recruited for this 
study. DNA and RNA were extracted from paired blood and whole tumour tissue from all
3 patients (forty tumours from patient 1, forty tumours from patient 2 and nine from 
patient 3). The exact anatomical location from which the majority of these tumours were 
excised is unknown, 20 of these neurofibromas were located in close proximity to each
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Table 3.1. Overview of results of the analysis of 89 tumours and paired blood DNA samples from three NF1 patients with 
a high tumour burden
Patient Germline Mutation
Somatic Mutation
LOH DirectSequencing
Somatic
Mutation
Detection
Rate
MSI Clinical Details
>6 CAL Spots
>550 Cutaneous Neurofibromas
E17: c.2875 C>T p.Q959X 7/40 19/40 65% 4/40 >2 Lisch Nodules
First Degree Relative with NF1
Abnormal Learning and Development 
Osteopenia_______________________
>6 CAL Spots
>550 Cutaneous Neurofibromas
E10b: c.1413-1414delAG 
p.KfsX4 15/40 9/40 60% 12/40
>2 Lisch Nodules
Sporadic
Abnormal Learning and Development 
MPNST in Pelvis
>6 CAL Spots
>550 Cutaneous Neurofibromas
>2 Lisch Nodules
E36: c.6756+2 T>G 0/9 7/9 78% 5/9 Sporadic
Abnormal Learning and Development 
Facial Plexiform Neurofibroma
Spinal Neurofibromas
Chronic lymphocytic leukaemia (B-CLL)
Total 22/89(25%) 35/89 (40%) 57/89 (64%)
21/89
(24%)
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other, i.e. adjacent tumours which were directly touching and sharing the underlying 
skin. These 20 tumours are shown by hatched shading in table 3.4. The remaining 
tumours are believed to be randomly distributed across the patients’ bodies. DNA and 
RNA were extracted using the methods described in sections 2.2.3.1.1 and 2.2.3.1.2.
3.2.2 Laser Capture Microdissection (LCM)
Laser micromanipulation enables microscopic high-resolution control of sample 
composition by allowing selection (or rejection) of user defined areas of tissue sections. 
Slides were prepared from FFPE tissue as described in section 2.2.4.2. Following 
immunohistochemical staining with S100 and H&E as described in section 2.2.4.3 and 
2.2.4.4, LCM was carried out using an Axiovert S100 (Zeiss) through which a pulsed 
ultra-violet PALM microlaser is interfaced and focused. LCM provides clear resected 
margins for the selected tissue without affecting the adjacent tissues. The user defined 
parameters for LCM were: cut Speed; 30, zoom; 5x, laser energy; 94 and laser focus; 
85. The cap from a 0.75ml microcentrifuge tube was cut off and labelled to correspond 
to the slide being cut. The cap was filled with 1pl of mineral oil and tissue sections 
(totalling approximately 100Mm2) were outlined on the computer screen which was 
attached to the microscope for the laser to cut. Sections of paraffin embedded tissue 
which had been laser cut were catapulted into the lid of the tube which was positioned 
above the slide. The bottom of the tube was then placed onto the cap and these were 
stored at -80°C prior to DNA extraction as described in section 2.2.3.1.6.
3.2.3 NF1 gene analysis
Schwann cell culture and LCM were validated as a strategy for enrichment of the NF1 
somatic mutation harbouring Schwann cell population. DNA and RNA from 13 
neurofibroma-derived Schwann cell lines and DNA samples derived from 35 LCM 
tumour samples were analysed by loss of heterozygosity (LOH) analysis, MSI analysis, 
multiplex ligation dependent probe amplification (MLPA) and direct sequencing of the 
NF1 gene. Following validation of these techniques, LCM was applied to the analysis of
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42 of the 89 tumour samples derived from three patients with high tumour burden in 
which somatic NF1 mutations were not identified (15 samples from patient 1, 23 
samples from patient 2 and 4 samples from patient 3) (figure 3.1). LCM of FFPE 
samples was used in this analysis as fresh whole tumour was not available for Schwann 
cell culture.
3.2.3.1 Loss of Heterozygosity (LOH) analysis at the NF1 locus
LOH analysis was completed on DNA from all neurofibromas and corresponding 
lymphocyte samples utilising a panel of fluorescently-tagged microsatellite markers and 
4 polymorphic RFLP’s (supplementary table 4 and supplementary table 5) that spanned 
the entire NF1 gene and also the majority of chromosome 17 (17p13 to 17q25). All 
reactions for microsatellite markers were carried out at an annealing temperature of 
56°C and RFLPs at an annealing temperature of 54°C. The following reagents and 
cycle conditions were used to amplify both microsatellite markers and RFLPs.
PCR Reaction 25pl Cvcle Conditions x35 Cvcles
DNA [6ng/pl] 5pl
Buffer 2.5pl 94° C 10 Minutes
Mg [50mM] 3pl
dNTP’s [10pM] 2 pi 94°C 1 Minute
Sense Primer [10pm/pl] 1pl Tm 1 Minute
Antisense Primer [10pm/pl] 1pl 72°C 1 Minute
Taq 0.05pl
H20 10.45pl 72°C 10 Minutes
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Validation Stage Test Stage
FFPE Tissue 
(N F = X , 
PF=4, 
MPNST= 1)
Patient 1 
V\tiole 
Tumour 
DNA 
(n=40)
Patient 2 
Whole 
Tumour 
DNA 
(n=40)
\M iole 
Tumour 
Tissue (n=13)
Patient 3 
V\hole 
Tumour 
DNA 
(n=9)
MSI 
(n=89) 
[22 MSI]
MMR 
Sequencing 
(n=89) [No point 
M utations]
TP53, RB1 & 
CDKN2A LOH 
(n=89) [5 LOH]
"  TP53 
Sequencing 
(n=89) [No Point 
O M u ta tio n s ] ^
Schwann 
Cell DNA
NF1 LOH, 
MLPA, 
Sequencing
11/13(85% )
somatic
mutations
detected
Primary
Tumour
DNA
4/13(31% )
somatic
mutations
detected
>f
NFl I 
MU 
Seque
LOH,
PA,
mcing
\
LCM
derived
DNA
\ t
HF1 LOH, 
MLPA, 
Sequencing
>f
28/35 (80%) 
somatic 
mutations 
detected
NF; Neurofibroma.PF; Plexiform neurofibroma, 
N/A; Not applicable
NF1 LOH 
(n=89) [22 LOH]
NF1 MLPA  
(n=89) [No deletions/ 
duplications]
LCM (n=42) 
[Schwann 
Cells N/A]
NF1 Sequencing (n=67) 
[35 Point Mutations]
57/89 (64%) somatic 
mutations detected
Figure 3.1. Flow diagram demonstrating the stages of validation of LCM and Schwann cell culture and the analysis of 89 
benign cutaneous neurofibromas from patients with high tumour burden.
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3.2.3.2Analysis of PCR products
The success of the PCR reaction was analysed by running the PCR product on a 1.5% 
agarose gel as described in section 2.2.3.2.1. For the microsatellite markers, a 1 in 
200pl dilution of the PCR product with dh^O was made and 2pl of the diluted product 
was combined with an 8pl solution of ROX (0.3pl) and HIDI (7.7pl) in a 96 well plate. 
The plate was then incubated for 2 minutes at 95°C in a thermal cycler to denature the 
DNA and capillary electrophoresis was carried out on an ABI 3100 sequencer. 
Genotyper and Genescan software were used to characterise the results (Applied 
Biosystems, Warrington, UK). Allelic loss was scored if the area under one allelic peak 
in the tumour was reduced relative to the other allele, after correcting for the relative 
peak areas with corresponding lymphocyte DNA (Dasgupta et al, 2003b). Microsatellite 
markers which were shown in the blood to be constitutionally homozygous were scored 
as non-informative.
To each of the successful RFLP PCR reactions, 10pl of the appropriate enzyme, buffer 
and BSA was added (supplementary table 5). The PCR product and digestion mix were 
then incubated at the appropriate temperature and for the required amount of time 
(supplementary table 5). Following the incubation, the whole reaction volume was run 
on a 3% agarose gel with 3pl of concentrated loading dye and run for an hour at 150V. 
The gel and band sizes were then analysed using UV light on a Gel Doc and the 
presence of LOH scored if there was a significant difference in intensity between the 
bands representing the two heterozygous NF1 alleles. At least two adjacent markers 
(microsatellite or RFLP) were required to show a reduced signal for LOH to be positively 
confirmed.
3.2.3.3 Multiplex Ligation-dependent Probe Amplification (MLPA)
An MLPA assay kit (MRC Holland) (SALSA P081/082 and SALSA P122) that contained 
probes covering the entire NF1 gene, surrounding regions and control probes was 
employed to screen for evidence of genomic deletions or insertions across the NF1 
gene using the protocol outlined by the manufacturers (MRC Holland). 250ng of test
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DNA in addition to a positive (characterised whole gene deletion) and a negative control 
(from a non-NF1 patient sample) were required for each assay. All incubations were 
completed on a thermal cycler. Briefly, the DNA was heated to 98°C for 5minutes and 
then cooled to 25°C. The relevant probes were mixed with the buffers and 2pl was 
added to the DNA and incubated for 1 minute at 95°C followed by 16hours at 60°C. 
Following the 16 hour incubation, the samples were incubated at 54°C and 32pl of a mix 
containing a ligase, ligase buffer and dH20 was added to each sample and mixed. This 
was incubated for 15 minutes at 54°C, for 5 minutes at 98°C and finally briefly at 60°C 
just prior to the plate being removed from the thermal cycler. 10pl of this reaction was 
added to a new plate and 30pl of a mix containing a PCR buffer and dH20  was added to 
each well in the new plate. Finally the plate was put back into the thermal cycler, 10pl of 
a mix containing PCR primers and polymerase was added and the PCR reaction was 
started using the following cycle conditions: 35x (95°C 30 seconds, 60°C 30 seconds, 
72°C 60 seconds), 72°C 20 minutes. After the PCR reaction was complete, 7.7pl of HiDi 
and 0.3pl of ROX was added to each reaction. The plate was then analysed on an ABI 
3100 analyser (Applied Biosystems, Warrington, Cheshire, UK). An excel spreadsheet 
(NGRL Manchester) was used to characterise the results.
3.2.3.4 Direct sequencing
Direct sequencing of all NF1 exons in genomic DNA and RNA was utilised to detect 
small sequence alterations in the remaining samples in which neither LOH nor deletions 
were found using the protocol outlined in section 2.2.3.2. All sequence alterations were 
fully characterised using an ABI 3730 analyser (Applied Biosystems) and Sequencher 
software (Genecodes, USA).
3.2.4 Analysis of modifying loci
In view of the exceptionally high burden of neurofibromas present in all three NF1 
patients (and the close proximity of some of the tumours studied), analysis was 
undertaken to screen for somatic mutations in four potential modifying loci; TP53, RB1,
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CDKN2A and MMR genes in all 89 neurofibroma samples using LOH analysis and 
direct sequencing (figure 3.1). Genetic aberrations in genes involved in cell cycle 
regulation, apoptosis and repair would affect multiple pathways and could contribute to 
an alternative mutational mechanism underlying the development of these multiple 
tumours.
3.2.4.1 Microsatellite Instability (MSI) analysis
MSI analysis was completed on all tumour and paired lymphocyte DNA samples with a 
standard panel of 10 fluorescently tagged microsatellite markers (supplementary table 
6). All reactions were completed at 58°C using the following reagents and cycle 
conditions
PCR Reaaents 2 5 pi Cvcle Conditions x35 Cycles
DNA [6ng/pl] 5pl
Buffer 2.5pl 94°C 10 Minutes
Mg [50mM] 3 pi
dNTP’s [10pM] 2pl 94°C 1 Minute
Sense Primer [10pm/pl] 1 pi 58°C 1 Minute
Antisense Primer [10pm/pl] 1pl 72°C 1 Minute
Taq 0.05pl
H20 10.45pl 72°C 10 Minutes
Success of the PCR reaction was analysed by running 3pl of the PCR product with 5pl 
of loading dye on a 1.5% agarose gel as previously described. A 1:200 dilution of the 
PCR product was made and 2pl of the dilution was added to 7.7pl of HIDI Formamide 
and 0.3pl of ROX. The electrophoresis mix was denatured for two minutes at 95°C and 
subsequently analysed on an ABI 3100 with Genescan and Genotyper software. The 
presence of new alleles in the tumour samples which are not found in corresponding 
blood DNA samples, indicate the presence of MSI.
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3.2.4.2 Analysis of somatic TP53, RB1 and CDKN2A mutations
LOH analysis and direct sequencing of the TP53, RB1 and CDKN2A genes was 
completed using the same methods and scoring systems that were applied to the 
analysis of the NF1 gene.
3.2.4.2.1 TP53 RB1 and CDKN2A LOH analysis.
DNA from all 89 tumour samples and matched lymphocyte DNA samples was analysed 
for LOH at four microsatellite markers flanking the TP53 gene, five microsatellite 
markers which flank the RB1 gene and four markers within the CDKN2A gene 
(supplementary table 7). All reactions were completed at an annealing temperature of 
56°C using methods outlined in section 3.2.3.1.
3.2.4.2.2 TP53 Direct Sequencing
All 89 tumour DNA samples and corresponding blood samples were screened by direct 
sequencing to detect small sequence alterations in exons 4-9 of the TP53 gene 
(17p13.1) using methods described in section 2.2.3.2, an annealing temperature of 
58°C and the primers detailed in supplementary table 8.
3.2.4.3 Analysis of Mismatch Repair genes (MMR)
21 tumour DNA samples (samples harbouring MSI) were sequenced to detect 
alterations in all exons of the four main MMR genes: MLH1 (NM_000249) (3p21.3), 
MSH2 (NM_000251) (2p22-p21), MSH6 (NM_000179) (2p16) and PMS2 (NM_000535) 
(7p22.2) using the methods described in section 2.2.3.2, an annealing temperature of 
60°C for MLH1 and MSH2 and 58°C for MSH6 and PMS2 and the primers in 
supplementary table 9.
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3.2.5 Bioinformatic analysis
To infer potential mutational mechanisms underlying somatic mutations in the NF1 gene 
in the 3 patients with exceptionally high tumour burden, sequences flanking these 
somatic mutations (±20 bp) were kindly screened by Professor Nadia Chuzhanova 
(Nottingham Trent University) for the presence of direct and inverted repeats and 
symmetric elements by means of complexity analysis (Gusev et al, 1999). Hypothetical 
mutational mechanisms involving microdeletion, microinsertion and indel mutations 
mediated by these types of repeats have been described previously (Chuzhanova et al, 
2003; Ball et al, 2005). In addition, flanking regions were screened for the presence of 
37 DNA sequence motifs of length £5 bp (plus their complements) known to be 
associated with site-specific cleavage/recombination, high frequency mutation and gene 
rearrangement (Abeysinghe et al, 2003) as well as various ‘super-hotspot motifs’ found 
in the vicinity of micro-deletions/-insertions and indels (Bacolla et al, 2004)
3.3 Results
3.3.1 Schwann cell culture
To assess the efficiency by which Schwann cell culture is able to enrich Schwann cells 
harbouring NF1 somatic mutations, 13 neurofibroma derived Schwann cell lines were 
generated and the associated NF1 mutational spectra was analysed by LOH, MLPA 
and whole gene sequencing. NF1 germline mutations were identified in all 3 patients 
from whom the 13 neurofibroma Schwann cell lines were derived and comprised a 90kb 
gene deletion, 132bp deletion and an In/del. One germline mutation had been 
previously reported and 2 were novel. NF1 somatic mutations were identified in 11/13 
(85%) of Schwann cell lines derived from neurofibromas, all of which were novel. The 
identified somatic mutations comprised of: 4 small deletions (1-180bp), 1 small 
insertion, 1 splice site mutation, 1 missense mutation and 4 LOH (table 3.2, figure 3.2).
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Table 3.2. Results of NF1 somatic mutation analysis in 13 neurofibroma-derived Schwann cell samples
Sample Germline NF1 Mutation
Previously
Reported/
Novel
Somatic NF1 Mutation Previously
Reported/
NovelLOH Somatic NF1 Point Mutation
T535A
90kb Gene Deletion Upadhyaya et al (1990)
T535B
T539 c.2410-1 G>T Novel
T544 c.3975delG; p.R1325fsX Novel
T536A
c.7127 132bpdel; p.G2376 Novel
LOH: J1J2-IVS38
T536B c.7169delG; p.R2390fsX6 Novel
T541.1 c.4741insG; p.GfsX19 Novel
T541.2 LOH: EV120-3NF1
T541.3 c.1888delG; p.V630fsX Novel
T541.4 LOH: EV120-3NF1
T543.1
c.373insATGTGTdelG; p.R125fsX4 Novel
c.3568del80bp; p.G1190fsX6 Novel
T543.2 LOH: J1J2-3NF1
T543.3 c.4388 C>T; p.S1463F Novel
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Figure 3.2. DNA sequence trace of the somatic NF1 frameshift mutation (c.1888delG 
p.V630fsX) from patient T541.3 (a) 5’-3’ sequence from neurofibroma tumour tissue, 
and (b) 5’-3’ sequence from Schwann cells cultured from the same neurofibroma (c) 3’- 
5’ sequence from Schwann cells cultured from the same neurofibroma. The frameshift 
G deletion was only detectable in the DNA trace from the cultured Schwann cells.
Tumour Sample and 
Marker
LOH Original Tum our DNA LOH (%) LOH LCM DNA sample LOH (%)
T 2 2 4 -3 N F 1
L _ xv A  J L  _ /v
86% _ _____ A 35%
1235.911 l244 48| 
|4&43| l41&4|
1235 95) 1244 47) 
136961 113~2S|
T184 — EV120 L a A 83% 28%
1192.611 |200 78| 
[6065] 15067]
[ 192 28 1 {200.43( 
l 2976) | 854]
T225 —IVS27 70% ^jJ\__________a / L 54%
[205 9^ 1216 511 12QS 3a l I 215 061 
124S3| 11325)
Figure 3.3. LOH traces from DNA from whole tumour samples T164.1, T224.1, T225.1 
and LOH traces of DNA derived from LCM of the same samples demonstrating that 
LOH is not obvious in the whole tumour samples in comparison to the LCM derived 
DNA.
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The extent of LOH in all samples was confined to the 17q11.2 NF1 gene locus between 
markers J1J2 and 3’NF1. Upon MLPA analysis, no deletions were seen in the samples 
with LOH indicating that the LOH is copy neutral and that mitotic recombination is likely 
to underlie the LOH seen in these tumours. Additionally, the missense mutation 
(c.4388C>T; p.S1463F) has been analysed functionally and bioinformatically in chapter 
4. For all Schwann cell lines, DNA from the original whole tumour sample and the 
Schwann cell derived DNA was analysed simultaneously. In 4 of the 11 samples in 
which somatic mutations were detected by Schwann cell culture, once the location of 
the somatic mutation was identified (two samples with LOH, one missense and one 1bp 
deletion), the mutation was also found to be present in the whole tumour DNA but was 
not originally obvious due to the low percentage of mutation harbouring cells (about 
20% in all samples) (table 3.2, tumours T536A, T541.2, T541.3, T543.3, figure 3.2). For 
the remaining 7 samples in which the somatic NF1 mutation had been identified by 
Schwann cell culture, the mutation could still not be identified in the original whole 
tumour sample.
3.3.2 Laser Capture Microdissection
The technique of LCM was validated to determine its effectiveness for improving NF1 
somatic mutation detection. The NF1 mutational spectrum was analysed by LOH, MLPA 
and whole gene sequencing in 35 DNA samples derived from LCM of FFPE whole 
tumour samples. Germline NF1 mutations were identified in 16/25 (64%) lymphocyte 
DNA samples, 8 of which were novel mutations. Somatic NF1 mutations were identified 
in 28/35 (80%) of tumour samples derived from the 25 unrelated patients (23/30 benign 
cutaneous neurofibromas, 4/4 plexiform neurofibromas and 1/1 MPNST) (table 3.3). In 
the 30 cutaneous neurofibroma samples, somatic mutations comprised of 1 nonsense 
mutation, 1 small 2bp deletion and 21 samples with LOH. Of the 4 plexiform 
neurofibroma samples, 3 had LOH and 1 sample had nonsense mutation. The single 
MPNST sample had a nonsense mutation. The extent of LOH in 21 of these samples 
was within the 17q11.2 NF1 gene locus between markers HHH202 and 3’NF1.
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Table 3.3. Results of NF1 somatic mutation analysis in DNA from LCM tumour samples
Patient Tumour Tumour Type Germline NF1 Mutation Previously Reported/ Novel Somatic NF1 Mutation Previously Reported/ NovelLOH Point Mutation
1 7209.8 NF c.4950 C>G; p.Y1650X Novel c.1318 C>T; p.R440X Heim ef al (1995)
2 T164.1 NF c.7285 O T ; p.R2429X Fahsold et al (2000) LOH: IVS27-3NF1
3
7206.1 NF
c.499delTGTT Novel
LOH: EV120-IVS38
7206.2 NF LOH. EV120-3NF1
7206.3 NF LOH. EV120-D17S928
7206.4 NF ND
4 7210.1 NF c.7458_7458delC; p72486feX15 Novel ND7210.2 NF ND
5
T224.1 NF
c.7127 132bpdel; p.G2376 Novel
LOH: IVS27-EV120
7258.1 NF LOH: J1J2-IVS38
7258.2 NF LOH: IVS27-IVS38
7204.2 NF LOH: J1J2-EV120
7224.2 NF LOH: J1J2-3NF1
6 7225.1 NF E10b: DEL [MLPA] Novel LOH: J1J2-IVS387225.3 NF LOH: IVS27-IVS38
7 T170.3 NF c.2041 C>T; p.R681X Ars et al (2000) LOH: IVS38-3NF1
8 T171 NF c.4084 C>T; p.R1362X Upadhyaya et al (1997) LOH: IVS27-IVS38
9 T174 NF 1.4 Mb deletion [MLPA] Kehrer-Sawatzki et al (2004) ND
10 T179.1 NF ND LOH: EV120-IVS38
11 T170.2 NF c.2041 O T ; p.R681X Ars et al, 2000 LOH: IVS38-3NF1
12 T173.1 NF ND LOH: EV120-IVS38
13 T173.2 NF ND ND
14 T179.2 NF ND LOH: EV120-IVS38
15 T192.4 NF E6-27a: Del [MLPA] Novel LOH: D17S796-EV120
16 T197A NF C.1318 0 T ;  p.R440X Heim et al, 1995 ND
17 T211.1 NF 90 kb del [MLPA] Upadhyaya et al, 1990 ND
18 T1281.2 NF ND LOH: J1J2-3NF1
19 T1281.4 NF ND LOH: J1J2-IVS27
20 7219.1 NF ND c. 1224-1225delGT; p.Y408fsX18 Novel
21 7220 NF ND LOH: IVS27-EV120
22 7205.1 Plex C.41960A; p.S1399X Novel c.4537 C>T; p.R1513X Side et al (1997)
23 T177 Plex C.3916 0 T ;  p.R1306X Park et al, 1998 LOH: IVS27-IVS387213 Plex Park et al, 1998 LOH: EV120-IVS38
24 T172 Plex ND LOH: D17S796-D17S928
25 T193 MPNST c.2870 del A; p.N957fsX Novel c.1312 G>T; p.E438X Novel
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Three samples, however, had longer characterised regions of LOH extending from 
D17S796 in the 17p13.2 region to D17S928 in the 17q25.3 region, and therefore 
encompassing most of chromosome 17. No genomic deletions were detected in any of 
the samples with LOH following MLPA analysis, indicating that mitotic recombination 
was the likely mechanism underlying LOH in these samples.
In 25 of the 28 tumour samples in which somatic mutations were identified by LCM; the 
somatic mutation could not be identified in the original whole tumour sample even once 
the location of the somatic mutation was known. In 3 of the 28 samples (T164.1, T224.1 
and T225.2), however, once the location of the mutation (LOH) in these tumours was 
known, the mutation could be observed in the original sample but at very low dosage 
(approximately 10-20% of cells). LOH was therefore likely to have been masked by 
heterogeneous cells in these tumours (figure 3.3).
3.3.3 Analysis of the germline and somatic NF1 mutational spectrum
NF1 germline mutations were detected in all the three patients and included: nonsense, 
2bp deletion and splice site alteration, the latter two both representing novel changes 
(table 3.4). Somatic mutations were initially identified in 47 whole tumour DNA samples 
from the cohort of 89 neurofibromas (53% mutation detection). No fresh tumour 
samples were available for Schwann cell culture but LCM was applied to the analysis of 
the somatic mutational spectrum in the remaining 42/89 benign cutaneous 
neurofibromas from 3 patients with high tumour burden. Following the application of 
LCM to the 42 cutaneous neurofibroma samples, the LCM derived DNA was re­
analysed for NF1 somatic mutations. Using LCM, a further 10 somatic mutations were 
identified in 10 neurofibroma samples (shaded grey in table 3.4). Overall, therefore 
somatic NF1 mutations were detected in 57/89 samples screened giving an overall 
mutation detection rate of 64% (22 LOH, 35 small lesions). Twenty eight of these 
mutations are novel (table 3.4). All somatic alterations were absent from the patients 
germline DNA. LOH was detected in 22/89 (25%) samples, comprising 18% of tumours 
in patient 1, 38% in patient 2 and no LOH was detected in patient 3.
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Table 3.4. Somatic and germline NF1 mutations identified in 89 tumours and paired 
blood DNA samples from three NF1 patients with a high tumour burden. Shading of 
consecutive tumour samples represents tumours found located in close proximity to 
each other
Patient Tumour
Germline
NF1
Mutation
Extent of LOH
Somatic
NF1
Mutation
Previously
Reported/Novel
NF1
Polymorphisms
T433 C.1660OG;P.Q554E Not Reported
T434 c.7699 O T ;  p.Q2567X
Fahsold et al, 
2000
T435 c.7702 C>T; P.Q2568X
Fahsold et al, 
2000
T436
IVS27, EV120, 
IVS38 (Intron 27- 
Intron 38)
T437 c.67A>T;P.I23L Not Reported
c.288+41G>A
(HOM)T438 Not Detected
T439
IVS27, EV120, 
IVS38 (Intron 27- 
Intron 38)
c.702 G>A 
p.L234L (HOM)
T440
IVS27, EV120, 
IVS38 (Intron 27- 
Intron 38)
c. 1528-32 T>C 
(HOM)
1 §111 c.2875C>T; c.586G>T;P.E196X Not Reported c. 1641+39 T>C I VS 10c (HOM)
C.5205+ 23T>C 
(HET)I I I
p.Q959X c.4687 
5bpdel; 
p. Ffs36X
Not Reported
T443 c.4691 G ins; p.Kfs36X Not Reported c.5546 +19 T>A
T444
HHH202, J1J2, 
IVS27, EV120, 
IVS38, 3'NF1 (5'- 
3' NF1)
IVS 29 (HET)
c.7125+37C>G
(HET)
MR Not Detected
n IVS27, EV120, IVS38 (Intron 27- Intron 38)
T447 Not Detected
T448
HHH202, J1J2, 
IVS27, EV120, 
IVS38, 3'NF1 (5 -  
3’ NF1)
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Patient Tumour
Germline
NF1
Mutation
Extent of LOH
Somatic
NF1
Mutation
Previously
Reported/Novel
NF1
Polymorphisms
T448
HHH202, J1J2, 
IVS27, EV120, 
IVS38, 3'NF1 (5*- 
3' NF1)
T449 Not Detected
T450 c.4084 C>T; P.R1362X
Upadhyaya et 
al, 1997
T452 Not Detectedllffj Not Detected
ill IVS27, EV120, IVS38 (Intron 27- Intron 38) c.288+41G>A
T455 Not Detected
(HOM)
Hill c.3709-2 IVS22 A>G Upadhyaya et al, 1997 c.702 G>A P.L234L (HOM)lilll C.6448A>T;P.K2150X Not Reported c. 1528-32 T>C (HOM)
c. 1641 + 3 9  T>C1
T458 c.2875
C>T;
P.Q959X
Not Detected
IMlf c.1641+2 I VS 11 T>G Not Reported IVS 10c (HOM)IB! c.7924 delT; p.SfsX16 Not Reported C.5205+ 23T>C (HET)
T461 Not Detected c.5546 +19 T>A 
IVS 29 (HET)
c.7125+37C>G
(HET)
T462 Not Detected
T463 c.2410-3  I VS 16 T>G Not Reported
T464 Not Detected
T465 Not Detected
T466 Not Detected
T467
c.5380 O T ;  
P.Q1794X Heim et al, 1995
T468
c.2041 O T ;  
P.R681X Ars et al, 2000
T469
C.1724
delCACA;
p.SfsXI
Not Reported
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Patient Tumour
Germline
NF1
Mutation
Extent of LOH
Somatic
NF1
Mutation
Previously
Reported/Novel
NF1
Polymorphisms
c.2875
C>T;
P.Q959X
Not Detected
1 m c.6085 deIG; p.VfsX8 Not Reported
T472 c.2088 G>A; p.W696X Not Reported
T473.1A
HHH202, J1J2, 
EV120, IVS38  
(57VF7 - Intron 
38)
T473.1B Not Detected
T473.1C
HHH202, J1J2, 
EV120 (5'NF1 - 
Intron 27)
T473.1D Not Detected
c.288+41 G>A 
(HET)T473.1E Not Detected
T473.2 Not Detected c.702G>A 
P.L234L (HET)
IH J1J2, EV120, IVS38 (5'NF1 - Intron 38) C.1641+ 39 T>C IVS 10c (HET)IB Not Detected c.2034A>G
2
T473.5
C.1413-
1414delAG; 
p. KfsX4
HHH202, JJ2, 
EV120, IVS38 
{5'NF1 - Intron 
38)
p.P678P (HET)
C.5205+ 23T>C  
(HET)
T473.6
c.889 delA; 
p.LfsX20 Not Reported C.5546 +19 T>A 
IVS29 (HET)
c.6903 G>C 
p.V2301 V (HET)
c.7125+36 C>G 
(HOM)
T473.7
J1J2, EV120 
(5'NF1 - Intron 
27)
T473.8
HHH202, J1J2, 
EV120, IVS38, 
3'NF1, EW207, 
D17S949, 
D17S1822  
(5'NF1 - 
17q25.2)
T473.9 Not Detected
T473.10
J1J2, EV120, 
IVS38 (5'NF1 - 
Intron 38)
T473.11
c.2451 insG; 
p.MfsX13 Not Reported
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Patient Tumour
Germline
NF1
Mutation
Extent of LOH
Somatic
NF1
Mutation
Previously
Reported/Novel
NF1
Polymorphisms
T473.12 c.1884 insA; p.YfsX5 Not Reported
| S | | |
c.5888 A>C; 
p.N1963T Not Reported
■
J1J2, EV120, 
IVS 38, 3' N F1, 
EW207, 
D17S949, 
D17S1822  
(5'NF1 - 
17q25.2)
T473.15
J1J2, EV120, 
IVS 38, 3' NF1 
(5-3 ' NF1) c.288+41 G>A
T473.16
J1J2, EV120, 
IVS 38, 3' NF1, 
EW207, 
D17S949, 
D17S1822  
(5'NF1 - 
17q25.2)
(HET)
c.702G>A 
p.L 234L (HET)
C.1641+ 39 T>C 
IVS 10c (HET)
T473.17
c.1413-
1414delAG;
p.KfsX4
c.7128 deIG; 
p.GfsX24 Not Reported c.2034A>G 
P.P678P (HET)
C.5205+ 23T>C 
(HET)
2 T473.18 c.3806 ins C; p.DfsX14 Not Reported
T473.19 Not Detected
T473.20
c.4087delA;
p.SfsX22 Not Reported
C.5546 +19 T>A 
IVS29 (HET)
T473.21
J1J2, EV120 
(5'NF1 - Intron 
27)
c.6903 G>C 
p.V2301V (HET)
T473.22 Not Detected c.7125+36 C>G 
(HOM)
T473.23 Not Detected
T473.24 Not Detected
T473.25
EV120, IVS38  
(Intron 27-lntron 
38)
T473.26 Not Detected
T473.27 Not Detected
T473.28 Not Detected
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Patient Tumour
Germline
NF1
Mutation
Extent of LOH
Somatic
NF1
Mutation
Previously
Reported/Novel
NF1
Polymorphisms
T473.29 Not Detected c.288+41G>A(HET)
T473.30
J1J2, EV120, 
IVS38, 3'NF1, 
EW207, 
D17S949 
(5'NF1 - 
17q23.3)
c.702G>A 
P.L234L (HET)
C.1641+ 39 T>C 
IVS 10c (HET)
T473.31
c.1413-
1414delAG;
p.KfsX4
Not Detected c.2034A>G 
P.P678P (HET)
C.5205+ 23T>C 
(HET)
c.5546 +19 T>A 
IVS29 (HET)
c 6903 G>C
2 111 J1J2, EV120 (5'NF1 - Intron 27)§|gg c.6478 A>G; P.S2160G Not Reported
T473.34
EV120, IVS38 
(Intron 27-lntron 
38)
T473.35 Not Detected pA/2301 V (HET)
T473.36 c.6859 deIG; p.DfsX18 Not Reported
c.7125+36 C>G 
(HOM)
T506.1
c.3745
del20bp;
p.SfsX8
Not Reported
T506.2
c.731-732 
delAA; 
p.AfsX5
Not Reported
c.288+41G>A
(HOM)
T506.3 Not Detected
c.702 G>A 
P.L234L (HOM)
m
c.6756+2 
T>G
c.2987 
insAC; p. 
RfsX16
Not Reported C.1641+ 39 T>C  
IVS 10c
3 c.480 deIG; 
p.RfsX5 Not Reported C.5205+ 23T>C  
(HET)
c.5546 +19 T>A
T506.6
c.7127-3bp 
IVS40 T>G Not Reported
T506.7 Not Detected IVS 29 (HET)
T506.8
c.3306insA;
p.LfsX3 Not Reported
c.7125+37C>G
(HET)
T506.9
c.6364 Del 
114bp; p. 
EfsX23
Not Reported
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a(i)
a (ii)
b(ii)
c ( 0 d(i)
aJUuL
Figure 3.4 (a-d) Examples of MSI profiles from four different tumours with markers (a i) 
MBAT 40.4 (1 p13) in blood and (a ii) in tumour sample, (b i) D17S250  (17q12) in the 
blood and (b ii) in the tumour, (c i) D 5S107  (5q11-q13) in the matched lymphocyte DNA 
sample and (c ii) in the tumour sample, (d i) MSI at marker D5S406  (5p15) in the blood 
DNA sample and (d ii) matched tumour sample.
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Figure 3.5. (a-c) Photos of the excision of five neurofibromas from one large 
neurofibroma capsule, (a) Original single neurofibroma capsule (including skin) from 
which five separate neurofibromas were excised, (b) Section of the neurofibroma 
pictured in figure 2a containing one of the five neurofibromas found in this one tumour 
capsule, (c) Figure showing the same neurofibroma which is depicted in figure 2b once 
it has been excised from the surrounding skin and neurofibroma capsule.
a. b. c. d. e.
310bp
190bp
120bp
Figure 3.6 (a-e) LOH of five separate neurofibromas from within the same capsule 
identified with marker HHH202.
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The extent of LOH ranged from just involving the 5’ end of the NF1 gene to the entire 
long arm of chromosome 17 (table 3.4). MSI was observed in 21/89 (24%) tumour 
samples studied. MSI in these samples was compared to the corresponding lymphocyte 
DNA samples in which the additional alleles were not present, indicating no MSI was 
present in the blood DNA (figure 3.4). No deletions were identified in the 89 samples 
using the NF1 MLPA kits indicating that LOH in these samples resulted from mitotic 
recombination. Interestingly, one individual tumour capsule which was not located 
adjacent to any other tumour, contained five separate neurofibromas, only two of which 
demonstrated LOH (figure 3.5 and figure 3.6). The somatic NF1 mutations in each 
tumour from each individual were all apparently independent events and the somatic 
mutational spectrum (table 3.1, table 3.4 and figure 3.7) did differ between the three 
patients as no nonsense and splice mutations were detected in patient 2 and no LOH, 
nonsense or missense mutations were identified in patient 3.
3.3.4 Analysis of somatic TP53, RB1, CDKN2A and MMR mutations
To identify potential modifying loci which may underlie the development of multiple 
neurofibromas in patients with high tumour burden, DNA from all 89 neurofibromas was 
analysed for alterations in the TP53, RB1, CDKN2A and MMR genes. No pathogenic 
TP53 somatic mutations were identified by direct sequencing. TP53 LOH was, however, 
detected in four samples (T440, T473.20, T506.1 and T506.9) at polymorphic markers 
within the TP53 gene (Alu1, codon 72 and exon 6 polymorphic markers) (figure 3.8). 
DNA from these samples was not derived from LCM. One of the four samples showed 
LOH at all three of these markers. The remaining three samples only exhibited LOH at 
two of the markers as the codon 72 polymorphism was uninformative. These four 
samples were also screened for deletions using the appropriate TP53 MLPA assay kit 
but no deletions were detected. The level of TP53 LOH observed at the second allele of 
each sample after correcting for the relative peak areas with corresponding lymphocyte 
DNA was between 37% and 66% (Alu1), 11% (codon 72) and between 35% and 57% 
(exon 6) (figure 3.8).
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(a) Frequency of Somatic Mutations in Cutaneous
Neuiofihromas from Patient 1
■  Small bp Insertion (fs)
■  Missense
■  Splice
□  Small bp Deletion (fs)
■  Nonsense
■  LOH
(b) Frequency of Somatic Mutations in Cutaneous 
Neuiofihiomas Fiom Patient 2
12%i
63% I
%
■  Small bp Insertion (fs)
□  Missense
□  Small bp Deletion (fs)
■  LOH
Frequency of Somatic mutations in Cutaneous 
Neuiofiluomas from Patient 3
□ Small bp Deletion (fs)
■  Small bp Insertion (fs)
■  Splice
Figure 3.7. Somatic NF1 mutational spectrum for patients 1-3. (a) Somatic mutational spectrum for 40 
tumours from patient 1 (Germline mutation: E17: c2875 C>T p.Q959P) (b) Somatic mutational spectrum 
for 40 tumours from patient 2 with an absence of nonsense and splice site mutations (Germline mutation: 
E10b: c.1413-1414delAG p.Kfsx4). (c) Somatic mutational spectrum for 9 tumours from patient 3 with an 
absence of LOH, nonsense and missense mutations (Germline mutation: E36: 6756+2 T>G).
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Figure 3.8. (a) LOH of four neurofibromas (T440, T473.20, T506.1 and T506.9) at TP53Alu1. (b) LOH in four neurofibromas (T440, 
T473.20, T506.1 and T506.9) at exon 6 of the TP53 gene. All percentages refer to the level of LOH of the second allele, (ci) 
Analysis of matched lymphocyte DNA with marker D13S118. (cii) LOH of the RB1 gene at D13S118  in tumour T468. (di) Analysis 
of matched lymphocyte DNA with marker D13S917  (dii) LOH of the RB1 gene at D13S917  in tumour T468. All percentages refer to 
the level of LOH of the second allele.
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These neurofibromas were not located adjacent to any other tumour and all four 
tumours had additional NF1 somatic mutations; comprising of, LOH (intron 27-38) and 
micro-deletions ranging from 1-114bp in three samples. One other sample (T468) also 
showed LOH of approximately 1Mb in length at two markers flanking the RB1 locus 
(D13S118 and D13S917) (figure 3.8 c and d). The mechanism of LOH could not be 
determined in this case by MLPA as the RB1 MLPA kit was unavailable in our 
laboratory. Additionally, in this tumour a somatic NF1 nonsense mutation was detected 
and this tumour was also not located adjacent to any other tumour. No CDKN2A LOH 
was identified at any of the markers that were analysed. Twenty one tumour samples 
exhibited MSI and their DNA was sequenced for the four main MMR genes but no 
pathogenic somatic mutations or polymorphic changes were identified.
3.3.5 Bioinformatic analysis
Bioinformatic analysis was performed by Professor Nadia Chuzhanova (Nottingham 
Trent University) on the ±20bp flanking sequences of the NF1 somatic mutations 
identified in the cohort of 89 neurofibromas from patients with high tumour burden. 
Fourteen out of 19 mutations (74%) found in the patient 1 were single basepair 
substitutions, apparently mediated by either direct or inverted repeats or both. In 
addition, for 13 of these mutations short (£5 bp) purine or pyrimidine tracts were found 
within ±20 bp of the mutation. Such purine/pyrimidine tracts are known to promote 
genetic instability through formation of non-B DNA structures (Bacolla et al, 2004). The 
remaining four microdeletions and one microinsertion were apparently mediated by 
direct/inverted repeat or symmetric elements. Only two (22%) somatic mutations in the 
second patient were single basepair substitutions whereas the majority of them were 
microlesions. Purine and pyrimidine tracts were found downstream and upstream of 
mutations E31:c.5888 A>C and E34:c.6478 A>G respectively. All four deletions in the 
second patient were deduplications (Kondrashov et al, 2004) mediated by inverted 
repeats. Two microinsertions (E16:c.2451insG and E12b:c.1884insA) were mediated by 
inverted repeats and inversion E22:c.3806insC was mediated by direct repeat. Somatic 
mutations found in the third patient do not differ dramatically from the second patient;
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they are all mediated by either direct or inverted repeats. In addition, short alternating 
purine-pyrimidine tracts with Z-DNA-forming potential were found in the vicinity of six 
mutations. Motif complement to the deletion hotspot, TGRRKM, was found in the vicinity 
of the remaining deletion E34:c.6364del114b
3.4 Discussion
3.4.1 Somatic mutation detection
This study has evaluated the efficacy of somatic NF1 mutation detection following 
enrichment of Schwann cells both by Schwann cell culture and by LCM. Following 
validation of these methods, LCM was employed to aid in the characterisation of the 
germline and somatic mutational spectrum of tumours from NF1 patients with high 
cutaneous neurofibroma burden. Few large scale studies have been conducted on the 
somatic mutational spectrum in benign cutaneous neurofibromas. The few previous 
reports in the literature, demonstrated great variation in the NF1 somatic mutational 
detection rate. In some earlier studies in which few neurofibromas were analysed, all 
somatic mutations were identified (Eisenbarth et al, 2000). In subsequent studies on a 
larger panel of samples, 12% of mutations were identified by John et al (2000), whilst 
Serra et al (2001b) identified 19% of somatic mutations. The study by Upadhyaya et al 
(2004) detected 35% of NF1 somatic mutations and the most recent study by Spurlock 
et al (2007) identified somatic NF1 mutations in 64% of neurofibroma samples. In 
addition to cellular heterogeneity and the overall complexity of the NF1 gene, low 
somatic mutation detection rates can be attributed to mutational detection methods 
used in earlier studies which were not sensitive enough to detect different types of NF1 
lesions. A recent study by Maertens et al (2006) demonstrated a significant 
improvement of somatic mutation detection rates, with 76% of mutations being identified 
in cutaneous neurofibromas. However, this was only after the introduction of culture 
methods to enrich Schwann cells which exclusively carry the NF1 somatic mutation, 
underlining the requirement for improved techniques for routine NF1 somatic mutation 
detection.
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3.4.2 Validation of Schwann cell enrichment strategies
In the present validation study, with the use of Schwann cell culture and LCM to target 
the Schwann cell population, the somatic mutation detection rate was 85% (11/13 
samples) and 80% (28/35 samples) respectively. Hence, LCM provides an increase in 
detection of 27% whilst Schwann cell culture increases the detection rate by 32%. 
Schwann cell culture and LCM also aided in the successful calling of several somatic 
mutations that were present, but not readily identifiable in DNA from the original whole 
tumour due mainly to the level of contaminating non-Schwann cell derived heterozygous 
DNA (figure 3.2 and figure 3.3). In this study involving 89 cutaneous neurofibromas, 
prior to the application of LCM somatic mutations were identified in 47 tumours (53%). 
However, usage of LCM allowed the detection of NF1 somatic mutations in an 
additional 10 tumours (64%) highlighting that Schwann cell enrichment results in an 
improved NF1 somatic mutation detection rate.
3.4.2.1 Schwann cell culture
Of the two techniques, Schwann cell culture is more sensitive for mutation detection in 
NF1-associated tumours. The results of Schwann cell analysis from the present study 
has even improved on the 76% mutation detection rate reported by Maertens et al 
(2006). This indicates that this study may be the most successful application of this 
technique to date, although the sample size (13 cutaneous neurofibromas) is only a 
third of the 38 tumours studied previously. Although application of this technique was 
successful, Schwann cell culture still has several disadvantages. It is laborious, time 
consuming and should be set up rapidly following removal of the tumour to ensure the 
viability of the cells. Schwann cell culture is only a prospective technique and is not 
always successful. Indeed, during the course of this study one neurofibroma derived 
Schwann cell sample failed to thrive and thus was not available for mutation analysis. 
Little is known of Schwann cell growth, but the small size of the tumour sample may 
have contributed to the failure of Schwann cell culture from this tumour. Schwann cells 
need to be in contact with each other for proper growth and if few Schwann cells are
152
present this is not possible. Moreover, care has to be taken not to introduce fibroblasts 
to the culture as these can rapidly overtake the Schwann cell culture. This means that 
larger neurofibromas with a well defined capsule are more suited to this method of 
culture as a large section can be taken from within the middle of the tumour, away from 
the skin where the majority of fibroblasts are found. However, fibroblasts are also found 
within these heterogeneous tumours but the culture conditions should ensure that they 
do not survive (see below).
The medium in which Schwann cells are grown requires a number of supplements to 
aid in the purification of the mutation harbouring population. These include IBMX, a 
competitive non-selective phosphodiesterase inhibitor. IBMX not only raises the level of 
intracellular cAMP in Schwann cells to promote growth but also aids in fibroblast growth 
inhibition, although it is only useful with sparse fibroblasts. (3-heregulin (HRG-(31) is a 
known mitogen of Schwann cells which binds to and activates EGF-like transmembrane 
receptor tyrosine kinases. Schwann cells unusually require a specific agent to increase 
cAMP to promote cell division, which is the role of both Forskolin which is a direct 
activator of adenylyl cyclase, and insulin which induces the activity of the cAMP 
response element binding protein (CREB) (Rahmatullah et al, 1998). Schwann cells are 
adherent cell lines which also require specific substrates for growth. The glycoprotein 
laminin is known to be essential for Schwann cell survival and enrichment due to the 
preference for attachment to such a substrate (Muir et al, 2001). Use of such 
supplements does, however, not only increase the time of media preparation but also 
the cost of long term culture. Finally, it was observed that Schwann cells do not respond 
well to changes in media especially in the context of freeze thaw for storage and revival 
of cell lines. Cell lines frozen early in the culture rarely survive cryopreservation, and so 
freeze thaw should be kept to a minimum.
3.4.2.2 Laser Capture Microdissection (LCM)
Although LCM was not quite as efficient as Schwann cell culture for improving the 
somatic mutation detection rate, during validation it still aided in the identification of 
28/35 (80%) of somatic NF1 mutations. LCM may also have broader applications as it
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has proved to be important in evaluating mutations in other tumour types including 
breast carcinomas (Zanni and Chan, 2011). However, LCM is potentially more 
problematic than cell culture as a substantial volume of tumour material is required to 
provide enough DNA to complete the full range of NF1 analyses whereas cultures 
provide a ‘limitless supply’. In this study approximately 400ng/pl of DNA was required 
for LOH, MLPA and sequencing analysis from LCM samples which equates to about 4- 
5x104 cells (Takeshima et al, 2001; Espina et al, 2006). Furthermore, FFPE samples 
often provide degraded DNA which means that the use of this DNA in downstream 
applications such as PCR is challenging (Edwards, 2007).
Of the 23 NF1 somatic mutations identified in cutaneous neurofibromas during 
validation of the LCM technique, 21 were copy neutral LOH (91%), a very high finding in 
neurofibromas in which LOH usually ranges between about 3% and 40% (Colman et al, 
1995; Daschner et al, 1997; Serra et al, 1997; Kluwe et al, 1999b; Eisenbarth et al, 
2000; John et al, 2000; Rasmussen et al, 2000; Serra et al, 2001; Upadhyaya et al, 
2004; De Raedt et al, 2006b; Laycock-VanSpyk et al, 2011). This LOH is unlikely to 
represent an artefact of the LCM technique as such a problem has not been previously 
reported in the literature. Moreover, in 3 samples, analysis of DNA from the original 
whole tumour alongside the LCM DNA indicated that the LOH in these tumours was 
already present in the original samples but undetectable due to the small percentage of 
mutation harbouring Schwann cells present (figure 3.3). LCM is a flexible technique 
which is applicable to both prospective and retrospective studies. It is clear that if fresh 
tissue is not available for Schwann cell culture of samples in which the somatic NF1 
mutation cannot be identified, then LCM represents a good alternative.
3.4.3 Analysis of NF1 somatic mutations in 89 cutaneous neurofibromas
Following validation of Schwann cell culture and LCM as an improved strategy for 
mutation detection, this study set out to characterise the somatic mutational spectrum in 
89 benign cutaneous neurofibromas from patients with high tumour burden with the aid 
of LCM to improve somatic NF1 mutation detection. Three unrelated NF1 patients, all 
with multiple cutaneous neurofibromas, (>550) and additional clinical complications
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(table 3.1) were recruited for this study. A major question is whether the cells of a 
tumour are monoclonally derived, descendent from a single founder cell with a specific 
somatic NF1 mutation or if a larger cluster of the normal cell population have undergone 
a change leading to a mixture of a subpopulation of cells in the tumour indicating that 
the cell is polyclonal with no distinct common origin? This study demonstrates that each 
somatic NF1 mutation resulted from an independent event, clearly indicating that 
although many of these tumours developed in very close proximity to each other, none 
of them were clonally-derived (table 3.4). Indeed, even in the situation where five 
tumours from within the same capsule were analysed, only two exhibited LOH, 
indicating that they are not all clonally derived (figure 3.5 and figure 3.6).
With the application of LCM to 42/89 benign cutaneous neurofibromas in which somatic 
NF1 mutations were not identified, 10 additional somatic mutations were identified, 
increasing the somatic mutational detection rate by 11% from 53% to 64%. The 
evaluation of Schwann cell culture demonstrated that the mutation detection rate in 
these 89 neurofibromas could have been improved even further if Schwann cell culture 
could have been used. This was not possible; however, as fresh whole tumour samples 
were not available. Undetected somatic mutations may be located in gene regions not 
screened in this study including the deep intronic regions, the 5’and 3’ UTRs and the 
NF1 promoter region (section 5.1). However, the problem of cellular heterogeneity is 
most likely to be the main reason for the low mutation detection rate based on 
observations that LCM was able to improve the ability to call mutations in some samples 
by enriching the mutation harbouring Schwann cell population (figure 3.2 and 3.3). 
Overall, LOH was detected in 25% of tumours. The results from the present study are in 
agreement with previous findings where LOH was detected in ~10-30% of samples 
(Upadhyaya et al, 2004; De Raedt et al, 2006b; Serra et al, 2007). Several previous 
studies by DSschner et al (1997) and John et al (2000) have also found little evidence 
for LOH, a similar finding to patient 3 in our study. Low levels of LOH detection, and 
inter-individual variability in the level of LOH may also be accounted for by cellular 
heterogeneity and also the methodology used for analysis by different studies. In this 
study, no genomic deletions were found by MLPA in tumour DNA exhibiting LOH,
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indicating that mitotic recombination is the likely mutational mechanism in these 
tumours (Serra et al, 2001).
Twenty eight of the somatic NF1 mutations identified are also novel sequence changes, 
a significant contribution to the NF1 somatic mutational spectrum. Furthermore, 
bioinformatic analysis shows that the majority of mutations were likely to be mediated by 
either direct or inverted repeats. There are also differences in the inter-individual NF1 
somatic mutational spectrum identified in the 3 patients studied (figure 3.7). A 
comparison of the germline and somatic NF1 mutations detected in these three patients 
failed to reveal any obvious correlation between the genotype and phenotype of the 
patients. Importantly, in some samples, prior to LCM analysis, the somatic mutation was 
not immediately obvious in DNA samples but following analysis of cDNA, frameshift 
mutations were identified and subsequently confirmed in the DNA sample, negating the 
need for LCM (T469 and T506.9, table 3.4). These samples harboured the larger of the 
frameshift deletion mutations and thus future studies employing cDNA instead of DNA 
sequencing may be important for identification of such somatic mutations.
3.4.4 Analysis of somatic TP53, RB1, CDKN2A and MMR mutations
This study also aimed to determine whether a different molecular mechanism of 
tumorigenesis might underlie the development of cutaneous neurofibromas from 
patients with high tumour burden. Mutations in the TP53, RB1 and CDKN2A genes 
have been found to contribute to the development of plexiform neurofibromas 
(Upadhyaya et al, 2008b; Stewart et al, 2008) and MPNSTs (Kourea et al, 1999; 
Nielsen et al, 1999; Mawrin et al, 2002; Mantripragada et al, 2008). Furthermore, 
individuals with germline MMR mutations often exhibit an ‘NF1- like phenotype’ (de 
Wind et al, 1995; Reitmair et al, 1995; Reitmair et al, 1996; Sohn et al, 2003; Gutmann 
et al, 2003; Chen et al, 2005; Feitsma et al, 2008). In view of the high tumour burden in 
these patients, such potential modifying loci (TP53, RB1, CDKN2A and MMR) were 
analysed to assess the contribution to cutaneous neurofibroma development in these 
patients. One tumour exhibited LOH which encompassed a large region of ~1Mb 
involving the entire RB1 gene. A further four tumours exhibited TP53 LOH at markers
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within the gene (figure 3.8). These were five independent tumours which were not 
located immediately adjacent to any other tumour. This suggests that there was no 
relationship between the anatomic location of the tumours and the development of 
additional somatic mutations. The distal and proximal flanking LOH markers for TP53 
did not show LOH indicating that LOH is restricted to the TP53 gene. However, no 
detectable TP53 deletions were identified by MLPA, suggesting mitotic recombination 
as the likely mutational mechanism. LOH may still be present in the remaining tumours 
in which no LOH of TP53 and RB1 was found due to uninformative markers in these 
samples. Histological findings demonstrated that the neurofibromas from the cohort 
analysed were composed of spindle cells with thin, wavy nuclei, embedded in a 
collagenous and myxoid stroma, characteristic of typical neurofibromas. Furthermore, 
no evidence for pleomorphic nuclei was found that would have been suggestive of 
atypical neurofibromas that could account for the presence of TP53 and RB1 LOH 
(Jokinen and Argenyi, 2010).
It has been suggested that the global somatic mutational spectrum may be important in 
explaining variable clinical expression observed in many NF1 patients. Whilst benign 
and malignant NF1 associated tumours exhibit biallelic inactivation of NF1, the 
accumulation of somatic abnormalities at unrelated loci represents a probable step 
towards malignant transformation. Therefore, the identification of LOH at TP53 and RB1 
loci, in addition to somatic NF1 mutations in these benign tumours, is an important 
finding as such somatic mutations are normally only associated with malignant NF1 
tumours and cutaneous neurofibromas are not known to develop into MPNSTs (Kourea 
etal, 1999; Nielsen et al, 1999; Mawrin et al, 2002; Mantripragada et al, 2008). If these 
genetic aberrations occur later during tumour formation it is possible that these 
mutations represent a step towards malignant progression. Additional somatic 
mutations involving genes from multiple genetic pathways could therefore indicate that 
in these patients, the occurrence of a high tumour burden may be due to somatic 
mutations of other modifying loci, in addition to their NF1 mutations.
In the current study, while genome wide MSI was detected in 24% of the neurofibromas 
(21/89); no sequence changes of the MMR  genes were identified. The significance of 
MSI in these tumours is unclear as the level of MSI reported here is similar to previous
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findings in neurofibromas and is much lower than has been identified in MPNSTs (50%) 
(Ottini et al, 1995; Serra et al, 1997; DeRaedt et al, 2006; Spurlock et al, 2007). 
Interestingly, patient 2 exhibited the highest level of MSI and had an MPNST while 
patient 3 had a malignant complication of B-CLL but had a significantly reduced level of 
MSI, similar to that seen in patient 1 who was without malignant abnormalities (table 
3.1). The correlation of MSI and additional malignant complications is therefore unclear 
and would warrant a much larger study to determine any relationship. The presence of 
MSI in these neurofibromas is likely to be due to generalised genomic instability, rather 
than evidence of specific defects in any MMR genes. Copy number abnormalities, 
sequence changes in the other MMR genes, or alterations to the methylation status of 
the MMR genes could also still account for the presence of MSI. However, due to 
insufficient tumour tissue, immunohistochemical analysis of MMR proteins was not 
possible.
3.4.5 Conclusions
The cellular and molecular heterogeneity associated with cutaneous neurofibromas is a 
major complication in the analysis of NF1 somatic mutations. In the present study, LCM 
and Schwann cell culture were validated as Schwann cell enrichment strategies. The 
results of this study indicate that such techniques represent future improvements for 
somatic NF1 mutation detection and may aid in the characterisation of mechanisms of 
NF1 somatic inactivation. This study has identified LOH at TP53 and RB1 loci in these 
tumours. This is a significant finding in benign neurofibromas as such TP53 and RB1 
LOH has only previously been detected in malignant MPNSTs. These novel findings, 
demonstrate for the first time, that the development of neurofibromas in NF1 patients 
with high tumour burden potentially differs from that of the discrete cutaneous 
neurofibromas present in the majority of NF1 patients.
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CHAPTER 4: Functional analysis of NF1 GRD missense mutations
4.1 Introduction
The NF1 gene has one of the highest mutation rates reported in human disorders. The 
germline mutational spectrum is well defined, with at least 1273 mutations characterised 
to date (HGMD). At least 150 of these are identified within the Gap related domain 
(GRD) of neurofibromin (HGMD), approximately 80% of which are truncating. The GRD, 
encoded by exons 20 to 27a (360 amino acids) (NM_000267) defines the major 
functional domain of neurofibromin as a negative regulator of the RasMAPK pathway 
(Gutmann et al, 1993). Neurofibromin functions as a RasGAP (GTPase activating 
protein) with extensive sequence homology to two mammalian RAS-GTPases, including 
p120GAP in addition to Iralp and Ira2p, two inhibitory regulators of the Ras-cyclic AMP 
pathway found in the yeast Saccharomyces cerevisae (Andersen et al, 1993). The 
downregulation of active Ras by GAP’s is a crucial step in the regulation of signal 
transduction of the RasMAPK pathway and is disrupted in a significant proportion of 
cancer-associated Ras mutants. Neurofibromin binds to Ras proteins through the GRD; 
promoting GTP hydrolysis by inducing the intrinsic GTPase activity of Ras, converting 
Ras from the active GTP-bound form to the inactive GDP bound form. This modulates 
RasMAPK signalling to alter cellular processes including cell proliferation and DNA 
synthesis (Ballester et al, 1990; Xu et al, 1990; DeClue et al, 1991; Cichowski and 
Jacks 2001; Arun et al, 2004; Gottfried et al, 2006) (Figure 1.2) Loss of function of the 
NF1 gene through mutation therefore leads to an amplification of the activity of the 
RasMAPK pathway and subsequently tumorigenesis.
The underlying mechanism of GTPase stimulation first involves the stabilisation of 
residues in the switch I and switch II regions of Ras. This is followed by stabilisation of 
the transition state of GTP hydrolysis by neutralisation of a developing negative charge 
on the GTP phosphate oxygen atoms during phosphoryl transfer. This occurs through 
the insertion of a catalytic arginine in to the active site (Scheffzek et al, 1997; Scheffzek 
et al, 1998; Resat et al, 2001). There are a number of regions in RasGAPs, which are 
known to interact with the switch regions in Ras; the finger loop, FLR region and
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a7/variable loop region (Ahmadazin et al, 2003). These regions undergo conformational 
changes between the active and inactive state and are thought to interact with Ras by 
binding to the Ras switch I region through the a7/variable loop, stabilisation of the finger 
loop by the FLR region and contribution of an arginine residue (R1276 in neurofibromin) 
to the catalytic region of Ras by the FLR region (Ahmadazin et al, 2003).
Less than ten studies have been previously completed on variants within the GRD of 
NF1 (Skinner et al 1991; Li et al, 1992; Poullet et al, 1994; Morcos et al, 1996; 
Scheffzek et al, 1996 and 1997; Upadhyaya et al, 1997; Klose et al, 1998; Ahmadazin 
et al, 2003). Li et al (1992) analysed the K1423E by site directed mutagenesis and 
measurement of phosphate release. The crystal structure of the GAP domain was 
determined by Scheffzek et al (1996 and 1997) and Morcos et al (1996) used a 
randomly mutagenised NF1-GRD library to screen for mutants capable of interacting 
with H-rasD92K, a protein which is defective in interaction with NF1. Furthermore, 
Ahmadazin et al (2003) have completed an extensive biochemical study on a few key 
residues within the GRD. These studies have offered new insights into the role of 
individual amino acid residues and their role in RAS-RasGAP interaction. However, 
fewer than 5 NF1-GRD mutants (K1423E, R1391K, R1391S and R1276P) have been 
functionally analysed to date.
Of all the known characterised NF1 mutations, approximately 80% represent truncating 
mutations including: small deletions and insertions, indels, large (Mb) microdeletions 
encompassing the majority or the whole of the NF1 gene in addition to some 
surrounding genes, as well as nonsense and splice site alterations (Fahsold et al, 2000; 
Ars et al, 2000; Thomas et al, 2010; HGMD). The mRNA derived from truncated alleles, 
may be removed by nonsense mediated mRNA decay (NMD). Truncated mRNA 
transcripts which are stable may still be translated resulting in either an unstable protein 
or a stable protein which might not possess any function. Inactivation of the remaining 
wild type NF1 allele in somatic cell types including Schwann cells and melanocytes 
results in the manifestation of the hallmarks of NF1. The same mutational mechanisms 
which act in the germline also occur as somatic lesions (Ivanov et al, 2011). However, 
loss of heterozygosity (LOH) is confined to the soma, occurring in up to 40% of 
neurofibromas (Laycock-VanSpyk et al, 2011) and at a higher rate in MPNSTs (85%), in
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conjunction with gains and losses at other genetic loci (Upadhyaya, 2011). Truncating 
mutations, do not account for all NF1 lesions, however, as synonymous and non- 
synonymous single nucleotide polymorphisms (SNPs) are common in the NF1 gene. 
Many are classed as missense mutations, occurring in patients in which no other NF1 
gene alteration has been identified and which segregate with the disease in the family. 
These missense mutations account for ~10-20% of all characterised germline and 
somatic NF1 mutations although due to the underlying amino acid substitutions 
involved, their pathogenicity is not always certain.
We have sufficient knowledge of Ras-RasGAP interaction but there are many questions 
which still require further investigation. For example, (i) are there critical amino acid 
residues which are absolutely required for RasGAP affinity for Ras? (ii) Are there 
residues which are important for promotion of catalysis by the arginine finger? (iii) 
Which residues are critical for stabilisation of the switch regions in Ras? It is clear that 
further studies are warranted as relatively few variants have been studied and 
consequently there is still insufficient evidence for the role of specific residues in 
neurofibromin which may be important for Ras interaction. Development of an effective 
technique for classification of variants into pathogenic and non-pathogenic changes, to 
further define the underlying mechanisms responsible for NF1 disease manifestation 
and tumour development is required. The main aims of this chapter were:
1. To develop a novel functional assay to better define the pathogenicity of 
missense variants located in the GRD.
2. To determine the reliability of bioinformatic software for functional analysis of 
missense variants (In collaboration with Matthew Mort, Cardiff University)
3. To identify the functional consequences of changes in the amino acid sequence 
in the NF1 GRD between the wild-type and mutant neurofibromin sequences.
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4.2 Materials
4.2.1 Ras ELISA buffers
Preparation of buffer solutions for the Ras activation ELISA assay as described by the 
manufacturer (Millipore, cat no: 17-497):
1x TBS
200ml 1x TBS by adding 10ml 20x TBS to 190ml of dh^O. Stored at room temperature 
1x TBST (Wash Buffer)
800ml 1x TBST was made by adding 2ml Tween 20 (v/v) and 40ml 20x TBS to 758ml 
dPfeO and stored at room temperature.
Binding/Blocking Buffer
For each 96 well plate 30ml 3%BSA in TBST was prepared by adding 10ml of 10% BSA 
in TBS to 20ml of 1x TBST. This was discarded following assay completion.
1x Mg Lvsis/Wash Buffer
5x lysis buffer was diluted 4:1 with 4 volumes dh^O to make a 1x solution. Protease 
inhibitors were added as needed.
Primary Antibody Solution
1pl of the primary anti-Ras antibody was added to 9pl of Binding/Blocking Buffer. 5pl of 
this mix was then added to 5ml of Binding/Blocking Buffer (1:10,000).
Secondary Antibody Solution
1pl of the secondary anti-mouse HRP conjugated antibody was added to 5ml 
Binding/Blocking Buffer (1:5,000).
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Chemiluminescent substrate
Each component was warmed to room temperature prior to use. The Chemiluminescent 
reaction buffer was added to the chemiluminescent detection reagent in a 2:1 ratio.
Epidermal Growth Factor (EGR (Sigma, cat no: E9644)
4.3 Methods
4.3.1 Plasmid preparation
Plasmid (19993 pGBT9-NF1 GRD) was obtained from Addgene (USA) (Morcos et al,
1996) which contained the Gap related domain (GRD) of the NF1 gene. Plasmids were 
received as stab cultures made by inoculating bacteria into a vial containing LB agar 
and the appropriate antibiotic. LB ampicillin agar plates were prepared as previously 
described in section 2.2.1.3. Using a sterile pipette tip the bacteria growing within the 
punctured area of a stab culture were streaked onto a plate. The plate was incubated 
for 16 hours overnight at 37°C. Liquid ampicillin LB was prepared as described in 
section 2.2.1.2 and starter cultures were prepared as described in section 2.2.1.5. The 
culture was centrifuged to pellet the bacterial cells then DNA was extracted using the 
Qiagen maxiprep kit (section 2.2.1.7) and glycerol stocks were made for long term 
storage (section 2.2.1.6).
4.3.2 Gateway technology with clonase II
4.3.2.1 attB PCR primer design
To generate PCR products suitable for use in a Gateway BP recombination reaction 
with a donor vector, an attB site was incorporated into the PCR product. The forward 
primer contained four guanine residues at the 5’ end followed by the 25 bp atfB1 site 
and 18-25bp of template or gene specific sequences. The last two nucleotides were 
needed to maintain the proper reading frame but could not be AA, AG or GA as this
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would have created a translation termination codon. The following primer was designed 
to allow for expression of an N-terminal fusion protein of interest.
aftB1 Specific Sequence
5-GGGG-ACAAGTTT GTACAAAAAAGCAGGCTT C-AT GGAAGTT CT GACAAAAAT CCTT C-3‘
The reverse primer contained four guanine residues at the 5’ end followed by the 25bp 
atfB2 site and 18-25bp of template or gene specific sequences. The primer had to
contain one additional nucleotide to maintain the proper reading frame with the a#B2
region. The following primer was designed to allow for the expression of a C-terminal 
fusion protein of interest.
attB2 Specific Sequence
5-GGGG-ACCACTTTGTACAAGAAAGCTGGGTC-AATTGGGCAGTATCTTTCCAGCAAC-3’
4.3.2.1 Creating entry clones
The above primers were used to generate entry clones through the BP recombination 
reaction using the PCR products containing attB sites and a donor vector. A 50pl PCR 
product was generated using the following reagents and cycle conditions:
PCR Reaaents 50pl Cvcle Conditions x35 cy(
DNA [10ng/pl] 5(jl 95°C 10 min
Buffer 5pl
Mg [25mM] 6 pi 95°C 1 min
dNTPs [10pM] 4 pi 70°C 1 min
F-Primer [5pm] 1 pi 72°C 1 min
R-Primer [5pm] 1pl
Taq 0.1pl 72 °C 10min
H20 27.5pl
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4.3.2.2 Purifying attB-PCR products
1-2pl of PCR product was analysed using agarose gel electrophoresis to verify the 
quality and yield. The entire remaining PCR product was then run on a 1.5% agarose 
gel with 4pl of concentrated loading dye. The product was then purified to remove aftB 
primers and any attB primer-dimers which can combine efficiently with the donor vector 
in the BP reaction, potentially causing background after transformation into E.coli. The 
MinElute gel extraction kit protocol (Qiagen, cat no: 28604) was used to purify the attB- 
PCR product as outlined in section 2.2.3.1.5.
4.3.2.3 BP recombination reaction
20-50fmol of the atfB-PCR product was required to perform the BP reaction. The 
amount of DNA in nannograms (ng) which was required was calculated using the 
following equation:
ng= (fmol) (N) (660 fg) (lug)
fmol 106 fg
The atfB-PCR product generated from the above primers and the NF1-GRD plasmid 
(Addgene) is 981 bp in length and contains the NF1 gap related domain. The amount of 
atfB-PCR product needed in the BP recombination reaction is calculated using the 
following equation:
(50 fmol) (981) (660 fa) ( 1na ) = 32.3ng of PCR product
Fmol 106fg
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The following components were added to a 1.5ml microcentrifuge tube at room 
temperature and mixed:
Components Sample PositiveControl Negative Control
AttB-PCR product (20-50 fmol) 1-7pl — 1-7pl
pDONR vector (150ng/pl) 1 pi 1 pi 1 Ml
pEXP7-tet positive control 
(50ng/uD
— 2pl —
TE Buffer, pH 8.0 to 8pl 5 pi to 10pl
The BP Clonase II enzyme mix was thawed on ice and briefly vortexed twice for 2 
seconds. 2pl of BP Clonase II enzyme mix was added to the sample and positive 
control vials. This was not added to the negative control vial. These mixes were then 
vortexed briefly twice for two seconds each time and then incubated overnight at 25°C 
to get a large yield of colonies. The following day 1pl of proteinase K solution was 
added to each reaction and incubated at 37°C for 10 minutes.
4.3.2.4 Transforming competent cells
omniMAX 2T1 bacteria (Invitrogen) were transformed using the protocol outlined in 
section 2.2.1.4. The cells were diluted 1 in 10 (20pl cells + 180pl of LB media) and 40pl 
and 160pl of cells were spread on to two LB agar plates containing Kanamycin 
(50mg/ml) (section 2.2.1.3). Starter cultures were produced (section 2.2.1.5) and 
following DNA extraction, the DNA was quantified using a Nannodrop 
Spectrophotometer (Thermo Scientific). DNA was amplified using the following 
conditions to confirm the presence of the insert using M13 primers as the M13 site is 
present in the donor vector: 5’-TGTAAAACGACGGCCAGT-3’ (M13 Forward) and 5’- 
CAGGAAACAGCTATGACC-3’ (M13 Reverse) and the protocol outlined in sections
2.2.3.2 and 2.2.3.3.
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4.3.2.5 LR recombination reaction
Following confirmation of the correct insert in the entry clones, the LR recombination 
reaction was performed to clone the gene of interest into a destination vector. Due to 
the downstream application to be undertaken and the methods of purification to be used 
a V5 tagged destination vector (pcDNA/V5DEST, Invitrogen) was chosen to clone in to. 
The reaction was set up as follows for both of the destination vectors and incubated at 
25°C for 16 hours on a heat block.
Components Sample Positive Control Negative Control
Entry Clone (50- 
150ng/reaction) 1-7pl
— 1-7pl
Destination vector (150ng/pl) 1pl 1pl 1pl
pENTR™ -gus (50ng/pl) — 2(jl —
TE Buffer, pH 8.0 to 8pl 5pl to 10|jl
4.3.2.6 Transforming competent cells
Following the incubation, 1pl of proteinase K was added to each tube and incubated on 
a heat block for 10 minutes at 37°C. The bacteria were thawed on ice (omniMAX 2Ti, 
Invitrogen) and transformed using the protocol outlined in section 2.2.1.4 using LB agar 
plates containing Ampicillin (50mg/ml). The QIAprep spin miniprep kit was then used to 
extract the DNA from the bacterial cells as outlined in section 2.2.1.7.
4.3.2.7 Sequencing of destination vectors
To confirm the presence of the insert of interest in the destination vector, the samples 
were sequenced using the following primers and the protocol outlined in section 2.2.3.2 
and 2.2.3.3.
Forward: T7 
Reverse: rBGH
5’-TAATACGACTCACTATAGGG-3’
5’-TAGAAGGCACAGTCGAGG-3’
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4.3.3 Mutagenic primer design
The oligonucleotide primers for site directed mutagenesis were designed individually 
according to the desired mutation (table 4.1, figure 4.1). The mutagenesis protocol 
requires 125ng of each oligonucleotide primer. The amount of primer required in 
picomoles was determined using the following equation:
X  pmoles of oligo = ng of oligo x1000
330 x #  of bases in oligo
Example: 125ng of a 25-mer: 125nq of oligo x 1000 = 15 pmole
330 x 25 bases
4.3.3.1 Missense mutations
Whole gene sequencing of the NF1 gene was completed on diagnostic and research 
lymphocyte DNA samples as described previously in sections 2.2.3.2 and 2.2.3.3 by the 
NHS molecular genetics diagnostic laboratory (Cardiff, UK) and by NF1 laboratory 
(Cardiff University). Samples were derived from individuals with a clinical diagnosis of 
NF1 and the 16 variants analysed in this study were the only variants identified as 
potential germline mutations in these individuals. They include: c.3610 C>G p.R1204G 
(Ars et al, 2000), c.3610 C>T p.R1204W, (Krkljus et al, 1998), c.3827 G>A p.R1276Q 
(Fahsold et al, 2000), c.3902T>G p.L1301R, c.3919 A>G p.l1307V, c.3971 C>A 
P.T1324N, c.3980 A>G p.E1327G, c.4007 A>G p.Q1336R c.4067 A>G, p.E1356G 
(Trovo et al, 2004), c.4171 A>G p.R1391G, c.4173 A>T p.R1391S (Upadhyaya et al,
1997), c.4193 T>A p.V1398D, c.4225 A>G p.K1409E, c.4235 C>G p.P1412R, c.4306 
A> C p.K1436Q and c.4388 C>T p.S1463F (figure 4.1, table 4.1). All mutations were 
non-synonymous NF1 missense located in the GRD. Five of these mutations have been 
reported previously and the remaining 11 are novel. Two of the missense mutations was 
additionally identified as a somatic mutation in neurofibromas in analysis in our lab 
(c.3827 G>A p.R1276Q and c.4388 C>T; p.S1463F). We also included the missense 
mutation c.4267 p.K1423E (Li et al, 1992) which has been previously identified as a
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germline mutation and a somatic mutation in an MPNST (Upadhyaya et al, 
unpublished), to act as a control in our analysis as mutations at this residue have been 
previously found to result in a protein which is 200-300-fold less active than the wild- 
type NF1 GRD (Li et al, 1992). Furthermore, we also re-analysed the c.4173 A>T 
p.R1391S missense mutation which was previously described in this lab (Upadhyaya et 
al, 1997). All mutations were analysed during the course of this study except p.K1436Q, 
p.R1391S, p.R1204W and p.V1398D which were analysed concurrently by Mark 
Richards (Cardiff University) following the protocol outlined here.
4.3.4 Site directed mutagenesis PCR
Site directed mutagenesis (Figure 4.2) is a technique by which specific mutations can 
be introduced into plasmid DNA to generate amino acid substitutions, insertions or 
deletions of 1 to several hundred base pairs in order to study their functional effects. 
There are several kits available for this method but we have chosen an in house 
technique as described below.
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T a b le  4 .1 .  P rim ers  used  for s ite  d ire c ted  m u ta g e n e s is  o f 12 N F 1  m is s e n s e  m u ta tio n s  and  th e  resu lting  s eq u en c in g  tra c e s  show ing  
the mutation of interest. The remaining 4 mutations (p.K1436Q, p.R1391S, p.R1204W and p.V1398D) were characterised by Mark 
Richards, Cardiff University
Exon Mutation Sense Primer Sequence
<5’-3’)
Antisense Primer Sequence
(5 -3 ’) Wild Type Mutant
21
c.3610
O G ;
P.R1204G
cagaaacagtattggctgatGggttt
gagagattggt
accaatctctcaaaccCatcagccaatact
gtttctg
T b H N  N
A f f lA
22
c.3827
G>A;
P.R1276Q
tgcagactctcttccAaggcaacagc
ttggc
gccaagctgttgcctT ggaagagagtctgc 
a
T "T" c c R C C
AaajA xA
T C C n R C G
AAAjM/1
23.1
c.3902
T>G;
P.L1301R
gctacctatctacaaaaactccGgg
atcctttattacgaattgtgat
atcacaattcgtaataaaggatccCggagtt
tttgtagataggtagc
a n a a (TV f  T n~T a
to(y\^ no(ys
3 fl a a h j  1 MR a a
23.1
c.3919 
A>G; 
p. 11307V
cctggatcctttattacga Gttgtgatc 
acatcctctga
tcagaggatgtgatcacaaCtcgtaataaa
ggatccagg
T A t t  A e t T £ T I  i  tc i T (  1 i f
/ A  a  ^ J \  a a  / W \
23.1
c.3971
C>A;
P.T1324N
gttagctttgaagtggatcctaAcagg
ttagaaccatcag
ctgatggttctaacctgTtaggatccacttca
aagctaac
Cf A' I T  £ £  t  r i T T c n  6
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Exon Mutation Sense Primer Sequence Antisense Primer Sequence
(5*-3’)
Wild Type Mutant
23.2
c.3980
A>G;
P.E1327G
ggccagtaaaataatgacattctgttt
cagggttaGaaccatcag
ctgatggttCtaaccctgaaacagaatgtca
ttattttactggcc
A A t J T t 1 3 a
fWvvy\PA
A A f  3 □ T a  a
23.2
C.4007
A>G;
p.Q1336R
gccttgaggaaaaccGgcggaacc
tccttca tgaaggaggttccgcCggttttcctcaaggc
t t t t g h irnr C C T G G  R T C
T 4 t 1 V t A A
23.2
c.4067
A>G;
p.E1356G
catcagttcctcctcaGgattcccccc
tcaacttc
gaagttgaggggggaatCctgaggagga
actgatg
Sr J V f  ri ri
/W A-rA
24
c.4171
A>G;
P.R1391G
gaagtgccatgttcctcGgatttatca
atcctgcc
ggcaggattgataaatCcgaggaacatgg
cacttc
$ f fl JT J t‘ A A"
A/TVv^aAaa
a a n a i l T R R
/vAn/vWva
24
C.4225
A>G;
p.K1409E
gtatgaagcagggattttagataaaG
agccaccacctag
ctaggtggtggctCtttatctaaaatccctgct
tcatac
n n n n n g £
w v v M
R R fl G fl G C
v\/vyv\Af
24
c.4235
C>G;
P.P1412R
tagataaaaagccaccaGctagaat
cgaaaggggc
gcccctttcgattctagCtggtggctttttatct
a
£ ft C t T R G
/YY\(VW\
C fl C G T R G
AAAa/W
26
c.4388
C>T;
P.S1463F
acgcaggtttttccttgatatagcatTt
gattgtcctacaag
cttgtaggacaatcaAatgctatatcaagga
aaaacctgcgt
r T A h t  C t g  r t T
NMklM
t t A fl T t t fi R 1 !
aaamaaA/mf T
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C.3610 C>T 
P.R1204W
C. 3610 C>G 
p.R1204G
c.4173 A>T 
p.R1391 S
c.4225 A>G 
P.K1409E c.4388C>T
p.S1463F
c.4193 T>A 
p.V1398D
c.3980 A>G 
P.E1327G
c. 3827 G>A 
P.R1276Q
c.4067 A>G 
P.E1356G
c.3902 T>G 
P.L1301R
c.4235C>G
P.P1412R
c.3919 A>G 
P.I1307V
c.4171 A>G 
P.R1391G
c.4306 A> C 
p.K1436Q
c.3971 C>A 
P.T1324N
c.4007 A>G 
P.Q1336R
2 7 a2 3 .1  - 2 3 . 2
Figure 4.1. Schematic representation of the gap related domain (GRD) of the NF1 gene showing the location of all 16 
missense mutations analysed in this study.
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Figure 4.2. (a) Schematic representation of site directed mutagenesis, (ai) Mutant strand synthesis; denaturation of the DNA template, annealing 
of mutagenic primers containing the desired mutation and extension and incorporation of primers with DNA polymerase, (aii) Dpnl digestion of 
template; digestion of parental methylated and hemimethylated DNA with Dpnl (Adapted from smith, 2007). (b) V5 tagged vector used in this study 
(Invitrogen) with the following properties: 7711 nucleotides; CMV promoter, T7 promoter/priming site, affR1 site, cccfB gene, chloramphenicol 
resistance gene, attR2 site, V5 epitope, V5 reverse priming site, TK polyadenylation signal, f1 origin, SV40 early promoter and origin, Neomycin 
resistance gene, EM7 promoter, Blasticidin resistance gene, SV40 early polyadenylation signal, pUC origin, Ampicillin (bla) resistance gene, bla 
promoter.
a ttR 2  V5 epitopeattR1
pcD N A  /V 5-D E S T
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The following reagents and cycle conditions and the vector generated using the method 
described above were used for site directed mutagenesis (figure 4.2). The presence of 
a PCR product was confirmed by electrophoresis by running 10pl of the PCR product on 
a 1.5% agarose gel as described in section 2.2.3.2.1.
PCR Reaaents 50 pi Cvcle Conditions x18 Cycles
DNA [10ng/pl] 5pl
Buffer 5pl 95°C 30sec
Mg [25mM] 5 pi
dNTPs [10pM] 5pl 95°C 30sec
DMSO [10%] 5pl 55°C 1 minute
F-Primer [125ng/pl] 1 pi 68°C 16minutes
R-Primer [125ng/pl] 1pl
Taq 0.5pl
H20 22.5pl
4.3.4.1 Dpnl digestion
1pl of Dpnl restriction enzyme (NEB, cat no: R0176S) (10U/pl) was directly added to 
each reaction and gently mixed. The plate was centrifuged and incubated at 37°C for 1 
hour.
4.3.4.2 Transformation into competent cells
The bacteria were thawed on ice (omniMAX, Invitrogen) and 2.5pl of the Dpnl reaction 
was transformed into 25ul of bacteria as described in section 2.2.1.4. The entire 
reaction was plated onto LB agar plates containing Ampicillin (50mg/ml). Starter 
cultures were prepared from single colonies as outlined in section 2.2.1.5 and DNA was 
extracted using the Qiagen Miniprep extraction kit following the method in section 
2.2.1.7. All extracted samples were sequenced following the protocol described in
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section 2.2.3.2 and 2.2.3.3 and using the following primers: 5’-
CCTTGATATAGCATCTGATTGTCC-3’ and 5’-CGTCTACTCTGGAACAATCAGG-3’
4.3.5 Plasmid DNA transfection
Plasmid DNA produced following site directed mutagenesis was transfected into 
HEK293 cells using lipofection as described in section 2.2.2.6.1.
4.3.6 Ras activation ELISA assay
4.3.6.1 Cell lysate sample preparation
Transfected cells were cultured as described in section 2.2.2. Three days following 
transfection, cells were serum starved for 4 hours using standard culture medium for 
HEK293 cells as described previously with the addition of 0.1%FBS instead of 10% 
FBS. Cells were then stimulated with EGF (100ng/ml2) which was added to the plate in 
drops and incubated at 37°C for 1 hour. Culture media was removed and cells were 
washed twice with ice-cold 1X PBS (Phosphate Buffered Saline). 1X Mg2+Lysis/Wash 
Buffer (0.5-1.0ml per 150 mm tissue culture plate) containing protease inhibitors was 
added to each well and cells were scraped from the plate with a rubber policeman. The 
cells in the lysis buffer were then transferred to a microcentrifuge tube and incubated on 
ice for 15 minutes. The tube was vortexed for 10 seconds or sonicated briefly for 10 
seconds and the sample was centrifuged at 14000 rpm for 10 minutes at 4°C. The 
supernatant was collected and protein concentration calculated using a Bradford Assay, 
a dilution series of BSA and a Nannodrop. Samples were kept cold and used 
immediately or frozen and stored at -80°C for 6 months.
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4.3.6.2 SDS page
Expression of the V5 tagged protein in untransfected controls and mutant cell lines was 
assessed by western blot using 30pl of each cell lysate and the protocol outlined in 
section 2.2.7. A V5 primary antibody (cell signalling) was used at a 1:5000 dilution.
4.3.6.3 Ras activation ELISA
Once expression of the V5 tagged mutant proteins was confirmed, the Ras activation 
Enzyme-linked immunosorbent assay (ELISA) was performed on all lysates as 
described in the manufacturers protocol and outlined below (Millipore, cat no: 17-497). 
As the missense mutation c.4267 p.K1423E (Li et al, 1992) is known to have 200-300- 
fold less activity than the wild-type NF1 GRD, this mutant was used to determine the 
activity of the test missense mutations based on the level of activated Ras (RLU) 
elicited in the Ras assay by this control.
4.3.6.3.1 Preparation of glutathione coated wells
The required number of glutathione bound strips were taped into the frame of the 96 
well plate and the remaining strips were stored with descant at 4°C. Each glutathione 
coated well was pre-rinsed with 200pl of Wash Buffer (TBST). The wash was flicked out 
of the wells and repeated twice more. For each well to be assayed, 2.5pl of 2pg/pl Raf- 
1-RBD was added to 47.5pl of Binding/Blocking buffer and 50pl was added to each well. 
The wells were sealed and incubated with rocking at 4°C, for 1 hour. After an hour the 
solution was flicked out as before and each well was washed with 200pl of Wash Buffer. 
The wash buffer was flicked out and the wash step was repeated 3 times.
4.3.6.3.2 Sample preparation
Up to 200pl of each sample was added to each well for a total amount of 10-100mg of 
cell lysate. A positive control was added to one well by combining 10pl of 5 mg/ml EGF
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stimulated HeLa cell lysate to 40pl of Binding/Blocking Buffer. To one well coated with 
Raf-1-RBD, only 50-200|jl of Binding/Blocking buffer was added to serve as a negative 
control. Wells containing sample lysate, positive control, and negative control were 
incubated at room temperature (RT) with mild agitation for 1 hour. The lysates were 
washed from the well three times with Wash Buffer as previously described.
4.3.6.3.3 Antibodies
50|jl of prepared primary antibody solution (1:10,000) was added to each well and 
incubated at room temperature with mild agitation for 1 hour. After an hour, the wash 
procedure was performed as previously described. 50pl of prepared secondary antibody 
solution (1:5,000) was then added to each well and again incubated at room 
temperature with mild agitation for 1 hour. During the incubation of the secondary 
antibody, the chemiluminescent substrates were warmed to room temperature for an 
hour prior to use. The wells were washed three times as previously described and then 
rinsed twice with 200pl of TBS, to remove Tween® 20.
4.3.6.3.4 Chemiluminescent substrate and luminometer
The Chemiluminescent substrate was prepared by mixing the room temperature 
solution in a 2:1 reaction buffer to detection reagent ratio. The substrate was incubated 
for 5 minutes and then 50pl added to each well. The Ras ELISA assay was measured 
using a microtitre plate luminometer (Applied Biosystems). Relative luminescence 
(RLU) was evaluated for each sample using the WINGLOW software (Perkin Elmer) 
between 5 and 60 minutes after the substrate was added.
4.3.7 Bioinformatic analysis
Fourteen of the sixteen missense variants located in the NF1 gene which were 
functionally analysed in this study, were also analysed with a computational model, 
MutPred (Li et a/, 2009, Mort et al, 2010) by Matthew Mort (Cardiff University). MutPred
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is designed to model the effect of changes in structural and functional sites within a 
protein between wild-type and mutant protein sequences. MutPred can be used to 
generate hypotheses as to the underlying molecular mechanism(s) responsible for 
disease pathogenesis. The effect of the coding region variants upon splicing [splice site 
disruption, cryptic splice site activation and exon skipping via loss of exonic splicing 
enhancers (ESE) and/or gain of exonic splicing silencers (ESS)] was ascertained using 
ESRPred and a neural network for splice site prediction (Krawczak et al, 2007). 
Evolutionary sequence conservation across an alignment of 44 vertebrate species was 
measured using the phyloP method (Pollard et al, 2010). PhyloP can measure 
acceleration (faster evolution than expected under neutral drift) as well as conservation 
(slower than expected evolution). A positive phyloP score represents a conserved 
nucleotide and a negative phyloP score indicates the nucleotide to be undergoing faster 
evolution than expected under neutral drift. Finally, SIFT was used to predict whether 
the mutation would be tolerated or damaging to the protein produced. Variants with 
SIFT scores £ than 0.05 are predicted to be deleterious
4.4 Results
4.4.1 Ras ELISA assay
Sixteen missense mutations were functionally analysed in this study, 4 of which were 
characterised by Mark Richards, Cardiff University (p.K1436Q, p.R1391S, p.R1204W 
and p.V1398D). All mutations were detected and characterised by direct sequencing of 
the NF1 gene as described in sections 2.2.3.2 and 2.2.3.3). The Ras activation ELISA 
assay generated fluorescence readings: relative light units (RLU) as a read out of the 
level of activated Ras in both mutant and control samples. Wild type NF1 had a level of 
activated Ras of -4x106 RLU (Figure 4.3). Only 5 of the 16 missense mutations studied 
here, yielded levels of activated Ras comparable with wild type NF1 (c.3919 A>G 
p.11307V, c.3980 A>G p.E1327G, c.4007 A>G p.Q1336R, c.4225 A>G p.K1409E and 
c.4235 C>G p.P1412R) (Figure 4.3), suggesting that these missense mutations are not 
deleterious to NF1 protein function. The previously studied c.4267 p.K1423E mutation
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(Li et al, 1992), demonstrated fluorescence levels of 6x106 RLU (Figure 4.3), showing 
concordance with previous findings that this missense mutation produces an NF1 
protein which is unable to attenuate Ras activation to the extent of the wild type 
neurofibromin and so results in higher levels of activated Ras. Eleven of the 16 studied 
missense mutations yielded fluorescence readings significantly higher than that of wild 
type NF1, but comparable with the c.4267 p.K1423E mutation (5x106-6.5x106 RLU) 
(Figure 4.3), demonstrating that these mutants elicit higher levels of activated Ras, with 
-200-300 fold less GRD activity: c.3610 C>G p.R1204G; c.3610 C>T p.R1204W, 
c.3827 G>A p.R1276Q; c.3902T>G p.L1301R; c.3971 C>A p.T1324N; c.4067 A>G, 
p.E1356G; c.4171 A>G p.R1391G, c.4173 A>T p.R1391S, c.4193 T>A p.V1398D, 
c.4306 A> C p.K1436Q and c.4388 C>T p.S1463F (figure 4.3) (p= 0.001, SPSS v16, 
independent samples t-test). To ensure that the wild type GRD contained within our 
control vector was actually functioning as a wild type protein we additionally completed 
a rescue experiment. The wild type GRD was transfected into NF1 deficient MPNST 
derived cell line (ST8815 and SNF96.2). The Ras ELISA assay was then completed on 
lysates from these cell lines in addition to untransfected MPNST cell lines (ST8814 and 
SNF96.2) and an untransfected HEK293 cell line containing wild type neurofibromin. 
We found that when the wild type GRD contained within our vector was transfected into 
MPNST cell lines; these cells elicited very similar levels of activated Ras as the wild 
type HEK293 cells. The MPNST cells containing the wild type GRD had a significantly 
reduced level of activated Ras in comparison to the untransfected MPNST cells (Figure 
4.4) (p=0.002, SPSS v16, independent samples t-test). Additionally, all mutants and 
control samples had the same level of V5 tagged protein expression by SDS PAGE 
(figure 4.5).
4.4.2 Bioinformatic analysis
For the 16 coding region variants listed in table 4.2 and figure 4.3, bioinformatic analysis 
was only available for 14. The bioinformatic data was in complete concordance with the 
results of the functional analysis. Analysis of the wild type neurofibromin protein 
sequence in comparison to the protein sequence of the mutant proteins analysed here
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predicted that 11 of the 14 mutations are likely to be deleterious. The remaining 3 
variants are predicted to be tolerated and are not expected to be disease causing. None 
of the variants were predicted to disrupt splicing through splice site disruption or cryptic 
splice site activation. Additional functional splicing analysis including; the minigene 
assay, may be required to definitively confirm the effects of these variants on splicing 
(Raponi et al, 2006; Bottillo et al, 2007; Raponi et al, 2009) (section 1.10.3).
The harmful effect of these variants is likely to be via disruption to protein 
structure/function. Measurement of sequence conservation across 44 vertebrate 
species indicated that these 11 mutations were located at highly conserved nucleotides; 
with a phyloP score in the range of 5.3-6.4 (a positive phyloP score indicates a 
conserved nucleotide). The remaining 3 mutations did not show strong evolutionary 
conservation. Furthermore, confident in silico hypotheses for the underlying mechanism 
of pathogenesis was generated for three of the 14 variants analysed (p.R1276Q, 
p.V1398D and p.S1463F; table 4.2 and figure 4.3). The mutation p.R1276Q is predicted 
to occur at a catalytic residue, resulting in the loss of this catalytic residue. p.V1398D is 
predicted to result in a gain of disorder. p.S1463F is likely to represent a polymorphism 
but MutPred and SIFT predicted it to be a pathogenic mutation. No predicted splicing 
abnormalities were identified in the 14 variants studied. In summary 11 of the 14 
missense variants analysed by bioinformatic analysis (Table 4.2 and figure 4.3) were 
predicted to have a functional effect whereas the remaining 3 variants are predicted to 
be neutral with respect to function.
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Table 4.2. Complete Results of the Ras ELISA assay and bioinformatic analysis of coding region variants in the NF1 
GAP-related domain. The MutPred Probability Score relates to the probability of a missense mutation having an effect on 
protein structure and/or function. Variants with SIFT scores £ than 0.05 are predicted to be deleterious.
Variant
Results of 
Functional 
Analysis
MutPred
Probability
Score
Mut Pred Hypothesis
SIFT Prediction 
(SIFT Score)
Experimentally 
determined (in-vivo) 
functional sites
Previously
Identified/Novel
Lab
Identified
c.3610 C>G P.R1204G Pathogenic 0.84 DAMAGING (0) Ars et al, 2000 MU
c.3610 C>T P.R1204W Pathogenic 0.81 DAMAGING (0) Krkljus et al, 1997 Service
c.3827 G>A P.R1276Q Pathogenic 0.98 Loss of catalytic residue at R1276 (P = 0.0404)
DAMAGING (0) Fahsold et al, 2000 MU
c.3902 T>G p.L1301R Pathogenic 0.91 DAMAGING (0) Novel MU
c.3919 A>G p. 11307V Not Pathogenic 0.47 TOLERATED (0.68) Novel MU
c.3971 C>A P.T1324N Pathogenic 0.36 DAMAGING (0.02) Novel MU
c.3980 A>G p.E1327G Not Pathogenic 0.45 TOLERATED (0.12) Novel MU
c.4007 A>G P.Q1336R Not Pathogenic ND ND Novel MU
c.4067 A>G p.E1356G Pathogenic 0.73 DAMAGING (0.05) Trovo et al, 2004 MU
c.4171 A>G p.R1391G Pathogenic 0.92 DAMAGING (0) Novel MU
c.4173 A>T P.R1391S Pathogenic 0.96 DAMAGING (0) Upadhyaya et al, 1997 MU
c.4193 T>A P.V1398D Pathogenic 0.81 Gain of disorder (P = 0.0412) DAMAGING (0) Novel MU
c.4225 A>G p.K1409E Not Pathogenic ND ND Novel MU
c.4235 C>G P.P1412R Not Pathogenic 0.48 TOLERATED (0.76) Novel Service
c.4306 A> C P.K1436Q Pathogenic 0.34 DAMAGING (0)
Phosphorylation in vivo 
at adjacent p.T1435 
PMID: 18452278
Novel Service
c.4388 C>T P.S1463F Pathogenic 0.46 Polymorphsim (0.46) DAMAGING (0.04) Novel MU
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RasGTP Levels in NF1 Missense Mutants
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Figure 4.3 Graph demonstrating the level of activated Ras (Ras-GTP) as a function of 
relative light units (RLU). Dashed line represents Ras-GTP in the wild type NF1 protein.
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Figure 4.4 Demonstration that the wild type GRD contained within the vector is able to 
rescue the level of activated Ras in NF1 null MPNST derived cell lines. Graph is 
representative of all cell lines analysed.
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Figure 4.5 Western blot of 12 V5 tagged mutagenised NF1-GRD vectors in HEK293 cell 
lines. Protein expression levels are the same across all cell lines. The p-actin control 
blot demonstrates there are unlikely to be off target effects of this vector.
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4.5 Discussion
This study set out to determine the pathogenicity of a number of missense mutations 
which have been previously identified in the GRD of the NF1 gene. The functional and 
biochemical analysis of missense mutations in the NF1 GRD is likely to yield important 
insights into the structure and function of the GRD and its ability to bind and attenuate 
Ras activity. It would also be important for determining the pathogenicity of potential 
NF1 germline and somatic missense mutations identified in patients, in addition to 
ascertaining whether there is any correlation between the phenotype of NF1 patients 
and their underlying GAP activity.
There are a number of possible mechanisms underlying the disruption to Ras-RasGAP 
interactions in NF1 proteins carrying GRD missense mutations. It is possible that these 
mutant proteins (i) are completely unable to bind with Ras, (ii) are able to bind with Ras 
but with impaired affinity, or (iii) are able to bind with normal affinity to RasGTP, but their 
ability to stimulate Ras may be severely impaired due to the loss of functionality through 
the amino acid substitution which has occurred. Alternatively, the level of the mutant 
neurofibromin in the cell could be very low if the mutation makes the protein unstable, 
which would result in binding with fewer Ras proteins leading to higher levels of 
activated Ras in the cell. In the context of the assay completed in this study, western 
blot analysis revealed that neurofibromin levels were the same in all mutants studied. 
This indicates that the missense mutations do not cause protein instability and so the 
loss of NF1GAP-Ras interaction in these mutants is not due to variation in protein 
levels.
Biochemical, functional and bioinformatic analysis are all important tools for dissecting 
the underlying pathogenesis of deregulated GAP function. A number of missense 
mutations which are located in the GRD have been previously analysed by several 
groups (Li et al, 1992; Poullet et al, 1994; Morcos et al, 1996; Upadhyaya et al, 1997; 
Klose et al, 1998; Ahmadazin et al, 2003). However, no in vitro assays has been 
designed for determining the pathogenesis of specific missense mutations in the NF1 
GRD which could rapidly and efficiently assay all variants within the GRD with high 
reproducibility. Previous NFI-GRD functional analysis have relied upon measuring the
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ability of rasGppNHp (guanylylimidodiphosphate, a nonhydrolyzable GTP analogue) to 
inhibit competitively NFI GRD stimulated hydrolysis of “P-labelled" RasGTP (Li et al, 
1992). Other studies used the nitrocellulose filter binding method which assays the 
amount of radio labelled nucleotide that remains bound to H-ras which is proportional to 
the extent of NF1 GRD-mediated GTP hydrolysis (Upadhyaya et al, 1997). Furthermore, 
RasGAP activity has also been assayed through the creation of an extensive NF1-GRD 
library to screen for mutants capable of interacting with H-rasD92K in a yeast two-hybrid 
screen (Morcos et al, 1996). These studies were suitable for the time at which they were 
developed but are laborious techniques which were only employed to determine the 
GAP activity of a limited number of mutants.
The combined use of site directed mutagenesis and a Ras ELISA is novel in the context 
of functional analysis of NF1 mutations. This assay is a simple and rapid technique, 
capable of analysing specific mutations and combinations of mutations using one 
mammalian vector and a reliable PCR and subsequent ELISA based assay, without the 
use of radio labelled nucleotides or the construction of multiple vectors. Site directed 
mutagenesis has also been employed in previous Ras-RasGAP assays (Li et al, 1992; 
Upadhyaya et al, 1997) but can represent a challenge if not optimised correctly. As 
experienced in this study, successfully incorporating some mutations into the vector 
occasionally required more than one attempt at transformation. Transformation 
efficiencies were generally fairly low with only about 10 colonies produced per 
transformation but at least 2 of these colonies were generally mutants. This study 
required stringent screening by direct sequencing of all colonies as occasionally 
additional mutations other than the desired variant may also become incorporated in the 
vector due to mismatches at the PCR stage. Kits for site directed mutagenesis such as 
the Stratagene kit (Agilent) can provide higher transformation efficiencies but such kits 
are not as cost effective as the in-house method used here.
Through optimisation, transformation efficiency was also improved with the use of an 
isopropanol DNA precipitation step which was added following Dpnl digestion, prior to 
transformation. Following precipitation, transformation efficiency was usually at least 
doubled with often 20-30 colonies generated. Future large scale analysis based on the 
technique described here would therefore benefit from blue/white selection with a vector
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containing the lacZ gene. Plating cells on x-gal and isopropylthiogalactoside (IPTG) 
avoids the necessity of screening all colonies by sequencing. Colonies carrying the lacZ 
gene are able to catalyse lactose or the artificial substrate x-gal into (5-galactosidase. 
Bacteria capable of this process turn blue, and those which don’t remain white. IPTG is 
an inducer that de-represses lacZ expression and should also be used as in some 
cases, not enough p-galactosidase is produced to turn the colony blue even if the lacZ 
gene is intact.
Overall, mutagenised vectors were generated for all desired mutations within a short 
time period using an appropriate vector which can be used to study the entire GRD. 
Additionally, this assay is versatile as it can be applied to a wide range of mutation 
types which occur within the GRD and could additionally be applied to the determination 
of the pathogenicity of truncating mutations in the same region. Furthermore, based on 
the extended sequence conservation outside of the GRD, it is possible that residues 
located adjacent to the GRD in neurofibromin may also serve to modulate GAP activity. 
Additionally, there is evidence that the cysteine serine rich domain (CSRD) located in 
the N-terminal of neurofibromin, may be able to regulate GAP activity following serine 
phosphorylation (Mangoura et al, 2006). Consequently, mutations in residues located in 
the CSRD could also result in altered GAP activity.
In this study we have identified 11 missense mutations which promote higher levels of 
Ras activity upon analysis of the mutant NF1 protein by an ELISA (figure 4.2, table 4.2). 
This suggests that the mutant proteins harbouring these missense mutations are 
defective in terms of their GAP function by comparison to the wild type neurofibromin. 
The bioinformatic analysis which was concordantly performed on these mutations, taken 
together with previous studies on some of these residues, provides new insight into the 
underlying mechanisms responsible for the reduction in Ras-RasGAP interaction in 
some of these mutants.
Mutations at K1423 have been reported many times in the literature (Li et al, 1992; 
Poullet et al, 1994; Morcos et al, 1996) and have been identified in NF1-associated 
neurofibromas and in an MPNST analysed in our lab. Li et al (1992) found that the 
K1423E mutation resulted in a 200 to 300-fold reduction of GAP activity. It is thought 
that the K1423 residue forms an intra-molecular salt bridge with an adjacent residue
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(E1437) in the a7/variable loop. Establishment of this intra-molecular bridge is an 
important component of the Ras-RasGAP interaction. Disruption of this salt bridge 
would be likely to result in negative charges which could interfere with the Ras-RasGAP 
interaction (Klose et al, 1998). K1423 is not located near to the Ras active site and thus 
would be unlikely to be involved in catalysis and more likely to be involved in the 
specificity of neurofibromin for Ras-GTP (Ahmadazin et al, 2003). In this study, we used 
the K1423E mutation as a positive control and have confirmed the results from Li et al, 
(1992), strengthening the evidence for the significance of this residue for GAP function. 
This observation demonstrates the validity of the approach adopted. The results were 
additionally determined to be reliable through independent validation using bioinformatic 
analysis as both sets of data demonstrated complete concordance.
The R1391 residue is known to be a supporting arginine residue in the FLR region, 
responsible for further stabilisation and orientation of the finger loop without directly 
contacting the active site in Ras (Scheffzek et al, 1996; Scheffzek et al, 1997; 
Ahmadazin et al, 2003). The R1391 residue has also been analysed numerous times in 
the literature including the R1391K variant by Skinner et a! (1991) and a GST tagged 
R1391S fusion protein by Upadhyaya et al (1997). It was found that the R1391S 
missense mutant was ~300 fold less active than wild-type NF1 (Upadhyaya et al, 1997), 
a finding which we have independently confirmed in this analysis (figure 4.2, table 4.3). 
Furthermore, the R1391G variant analysed in this study revealed the highest level of 
GTP-bound Ras (6x106 RLU, -400-fold reduction in GAP activity) of all the 16 missense 
mutations analysed in this study. R1391G and R1391S were also subjected to 
bioinformatic analysis. These variants have a MutPred score of 0.92 and 0.96 
respectively, indicating that these mutations are damaging to protein function. 
Bioinformatic analysis of this residue did not, however, generate a hypothesis as to the 
underlying mechanism responsible for loss of protein function caused by these 
mutations. Taken together, these results suggest that this residue is of great 
significance to GAP function as evidenced by different substitutions at this residue 
having the same negative effect on GAP function.
It has been seen through both structural and biochemical data that a crucial feature of 
GAP function is the contribution of an arginine finger which projects into the active site
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of Ras. This process is known to result in the stabilisation of the transition state for the 
GTPase reaction (Scheffzek et al, 1999; Resat et al, 2001; Ahmadian et al, 2003). One 
of the key mutations to be analysed in this study is therefore the R1276 residue, a 
crucial component in the Ras-RasGAP interaction as it corresponds to the arginine 
finger residue, responsible for engaging the catalytic site in Ras. The R1276Q mutation 
has been identified as a potential germline mutation and as a somatic mutation in a 
neurofibroma (Thomas et al, 2011, submitted). Previous studies by Klose et al (1998) 
have identified R1276P in a malignant schwannoma. It was determined that a 
substitution of a proline at this residue results in a reduction in binding affinity for Ras 
(6.6-fold) but crucially, this mutation severely compromises GTP hydrolysis (Klose et al,
1998). For this reason we have analysed R1276Q and have found that this alteration 
results in an increase in GTP-bound Ras by approximately 200-fold compared to the 
level observed with wild type neurofibromin. Concurrent bioinformatic analysis also 
confirmed this residue to be of importance to the catalytic activity of neurofibromin. 
MutPred analysis predicted that loss of a catalytic residue at R1276 (p=0.0404) is 
responsible for loss of function of neurofibromin harbouring this mutation. This arginine 
residue would therefore appear to be crucial for the catalytic activity of the arginine 
finger and so presumably plays an important role in stabilisation of the protein-protein 
interaction and the transition state for GTP hydrolysis. Thus it is indicated that this 
residue is absolutely required for GAP function (Ahmadian et al, 2003).
Thirteen of the 16 residues analysed in this study, 10 of which are novel, have not been 
previously investigated functionally: c.3610 C>G p.R1204G (Ars et al, 2000), c.3610 
O T p.R1204W (Krkljus et al, 1998) c.3902T>G p.L1301R, c.3919 A>G p.M307V, 
C.3971 C>A p.T1324N, c.3980 A>G p.E1327G, c.4007 A>G p.Q1336R, c.4067 A>G, 
P.E1356G (Trovo et al, 2004), c.4193 T>A p.V1398D, c.4225 A>G p.K1409E, c.4235 
C>G p.P1412R, c.4306 A> C p.K1436Q and c.4388 C>T p.S1463F (table 4.1, table 4.2 
and figure 4.1). Eight of these missense mutations were found to be deleterious to 
protein function (p.R1204G, p.R1204W, p.L1301R, T1324N, p.E1356G, p.V1398D, 
P.K1436Q and p.S1463F). MutPred scores between 0.34 and 0.91 were generated for 
these mutations indicating that all mutations are likely to elicit a damaging effect on 
neurofibromin function. Although p.K1436Q had a MutPred score of only 0.34 it was
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designated as pathogenic as a phosphorylation event has been identified in vivo at an 
adjacent residue to p.K1436Q (p.T1435) which is likely to be affected by this mutation. 
Five of the mutations analysed here are likely to be neutral changes with levels of 
activated Ras which corresponded to that seen in wild type NF1 (p.l1307V, p.E1327G, 
P.Q1336R, p.K1409E and p.P1412R) (Table 4.2, Figure 4.3). Bioinformatic analysis was 
not completed on two of these residues (p.Q1336R and p.K1409E) but for the 
remainder, the functional analysis was correlated with bioinformatic analysis where 
these mutations were designated MutPred scores between 0.45 and 0.48, further 
evidence that these mutations are non-pathogenic.
Due to the large size of the NF1 gene and its protein product, it is only possible to 
generate a mammalian expression vector containing a small proportion of the gene. The 
vector used in this study only contained the GRD and thus it would be important to 
determine the effect of these mutations in the context of the whole NF1 protein in 
addition to the GRD in this assay. However, the results from the present study 
demonstrate the suitability of this assay to determine whether identified NF1 gene 
variants are neutral or disease causing and the bioinformatic analysis provides insight 
into the underlying mechanisms of GAP deregulation.
In conclusion, 16 variants, encompassing 14 different amino acid residues within the 
GRD were analysed in this study (table 4.2). Eleven variants were found to be 
pathogenic through both functional and bioinformatic analysis consisting of nine 
different amino acid residues. The results from this study therefore indicate that there 
are many residues in the GRD which are crucial for GAP activity as determined by the 
level of Ras-GTP identified by the ELISA employed in this study. NF1 GAP activity is 
crucial to the regulation of the RasMAPK pathway in such a way that a therapeutic 
approach for the treatment of patients is an attractive prospect. Small molecules that 
are able to mimic GAP activity in cells derived from the neural crest could in principle 
restore NF1 protein function in patients with RasGAP mutations that vastly affect the 
Ras-GAP interactions.
This study has confirmed previous data on three residues (K1423E, R1391 and R1276) 
which are highly significant for neurofibromin function in addition to analysing a further 
11 residues located in the GRD. This data is not only important for distinguishing
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pathogenic mutations from non pathogenic mutations which are clearly useful for 
diagnosis and tumour related studies, but is also of significance for yielding important 
new insights into the GRD structure and function in addition to the mechanism of mutant 
NF1-Ras interactions.
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CHAPTER 5: CpG methylation analysis of NF1-associated tumours
5.1 Introduction
Whilst our understanding of the molecular mechanisms which underlie tumorigenesis in 
NF1 is continually evolving, the overall detection of somatic mutations remains low and 
there are many aspects of NF1 tumour formation and malignancy that remain unclear. 
Loss of function of tumour suppressor genes (TSGs), such as NF1, is mainly associated 
with DNA mutations including base substitutions, splicing alterations, gene deletions, 
insertions and duplications, however, the epigenetic process of DNA methylation, is 
frequently becoming associated with loss of gene expression due to the inverse 
relationship between the level of gene methylation and transcriptional activity 
(Rodenhiser et al, 1993). Aberrant methylation can therefore lead to loss of tumour 
suppressor function in tumour related genes as outlined in table 1.8 (Esteller et al, 2000; 
Baylin et al, 2001; Alqhist et al, 2008; Wang et al, 2008; Wang et al, 2009; Lin et al, 
2009). In the NF1 gene, the low level of somatic mutation detection, the spontaneity of 
new mutations and the high proportion of mutations involving CpG dinucleotides 
suggests that NF1 gene methylation in addition to methylation of other genomic loci 
may be involved in NF1 tumorigenesis.
Epigenetic modifications of the human genome include heritable posttranslational 
modifications of histones which are associated with chromatin, such as methylation and 
acetylation. Methylation is, however, the only known epigenetic modification of DNA, 
occurring exclusively at approximately 3-4% of 5-Cytosine associated with CpG sites, 
although non-CpG methylation can occur (Hotchkiss et al, 1948; Esteller and Herman, 
2002). Cytosine methylation is a heritable mark which if stable, can be passed from 
mother to daughter. Methylation is an important regulator of a number of processes 
including: embryonic development, transcription, chromatin structure, X chromosome 
inactivation genomic imprinting, genomic instability and carcinogenesis (Riggs and 
Pfeifer, 1992).
The molecular basis of normal DNA methylation is not fully understood although three 
DNA methyltransferases (DNMT1, DNMT3A, and DNMT3B) have been identified which
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are thought to establish and maintain DNA methylation. DNA methyltransferase-3 
proteins are involved in de novo methylation of CpG dinucleotides, particularly in 
parental imprinting. Indeed, knockout of Dnmt3a or Dnmt3b in mice is lethal as a result 
of loss of de novo methylation (Okano et al, 1999). DNMT1, however, methylates 
recently synthesized DNA in cooperation with MECP2, a methyl-CpG-binding protein 
which is capable of producing a copy of the parental DNA methylation pattern to the 
daughter DNA strands during cell division (Kimura and Shiota, 2003). DNMT1 
additionally interacts with other proteins, including; transcription factors (p53, STAT3, 
and HP1), histone modifiers (HDAC1, HDAC2), and ligands (DAXX) resulting in 
repression of target genes (Rountree et al, 2000; Muromoto et al, 2004; Esteve et al, 
2005; Smallwood et al, 2007). Dnmtl mutations in murine embryonic stem (ES) cells 
results in a reduction by two thirds in Cytosine methylation and moreover, germline 
mutation of Dnmtl triggers abnormal development and embryonic lethality (Li et al, 
1992).
The mechanism by which an increase in methylation results in silencing of gene 
expression is also not well known, although several models have been postulated. Gain 
of methyl groups is thought to involve a reduction in affinity or even a physical barrier to 
hinder binding of transcription factors in the methylated sequence. Furthermore, a steric 
block by methyl-CpG binding proteins (MDBP) may act as transcriptional repressors 
and additionally recruit complexes including histone deacetylases, consequently altering 
chromatin structure (Boyes and Bird, 1991; Nan et al, 1993; Jones and Laird, 1999). 
Aberrant increases in methylation in CpG rich regions of known tumour related genes 
(hypermethylation) can therefore act to ‘silence’ gene expression and lead to 
tumorigenesis. Conversely, hypomethylation events, although less frequent than 
hypermethylation, affect mainly intragenic and intronic regions of the DNA, specifically 
repeat sequences and transposable elements, and can result in chromosomal instability 
and increased mutational events (Watanabe and Maekawa, 2010). Altered methylation 
patterns are additionally exhibited in intronic regions, coding regions downstream of the 
promoter and even areas immediately adjacent to CpG rich regions (island shores), 
indicating that these regions may also contribute to gene regulation (Li et al, 2003; 
Ortmann et al, 2008).
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CpG islands, located in coding and non-coding regions are most commonly associated 
with transcription start sites and encompass a high concentration of CpG dinucleotides 
(Bird et al, 1986) Indeed, 70% of human promoters encompass CpG islands (Saxonov 
et al, 2006) and in frequently expressed genes, most promoter CpG sites are usually 
unmethylated, except in the case of X-chromosome inactivation (Riggs and Pfeifer, 
1992). Whilst most objective definitions for CpG islands have limitations, it is widely 
accepted that a CpG island consists of 200bp regions with a greater than 50% GC 
content and an observed/expected CpG ratio above 60% (Gardiner-Garden and 
Frommer, 1987). Recent analysis has, however, suggested that regions greater than 
500bp with a GC content above 55% and observed/expected CpG of 0.65 are more 
representative of true CpG islands (Takai and Jones, 2002) Using stringent CpG island 
analysis criteria (Gardiner-Garden and Frommer, 1987), there are only two defined NF1 
CpG islands; one in the promoter and a second located in intron 39 which is also 
associated with a pseudogene located in the promoter region of adenylate kinase 3 
(AK3L1) on chromosome 1p31.3. Across the 283kb NF1 gene region, there are 
approximately 2,420 CpG dinucleotides, of which only about 120 are located in coding 
regions.
Through the process of deamination, Cytosine spontaneously deaminates to Uracil 
which is efficiently recognised as a non-DNA base and consequently removed by Uracil- 
DNA-glycosylase (Cooper et al, 2010). When 5-methylcytosine (5mC) is present, 
however, spontaneous deamination instead yields thymine which consequently creates 
G-T mismatches (Shen et al, 1994). The process by which these mismatches are 
removed is highly error prone, involving first removal by methyl-CpG binding domain 
protein 4 (MBD4) in conjunction with thymine DNA glycosylase, followed by base 
excision repair (BER) (Waters et al, 2000). Hypermutability of CpG sites due to the 
process of deamination is thought to underlie 25% of all single base-pair substitutions 
(Cooper and Youssoufian, 1988; Cooper and Krawczak 1993) and indeed up to 20% of 
NF1 point mutations have been found to occur at CpG dinucleotides (Krkljus et al, 1997; 
Fahsold et al, 2000; DeLuca et al, 2004), a finding which is comparable with other 
TSGs, including RB1 (20-25%) (Cowell et al, 1994).
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Whilst the majority of DNA methylation occurs at CpG dinucleotides, recent analysis of 
mutations in 2113 genes determined that 10% of mutations involved CpNpG 
trinucleotides (Cooper et al, 2010). In the NF1 gene there are approximately 5000 each 
of CTG and CAG trinucleotides at which up to 3% of NF1 mutations have been 
identified, indicating that non-CpG sites also play a role in NF1 tumorigenesis (Fahsold 
et al, 2000). The NF1 gene also contains a well-defined isochore boundary within which 
there is a change in the GC content from 37% in the proximal part of the NF1 gene 
rising to 51% after the 3’ region (Bernardi, 2000; Schmegner et al, 2005). Precise 
sequence localisation for this boundary has not been defined, but it is known to 
represent the boundary between high and low recombination frequencies, potentially 
influencing the NF1 mutation rate (Eisenbarth et al, 2000; Schmegner et al, 2005). 
Methylation of NF1 CpG residues has been detected in developing mouse embryos 
(Haines et al, 2001) and 92% of CpG sites in exons 28, 29, and 31 were found to be 
methylated in sperm DNA (Rodenhiser et al, 1993; Andrews et al, 1996). The 
methylation status of the NF1 promoter has also been reported to alter luciferase 
reporter activity (Zou et al, 2003), however, investigation of NF1 promoter methylation in 
NF1 patient derived blood samples, cutaneous neurofibromas, plexiform neurofibromas, 
plexiform derived Schwann cell cultures (Fishbein et al, 2005), MPNSTs (Horan et al, 
2000; Luijten et al, 2000; Harder et al, 2004) and pilocytic astrocytomas (Ebinger et al, 
2005) suggested there was little evidence for a role of NF1 promoter methylation in NF1 
tumorigenesis (Ebinger et al, 2005).
There are numerous techniques for methylation analysis which have been employed in 
previous NF1 methylation studies. Bisulphite DNA conversion involves the use of 
sodium bisulphite which reacts selectively with unmethylated Cytosine converting it to 
Uracil. However, sodium bisulphite does not react with methylated Cytosines, leaving 
them unchanged. This reaction requires an initial denaturation step as it is dependent 
on the availability of single-stranded DNA (Frommer et al, 1992). Methylation specific 
PCR involves the use of primers which are designed to take advantage of the sequence 
differences which arise following bisulphite conversion (Herman et al, 1996). This 
method, whilst being both rapid and reliable, carries the limitations of PCR-based 
analysis and is not always sensitive enough to detect hypermethylation, particularly in
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heterogeneous tumours such as those studied here. Quantitative methylation PCR (Q- 
MSP) has also been developed which primarily relies on relative quantification, using 
fluorescent probes to detect methylation in bisulphite converted samples. Q-MSP has 
increased specificity and sensitivity for methylation detection and is comparable to 
quantitative multiplex-methylation-specific PCR (QM-MSP) (Herman et al, 1996; Eads et 
al, 2000; Cohen et al, 2003; Jeronimo et al, 2004). The recent development of DNA 
pyrosequencing now permits efficient detection of methylation at individual and multiple 
CpG dinucleotides using a directly quantitative approach (Colella et al, 2003). 
Pyrosequencing, is another bisulphite based method which determines the proportion of 
methylated bases at a CpG site based on the generation and detection of a light signal 
which is proportional to the amount of incorporated nucleotide. Pyrosequencing has 
many applications in cancer genetics and has most recently been employed to measure 
LINE-1 methylation in colon cancer and TP53 pathway genes in breast cancer (Irahara 
et al, 2010; Ronneberg et al, 2011).
Previous contradictory observations on the role of NF1 gene methylation are based on a 
small number of studies and completed on small samples sizes. Previous analyses 
involved the use of relatively insensitive methods and were only aimed at the promoter 
which encompasses approximately 1% of the total CpG sites in the NF1 gene 
(Rodenhiser et al, 1993; Horan et al, 2000; Luijten et al, 2000; Harder et al, 2004; 
Fishbein et al, 2005; Zou et al, 2003). It is clear, therefore, that sensitive analysis of 
methylation throughout the entire NF1 gene in a large panel of samples is warranted. 
Furthermore, as alterations in additional genetic loci are known to be involved in the 
development of NF1-associated benign and malignant tumours, methylation analysis of 
candidate modifying loci should also be investigated. The main aims for this chapter 
are:
1. To screen the promoter, introns and coding regions of the NF1 gene for 
methylation in a large panel of NF1-associated benign and malignant tumours 
using pyrosequencing.
2. To analyse methylation at potential modifier loci (RASSF1A and MGMT) using 
pyrosequencing in NF1-associated benign and malignant tumours.
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5.2 Materials
5.2.1 Reagents
CpG genome DNA modification kit (Chemicon, cat no: S7824)
EpiTect PCR control DNA set (Qiagen, cat no: 59695)
Streptavidin Sepharose beads (GE Healthcare, cat no: 17-5113-01)
Pyrosequencing reagents (All Qiagen)
Binding buffer, (cat no: 979306)
Denaturing solution, (cat no: 979307)
Wash buffer, (cat no: 979308)
Annealing buffer, (cat no: 979309)
PyroMark Gold Q96 reagents, (cat no: 972812)
Pyrosequencing consumables (All Qiagen)
PyroMark Q96 plate low (PSQ) (cat no: 979002)
PyroMark Q96 cartridge (cat no: 979004)
5aza2dc (Sigma, cat no: A3656)
5.2.2 Equipment
PvromarkQ96 ID Pvrosequencer (Qiagen)
Vacuum prep workstation (Qiagen)
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5.3 Methods
5.3.1 Patient samples
82 tumour derived DNA samples with undetectable mutations from 40 patients were 
screened for NF1 (NM_000267) whole gene methylation levels in addition to RASSF1A 
(NM_007182) and MGMT (NM_002412) promoter methylation. Of the 82 tumours 
analysed, 67 were benign cutaneous neurofibromas, 11 plexiform neurofibromas and 4 
MPNSTs. NF1 germline mutations were identified in 34/40 patients. The methylation 
status of samples with and without characterised somatic and germline NF1 mutations 
was determined with the use of an additional 3 neurofibroma derived Schwann cell 
lines, 3 MPNST derived cell lines and 10 tumour samples (6 neurofibromas, 2 plexiform 
and 2 MPNSTs) all with characterised NF1 somatic and germline mutations. 
Hemizygous NF1~/+ fibroblast cell lines from NF1 patients (matched with affected tumour 
tissue) and a HEK293 cell line served as controls. DNA extracted from the spleen, 
spinal root and placenta (matched with an MPNST, plexiform neurofibroma and 
cutaneous neurofibroma from one patient) were also screened to determine the levels 
of tissue specific methylation. Lymphocyte DNA samples, matched with tumour DNA 
samples as well as blood DNA samples from non-NF1 patients were used to assess 
methylation levels in peripheral blood. Furthermore, Epitect control DNA samples were 
employed to prevent false positive results and problems with bisulphite conversion. All 
tissue DNA samples including tumours and tissue from the spleen, placenta and the 
spinal root were macrodissected from the surrounding tissue. DNA, RNA and cDNA 
were extracted as previously described in sections 2.2.3.1.1, 2.2.3.1.2 and 2.2.3.3.
5.3.2 Cell lines
Three human MPNST derived cell lines (ST8814, T529 and T530) and NF1-patient 
derived fibroblast cell lines were maintained as described in section 2.2.2.
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5.3.3 CpG analysis
To ensure that all CpG rich regions in exons and introns of the NF1 gene were included 
in our analysis, the entire DNA sequence of the NF1 gene in addition to the promoter 
region of the RASSF1A and MGMT genes was submitted to CpG island searcher 
software (v. 10/29/04) (Takai and Jones, 2002). The DNA sequence was analysed using 
the following criteria which encompasses both the upper and lower limits of the 
definitions for a CpG island (Gardiner-Garden and Frommer, 1987; Takai and Jones, 
2002): >200bp regions, >50% GC content, an observed/expected ratio >60% and at 
least a 100bp gap between adjacent islands to avoid merging CpG islands (Gardiner- 
Garden and Frommer, 1987). Twenty-three NF1 CpG rich regions (including the NF1 
promoter and AK3L1 pseudogene CpG islands), a CpG island in the MGMT promoter 
and a CpG island in the RASSF1A promoter region approximately 300bp upstream of 
the RASSF1A ATG were identified. For the NF1 methylation analysis, the AK3L1 
pseudogene CpG island was excluded from the analysis due to problems with primer 
specificity. Therefore, a total of 22 CpG regions for NF1 methylation analysis, covering 
all large CpG islands and GC rich regions and encompassing 353 CpG sites within the 
NF1 gene were analysed (figure 5.1).
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Figure 5.1 Schematic representation of the NF1 gene identifying CpG islands used for NF1 methylation analysis. Not drawn to 
scale. The arrow represents the transcription start site and hexagon denotes the translation termination site.
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5.3.4 CpG Genome modification procedure
CpG modification of genomic DNA was achieved using a CpG modification kit. DNA 
was diluted to 10ng/pl in a 1.5ml microcentrifuge tube. 7pl of 3M NaOH was added and 
the contents of the tube were mixed and incubated for 10 minutes at 50°C. After the 10 
minute incubation, 550pl of DNA modification reagent I was added, vortexed and 
incubated at 50°C for 4-16 hours (protected from the light).
Reagent
Number Reagent (g) dH2 0  (ml) pH Temperature Additional Reagents
1 0.227 0.571 5 Room
2 1.35 0.75 - Room 1 pi p-mercapto- ethanol 20ml dH2 0
DNA modification reagent III was resuspended by vortexing and drawing in and out of a 
pipette tip up to 10 times. 5pl of DNA modification reagent III was added to each of the 
solutions as well as 750pl of DNA modification reagent II. The solutions were mixed 
briefly and incubated at room temperature for 5-10 minutes. The tubes were centrifuged 
at 5000xg for 10 seconds to give a white pellet and the supernatant was discarded. 1ml 
of ethanol was added to the tubes, vortexed and centrifuged for 10 seconds at 5000xg. 
The supernatant was discarded again and this step was repeated twice more. On the 
final ethanol wash, the tube was centrifuged at high speed for 2 minutes and the 
supernatant was discarded.
50pl of 20mM NaOH/90% ethanol was added to each of the tubes and vortexed to 
resuspend the pellet. The samples were incubated at room temperature for 5 minutes 
and centrifuged at 5000xg for 10 seconds. 1ml of ethanol was added to the tubes, 
vortexed, centrifuged and the supernatant was removed, this was repeated and the 
tubes were then centrifuged at high speed for 3 minutes. All supernatant was removed 
from the tubes and they were left to air dry for 10-20minutes. 25pl 1xTE was added to 
each tube. This was incubated for 15 minutes at 50-60°C to elute the DNA from DNA 
modification reagent III. Finally the DNA was centrifuged at high speed for 2-3 minutes 
and the supernatant was transferred to a new tube.
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5.3.5 Assay design and PCR optimisation
Design of PCR and sequencing primers was carried out using the Qiagen 
Pyrosequencing Assay Design software, requiring the generation of one set of primers 
to amplify the target area, one of which (forward or reverse) was biotinylated and a third 
primer was required for sequencing. The biotinylated primer was HPLC purified and the 
second PCR primer and the sequencing primer were purified using standard methods. 
Assay design was completed using the Qiagen assay design software and this was 
loaded onto the Pyromark ID Pyrosequencer (Qiagen). Each individual primer set was 
optimised separately. PCR primers and PCR conditions are listed in table 5.1 and the 
standard PCR reaction conditions and thermal cycling conditions are as follows:
Reaction Volume 50pl Cvcle Conditions: x45 cycles
DNA [10ng/pl] 5 pi
Buffer 5pl 95°C 5minutes
Mg [25mM] 4pl
dNTPs [10pM] 2.5pl 95°C 15seconds
Sense Primer [10pM/pl] 1 Ml Tm 30seconds
Antisense Primer [10pM/pl] 1pl 72°C 15seconds
Taq 0.15pl
H20 31.35pl 72 °C 5minutes
On the first time of running a PCR amplified product on the Pyromark, the PCR product 
was checked by running 10pl of product with 5pl of loading dye on a 1.5% gel before 
Pyrosequencing. Product concentration could then be eliminated if Pyrosequencing 
reactions failed. Each set of Pyrosequencing reactions required 5 controls including: (i) 
a repeat PCR with no sequencing primer added to the (PSQ) plate, (ii) a well containing 
sequencing primer alone, (iii) a well containing biotinylated primer alone, (iv) a well 
containing biotinylated and sequencing primer and (v) a negative (no DNA) PCR control
2 0 0
Table 5.1 Primers used in Pyrosequencing analysis.
CpG
Region
PCR
Conditions Strand Label Forward Primer (5'-3') Label Reverse Primer (5'-3') Sequencing Primer
1 52C 2.5mM Mg TOP GTTTGAGGGAGGAGTGTAGG BIOTIN CTCAAAACACCTTTAAAACCTTACATTC GGGAGGAGTGTAGGT
1 52C 2.5mM Mg TOP GGAGG rA G IG IA I IT IA  I IT  11 ITT GAGA BIOTIN CTAACCCCAAAACATCCACTCCCATC AG 1A IAG ITTTII IAGGAGAT1AG
1 54C 2.5mM Mg TOP GGGGGAGGGGATAGTTGTA BIOTIN CTCCTAAAAATAACCTCATCTAACTCCTCT GGGGATAGTTGTAGGG
1 54C 2.5mM Mg TOP GGATGTTTTAGGGTTAGTTTTGGTAT BIOTIN ACACCCCACCCAAAATAAAATCCTTT GTTAGAAGGTTTAGAGGAGTTA
2 51°C 3mM Mg TOP TGGGGGTGGGGATAGAGTA BIOTIN ATCCCCCCTTCCCTTCTC AGGTGAGGGGAGGTA
3 48C 3.5mM Mg BOTTOM GAGGGTATATAAGATAGGTTTTAGGG BIOTIN CCATCTAAATTTAATAATTACCCCCTTAC ATAAGATAGGTTTTAGGGT
4 52C 2.5mM Mg TOP BIOTIN GGGAGAAAAAGTTTTGTATGTATTGA CACCACACCCAACTAAT7TTTATAT TTAATAAAAATAAAATTTCACT
5 43°C 3.5mM Mg TOP BIOTIN TGTTATTTAGGTTGGAGTGTAATG AACACAATAAAACACCTTCTCTATTA TCTATTAAAAATACAAAAATTAAC
6 52C 3.5mM Mg TOP TTGTAGTTTAGGTTGGAGTGTAGTG BIOTIN ACATAAAAACCAACACCTATAATCCCAACT GTTGGAGTGTAGTGG
7 48C 2.5mM Mg TOP ATTAGGGAGTTTGAGGTAGGAGAAT BIOTIN TCACTCTTATCACCCAAACTAAAATACAAT GAGGTAGGAGAATGG
8 51 °C 3mM Mg TOP BIOTIN TGAGGGTTTGTTGTAGTAATTG CCACCACCACACCTAACTATTTTT TTTAATAAAAATAAAAATTTCAC
9 52C 2.5mM Mg TOP BIOTIN GGAGGTTAAGGTGGGTAGAT CCTCCCCAATTCATACCATTCTCCTACCT ACCATTCTCCTACCTC
10 48C 3.5mM Mg BOTTOM GAATAAGGTTAGGAGTAGTGGTTTAAGT BIOTIN ACCTCCTAAATTCATACCATTCTCC AAAAATATAATAAAAATTAGTTGG
11 49C 3.5mM Mg BOTTOM ATGAATTTAGGAGGTAGAGATTGTAG BIOTIN ACCCCCCCAATTTCATTTAATATTTCCTT AGGTAGAGATTGTAGTG
12 51C 2.5mM Mg TOP AGGAGGTTGAGATAGGAGAAT BIOTIN CTCACTCTATCACCCAAACT GTTGAGATAGGAGAATGG
13 51°C 3mM Mg BOTTOM GTTTAGGTTGGAGTGTAATGGTATA BIOTIN ACCCCATCTCTACTAAAAATACAA TGGAGTGTAATGGTATAAT
14 48C 3.5mM Mg TOP GGTTGGTTGTn 11 AAAI ITAGTGG BIOTIN CCTAAAATTCACCCCATTCTCCTACCT GTGGTGAAAGAAAATGAT
15 44C 3.5mM Mg BOTTOM AGGTTAGGAGATGGAGATTATTT BIOTIN CTCTATTACCCAAACTAAAATACAA AGGTTGAGGTAGTAGAA
16 44C 3.5mM Mg BOTTOM AGT 1111IAAG IA G 11GGGA11ATAGG BIOTIN ATCAAAAAATCAAAACCATCCTAAC GTTGGGATTATAGGTGT
17 52C 2.5mM Mg TOP GAGGTTAGGAGATAGAGATTATTTTGGTTA BIOTIN AACCCCATCTCAACTCACTACAAACTC ATTAAAAATATAAAAATTTAGTTGG
18 44C 3.5mM Mg TOP GGAGTTTGAGATTAGTTTGGTTAATATG BIOTIN CCCCTCCCAAATTCAAACA GTTTGGTTAATATGATGAAGT
19 48C 2.5mM Mg BOTTOM ATTGAGTAGTGTTTTAGGGATATTTT BIOTIN AAACCATTATCCAATCTATCATTCATAT TGTTGGGGGATAGAG
20 54C 2.5mM Mg TOP AGGGTAGATTAAGAGGTTAGGAG BIOTIN AAAAACCATCTCCACTCACTACA TTGAGATTATTTTGGTTAATATAG
21 44C 3.5mM Mg BOTTOM GGTGAGATGGTAAAGTAGTATATAGAGA BIOTIN CACTTCACAAATTTTATCCAAAACT TTTGGTTTTAGATTATGTGATTATA
22 43C 2.5 Mm Mg TOP TGGAAGGAAAAGAAGAAGTAATT BIOTIN AAACTACCAACCCTTCTTTACTTCTACAC G T lG T il 111111 1 1 1 1 IAG
22 50C 4mM Mg TOP TTGGTGTGTAGTAGGTTATGIIA I I I BIOTIN OTI C ITCT'I rTCC rTCCAAAAC 1 AAA 11 AGTATATTTTATAATATTTGTATAG
MGMT 44C 2.5mM Mg TOP ATTAGGGGAGAGGTATTAGGAGG BIOTIN ACCAAATAACCCCTACCTTTTCCTATCAC TAGGAGGGGAGAGAT
MGMT 54C 2.5mM Mg TOP ATTAGGGGAGAGGTATTAGGAGG BIOTIN ACCAAATAACCCCTACCTTTTCCTATCAC AGTAGGATAGGGATTTTTATTAAG
RASSF1A 50C 2.5mM Mg TOP AGGTATTTAGGAGGTTGAGGTAGAAGA BIOTIN AACACAAAACTTCCCCTTTCCTCATT GGTTGAGGTAGAAGAAT
RASSF1A 50C 2.5mM Mg TOP GTTAAAGGTGTTTAGTI1 11 1 1 1 ITAAGTA BIOTIN CCACCATACCCAACTAATT11 lATATTI 1 T TTAAGTAAATGGGTAGATGT
RASSF1A 54C 2.5mM Mg TOP GGAGTTTGAGATTAGTTTGGTTAATATG BIOTIN TCCCCTTTCCTCATTAACAAT TTGGTTAATATGGTGAAA I T I
Table 5.2. Details of primers used in Real Time PCR analysis.
Primer Primer Location Target/E ndogenous Sense primer sequence (S'-S1) Tm Length Antisense primer sequence (5-3') Tm Length Amplicon Length
NF1 Promoter NF1 Promoter Target GGACGTGACGTATTCATCAGTTCA 60°C 21bp AACCTTTTCAATACATATCATTAACTTCATG 58°C 31 bp 53bp
RASSF1A Promoter RASSF1A Promoter Target GGCAGAAGAATCGCTTGAACC 60°C 21bp ATTTCGGCTCACCGCAAC 58°C 18bp 51 bp
B2M Exon 2 Endogenous CCCCCACTGAAAAAGATGAGTAT 61°C 23bp CAAAGTCACATGGTTCACACGG 64°C 22bp 50bp
2 0 1
5.3.6 Preparation for pyrosequencing
Pyrosequencing was carried out as previously described (Uppsala, Sweden) using Q96 
Pyro Gold reagents (Qiagen) on a Pyromark Q96 Pyrosequencer (Qiagen). 90 minutes 
prior to use, the PyroMark Q96 ID was switched on to allow adequate time to stabilise. 
A heat block was set at 80°C and all reagents and primers (sequencing primer and 
biotinylated for control well) were removed from the freezer to warm to room 
temperature. Finally the vacuum pump was switched on with the vacuum kept closed 
and each reservoir on the Vacuum Prep Workstation (Qiagen) was filled with 180mls of 
ethanol, denaturation solution and wash buffer following the manufacturers’ protocol.
3pl of streptavidin sepharose beads per sample were added to 37pl of binding buffer 
per sample and the 40pl binding buffer/beads solution was added to an equal volume of 
PCR product in the 96 well plate in which the PCR was completed. The plate was then 
sealed and shaken for 15 minutes at room temperature. 0.4pM sequencing primer was 
added to 40pl of annealing buffer and this was aliquoted into the appropriate wells on a 
PSQ plate.
The PCR product attached to the beads was combined with the sequencing primer 
using the Vacuum prep tool. The beads containing the immobilised templates were 
captured by the probes on the vacuum prep tool. The probes were washed in 70% 
ethanol for 10 seconds followed by 10 seconds in the trough containing denaturation 
solution and a final 10 seconds in the wash buffer. The vacuum was then turned off and 
the beads were released in to the PSQ plate containing the sequencing primer. The 
plate containing the samples was incubated on a heat block for 2 minutes at 80°C to 
assist in the annealing of the primer to the template. The plate was then removed and 
placed on the PyroMark after it had cooled to room temperature.
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5.3.7 Running the pyrosequencing assay
The assay run file containing the details of the sequencing run and the instrument 
parameters were loaded onto the pyrosequencer prior to starting the run. Enzyme and 
substrate mixtures were reconstituted with high purity water and mixed gently by 
inverting a few times. The Q96 cartridges were filled with the appropriate reagents 
(enzyme, substrate and dNTPs) and the cartridge was placed in the Pyromark along 
with the PSQ plate and the run was started. Results were analysed using the Q96 
Pyrosequencing software (Qiagen). The average methylation was calculated across all 
CpG dinucleotides in one amplified fragment to give a score of mean methylation for 
each CpG island.
5.3.8 Gene expression analysis
Relative quantification was used to correlate methylation status of NF1 and RASSF1A 
genes with their gene expression using the method and conditions outlined in section 
2.2.5 and the primers outlined in table 5.2. All data was analysed with the ABI 7500 
SDS System software (Applied Biosystems)
5.3.9 5-Aza-2’-deoxycytidine cell line treatment
5-Aza-2’-deoxycytidine (5aza2dc) is a demethylating agent which is incorporated into 
DNA of dividing cells. Following cell treatment with 5aza2dc, a rapid loss of DNA 
methyltransferase activity is observed as the enzyme becomes irreversibly bound to the 
5aza2dc residues in DNA (Christman, 2002). Three cell lines derived from NF1 
malignant tumours (ST8814, T529, T530) were treated with 5aza2dc at concentrations 
of 1pM, 5pM, 10|jM, 20pM and 30pM. 2x105 cells were seeded 24 hours prior to 
treatment in 6 well plates using the appropriate medium as described in section 2.2.2. 
All cells were treated with freshly made 5aza2dc for 4 days with the culture medium 
changed every 24 hours for freshly made 5aza2dc. Pilot tests assessed the minimum 
time required for the drug to elicit a response. One aliquot of cells from each cell line
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was left untreated as a control. Cells were harvested after 4 days, from which DNA was 
extracted for methylation analysis and RNA for RASSF1A gene expression analysis 
using the protocols described above and in section 2.2.5. The effect of 5aza2dc drug 
removal was also assessed. Cells were cultured for 21 days and treated only for the first 
7 days with 5aza2dc (20pM) followed by 14 days in which the drug treatment was 
withdrawn and replaced with normal growth medium.
5.3.10 5aza2dc treatment cell survival and cell death assay
The toxicity of 5aza2dc on cultured MPNST tumour cells was determined by seeding 
the cells as above and treating with a series of 5aza2dc concentrations (10pM, 20pM, 
30pM, 40pM and 50pM). One aliquot of cells was left untreated as a control. Cells were 
treated over 4 days; the medium was changed daily with freshly prepared 5aza2dc. 
Trypan Blue (Gibco) and a Haemocytometer were used to assess living and dead cells 
grown in each drug concentration as described in section 2.2.2.3. All experiments and 
measurements were carried out in triplicate.
5.3.11 Statistical analysis
All statistical analysis was completed using SPSS (v16) and the independent samples 
T-Test.
5.4 Results
5.4.1 NF1 gene methylation
Epitect control DNA samples (Qiagen) were initially used to establish the baseline levels 
of methylation in the pyrosequencing assay. The ‘unmethylated control’ demonstrated 
12% methylation and the ‘methylated control’ was 96% methylated. The NF1 gene was 
methylated at 20 of the 22 CpG rich regions analysed in tumour derived samples and 
controls, with the exception of CpG island 22 (exon 49) which was only methylated in
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tumour derived samples. Methylation in tumour samples at all 20 CpG islands was 
significant when compared to the Epitect unmethylated control (p=0.05 -  p= 0.001). 
These methylated regions encompassed the promoter, but none of the other known 
functional domains of neurofibromin (table 5.3). Nine CpG regions located within intron 
1 (CpG regions 3-11), all exhibited similar levels of methylation across different tumour 
types; although the methylation level was highly variable between the CpG regions 
(12%-83%) and one CpG region was not methylated (table 5.3). Two CpG rich regions 
located within 600bp of each other in intron 5 (14 and 15) demonstrated the same levels 
of methylation across all samples although one was methylated (57%); the other was 
not significantly methylated (16%). A 200bp fragment located at the 5’ intron/exon 
boundary of the last exon, 49 (CpG region 22) was also analysed using the sequence 
shown here (CpG sites are bold and italicised with the intron in lower case and exon in 
upper case):
cgcctaatgattgtttcctagaatgtgtccccgttgttaagcgacacatgactgcaatgaaattcagtcctggaaggaaaag 
aagaagtaactggctgttctctttttctccagGAAT CGACAAGGAGAACGTT GAACT CT CCCCT ACC 
ACTGGCCACTGTAACAGTGGACGAACTCGCCACGGATCCGCAAGCCAAGTGCAGA 
AGCAAAGAAGCGCT GGCAGTTT
This was the only CpG rich region to exhibit significant differences in methylation levels 
between the tumour derived samples (primary tumour and tumour derived cell lines) 
(exhibiting ~86% methylation), the fibroblast control cell lines (~58% methylated) 
(p=0.008) and the lymphocyte DNA (~22% methylated) (table 5.1, figure 5.2a). This 
cluster of CpG sites also showed variable methylation levels in the three different tissue 
types; as DNA from the spinal root was 80% methylated whilst methylation in the 
placenta and spleen was 24% and 26% respectively. No significant differences in 
methylation were, however, identified between benign and malignant tumour types 
(p=0.2) or between NF1 and non-NF1 lymphocyte blood DNA samples (p=0.4). There 
was also no difference in the level of methylation in the tumour samples in which the 
NF1 germline or somatic mutation had previously been identified in comparison to 
samples in which the NF1 somatic mutation was unknown (p=0.4).
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It is also possible that our initial CpG analysis could have highlighted GC rich genomic 
sequences which are associated with Alu repeats due to the lower stringency of this 
search. Analysis of the sequences of the NF1 CpG rich regions investigated in this 
study indicates that only regions 7 and 18 have evidence of a possible association with 
Alu repeats due to the presence of a 3’ A-rich region and additionally CpG island 12 
which has evidence of a central A-rich region. For the remaining 19 CpG rich regions, it 
is unlikely that these sequences reflect Alu repeat regions (Batzer and Deininger, 2002). 
This was confirmed definitively using repeat masker (http://www.repeatmasker.org).
5.4.2 RASSF1A and MGMT promoter methylation
The methylation status of the RASSF1A promoter exhibited up to 81% average 
methylation in benign and malignant tumour DNA and -21%  in fibroblast control 
samples (p=0.001). NF1 lymphocytes and control lymphocyte DNA only exhibited -15- 
20% methylation (figure 5.2b). No significant difference in RASSF1A methylation was 
identified between benign and malignant tumour types (p=0.7). No significant difference 
in MGMT promoter methylation was identified in tumour samples in comparison to 
matched controls (p=0.9).
5.4.3 Gene expression analysis
NF1 gene expression was analysed in tumour derived samples, controls and blood DNA 
samples derived from NF1 patients. The NF1 gene was found to exhibit a 2 to 6-fold 
decrease in gene expression across all sample types but we were unable to correlate 
NF1 gene expression with NF1 methylation status. RASSF1A gene expression was, 
however, found to be correlated with the level of RASSF1A promoter methylation (figure 
5.3a). Tumour derived samples and tumour cell lines were 81% methylated and 
demonstrated up to a 5-fold decrease in RASSF1A gene expression (Figure 5.3b) in 
comparison to the control matched fibroblast cell lines and tissue matched blood 
samples which demonstrated normal RASSF1A gene expression and were not 
significantly methylated (15-20%) (p=0.001).
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Table 5.3 Pyrosequencing results showing the average methylation at each CpG island in all samples analysed. ND. Not done.
Sample Type
Mean Methylation at Each CpG Island
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Rassfla MGMT
NF1
Promoter
Exon
1
Intron
1
Intron
1
Intron
1
Intron
1
Intron
1
Intron
1
Intron
1
Intron
1
Intron
1
Intron
2
Intron
4b
Intron
5
Intron
5
Intron
29
Intron
29
Intron
29
Exon
31
Intron
32
Intron
40
Exon
49 Promoter Promoter
Neurofibroma 72 34 14 65 36 82 54 49 45 41 52 59 57 18 58 50 48 53 97 67 67 90 81 20
Rexiform 71 35 18 67 36 83 53 48 46 46 55 58 61 20 54 53 48 52 94 68 69 78 83 19
MPNST 73 33 12 62 33 82 54 50 44 43 58 56 62 15 56 53 46 55 87 65 70 89 81 20
Schwann Cell Lines 74 32 13 65 34 82 55 51 42 42 56 57 62 17 55 54 47 50 90 66 71 75 80 19
Fibroblast Cell Lines 70 34 18 63 35 85 52 48 43 42 55 57 60 17 57 52 50 51 89 68 72 58 21 22
Spleen 72 32 11 61 36 83 50 49 46 45 56 58 63 16 55 51 47 56 85 69 65 26 ND ND
Spinal Root 73 31 13 64 38 84 50 51 44 44 52 59 58 15 58 55 51 57 90 65 64 80 ND ND
Racenta 72 30 12 62 37 82 51 48 43 44 51 60 58 14 56 54 52 50 83 66 69 24 ND ND
NF1 Blood 75 33 15 66 38 82 52 51 48 44 60 59 58 13 58 53 50 55 93 67 68 22 16 21
Non NF1 Blood 74 34 11 64 36 81 53 49 45 43 55 57 57 17 57 50 49 55 87 68 70 25 15 20
Unmethylated Control 10 11 15 12 13 12 16 10 15 10 10 11 15 14 12 11 10 16 12 10 10 17 14 18
Methylated Control 97 99 100 96 96 100 100 95 96 99 100 96 99 97 97 96 100 95 100 96 97 99 97 96
Average Tumour 
Methylation 72 33 14 64 36 83 52 49 45
44 55 58 59 16 57 52 49 54 89 67 68 86 81 20
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Figure 5.2 (a) Pyrosequencing traces (Pyrograms) of matched tumour (MPNST), control sample and blood sample for CpG region 
22 (exon 49, NF1 gene), (b) Pyrosequencing traces of RASSF1A promoter in tumour (MPNST), control sample and blood samples.
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Figure 5.3 (a). RASSF1A promoter fold-change in gene expression in a control blood sample, NF1 
tumour matched blood sample, fibroblast control sample and a tumour sample (MPNST) (p=0.001). 
Profiles are representative of all samples studied, (b) RASSF1A gene expression dose dependent 
response to 5aza2dc treatment of MPNST cell line (ST8814). (c) Gene expression profiles of an MPNST 
cell line (ST8814) treated with 5aza2dc over 4 days followed by drug removal until day 21. Profiles are 
representative of all cell lines studied
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Figure 5.4. Pyrograms and methylation status of MPNST cell line (ST8814) treated with 5 concentrations of 5aza2dc (1, 5, 10, 20 
and 30pM). Pyrograms are representative of all cell lines treated.
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Figure 5.5 Graphs showing the level of (a) living cells and (b) dead cells in an MPNST 
cell line (ST8814) treated with increasing 5aza2dc drug concentrations. Graphs are 
representative of all cell lines studied.
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5.4.4 5aza2dc celI line treatment
MPNST tumour-derived cell lines with RASSF1A promoter hypermethylation and 
decreased RASSF1A gene expression demonstrated a dosage-dependent response in 
gene expression when treated with 5aza2dc at 1-30pM concentrations over 4 days 
(figure 5.3b). All tumour derived cell lines demonstrated complete normalisation of 
RASSF1A gene expression at both 20pM and 30pM concentrations of 5aza2dc. 
Treatment for four days was determined to be the minimal treatment period needed to 
induce a return of gene expression to normal levels (figure 5.3c) and the effect was 
found to be transient following drug withdrawal as RASSF1A gene expression returned 
to a level comparable with that seen prior to treatment after 21 days (figure 5.3c). The 
dosage-dependent normalisation of RASSF1A gene expression was also correlated 
with a dosage-dependent reduction in methylation status (64% to 32%) as seen by 
pyrosequencing (figure 5.4). Concentrations of 5-aza2dc over 30pM were found to lead 
to significant cell death in comparison to untreated controls (figure 5.5).
5.5 Discussion
Despite the high mutation rate associated with the NF1 gene, it has proven difficult to 
successfully identify both germline and somatic NF1 mutations indicating that additional 
mechanisms of gene inactivation in addition to the effect of modifying loci may be 
involved in NF1 tumorigenesis. It is postulated therefore that increased methylation of 
the NF1 gene, in addition to methylation at other modifying loci could be involved in 
somatic NF1 gene inactivation and tumour progression. This comprehensive study is 
the first to use pyrosequencing to analyse methylation levels in all CpG rich regions 
located within the promoter and the NF1 gene in addition to the promoters of possible 
modifier loci; RASSF1A and MGMT  in a large cohort of NF1 -associated tumours, 
matched blood samples and patient derived tissue samples.
2 1 2
5.5.1 NF1 pyrosequencing analysis
Pyrosequencing offers many advantages over technologies such as methylation specific 
PCR (MSP), Q-MSP, southern analysis and bisulphite PCR which have been employed 
in previous NF1 methylation studies (Rodenhiser et al, 1993; Horan et al, 2000; Luijten 
et al, 2000; Harder et al, 2004; Fishbein et al, 2005). The data generated by 
pyrosequencing are actual sequences rather than fluorescence data, false positive 
results can be abolished with the use of additional probe sequences and this 
methodology can also detect partially methylated sequences that are located outside of 
the priming sites (Colella et al, 2003). Pyrosequencing therefore provides rapid, 
sensitive, accurate and quantifiable detection of methylation at single and multiple CpG 
sites, and represents a significant improvement on methods used in previous NF1 
methylation studies (Rodenhiser et al, 1993; Horan et al, 2000; Luijten et al, 2000; 
Harder et al, 2004; Fishbein et al, 2005).
Thus, the present study has re-analysed the entire large NF1 promoter CpG island and 
the results generated represent quantitative data of methylation across the NF1 
promoter, an improvement on earlier results, mainly based on visual inspection of bands 
on a gel (Rodenhiser et al, 1993; Horan et al, 2000; Luijten et al, 2000; Harder et al, 
2004; Fishbein et al, 2005). Despite the improvement in methodology and increased 
sample size, our findings are in agreement with previous studies both in NF1-associated 
tumours and patient derived blood samples, confirming that NF1 promoter methylation 
is unlikely to contribute to NF1 tumorigenesis (Rodenhiser et al, 1993; Horan et al, 
2000; Luijten et al, 2000; Harder et al, 2004; Fishbein et al, 2005; Ebinger et al, 2005). 
Previous NF1 methylation analysis has, however, only concentrated on the promoter 
region and a few select exons, encompassing as little as 1% of the CpG sites within the 
NF1 gene. This study has analysed 353 CpG sites representing a further 15% of NF1 
CpG dinucleotides. The remaining sites were not analysed in this study as they are 
scattered throughout the NF1 gene. These regions by definition are unlikely to represent 
CpG islands at which methylation could occur. They were not detected with the CpG 
searcher software as a CpG island requires greater than 50% GC content in a 200- 
500bp region with at least 100bp between each region.
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Previous studies have found methylation in both coding regions downstream of the 
promoter (exon 4 of the c-fos gene) and within intronic regions (intron 1 of the PRAME 
gene) (Li et al, 2003; Ortmann et al, 2008). In view of these findings, all CpG rich 
regions throughout the NF1 gene were analysed. Indeed only 120 of the 2,420 CpG 
sites within the NF1 gene are located within exons. This study has identified 22 CpG 
rich regions, only 4 of which encompass exonic sequences (the promoter region, exon 
1, exon 31 and exon 49). Excluding the promoter region, which has been previously 
analysed, this extensive study has expanded on limitations of earlier studies by 
assessing an additional 21 CpG rich regions throughout the NF1 gene. The results from 
our analysis indicates that whilst there is evidence for methylation at 20 of the 22 
defined NF1 CpG rich regions, only a single CpG region (region 22), located at the 5’ 
region of exon 49 exhibited significant differential methylation between tumour samples 
and controls. However, methylation at this region is unlikely to play a direct role in NF1 
tumorigenesis as NF1 methylation was not correlated with NF1 gene expression (table 
5.3, figure 5.1 and figure 5.2a).
5.5.2 Hypermutability of CpG dinucleotides and NF1 mutations
There are a number of regions of high and low methylation at adjacent NF1 CpG 
regions observed in this study (e.g. 3-11 and 14-15) (table 5.3) The high mutability of 
CpG dinucleotides within GC rich regions and the switch between methylated and 
unmethylated CpG sites may therefore contribute to increased instability and the high 
mutation rate associated with the NF1 gene (Cooper and Youssoufian, 1988; 
Rodenhiser eta!, 1993). There is, however, no evidence from published mutational data 
(HGMD) of any obvious mutational clustering in such regions, although CpG regions 13- 
14 are located near to exon 4b which may represent a ‘warm’ spot for NF1 mutations 
(Fahsold et al, 2000; Ars et al, 2003; DeLuca et al, 2004). Approximately 20% of all NF1 
mutations are associated with CpG dinucleotides and 3% with CpNpG sites (Cooper 
and Youssoufian, 1988; Cooper and Krawczak 1993 Krkljus et al, 1997; Fahsold et al, 
2000; DeLuca et al, 2004). Analysis of all published NF1 mutations (HGMD) has 
identified 19 mutations associated with CpG dinucleotides including the commonly
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identified C.5839T; p.R1947X in exon 31 (Andrews et al, 1996). All but 1 of these 19 
mutations is recurrent, confirming earlier findings that these CpG sites may represent 
mutational hotspots.
5.5.3 Tissue specific methylation
Tissue specific genes are usually methylated, except in the tissue in which the gene is 
expressed, although this can be disrupted in instances of aberrant methylation (Yisraeli 
and Szyf, 1984). Thus, the level of tissue specific methylation in the NF1 gene and 
RASSF1A and MGMT promoters in samples from the spleen, spinal root and placenta 
was also analysed. No difference in methylation of the RASSF1A and MGMT promoters 
was identified in the tissues analysed in this study. However, tissue specific NF1 
methylation at CpG region 22 (Exon 49) was identified which was concordant with the 
known expression pattern of the NF1 gene (DeClue et al, 1991; Daston et al, 1992; 
Norlund et al, 1993). This indicates that aberrant methylation in the brain and central 
nervous system may modulate gene expression in the different tissue types. Indeed, 
recent evidence from twin studies suggests that methylation patterns of the normal NF1 
allele may also have a role in modification of the NF1 phenotype (Harder et al, 2010). 
The methylation status of the NF1 gene, RASSF1A and MGMT promoters were similar 
in all NF1-associated benign and malignant tumour types (benign cutaneous 
neurofibromas, plexiform neurofibromas, and MPNSTs). This indicates that the 
methylation status of these genes is not tumour-type specific and is more likely, as 
previously suggested, to be an early tumorigenic event which is not associated with 
malignant transformation (Baylin et al, 2001). Similarly, the methylation status of the 
NF1 gene and RASSF1A and MGMT  promoters was comparable in samples with and 
without NF1 germline and somatic mutations, an indication that methylation is unlikely to 
be dependent on mutation status and that methylation of CpG dinucleotides in these 
genes is unlikely to be the sole molecular mechanism underlying NF1 tumorigenesis.
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5.5.4 Promoter methylation of modifying loci
Methylation of additional genomic loci, including the MSH2 promoter (Titze et al, 2010) 
has been identified in peripheral blood samples from NF1 patients, suggesting that 
unrelated genomic loci may act as modifiers for NF1. Whilst many genes are associated 
with specific cancer types, RASSF1A and MGMT represent candidate modifier genes 
for NF1 tumorigenesis based on their cellular roles and earlier associations with cancer 
(table 1.8). The RASSF1 gene is a TSG with seven encoded isoforms (A-G), exhibiting 
differential expression. RASSF1A is ubiquitously expressed and has two isoform 
specific 5’ exons, an N-terminus with high homology to the protein kinase C conserved 
region 1 domain and four exons in common with the other isoforms (exons 3-6), which 
are known to encode a RAS association domain (Ponting and Benjamin, 1996). High 
levels of RASSF1A methylation have been identified in numerous cancers (table 1.8) 
including 40% of lung cancers, adenocarcinoma of the cervix and importantly, colorectal 
cancer, in which concurrent NF1 somatic mutations have also been identified (Cohen et 
al, 2003; Ahlquist et al, 2008; Lin et al, 2009; Wang et al, 2009). RASSF1A is thought to 
interact with KRAS through the Ras association domain and is known to have several 
key cellular effects including promotion of apoptosis, cell cycle arrest, and maintenance 
of genomic stability (Ahlquist et al, 2008; Lin et al, 2009; Wang et al, 2009).
MGMT functions by repairing inappropriately methylated guanine residues in DNA and 
consequently MGMT expression protects against G:C to A:T DNA transitions. Aberrant 
MGMT methylation therefore commonly occurs concurrently with G:A mutations in the 
KRAS and TP53 genes in colorectal cancer. (Esteller et al, 2000). MGMT 
hypermethylation is identified in a number of different cancers (table 1.8) and it has 
been postulated that elevated levels of MGMT promoter methylation in colonic mucosa 
may be a predisposing factor for neoplastic progression (Esteller et al, 2000). Whilst 
there was no significant difference in MGMT promoter methylation in the tumour 
samples and controls analysed here, this study demonstrates for the first time that 
RASSF1A methylation may be an early event in the development of benign and 
malignant NF1-associated tumours. Importantly, 5aza2dc treatment of MPNST tumour- 
derived cell lines was able to reduce methylation and rescue RASSF1A gene
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expression. Whilst the toxicity of this agent was assessed, the affect of this agent on 
other genes was not determined. It has been found that catalytic DNA methylase 
inhibitors may also activate pro-metastatic genes due to their broad demethylating 
activity (Szyf et al, 2004). Hence, a balance must be reached between achieving an 
anti-tumorigenic effect and consequential activation of other genes through global 
hypomethylation. However, the results of this study demonstrate that patients with NF1- 
associated tumours which harbour pathogenic aberrant methylation patterns could 
benefit from treatment with inhibitors of DNA methyltransferases, analogues of which 
are currently in clinical cancer trials (Christman, 2002).
5.5.5 Implications for future NF1 methylation analysis
One of the biggest challenges for genetic analysis is the choice of appropriate controls. 
The nature of NF1 tumours means that it is especially difficult to find appropriate 
controls. In the methylation analysis, Epitect control DNA were crucial for ensuring that 
the pyrosequencing reaction was not biased with effects of poor bisulphite conversion. 
Both the methylated and non-methylated controls were also useful for determining the 
upper and lower limits of the assay by which tumour samples could be compared. The 
most appropriate negative control for NF1-associated tumour analysis would be normal 
peripheral nerve. This is not easy to obtain, however, and so was not available for this 
analysis. Therefore, DNA or cDNA from NF1+/~ fibroblasts were used as an alternative. 
Furthermore, whilst blood is not a control for a tissue sample, lymphocyte DNA derived 
from NF1 patients was compared to NF1 tissue samples to identify tumour specific 
changes. Non-NF1 DNA samples were also used as controls for alterations which may 
occur in NF1 blood DNA. This control in itself is also problematic as even though an 
individual does not have NF1, it is possible that they have other unidentified alterations 
in their DNA. The controls used in this study are appropriate for the context of this 
analysis, in the future, however, it would be important to utilise normal nerve to provide 
a direct comparison.
217
The role of non-CpG methylation in the NF1 gene has not been analysed in this study. 
Although no evidence of CpNpG methylation has been identified previously in the NF1 
promoter (Horan et al, 2000), the high proportion of CpNpG sites in the NF1 gene and 
presence of mutations involving CpNpG trinuncleotides in the NF1 gene (Cooper et al, 
2010) indicates that in future NF1 gene methylation analysis at CpNpG sites is 
warranted. This study has evaluated methylation at all CpG rich regions within the NF1 
gene which fall within the recognised CpG island definitions (Gardiner-Garden and 
Frommer, 1987; Takai and Jones, 2002) in addition to the RASSF1A and MGMT 
promoters. However, CpG methylation in surrounding genes which are commonly lost in 
patients with microdeletions was not investigated. Indeed, this is an important 
consideration for future studies as evidence for methylation at NF1 flanking markers has 
been previously identified and is suggested to modulate the NF1 phenotype 
(Rodenhiser et al, 1993).
In this study, methylation analysis was only completed on two candidate genes in 
addition to the NF1 gene; RASSF1A and MGMT. These genes were selected due to 
their association with the highest number of other cancer types which suggested that 
they may also be important to NF1 tumorigenesis (table 1.8). As methylation of 
RASSF1A was found to play a potential role in NF1 tumour development, it is possible 
that other modifying genes such as CDKN2A, MLH1, APC and RARB may also be 
involved. Future studies could benefit from ‘next generation’ sequencing technologies 
which may be more suited to analysis of methylation of genome wide modifying loci (the 
‘methylome’) instead of 96 well based sequencing technologies such as 
pyrosequencing.
5.5.6 Conclusions
This comprehensive study is the first study to analyse all defined large CpG islands and 
CpG rich regions in the NF1 gene and RASSF1A and MGMT promoters in NF1- 
associated tumours using pyrosequencing. The results presented here clearly indicate 
that NF1 gene methylation is unlikely to be the singular causative mechanism for 
tumorigenesis in NF1-associated tumours, but may instead play a role in modulating
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gene expression. Importantly, a likely correlation between RASSF1A promoter 
methylation and gene silencing has been identified in the cohort of NF1-associated 
tumours studied here, which was also functionally dissected with the 5aza2dc 
methylation inhibitor. These studies indicate that global analysis of epimutational 
changes is necessary to fully understand the mechanisms of tumorigenesis and 
malignancy in NF1.
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CHAPTER 6: Functional analysis of MPNST associated somatic alterations
6.1 Introduction
This chapter focuses on genetic alterations underlying the development of malignant 
peripheral nerve sheath tumours (MPNSTs) and has two main sections, (i) The 
molecular heterogeneity of MPNSTs is explored, (ii) The cMET and RhoGTPase 
pathways are functionally dissected to ascertain their contribution to NF1 malignancy 
and importantly, to deduce their potential as therapeutic targets.
Malignant complications such as brain tumours, optic gliomas and MPNSTs are less 
frequent but potentially more serious manifestations of NF1 (reviewed by 
Upadhyaya, 2011). MPNSTs can occur sporadically or develop from the malignant 
transformation of pre-existing plexiform neurofibromas (PNF), which occur in some 
10-15% of patients, marked by a rapid change in size of the neurofibroma (Evans et 
al, 2002). MPNSTs most commonly originate in the nerve roots, extremities and 
pelvis, but can also occur at other sites. These tumours usually present as enlarged 
masses which cause disability, neurological deficits and pain due to pressure on 
surrounding tissues (Reviewed by Katz et al, 2009).
MPNSTs are a significant cause of morbidity and mortality. Often, upon first 
presentation, the majority of MPNSTs are already non-resectable as the tumour is in 
a late stage of development and metastases are present, most commonly in the 
lung, but also in the liver and brain. Consequently, the 5 year survival rate for 
individuals with these tumours is as low as 20-50% and even lower for 10 year 
survival (7.5%) (Katz et al, 2009). Importantly, mortality is often associated with 
limited treatment options for MPNSTs. Complete surgical excision with clear margins 
is the core therapy for MPNSTs. Although chemotherapy has been employed in 
MPNST treatment, it remains controversial and shows limited effectiveness 
(supplementary table 1). Furthermore, ~3-10% of all patients with sporadic and NF1- 
associated MPNSTs have a history of radiation treatment for a previous malignancy 
(Ferner et al, 2002; De Raedt et al, 2003; Ferner et al, 2004; Sharif et al, 2006). 
There are a number of risk factors for the development of MPNSTs, including the 
presence of deep plexiform neurofibromas or those involving the brachial and 
lumbosacral plexuses, a family history of other cancers and a germline NF1 
microdeletion (Ferner et al, 2002; De Raedt et al, 2003; Sharif et al, 2006). These
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identified risks indicate that such individuals should undergo a more aggressive 
screening approach.
Although there are differences in survival for patients with NF1-associated MPNSTs 
and sporadic MPNSTs, these tumours cannot be completely distinguished from each 
other on the basis of their underlying genetic alterations (Holtkamp et al, 2004; 
Watson et al, 2004). However, some studies have determined that specific genetic 
aberrations such as Nm23-H1 expression, nuclear expression of p53 and gains at 
16p or losses from 10q or Xq are closely associated with poor survival, often found in 
advanced or metastatic disease. Such patients may therefore be in a high risk group 
(Fang et al, 2009; Brekke et al 2009; Brekke et al, 2010). There are, however, no 
clear associations with other clinical risk factors including: histological grade, tumour 
location, metastasis, recurrence, age, or survival of the patient (Watson et al, 2004; 
Brekke et al, 2010).
A pathological diagnosis of an MPNST is very important but is also equally as 
challenging due to significant cellular, molecular and architectural tissue 
heterogeneity. Tumour heterogeneity is a notoriously challenging aspect of cancer 
biology, responsible for introducing very significant complexity into both the study of 
the underlying mechanisms of tumour development and the therapeutic context 
(Visvader, 2011; Gibson et al, 2010; Kalamarides et al, 2011). Tumour heterogeneity 
has been modelled using a number of different biomarkers to identify the extent of 
heterogeneity at the cellular, molecular and genome architectural levels (Singh et al, 
2010; Liu et al, 2010). Cellular heterogeneity is a well established feature of NF1- 
associated tumours, particularly in benign cutaneous neurofibromas in which only 
the Schwann cells harbour NF1 mutations, although the tumours also contain 
fibroblasts, mast cells, perineural cells and axons (Kimura et al, 1974; Le and 
parade, 2007). As with benign neurofibromas, malignant NF1-associated tumours 
are also known to be heterogeneous in nature.
Generally, the heterogeneity within an MPNST is a result of the initial stages of 
growth, in different regions at separate times (Spurlock et al, 2010). Such tumours 
invariably contain diverse subpopulations of tumour cells, including benign and 
malignant cells, fibroblasts and infiltrating inflammatory cells (Friedman et al, 1999). 
MPNSTs therefore have histological features which are reminiscent of both benign 
and malignant NF1 associated tumours with high cellularity, nuclear pleomorphism,
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presence of atypical cells with prominent mitoses and necrosis (Reuss and Von 
Deimling, 2008). Furthermore, heterogeneity can additionally be generated through 
de-differentiation into skeletal muscle which resembles rhabdomyosarcoma and is 
known as a malignant triton tumour (MTT) (Stasik and Tawfik 2006).
At the molecular level, malignant tumours are recognised as being highly 
heterogeneous in terms of both their accumulated genetic mutations and their 
phenotypic expression profiles (Kourea et a/, 1999; Nielsen et al, 1999; Mawrin et al, 
2002; Mantripragada et al, 2008). Analysis of molecular and cellular heterogeneity 
using a variety of methods promises to generate important new insights into tumour 
biology as well as the underlying processes of tumorigenesis. Understanding the 
molecular heterogeneity of malignant tumours in the context of the underlying 
background cellular and genome architectural heterogeneity will allow both 
therapeutic sensitivities and the efficacy of potential drug treatments to be 
comprehensively evaluated.
In addition to molecular heterogeneity, the paucity of well-defined histological criteria 
further adds to the complexity of MPNST diagnosis. A diagnosis of an MPNST can 
be made if there is an association of the tumour with a pre-existing neurofibroma or 
peripheral nerve and if the tumour has histopathological features commonly 
associated with an MPNST. MPNSTs can be deemed ‘low grade’ if there is a lack of 
mitotic activity, as these tumours rarely metastasise and may therefore represent a 
transition stage between neurofibromas and MPNSTs (Ferner et al, 2008). Prior to 
biopsy analysis and microscopic examination, MPNST diagnosis is based on 
radiological imaging, most commonly magnetic resonance imaging (MRI) which can 
determine neuronal from non-neurogenic tissue. MPNSTs are not, however, readily 
distinguishable from plexiform neurofibromas upon CT or MRI analysis but positron 
emission tomography (PET) scans using [18F] fluorodeoxyglucose (FDG), an 
analogue of glucose can be utilised in MPNST diagnosis as there is a higher level of 
uptake of glucose in malignant tumours (Ferner et al, 2008). FDG-PET-CT is 
currently being trialled as part of the follow up procedure for deep neurofibromas 
(Ferner et al, 2008).
There are currently no prognostic or predictive biomarkers for MPNSTs; as such that 
progression of a pre-existing plexiform neurofibroma to an MPNST cannot be 
determined in advance based on the molecular profile of the tumour. Similarly, the
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full spectrum of genes affected in such tumours is still unknown; indicating that 
without detailed knowledge of the mutational spectrum of MPNSTs, targeted therapy 
would be a significant challenge. Somatic NF1 gene inactivation resulting in a loss of 
the wild type NF1 allele is known to lead to NF1-associated tumour development. 
This functional NF1 loss does not, however, explain the malignant transformation of 
benign plexiform neurofibromas to MPNSTs, indicating that alterations of numerous 
additional genetic and potentially epigenetic loci are required to facilitate malignancy. 
A number of critical cell cycle related genes including TP53, CDKN2A and RB1, as 
outlined in section 3.1, have previously been identified as potential drivers of 
malignant transformation (Kourea et al, 1999; Nielsen et al, 1999; Mawrin et al, 
2002; Mantripragada et al, 2008; Stewart et al, 2008; Upadhyaya et al, 2008). Such 
changes have only previously been identified in MPNSTs and plexiform 
neurofibromas. Although benign cutaneous neurofibromas have never been shown 
to undergo malignant transformation, LOH of TP53 and RB1 genes was recently 
described in cutaneous neurofibromas derived from NF1 patients carrying a high 
tumour burden (Thomas et al, 2010) (Chapter 3). Moreover, consistent with a role for 
additional genetic loci in NF1 malignant transformation, mouse models harbouring 
Nf1 and p53 mutations develop malignant NF1-associated tumours (Cichowski et al, 
1999; Vogel et al, 1999; Reilly et al, 2000) (section 1.8.3.3). Further weight to the 
evidence that alterations in other genes act as modifiers of NF1 tumour development 
was demonstrated in a recent study by Spurlock et al (2010), in which one tumour 
exhibited features of both benign and malignant tumours. This tumour demonstrated 
molecular evolution between benign and malignant states, accompanied by 
significant genetic alterations, not present in the benign section.
High throughput whole genome analysis with microarrays has proven to be one of 
the most effective and efficient methods for analysis of large cohorts of genes and 
samples, across multiple tumour types. A number of previous studies have screened 
for copy number variations (CNV) and gene expression changes in benign and 
malignant NF1-associated tumours (Lothe et al, 1996; Bridge et al, 2004; Watson et 
al, 2004; Holtkamp et al, 2004; Storlazzi et al, 2006; Thomas et al, 2007; Shen et al, 
2007; Kresse et al, 2008; Mantripragada et al, 2008; Mantripragada et al, 2009; 
Brekke et al, 2009; Miller et al, 2009; Pemov et al, 2010; Brekke et al, 2010; 
Subramanian et al, 2010; Chai et al, 2010) (table 6.1). One of the first
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comprehensive high resolution array comparative genomic hybridisation (CGH) 
studies of genome wide alterations by Mantripragada et al (2008) revealed that such 
techniques are effective in distinguishing between the molecular signatures in benign 
and malignant NF1 patient derived tumours, in tumour derived cell lines (Fang et al, 
2009; Miller et al, 2009) and even between cutaneous neurofibromas and plexiform 
neurofibromas (Holtkamp et al, 2004; Mantripragada et al, 2008) (table 6.1).
Copy number gains have been found to be more frequent than deletions in MPNST 
samples (62% vs. 38%) (Mantripragada et al, 2009), although, this is in conflict with 
a more recent study in which there was a loss of expression of a large number of 
genes, rather than widespread increase in gene expression (Subramanian et al, 
2010). Furthermore, differences in genetic alterations in sporadic and NF1 
associated MPNSTs have been studied with oligonucleotide and 
immunohistochemical-based tissue microarrays (TMAs) (Holtkamp et al, 2004; 
Watson et al, 2004; Brekke et al, 2009). More recently, miRNA have become a major 
focus of research into the factors contributing to malignancies as it is suggested that 
deregulation of miRNAs may contribute to malignant transformation (Subramanian et 
al, 2010; Chai etal, 2010)
Despite the plethora of previous array-based investigations (table 6.1), only a few 
relevant genes have been identified in multiple MPNSTs which are consistently 
modified and thus may represent key ‘drivers’ of NF1 malignant transformation 
instead of being merely ‘passengers’. Furthermore, the translation of genetic array 
findings on MPNSTs into functionally meaningful results is rare, with only a few 
reports of functional studies in the literature. MPNST development is clearly a 
complex, multistep process in which alterations to multiple pathways are to be 
expected. Whole genome analysis and in particular investigation of key signalling 
and regulatory pathways will be crucial to determining the underlying molecular 
mechanisms involved in MPNST tumorigenesis. The aims of this chapter are:
1) To determine the extent of molecular heterogeneity in NF1-associated 
MPNSTs.
2) Dissection of cMET and RhoGTPase pathways to ascertain their role in NF1 
malignancy
3) To identify therapeutic targets for MPNSTs
224
Table 6.1. Genes identified by oligonucleotide microarrays and array CGH as being
differentially expressed in benign and malignant NF1-associated tumours
Gene/Genetic Loci Type of Alteration Reference
NCAM
MBP
L1CAM
Overexpression
P1P
Watson et al, 2004
IGF2
FGFR1
MDK
K/67
Down-regulation
HGF
ANGPT1
uPA
Overexpression Thomas et al, 2007
Tenascin C ( TNC) Upregulation
Levy et al, 2007
Tenascin XB (TNXB) Down-regulation
ITGB4
PDGFRA
MET
TP73
HGF
Amplification
NF1
HMMR/RHA MM 
MMP13 
L1CAM2 
p 16INK4A/ CDKN2A, 
TP53
Deletion
Mantripragada et al, 2008
HMMR/RHA MM 
MMP13 
p 16INK4A/CDKN2A 
ITGB4
Copy number alterations
Complex karyotypes 
Triploid/tetraploid chromosomes
Clonal cytogenetic 
abnormalities, losses 
and imbalances Fang et al, 2009
9p, 12q21-q32, X-chromosome Deletion
17q25 Gain
1p35-33, 1p21, 9p21.3, 10q25, 11q22-23, 
17q11, 20p12.2 Losses
1q25, 3p26, 3q13, 5p12, 5q11.2-q14, 
5q21-23, 5q31-33, 6p23-p21, 6p12, 6q15, 
6q23-q24, 7p22, 7p14-p13, 7q21, 7q36, 
8q22-q24, 14q22, 17q21-q25.
Gains
Mantripragada et al, 2009
8q, 17q, 7p Gains
Brekke etal, 2010
9p, 11q, 17p Losses
miR-34a Down-regulation Subramanian et al, 2010
miR-10b Upregulation Chai et al, 2010
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6.2 Materials
6.2.1 shRNA
RAC1 shRNA vectors (NM_004850)
Ampicillin and puromycin resistance cassettes (Sigma)
TRCN000000977 (50% KD)
TRCN000000978 (80% KD)
TRCN000000979 (60% KD)
TRCN000000980 (70%KD)
TRCN000196793 (79% KD)
ROCK2 shRNA Vectors (NM_006908)
Ampicillin and puromycin resistance cassettes (Sigma)
TRCN000004871 (50% KD)
TRCN000004870 (60% KD)
TRCN000004869 (88% KD)
TRCN000004872 (80% KD)
TRCN000004873 (85% KD)
pLK0.1-non target shRNA
Ampicillin and puromycin resistance cassettes (Sigma cat no: SHC202) 
Heoatocvte Growth Factor (HGF) (Sigma, cat no: H1404) 
cMET  Inhibitors: PF-4217903 (Pfizer) and SU11274 (Sigma)
BD Matriqel Basement Membrane Matrix (1 mg/ml) (BD, cat no: 356234)
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6.3 Methods
6.3.1 Patients samples
6.3.1.1 MPNSTs for analysis of molecular heterogeneity
Ten unrelated patients, all exhibiting the NIH diagnostic criteria for NF1 were 
analysed in this study to determine the extent of heterogeneity in MPNSTs. 
However, full clinical details were not available from all patients (table 6.2). A total of 
10 MPNSTs derived from these patients were carefully and individually macro 
dissected to yield clean sections which were in turn further subdivided. The number 
and size of the various sections and subsections was mainly dependent upon the 
size of the original tumour (table 6.2 and table 6.3). DNA was extracted from all 
sections of tumour samples and corresponding constitutional (blood) samples by 
means of the methods outlined in sections 2.2.3.1.1 and 2.2.3.1.3.
6.3.1.2 Functional analysis of cMET and RhoGTPase pathways
Initially, 14 MPNST samples and control tissue samples were used in relative 
quantification experiments to determine the level of gene expression of 14 genes 
found to be altered in MPNSTs. These fourteen genes, plus the B2M (NM_004048) 
endogenous control, included: CDK4 (NM_000075), CMET (NM_001127500), ITGB8 
(NM_002214), LIMK1 (NM_002314), MMP12 (NM_002426), PDGFA (NM_002607), 
PDGFRL (NM_006207), PRKCA (NM_002737), PTK2 (NM_153831), PIK3CA 
(NM_006218), RAC1 (NM_018890), ROCK2 (NM_004850), TRIO (NM_007118) and 
TOP2A (NM_001067). Samples for relative quantification were macro-dissected and 
test and control mRNA was extracted as previously described in sections 2.2.3.1.2 
and 2.2.3.3. Rin/RQI was not done but mRNA concentration and quality was 
quantified using a nannodrop spectrophotomer (Thermo scientific) and all samples 
were subjected to gel analysis to assess contamination and integrity. mRNA 
extracted from NF1+/' fibroblasts which were matched with MPNST samples served 
as control samples.
227
Table 6.2. Clinical details of the ten NF1 patients from whom the MPNSTs analysed in this study were taken.
Tumour TumourNumber
Size of 
Tumour Germline Mutation
Patient 
Age and 
Sex
Patient
DOB
Age at 
diagnosis
Post Op 
survival 
[months]
Grade Location of Tumour
1 T196.22 10cm x 10cm Exon 2 and 3 deleted ~64kb deletion 4 5 / M
20-Feb-
62 42 12 High Neck
2 T516 6cm x 2cm 4 8 / F 31-Mar- 73
Unknown Right Axilla
3 T517 1cm x 1cm Whole Gene Deletion 6 3 / M 26-Feb-58
High Thoracic Nerve Root
4 T518 5cm x 2cm Unknown Unknown
5 T519 1cm x 1cm c.1133 1136 del ACTG; 
p.D378fsX8 4 9 / M 45
High Thoracic
6 T521 6cm x 3cm c.1754 1757 del TAAC; 
p.L585fX19 2 4 / M 26-Jul-82 24 alive
Low Right Hamstring
7 T522 3cm x 2cm High Back
8 T523 3cm x 1.5cm Unknown Unknown
9 T524 3cm x 1cm Unknown Unknown
10 T525 5cm x 5cm c.5234 O G ; p.S1745X 1 9 / F 09-Dec-87 17 21
High - Radiation 
Induced
Unknown
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Table 6.3 Analysis of molecular heterogeneity with respect to five genes (NF1, TP53, 
RB1, CDKN2A and PTEN) in 10 MPNSTs. LOH; -100%  LOH of the second allele 
has occurred. 50% LOH; -50%  of the second allele lost. 1 2; heterozygous marker.
Tumour Tumour Tumour Tumour Gene Analysed
Number Section Subsection NF1 TP53 RB1 PTEN CDKN2A
1 LOH LOH LOH LOH LOH
2 LOH LOH LOH LOH LOH
3 LOH LOH 50% LOH LOH LOH
4 1 2 1 2 1 2 1 2 1 2
A 5 LOH LOH 50% LOH LOH LOH
6 LOH LOH LOH LOH LOH
7 LOH LOH LOH LOH LOH
8 LOH LOH 50% LOH 50% LOH LOH
9 1 2 LOH 1 2 LOH LOH
10 1 2 LOH 1 2 LOH LOH
1 LOH 50% LOH 50% LOH 50% LOH 1 2
2 LOH 50% LOH 50% LOH 50% LOH 1 2
3 LOH 50% LOH 50% LOH 50% LOH 1 2
4 LOH 50% LOH 50% LOH 50% LOH 1 2
B 5 50% LOH 50% LOH 50% LOH 50% LOH
1 2
6 LOH 50% LOH 50% LOH 50% LOH 1 2
7 LOH 50% LOH 50% LOH 50% LOH 1 2
8 LOH 50% LOH 50% LOH 50% LOH 1 2
9 LOH 50% LOH 50% LOH 50% LOH 1 2
1 T196.22 10 LOH 50% LOH 50% LOH 50% LOH 1 2
1 LOH LOH 50% LOH LOH 1 2
2 LOH LOH 50% LOH LOH 1 2
3 LOH LOH 50% LOH LOH 1 2
4 LOH LOH 50% LOH LOH 1 2
5 1 2 LOH 1 2 50% LOH 50% LOH
6 LOH LOH 50% LOH LOH 50% LOH
7 LOH LOH 50% LOH LOH 50% LOH
8 LOH LOH 50% LOH LOH 50% LOH
9 LOH LOH 50% LOH LOH 50% LOH
10 LOH LOH 50% LOH LOH 50% LOH
1 LOH LOH 50% LOH LOH 50% LOH
2 LOH LOH 50% LOH 50% LOH 1 2
3 LOH LOH 50% LOH LOH LOH
4 LOH LOH 50% LOH LOH LOH
D 5
LOH LOH 50% LOH LOH LOH
6 LOH LOH 50% LOH LOH LOH
7 LOH LOH 50% LOH LOH LOH
8 LOH LOH 50% LOH LOH LOH
9 LOH LOH 50% LOH LOH LOH
10 LOH LOH 50% LOH LOH LOH
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Tumour Tumour Tumour Tumour Gene Analysed
Number Section Subsection NF1 TP53 RB1 PTEN CDKN2A
1 LOH 1 2 1 2 1 2 1 2
2 LOH 1 2 1 2 50% LOH 1 2
3 50% LOH 1 2 1 2 1 2 1 2
4 LOH 1 2 1 2 50% LOH 1 2
1 T196.22 E
5
6
1 2 
50% LOH
1 2 
1 2
1 2 
1 2
0% 
50% LOH
1 2 
1 2
7 50% LOH 1 2 1 2 0% 1 2
8 LOH 1 2 1 2 1 2 1 2
9 LOH 1 2 1 2 1 2 1 2
10 LOH 1 2 1 2 1 2 1 2
A 1 LOH 50% LOH 1 2 1 2 1 2n
2 1 2 50% LOH 1 2 1 2 1 2
0 T516 B
1 50% LOH 50% LOH 1 2 1 2 1 2
t .
2 50% LOH 50% LOH 1 2 1 2 1 2
c 1 1 2 1 2 1 2 1 2 1 2\ j
2 1 2 12 1 2 1 2 1 2
A 1 LOH 50% LOH 1 2 1 2 1 2
'X T517
r \
2 LOH 50% LOH 1 2 1 2 1 2o
B
1 LOH 50% LOH 1 2 1 2 1 2
2 1 2 1 2 50% LOH 1 2 1 2
A 1 1 2 50% LOH 50% LOH 1 2 1 2r \
2 LOH 12 50% LOH 1 2 50% LOH
A T518 B
1 LOH 50% LOH 1 2 1 2 1 2
* t
2 1 2 1 2 1 2 1 2 1 2
p 1 1 2 1 2 1 2 1 2 1 2
2 1 2 1 2 1 2 1 2 1 2
A 1 1 2 50% LOH 50% LOH 1 2 1 2
c T519
r \
2 50% LOH 50% LOH 50% LOH 1 2 1 2
0
B
1 50% LOH 50% LOH 1 2 1 2 1 2
2 50% LOH 50% LOH 50% LOH 1 2 1 2
A 1 LOH 1 2 1 2 1 2 1 2
e T521
A
2 LOH 12 1 2 1 2 1 20
B
1 LOH 1 2 1 2 1 2 1 2
2 LOH 1 2 1 2 1 2 1 2
7 T522 A 1 LOH 1 2 1 2 1 2 1 2I A
2 LOH 1 2 1 2 1 2 1 2
8 T523 A
1 LOH 1 2 1 2 1 2 1 2
A
2 LOH 1 2 1 2 LOH 1 2
r \ T524 A
1 LOH 1 2 1 2 1 2 LOH
y A
2 LOH 1 2 1 2 1 2 LOH
A 1 LOH 1 2 1 2 1 2 1 2
10 T525
A
2 LOH 1 2 1 2 1 2 1 2
B
1 LOH 1 2 1 2 1 2 LOH
2 LOH 1 2 1 2 1 2 LOH
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6.3.2 Cell lines
MPNST cell lines (ST8814, SNF96.2 and T532) were used in the functional analysis 
of the cMET/RhoGTPase pathway. All cell lines were grown as described in section 
2 .2 .2 .
6.3.3 Analysis of molecular heterogeneity in MPNSTs
6.3.3.1 Loss of Heterozygosity analysis (LOH)
Molecular heterogeneity was determined by differences in the level of LOH between 
sections of the same sample. LOH analysis was completed on all sections from the 
10 MPNSTs and corresponding lymphocyte DNA samples by utilising a panel of 
fluorescently tagged microsatellite markers in the five genes investigated: NF1 TP53, 
RB1, CDKN2A and PTEN  and the method outlined in section 3.2.3.1 (supplementary 
tables 4 and 7). Samples exhibiting -50%  loss of the second allele were termed 
‘50% LOH’ whereas a marker which demonstrated no LOH was simply classed as 
heterozygous (‘1 2’).
6.3.3.2 p53 Immunohistochemistry analysis (IHC)
Immunohistochemical analysis of p53 was performed on sections derived from 5 
MPNSTs (T196.22, T516, T517, T518 and T519) which were found by LOH analysis 
to exhibit molecular heterogeneity with respect to the TP53 gene (table 6.3). 
Immunohistochemistry was performed using a standard protocol as described in 
section 2.2.4 using pre-diluted mouse anti-p53 monoclonal primary antibody.
6.3.4 MPNST copy number variation and gene expression analysis
6.3.4.1 Affymetrix analysis of MPNSTs
An Affymetrix SNP 6.0 array was previously performed on DNA from 20 NF1- 
associated tumours; 5 benign plexiform neurofibromas and 15 MPNSTs (Upadhyaya 
et al, unpublished data). This array contains approximately 1.8x106 nucleotide
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probes, combines 906,600 SNP and 946,000 CNV probes that encompass the 
human genome at a median probe distance of about 700bp. This array permits the 
simultaneous assessment of LOH and copy number alterations (CNAs) associated 
with inherited diseases and cancer (Suzuki et al, 2008). Paired CNV and LOH 
analyses involved the comparison of tumour DNA against the matched patient 
lymphocyte DNA, while unpaired CNV analyses compared tumour DNA against 
reference data derived from the 270 normal individuals catalogued in the HapMap 
sample database. Each positive tumour-specific alteration was assessed 
bioinformatically to determine which genes were either contained within, or 
overlapped, each identified genomic region. Several software tools, including 
GeneGO’s MetaCore Software, were then applied to identify those biological 
pathways potentially affected by the genes involved in these tumour-specific CNAs.
6.3.4.2 Relative quantification (qPCR)
From the derived array CGH data, the relative copy number of 14 genes found to be 
affected by tumour-specific CNAs was independently assessed by relative 
quantification on a panel of 14 MPNST samples and 5 MPNST derived cell lines. 
These fourteen genes, plus the B2M  (NM_004048) endogenous control, included: 
CDK4 (NM_000075), CMET  (NM_001127500), ITGB8 (NM_002214), LIMK1 
(NM_002314), MMP12 (NM_002426), PDGFA (NM_002607), PDGFRL 
(NM_006207), PRKCA (NM_002737), PTK2 (N M J  53831), PIK3CA (NM_006218), 
RAC1 (NM_018890), ROCK2 (NM_004850), TRIO (NM_007118) and TOP2A 
(NM_001067). Relative quantification was completed using the method described in 
section 2.2.5 and the primers and conditions in table 6.4.
6.3.5 Functional analysis of cMET and RhoGTPase pathways
From the Affymetrix array and qPCR data it was concluded that three genes which 
were found to be amplified could be functionally analysed to determine the effect of 
alterations in these genes on the malignant potential of cells derived from MPNSTs. 
The three genes selected for further functional analysis were: cMET and the 
RhoGTPase pathway genes; RAC1 and ROCK2. The hepatocyte growth factor 
(HGF) and its receptor; cMET have previously been implicated in MPNST
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development in earlier array studies (Mantripragada et al, 2008). The recurrence of 
cMET alterations in these tumours indicates that alterations in the cMET pathway are 
of importance to MPNST tumorigenesis. RAC1, ROCK2, LIMK1, PTK2, TRIO and 
PRKCA all belong to the RhoGTPase pathway and were also found to harbour 
increased copy number by microarray and were independently confirmed by qPCR. 
The RhoGTPase pathway regulates cellular processes such as cytoskeletal 
regulation, cell cycle regulation, cell polarity and cell migration indicating that this 
pathway may be especially important for the migratory potential of cells derived from 
MPNSTs. All assays described below were performed on MPNST cell lines which 
were found to exhibit amplification of cMET, RAC1 and ROCK2. All assays were 
repeated a minimum of three times and results are representative of all MPNST cell 
lines studied.
6.3.5.1 cMET Inhibition in MPNST derived cell lines
Concomitant amplifications of HGF, MET, and PDGFRA genes were revealed in 
MPNSTs, in a previous study by Mantripragada et al, (2008) indicating that there 
may be a putative role for the p70S6K pathway in NF1 tumorigenesis. The proto 
oncogene c-met encodes the cMET transmembrane tyrosine kinase receptor for 
which HGF (hepatocyte growth factor/hepatopoietin/scatter factor) is the main ligand 
(Cooper et al, 1984; Naldini et al, 1991). The paracrine signalling mechanism 
between epithelial cells expressing the cMET receptor, and mesenchymal cells in 
which the ligand HGF is expressed, is postulated to be important in processes 
including wound healing, embryogenesis, regeneration, and tumour progression. 
This indicates that alteration of cMET signalling may be important to MPNST 
progression from benign neurofibroma (Weidner et al, 1993; Rosen etal, 1994).
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Table 6.4. Primer sequences function and results for all 14 genes and the endogenous control used in the relative quantification
analysis of genes found to be differentially expressed by microarray.
Gene Sense Primer Sequence (5'-3’) Antisense Primer Sequence (5'-3a) Size
(bp)
Chromosome
Location
Pathway/function Gene Expression
B2M CCCCCACTGAAAAAGATGAGTAT CCGTGTGAACCATGTGACTTTG 50 15q21.1 Endogenous Control Endogenous Control
CDK4 GCCTAGATTTCCTTCATGCC GGTGACAAGTGGTGGAACAG 81 12q14.1 cell divsion kinase Down-regulated
CMET TTACATTCTGAAGCCGTTTTATGC CCCAATGACCTGCTGAAATTG 51 7q31.2 Hepatocyte growth factor receptor Upregulated
ITGB8 TGAACGTTGTGATATTGTTTCCAA AAGCAAAGGCTGCTCAGTTGA 51 7p15.3 Integrin Pathway Upregulated
LIMK1 GTGTCCATCCCAGCCTCATC GCGTGGACTTTCAGTCTCCATT 51 7q11.23 RhoGTPase Pathway Upregulated
MMP12 CTTTTGGACCTGGATCTGGC ATGCACATTTCGATGAGGACG 51 11q22.2 Matrix metalloproteinase Down-regulated
PDGFA GTCTGCAAGACCAGGACGGT TTCCTCGGAGTCAGGTCGAC 51 17p22.3 PDGF Receptor Upregulated
PDGFRL TTCAGCACCAAAGACGCAGT GCAAGTGCTGGATAAAGGTCG 51 8p22 PCX3F Receptor Ligand Upregulated
PRKCA TCGAACAACAAGGAATGACTTCA CCTTTCCTTTGGAGTTTCGGA 51 17q24.2 RhoGTPase Pathway Upregulated
PTK2 CCTCCAAATTGTCCTCCTACCC TTATGACGAAATGCTGGGCC 51 8q24.3 RhoGTPase Pathway Upregulated
PIK3CA ACTTTGTGACCTTCGGCTTT CAATTTCTCGATTGAGGATCTTT 89 3q26.32 P13K-PTK-RAS No change/Down-regulated
RAC1 ACACCGAGCACTGAACTTTG TGTCTGCACCTCCTAACTGC 75 7p22.1 RhoGTPase Upregulated
R0CK2 AACCTGTCAAGCGTGGTAATGA GTGCGGAGAAAAGAGAAGGAGA 51 2p25.1 RhoGTPase Pathway Upregulated
TRIO AACCAAAGAGAGAGTGAAGCTATTGATA CTGGCTGATGGCTTTTGTGA 51 5p15.2 RhoGTPase Pathway Down-regulated
T0P2A ATGGGAAGAGCTGGTGAGAT TCACCnTCAGCCTGATTTG 78 17q21.2 DNA topoisomerase Down-regulated
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6.3.5.1.1 Cell line treatment with cMET inhibitors 
Twenty-four hours prior to treatment, MPNST cell lines (ST8814, SNF96.2 and T532) 
were seeded at a concentration of 2x106 in 6 well plates and grown in medium as 
described in section 2.2.2. On the day of treatment, cells were serum starved for 4 
hours in 2ml of DMEM+0.1% FBS and 1% Pen/strep. Following serum starvation, 
fresh starvation medium was added to remove residual HGF and other growth 
factors secreted by the cells. After 1 hour, cells were treated with the cMET inhibitor 
PF-4217903 (Pfizer) at different concentrations (1pM, 10pM and 100pM) or 
SU11274 (Sigma) (10pM) for 30 minutes. Pilot studies completed by Dr Andrew Tee 
(Cardiff University) determined that 10pM SU11274 elicited the required inhibitory 
effect in MPNST cell lines. The media was then removed from each well and the 
appropriate cells were stimulated with HGF (100ng/ml2) which was added as small 
drops to the plate and incubated for 1 hour. Cells were lysed as described in section 
2.2.7.
6.3.5.2 RhoGTPase pathway shRNA knockdown
The RhoGTPase pathway regulates cellular processes such as cytoskeletal 
regulation, cell cycle regulation, cell polarity and cell migration indicating that it may 
be important for the migratory capacity and potential for metastasis in MPNST cells. 
Rac1 RhoGTPases are ubiquitously expressed small G proteins with similar modes 
of action as Ras (Reviewed by Karlsson et al, 2009). Activators of the RhoGTPase 
pathway include lysophosphatidic acid (LPA) and sphingosine-1 phosphate (S1P) 
which promotes the exchange of GDP for GTP which is catalysed by RhoGEFs 
including Vav3 and TRIO resulting in the activation of the RhoGTPase and 
subsequent downstream pathways (Liao et al, 2007). Similarly, the weak intrinsic 
GTPase activity of RhoGTPases is catalysed by GAPs, which results in the 
cessation of Rho signalling. An extra level of control is exhibited by Rho guanine 
nucleotide dissociation inhibitors (GDIs) which inhibit the activation of the GDP 
bound form of RhoGTPases so that it is unable to bind to its downstream effectors. 
Furthermore, GDIs promote shuttling of RhoGTPases between different membrane 
compartments (DerMardirossian and Bokoch, 2005). Rho kinases (ROCKs) are 
protein serine threonine kinases which act as downstream effectors of RhoGTPases 
such as RhoA, following Rho activation upon GTP charging.
235
6.3.5.3 short hairpin RNA (shRNA) plasmid preparation
RAC1 and ROCK2 have not previously been investigated in MPNSTs although their 
normal functional roles indicate that they may be crucial to MPNST development. 
RNA interference (RNAi) is a natural process by which a gene can be targeted with 
high specificity to result in knockdown of its expression (Rao et al, 2009). This 
mechanism presents an unparalleled opportunity for personalised therapy by 
selectively targeting upregulated genes which may be crucial for the survival of 
tumour cells. Thus, methods of mediating RNAi have been developed which include 
short interfering RNA (siRNA), short hairpin RNA (shRNA) and bi-functional shRNA. 
There are advantages and disadvantages for all three methods, specifically; siRNA 
are simple to manufacture but are transient where as shRNA constructs allow for a 
higher level of potency and sustainability through the use of low copy numbers, 
importantly leading to less off-target effects (Rao et al, 2009).
Human shRNA for RAC1 and ROCK2 are available (Sigma) and thus shRNA against 
both genes were used in conjunction with cellular assays to knockdown the 
upregulated gene expression in MPNST-derived cell lines to determine their role in 
MPNST development. ShRNA were chosen based on whether they had been 
previously validated, the level of expected knockdown and the target sequence. Five 
shRNA clones for RAC1 and ROCK2 (Sigma) were received as glycerol stocks. 
Plasmid DNA was obtained following the protocol described in section 2.2.1. Large 
scale cultures were produced from starter cultures and DNA was subsequently 
extracted from these cultures using the method outlined in section 2.2.1.8.
6.3.5.4 shRNA transfection
4x105 MPNST cells (ST8814, SNF96.2, T532) were transfected in 35mm plates 
(Helena Biosciences, cat no: 93040) using 2.5pg of shRNA and the method outlined 
in section 2.2.2.6.2. A shRNA scrambled vector (Sigma) served as a control in all 
experiments. Stable knockdown was created as described in section 2.2.2.6.3.
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6.3.6 Western blot
Prior to application of downstream assays, a western blot was run to analyse gene 
expression in addition to the knockdown efficiency of shRNA clones as described in 
section 2.2.7. Sample extracts were resolved on NuPAGE Novex 4-12% Bis-Tris gel 
(RAC1 -  21kDa) and NuPAGE Novex 3-8% Tris-Acetate gels (RO CK2 -  120kDa 
and phosphorylated-cMET -  120kDa). Prior to western analysis of cMET, 
Immunoprecipitation with the cM E T  antibody was required (section 2.2.6). Off target 
affects have been observed when using shRNA (Jackson et al, 2003). Consequently, 
multiple clones were used as the probability of getting off target affects in all clones 
is unlikely. Control blots of b-actin were used to determine whether the shRNA and 
inhibitors target other sequences in the cell lines studied (figure 6.1).
ST8814 MPNST cell line
(i)
Anti-Rac1
Anti-actin
Anti-ROCK2|
Anti-actin
shRNA oO (ii)
cMET-inhibitor (nM) 
HGF
cMET (P)-Y 
p-Actin
1 10 100 SUi
+ +  +  + +
«
Figure 6.1. (i) Western blot assay of cell lines transacted with 5 Rac1 and RO CK2  
shRNA clones in addition to one cell line transfected with a scrambled control. P- 
actin control blots were completed to ensure expression was unaffected in genes not 
targeted by the shRNA. RAC1  and R O C K 2  shRNA generated -50-88%  reduction in 
RAC1 and ROCK2 protein expression, (ii) Western blot of phosphorylated cMET and 
p-actin in cell lines treated with c M E T  inhibitors: PF-4217903 (Pfizer) or SU11274 
(Sigma). cM E T  inhibition reduced c M E T  expression in comparison to untreated 
controls. Control p-actin blots were used to confirm the absence of off target effects.
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6.3.7 Cellular assays
6.3.7.1 shRNA wound healing assay
Confluent monolayers of MPNST cells were cultured as above in 35mm laminin- 
coated plates, serum starved with 1% FBS for 24 hours and then wounded using a 
pipette tip, drawn across the monolayer to create a gap in which no cells were 
present. Non-adherent cells were removed by washing twice with PBS. Cells were 
incubated in standard conditions as previously described and images of wound 
healing were taken at 0, 12 and 24 hours post wounding using a standard camera 
and microscope (Leica).
6.3.7.2 shRNA adhesion assay
35mm plates were initially coated in laminin (10mg/ml) or fibronectin (5mg/ml) and 
incubated at 37°C for 1 hour. Both adhesive substrates were used to determine 
whether MPNST cells harbouring RAC1 and ROCK2 up-regulation have a 
preference for a specific substrate as is seen with other cell types (Nakagawa et al, 
2001; Lock and Hotchin, 2009). Plates were washed twice with wash buffer (0.1% 
BSA in DMEM) and then blocked for an hour at 37°C with blocking buffer (0.5% BSA 
in DMEM). Finally the plates were washed twice more with wash buffer and chilled 
on ice. Cells were seeded at a concentration of 1x106 on to the coated and blocked 
plates and incubated at 37°C in a humidified incubator for 30 minutes. The 
percentage of adherent cells was then determined by fixing the cells with methanol 
and acetone (1:1) for 20 minutes at -20°C. Cells were then stained with Crystal Violet 
(5mg/ml) in ethanol for 10 minutes, followed by a stringent wash with dhfeO until the 
water ran clear. Crystal violet stained cells were eluted with 1%SDS and the 
absorbance was read at 550nm on a Genova MK3 Lifescience Analyser (Jenway).
6.3.7.3 shRNA and cM ET  inhibition migration assay
For MPNST cell lines transfected with RAC1 and ROCK2 shRNA in addition to 
MPNST cell lines treated with inhibitors of CMET, transwell permeable supports with 
6.5mm diameter inserts, 8.0pm pore size and a polycarbonate membrane (Corning
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Incorporate, cat no: 3428) were used to perform migration assays. Cells were grown 
as previously described, then harvested by trypsinisation with Trypsin -EDTA. 1x106 
cells were washed three times and then resuspended in 1% FBS and DMEM. These 
cells were then seeded in the upper chamber of the Transwell and the lower 
chamber was filled with 600pl of standard culture medium (10% FBS) and 5mg/ml 
fibronectin, as an adhesive substrate. Cells were incubated at 37°C 5% CO2 for 24 
hours after which the Transwell was removed and the membrane was fixed and 
stained as described above. Cells which had not migrated were removed from the 
top chamber with a cotton swab. The percentage of migrated cells was evaluated by 
imaging on a standard microscope (Leica) and by the absorbance of crystal violet 
eluted with 1%SDS at 550nm on a Genova MK3 Lifescience Analyser (Jenway).
6.3.7.4 shRNA invasion assay
A similar protocol was used as in the migration assay for cell lines transfected with 
RAC1 and ROCK2 shRNA, but the top chamber of the Transwell was filled with 
100pl of BD Matrigel Basement Membrane Matrix (1 mg/ml). The Matrigel was 
incubated at 37°C for 4 hours to allow it to gel. Cells were then seeded and 
incubated as above for 3 days. The number of invaded cells was determined by 
fixation and staining, analysis under the microscope and elution of crystal violet with 
1% SDS as above. Absorbance was read at 550nm on a Genova MK3 Lifescience 
Analyser (Jenway).
6.3.8 Statistical analysis
All statistical analysis was completed with SPSS (v16) using the independent 
samples T-Test. Absorbance measurements at 550nm from cell staining with crystal 
violet were converted into cell numbers following calibration of the 
spectrophotometer with a dilution series of cells.
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6.4 Results
6.4.1 Analysis of molecular heterogeneity in MPNSTs
6.4.1.1 LOH analysis
10 MPNST tumours of varying sizes, derived from 10 different individuals, were 
independently sectioned and the LOH of five genes (NF1, TP53, RB1, CDKN2A and 
PTEN) was analysed for each section. LOH of the NF1 gene was identified in all 10 
tumours. In addition, LOH was noted for the TP53 gene (five tumours, T196.22, 
T516, T517, T518 and T519), the RB1 gene (four tumours, T196.22, T517, T518 and 
T519), the CDKN2A gene (four tumours, T196.22, T518, T524 and T525) and the 
PTEN  gene (two tumours, T196.22 and T523) (table 6.3, figure 6.2). In only two of 
the ten tumours (T521 and T522) was LOH not found in at least one of the four loci 
other than NF1 (i.e. TP53, RB1, CDKN2A or PTEN). Further, seven of the ten 
tumours (70%) were found to exhibit intra-tumoural molecular heterogeneity with 
respect to at least one gene, as defined by a varying level of LOH within the same 
tumour (T196.22, T516, T517, T518, T519, T623, T525) (i.e. between the 
subsections). Additional cytogenetic analysis was not available to confirm the LOH 
identified.
Some of the larger tumours (e.g. T521) were found to exhibit no molecular 
heterogeneity whereas some smaller tumours (e.g. T523) displayed molecular 
heterogeneity albeit only with respect to a specific gene. Additionally, five of the 
tumours analysed in this study were known to be high grade (T196.22, T517, T519, 
T522 and T525). Four of these high grade tumours in our cohort exhibited molecular 
heterogeneity (viz. T196.22, T517, T519 and T525) whereas such heterogeneity was 
absent in the remaining sample graded as high (T522). The extent of LOH in the 
NF1 gene was also found to vary between sections of the same tumour. Thus, some 
sections displayed LOH over the entire NF1 gene and surrounding regions whereas 
other sections of the same tumour only exhibited LOH within a portion of the NF1 
gene (table 6.5; T196.22, T522, T525).
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6.4.1.2 Immunohistochemistry analysis of p53
IHC analysis of the tissue distribution of p53 was found to correlate broadly with the 
results of the LOH analysis (figure 6.3). Thus, different sections of the five MPNST 
tumours analysed were found to display differences in staining for p53 that closely 
matched the presence or absence of LOH for the TP53 gene (table 6.3). For 
example, sections A, C and D of T196.22 displayed complete LOH of the TP53 gene 
in the majority of MPNST sections and this was reflected in higher p53 expression as 
seen by IHC in these samples (figure 6.3, B and C). Conversely, section E (T196.22) 
showed no p53 expression by IHC peroxidase staining and this section was found 
not to display any LOH (figure 6.3, D). Additionally, section B (T196.22) showed 
lower levels of staining (figure 6.3 B) than that of T196.22 section C (figure 6.3 C) but 
more than that of T196.22 section E (figure 6.3 D). These results correlate with those 
of the LOH analysis in which section T196.22 section B was found to have 50% LOH 
but section T196.22 section C had 100% LOH and section E (T196.22) had no LOH. 
p53 positivity by IHC has previously been reported in 60% of MPNSTs whereas 
neurofibromas are p53 immunonegative (Liapis etal, 1999).
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Table 6.5. Extent of LOH in 5 genes (NF1, TP53, RB1, CDKN2A and PTEN) in 10 MPNSTs
Tum our Tum our Gene Analysed and Extent o f LOH
Num ber NF1 TP53 RB1 PTEN CDKN2A
1 T196.22
LOH: D17S799-D17S1822 LOH: TP53 lnv-D17S938 LOH: D13S118- LOH: D10S215-D10S2491 LOH: D9S304-D9S748
(17p11.2-17q25.2) (TP53 Intron 1-5TP53) D13S119 (5'-3'RB1) (10q22-23-10q23-23) (9p21.1-9q32)
o T516
LOH: IVS27-IVS38 LOH: TP53 lnv-TP53 E:6£.
(Intron 27-38) (TP53 Intron 1-Exon6) No LOH No LOH No LOH
'X T517
LOH: IVS27-IVS38 LOH: TP53 lnv-TP53 E:6 LOH: RB1.2-RB1.26
(Intron 27-38) (TP53 Intron 1-Exon6) (Exon2-26) No LOH No LOH
4 T518
LOH: J1J2-3'NF1 LOH: TP53 lnv-TP53 E:6 LOH: RB1.2-RB1.26 LOH: D9S304-D9S 748
(Intron 27-38) (TP53 Intron 1-Exon6) (Exon2-26) No LOH (9p21.1-9q32)
5 T519
LOH: IN/S38-3'NF1 LOH: TP53 lnv-TP53 E:6 LOH: D13S917-RB1.26
(Intron 38-3'A/Ff) (TP53 Intron 1-Exon6) (5'RB1-Exon 26) No LOH No LOH
a T521
LOH: J1J2-EV120u
(Intron 27-38) No LOH No LOH No LOH No LOH
7 T522
LOH: D17S799-3’NF1/
(17p11.2- 3'NF1) No LOH No LOH No LOH No LOH
8 T523
LOH: J1J2-D17S250 LOH: D10S215-D10S2491
(Intron 27-3'NF1) No LOH No LOH (10q22-23-10q23-23) No LOH
Q T524
LOH: J1J2-3'NF1 LOH: D9S304-D9S 748
(Intron 27-38) No LOH No LOH No LOH (9p21.1-9q32)
10 T525
LOH: D17S799-D17S1822 LOH: D9S304-D9S748
(17p11.2-17q25.2) No LOH No LOH No LOH (9p21.1-9q32)
Total with LOH 10 5 4 2 4
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Gene
Tumour Section NF1(J1J2) TP53(Alu1) PTEN(D10S2491)
A
B
C
D
'V » L a a A_
E
All Sections
Figure 6.2. LOH patterns in three genes (NF1, TP53 and PTEN) within five sections (A-E) derived 
from a single tumour (T196.22). ‘All sections’ represents the overlaid LOH results from all five sections 
(A-E) illustrating the different levels of gene-specific LOH observed within a single tumour.
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Figure 6.3. Immunohistochemical analysis of TP53. A. Positive control; Breast carcinoma localised 
positive stain for TP53. B. T196.22,B5; Slight localised positive TP53 staining in a few cells. C. 
T196.22,05; Localised positive and negative staining for TP53. D. T196.22,E5; Lack of TP53 
immunohistochemical staining.
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6.4.2 Functional analysis of cMET and RhoGTPase pathways
6.4.2.1 Relative quantification
Whilst not all 14 MPNST samples and MPNST cell lines exhibited altered gene 
expression in every gene analysed, overall, 9/14 genes analysed by qPCR 
(excluding the endogenous control) demonstrated a trend towards amplification; 
CMET; ITGB8, LIMK1, PDGFA, PDGFRL, PRKCA PTK2, RAC1 and ROCK2 (table
6.4 and figure 6.4). Conversely, 5 genes demonstrated either very little amplification, 
or a deletion; CDK4, MMP12, PIK3CA, TRIO, TOP2A. These results were fully 
correlated with the results from the array which was conducted prior to this study.
6.4.3 CMET inhibition in MPNST cell lines
Treatment of malignant MPNST-derived cell lines (ST8814, SNF96.2 and T532) with 
cMET inhibitors PF-4217903 (Pfizer) and SU11274 (Sigma) at different 
concentrations (1pM, 10pM and 100pM) resulted in a reduction in activated cMET 
(phosphorylated cMET) as determined by a reduction in phosphorylated cMET 
protein levels by western blot at all concentrations of inhibitors (figure 6.1). Inhibition 
of cMET  by PF-4217903 produced a lesser reduction in gene expression at all 
concentrations than was seen with the inhibitor SU11274. Treatment with different 
concentrations of PF-4217903 did not produce a significant dosage-dependent 
effect.
6.4.3.1 CMET migration assay
As SU 11274 had the most potent affect on cMET gene expression in MPNST cell 
lines, migration assays were also performed on MPNST cells following treatment 
with the inhibitor. Inhibition of cMET  resulted in a significant decrease in cell 
migration in comparison to untreated controls (p=0.043) (figure 6.5). Results are 
representative of all MPNST cell lines analysed.
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PTK2
Figure 6.4. Graphical representation of the gene expression of 14 genes in 14 
MPNST samples. All genes were originally found to be altered in MPNSTs in 
comparison to benign plexiform neurofibromas by microarray analysis. Graphs are 
representative of findings in MPNSTs and MPNST-derived cell lines.
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6.4.4 RAC1 and ROCK2 targeted knockdown
All of the 5 clones used for RAC1 knockdown in ST8814 cell lines produced some 
knockdown effect (figure 6.1). No off target affects were observed (figure 6.1). 
Densitometry was completed with image J software to quantify the signal from all 
western blots. Two RAC1 clones (TRCN000000977, 50% KD and TRCN000000978, 
80% KD) and two ROCK2 clones (TRCN000004871, 50% KD and TRCN000004872, 
80% KD) were selected for use in the wound healing, migration, invasion and 
adhesion assays.
6.4.4.1 Wound healing assay
Cells transfected with RAC1, ROCK2 and scrambled control shRNA were seeded on 
laminin and wounded with a pipette tip. Between 0 and 12 hours post wounding, 
cells migrated across the wound. RAC1 and ROCK2 wound healing was, however, 
reduced in comparison to control scrambled shRNA (figure 6.6). Due to the kinetics 
of wound healing, by 24 hours wound healing was complete on all shRNA cell lines 
as evidenced by the lack of any visible gap in the cell monolayer. MPNST cell 
doubling time is approximately 20.44 hours (ST8814) (Vahidnia et al, 2007). Wound 
healing is unlikely to have been affected by cell proliferation as wound healing was 
observed by 12 hours in the scrambled control cell line. Wound healing occurred 12- 
16 hours earlier in the control cell line than RAC1 and ROCK2 cell lines (16-24 
hours). Results are representative of all cell lines (ST8814, SNF96.2 and T532). All 
experiments were repeated a minimum of 3 times.
6.4.4.2 Adhesion assay
Cells were transfected with RAC1, ROCK2 and control shRNA on both Laminin and 
fibronectin. Adhesion on both laminin and fibronectin is significantly increased in 
samples containing RAC1 and ROCK2 80% knockdown in comparison to cell lines 
transfected with the scrambled control shRNA (p=0.02) and (p=0.05) respectively 
(figure 6.7 i-iv). RAC1 knockdown (50% and 80%) results in more cell adhesion than 
ROCK2 knockdown (50% and 80%) but this difference is not significant (p=0.07). 
There was no significant difference between adhesion on fibronectin or on laminin in
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cell lines carrying both RAC1 and R0CK2  knockdown (p=0.2). Replicates were 
produced and results are representative of all cell lines studied (ST8814, SNF96.2 
and T532).
6.4.4.3 Migration assay
Migration of cells transfected with RAC1, ROCK2 and control shRNA was assessed 
by seeding of cells on polycarbonate membranes followed by assessment of cell 
numbers through crystal violet staining. Migration of cells was significantly reduced in 
cell lines carrying RAC1 and ROCK2 80% knockdown in comparison to cells 
transfected with a scrambled vector (p=0.03 and p=0.05 respectively) (figure 6.8). 
The reduction in migration was similar in cells transfected with both RAC1 and 
ROCK2. About 1.34x106 fewer cells (approximately 43% reduction) migrated through 
the membrane in the cell line with the RAC1 80% knockdown and around 1.3x106 
fewer cells (approximately 40% reduction) migrated in the ROCK2 80% knockdown 
cell line compared to the scrambled control. Results are representative of all cell 
lines and replicates (ST8814, SNF96.2 and T532).
6.4.4.4 Invasion assay
Invasion of cells transfected with RAC1, ROCK2 and control shRNA was determined 
by seeding cells on Matrigel basement membrane on polycarbonate membranes. A 
significant reduction in the invasion activity of cell lines transfected with both RAC1 
and ROCK2 shRNA (80% KD) was observed in comparison to the scrambled control 
(p=0.05 for both) (figure 6.9 and figure 6.10). RAC1 and ROCK2 knockdown elicited 
similar reduction of invasive potential. Approximately 1.85x106 fewer cells 
(approximately 54% reduction) invaded the Matrigel and membrane in the cell line 
with the RAC1 80% knockdown and about 1.8x106 (approximately 28% reduction) in 
the ROCK2 80% knockdown compared to the control scrambled cell line. All 
experiments were repeated and results were comparable in all cell lines (ST8814, 
SNF96.2 and T532).
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Figure 6.5. Migration of ST8814 cells following treatment with cMET  inhibitor SU11274. Migration of 
M PNST cell lines was significantly reduced following cM ET  inhibition (p=0.043)
0 Hours 12 Hours
Scrambled
Vector
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Figure 6.6. Wound healing assay on M PNST cell line ST8814. Cells were seeded on laminin, 
synchronised in 1%FBS for 24hours and wounded with a pipette tip. Wounds were followed up for 
24hours. Reduction in the rate of wound healing can be seen in the cell lines carrying RAC1 and 
ROCK2  knockdown. Cells were imaged on a microscope at x10 magnification (Leica).
249
(')
(iii)
(ii)
p=0.0 22 £
0 8 -
c "5® u
Rac1 80% KD Rac1 50% KD Scrambled
R«ic1 shRNA Clones
4
2
1
p=0.05oo =
</> </>
—  — o <
.11  08
11 0 6  
<  = 0 4
4) °
|  =£ 0.2
0
ROCK2 80%  KD ScrambledROCK2 50%  KD
(iv)
ROCK2 shRNA Clones
p=0.02
<  r= 0 4
Rac1 80% KD Rac1 50% KD Scrambled
4
2
1
p=0.05oo w
</>
I s  08
I  |  0.6
<  c  0.4
4> S 
|  ® 0.2 7=
2 3  0
ROCK2 80% KD ROCK2 50% KD Scrambled
Racl shRNA Clones ROCK2 shRNA Clones
Figure 6.7 Adhesion assay on MPNST cell line ST8814. (i) ST8814 cells transfected with RAC1 shRNA seeded on laminin. (ii) ROCK2 shRNA transfected 
cells seeded on laminin. (iii) Cells transfected with RAC1 shRNA on fibronectin (iv) ROCK2 shRNA transfected cells seeded on fibronectin. Adhesion is 
significantly increased in samples containing RAC1 and ROCK2 knockdown in comparison to cell line transfected with the scrambled control shRNA (p=0.02) 
and (p=0.05) respectively. RAC1 knockdown results in more cell adhesion than ROCK2 knockdown but this difference is not significant (p=0.07). No 
significant difference between adhesion on fibronectin or laminin was observed in cell lines carrying both RAC1 and ROCK2 knockdown (p=0.2).
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Figure 6.8. Migration assay on ST8814 cell lines, (i) Migration of cells transfected with RAC1 shRNA. (ii) Migration of cells 
transfected with ROCK2 shRNA. Migration of ST8814 cells was significantly reduced in cell lines carrying RAC1 and ROCK2 
knockdown in comparison to ST8814 cells transfected with a scrambled vector (p=0.05 and p=0.03 respectively).
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Figure 6.9. Invasion assay on ST8814 cell lines (i) Invasion of cells transfected with RAC1 shRNA. (ii) Invasion of cells transfected 
with ROCK2 shRNA. The invasion activity of ST8814 cell lines was significantly reduced in both cell lines with RAC1 and ROCK2 
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Figure 6.10. Invasion assay on ST8814 cell lines transfected with Rac1, ROCK2 and 
scrambled control shRNA. Cells were stained with crystal violet (5mg/ml) and images 
were taken at x10 magnification (Leica). RAC1 and ROCK2 knockdown elicited a 
reduction in the invasive potential of ST8814 cell lines as evidenced by the lack of 
RAC1 and RO CK 2  shRNA transfected cells on the underside of the membrane 
following 3 days of incubation.
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Figure 6.11. Migration of MPNST cells (ST8814) following treatment with 
Rapamycin. Migration was significantly reduced in comparison to untreated controls 
(p=0.009).
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6.5 Discussion
6.5.1 Molecular heterogeneity in MPNS Ts
Cellular heterogeneity is a well known complication in the analyses of NF1- 
associated tumours. By contrast, heterogeneity at the molecular level in NF1- 
associated tumours has scarcely been addressed. In this study, the extent of 
molecular heterogeneity within and between 10 MPNSTs, derived from 10 unrelated 
NF1 patients was determined by examining the differences in the levels of LOH at 
the NF1, TP53, RB1, CDKN2A and PTEN gene loci. The results of this study 
indicated that 70% of the MPNST tumours analysed exhibit molecular heterogeneity 
between sections of the same tumour sample. This heterogeneity was especially 
evident in the case of those sections from the same tumour which were anatomically 
adjacent to each other prior to dissection but which had nevertheless been found to 
differ with respect to the degree of LOH. Indeed, some sections were found to be 
entirely devoid of LOH for all five gene loci analysed, but were located beside 
sections exhibiting complete LOH for one or more of these genes (e.g. T196.22 
section A4). Prior to dissection, in a number of the MPNST tumour sections under 
study, there were clearly defined centrally located tumour portions (T196.22 
subsection 5 A-E, T516 section B, T518, section B). These areas corresponded to 
the sections in which different levels of LOH and subsequently TP53 staining were 
identified (T196.22 section B5; T196.22 section C5; T196.22 section E5, figure 6.3) 
The observation that TP53 LOH correlates directly with p53 expression, as 
demonstrated here, has been observed in previous studies (Gbtte et al, 2001; Otis et 
al, 2002). However, the precise relationship between TP53 LOH and p53 protein 
expression remains unclear since some studies have identified p53 expression in 
tumours which have no TP53 LOH. This may be explicable in terms of the presence 
of two TP53 alleles, one mutant and the other wild-type in a given cell type, resulting 
in the production of both wild-type and mutant p53 protein. As a consequence, p53 
may be detected by IHC even in the absence of p53 function. This suggests that in 
the context of evaluating tumour heterogeneity, IHC analysis is unlikely to be as 
reliable as other molecular genotyping methods. IHC analysis could therefore be 
replaced by more accurate methods including AQUA (Camp et al, 2002; McCabe et 
al, 2005) and tissue analysis with multiplex quantum dots (QD) (Liu et al, 2010), to
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yield a digital map of molecular and cellular heterogeneity to improve the sensitivity 
of detection and the prediction of a therapeutic response.
p53 is associated with malignant transformation in NF1-associated tumours 
(Upadhyaya et al, 2008) and LOH of the TP53 gene was identified in 5 of the 10 
tumours under study (table 6.3). TP53 has also been found to manifest in intra- 
tumoural molecular heterogeneity with respect to its mutation in other tumour types, 
including breast cancer (Lennington et al, 1994; Clark et al, 2011). In pancreatic 
cancer, molecular heterogeneity is evident in cells with different capacities for 
initiating metastasis (Campbell et al, 2010) suggesting that molecular heterogeneity 
may well prove to be the rule rather than the exception. If the molecular 
heterogeneity identified in this set of tumours was to emerge as relevant to MPNST 
development, we may have to revise our view not only of MPNST tumour biology but 
also of the basic processes underlying MPNST tumorigenesis.
It might be assumed that, owing to the large size of some of the MPNST tumours, 
they would be divisible into a larger number of sections thereby allowing molecular 
heterogeneity to be assessed more clearly. However, the size of the tumour was not 
found to correlate with the level of molecular heterogeneity detected (table 6.2 and 
table 6.3). It is, however, possible that intra-tumoral molecular heterogeneity could 
be related in some way to the grade of tumour, at least for those tumour samples 
analysed here (table 6.2). A larger study is clearly warranted in order to determine 
whether these results could be replicated in a larger set of NF1-associated MPNSTs. 
However, such a study will be laborious and time consuming to set up, especially as 
MPNSTs are quite rare.
The pathological diagnosis of an MPNST is usually held to represent the ‘gold 
standard’ for the purposes of analysis and currently relies on the examination of not 
just one, but a number of different sections. The results of this study and from other 
previous studies on solid tumours (Alizadeh et al, 2000; Whitehall et al, 2002; Stingl 
et al, 2007), are broadly illustrative of the importance of careful dissection in the 
analysis of large tumours and suggests that in the interest of diagnostic accuracy, 
molecular analysis should be performed on several tumour sections alongside a 
pathological diagnosis. The clear implication for those studies that involve microarray 
analysis is that replicates across several sections would be advisable.
The results of this study therefore have important implications for molecular studies 
of NF1-associated tumour specimens. Although molecular techniques currently
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employed in mutation detection in large solid tumours are adequate for identifying 
and characterising the underlying molecular and genetic aberrations, the potential for 
molecular heterogeneity means that a single dissected piece of tumour should not be 
assumed to be representative of the tumour as a whole; as a consequence, some 
somatic mutations may well be missed.
Genomic instability and high intra-tumoral genetic heterogeneity may synergize so 
as to accelerate the evolutionary processes within the tumour leading to the 
development of resistance to cytotoxic and targeted anti-cancer drugs. 
Improvements clearly need to be made to the treatment regimes for patients with 
MPNSTs. The results from this study indicate that whilst drugs can be developed in 
vitro that would be capable of targeting the genes involved in the genesis of 
MPNSTs; the efficacy of these drugs is likely to be somewhat limited unless the 
cellular, molecular and architectural heterogeneity of the tumour are considered 
alongside the tumour microenvironment. This study represents the first systematic 
analysis of molecular heterogeneity in MPNSTs associated with NF1. The molecular 
heterogeneity evident at a number of different gene loci indicates that there is an 
urgent need not only for the integration of molecular and morphological biomarkers 
in cancer diagnosis but also for the development of specific treatments for NF1- 
associated MPNSTs.
6.5.2 Functional analysis of cMET and RhoGTPase pathways
Translation of genetic findings into functionally meaningful results is not normally 
available, with only a few reports of functional studies on NF1-associated MPNSTs in 
the literature based on array findings. Miller et al, (2009) identified SOX9 as a 
potential biomarker as it was strongly expressed in NF1-related tumours and 
resulted in MPNST cell death when the expression was reduced. Furthermore, anti- 
TNC antibodies, (already used successfully in clinical trials to treat malignant human 
gliomas, (Levy et al, 2007)) and antisense inhibitors of miR-10b have been used in 
MPNST cells producing a reduction in cell proliferation, migration and invasion (Chai 
et al, 2010). It is therefore suggested that assessment of the genetic composition of 
individual tumours and subsequent targeted therapy could be an appropriate new 
therapeutic strategy for NF1.
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All of the 14 genes analysed by relative quantification in this study have important 
implications for tumorigenesis and malignancy in NF1. However, amplification of the 
cMET and RhoGTPase pathways in particular, is a highly significant finding. Indeed, 
cMET and its ligand HGF have been previously found to be altered in MPNSTs 
(Mantripragada et al, 2009) and moreover, 6 genes from the RhoGTPase pathway 
including RAC1 and ROCK2 were all altered in the cohort studied, demonstrating 
that this pathway may be of significance to MPNST pathogenesis. Overexpression of 
genes in the cMET/RhoGTPase pathway in MPNST cell lines provides a valuable 
opportunity to functionally evaluate how modification of these genes may result in 
NF1 malignant progression and subsequent metastasis.
6.5.2.1 cMET pathway
In this study, small molecule inhibition of cMET in MPNST cell lines, followed by 
cellular migration assays demonstrated a reduction in cM ET  gene expression which 
was correlated with a decrease in the migratory capacity of these cell lines. Thus, the 
results of this study signify that increased cMET copy number and gene expression 
in MPNSTs is likely to be contributing to the malignant and metastatic potential of 
MPNST cells.
The combined activation of two genes: HGF and its receptor cMET are also known 
to be altered in the development of a number of other solid tumours (Jiang et al, 
1999). NIH3T3 cells co-transfected with cMET and HGF  was found to result in 
tumorigenesis as evidenced in vitro by increased cell motility, collagenase activity, 
and additionally by invasiveness and metastatic activity in vivo (Rong et al, 1992; 
Rong et al, 1993; Rong et al, 1994). HGF has been shown to be a strong mitogen for 
rodent Schwann cells and may act as a paracrine growth factor or contribute to an 
autocrine signalling loop (Krasnoselsky et al, 1994). Importantly HGF and cMET 
alterations have been detected in benign neurofibromas (Krasnoselsky et al, 1994; 
Rao et al, 1997; Watanabe et al, 2001) and MPNSTs (Rao et al, 1997; Fukuda et al, 
1998; Watanabe et al, 2001; Mantripragada et al, 2008). Additionally there was a 
significant difference in the degree of cMET and HGF  expression in benign and 
malignant tumours, with MPNSTs demonstrating a higher level of gene expression 
(Rao et al, 1997; Mantripragada et al, 2008). Co-localisation of HGF and cMET 
expression in a number of MPNSTs has also been suggested to be indicative of
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biologically aggressive tumours (Rao et al, 1997) Concomitant overexpression of 
both cMET and HGF  in addition to PDGFRA may therefore promote NF1 
tumorigenesis and malignancy through the formation of an autocrine signalling loop, 
also indicating that there may be a putative role for the p70S6K pathway in NF1 
tumorigenesis. Despite numerous associations of the cMET pathway with NF1 
tumorigenesis, this is the first study to functionally define the role of cMET 
upregulation in MPNST tumorigenesis. This study indicates that inhibition of cMET 
receptor activation with small molecular inhibitors such as SU11274 and PF- 
4217903 in NF1-associated tumours may be an attractive prospect for personalised 
therapy of MPNSTs harbouring cMET activation.
However, it is also essential to consider that specifically targeting the gene which is 
amplified in MPNSTs may not efficiently inhibit tumour growth due to complex 
feedback mechanisms and signalling loops which exist within cells. There are a 
number of downstream signalling pathways which are activated by cMET including 
ERK1/2, STAT3, RhoGTPase (see below), and AKT (Birchmeier et al, 2003). As part 
of pilot tests for this study, MPNST cells were also treated with the mTOR inhibitor 
rapamycin, using the same methods as described for the cMET  inhibition analysis (in 
collaboration with Dr Andrew Tee, Cardiff University). Interestingly, there was a 
significant decrease in the migratory activity of the MPNST cell lines following 
rapamycin treatment (p=0.009) (figure 6.11). This indicates that pathways 
downstream of cMET including the mTOR/AKT pathway may also be important in 
malignant progression.
In a recent study by Banerjee et al (2010) using a cell-based high-throughput 
chemical library screen of A/Ff-deficient MPNST cells, they identified hyper­
activation in signal transducer and activator of transcription-3 (STAT3) in A/F7- 
deficient primary astrocytes, neural stem cells, mouse glioma cells, and human 
MPNST cells. STAT3 is known as a multifunctional transcription factor which cycles 
between the cytoplasm and nucleus in its un-phosphorylated basal state (Liu et al, 
2005). Following activation of cMET as a result of binding of the ligand HGF, STAT3 
is recruited to cMET and is consequently phosphorylated resulting in its nuclear 
accumulation (Boccaccio et al, 1998). Further dissection of the activation of STAT3 
in A/F7-deficient cell lines concluded that STAT3 hyper-activation occurred through 
Ser727 phosphorylation which consequently resulted in increased cyclin D1 
expression (Banerjee et al, 2010). STAT3 regulation in A/F7-deficient cells of murine
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and human origin was also noted to occur in a TORC1- and Rac1-dependent 
manner indicating that STAT3 could also represent an attractive prospect for therapy 
of NF1 associated MPNSTs (Banerjee et al, 2010). Based on the findings presented 
here, pilot tests employing STAT3 shRNA to knockdown STAT3 in MPNST cell lines 
is currently ongoing.
6.5.2.2 RhoGTPase pathway
Amplification of both RAC1 and ROCK2 was identified by microarray and relative 
quantification in MPNSTs. Cell migration is a critical process which upon 
deregulation can result in pathological consequences including tumour angiogenesis 
and metastasis. Migration, invasion, wound healing and adhesion assays have been 
previously employed to assess tumour cell invasion and its modulation. These 
assays were utilised in this study to determine the functional effect of increased 
RAC1 and ROCK2 copy number and expression on MPNST cell lines. A significant 
reduction in wound healing, migratory and invasive behaviour in addition to a 
significant increase in adhesion of cell lines was identified in MPNST cell lines 
following targeted knockdown of both RAC1 and ROCK2 with shRNA. Rapid wound 
healing (cell spreading) as observed in the MPNST cells indicates that these cells 
are highly migratory. This assumption was confirmed with migration and invasion 
assays which demonstrated that MPNST cells are able to migrate towards a chemo- 
attractant, even through basement membrane matrix. Such cells may therefore be 
able to invade neighbouring tissues during the process of metastasis. Furthermore, 
MPNST cells transfected with scrambled shRNA are less adhesive than cells 
harbouring a knockdown of RAC1 and ROCK2 further suggesting that they would be 
able to migrate to other sites in the process of metastasis. As outlined below, the 
results presented here, in concert with the known properties of the members of the 
RhoGTPase pathway, indicate that deregulation of RhoGTPase signalling may play 
an important role in the malignant potential of cells harbouring biallelic NF1 
inactivation.
6.5.2.2.1 Targeting RAC1 
Alteration of the RhoGTPase RAC1 has been identified in multiple solid cancer types 
including testicular, gastric and breast cancer in addition to chronic myelogenous
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leukaemia (CML) and primary human schwannoma cells (supplementary table 10) 
(Harnois et al, 2003; Kaempchen et al, 2003). Expression of the fusion protein Bcr- 
Abl is the major determinant of CML development and it has been demonstrated to 
activate RhoGTPases including RAC1 (Harnois et al, 2003). Moreover, CML can be 
induced in mice deficient in Rac1, Rac2 or both (Thomas et al, 2007). Indeed, in 
vitro, RAC1 and RAC2 are shown to be crucial for the growth promoting effect of the 
Bcr-Abl fusion protein on haematopoietic precursor cells (Thomas et al, 2007). 
Evasion of cell death by alteration of expression of genes involved in survival is a 
key mechanism by which cancer cells can persist. Activation of RhoGTPases such 
as RAC1 has been show to result in increased apoptosis in a cell specific manner, 
for example promoting Fas dependent apoptosis of T cells (Ramaswamy et al,
2007). This is evidenced by RAC1b over expression which leads to increased 
survival in colorectal tumour cells (Matos and Jordan, 2008).
In addition to alteration of apoptosis mechanisms, the process of angiogenesis 
involves blood vessel formation and innervation of solid tumours and is crucial for the 
growth of solid tumours. RhoGTPases have been found to mediate specific 
processes during angiogenesis including proliferation, survival, migration of 
endothelial cells and regulation of neoangiogenesis, involving the modulation of 
hypoxia inducible factor (HIF) (Turcotte et al, 2003; Bryan and D'Amore, 2007). 
Furthermore, a crucial aspect of malignant tumour formation and the occurrence of 
metastasis is the development of migratory properties in cells. RhoGTPase driven 
migration generally occurs by the mesenchymal mechanism, as opposed to 
amoeboid migration, with distinct RhoGTPases mediating two forms of migration 
involving either the induction of membrane protrusions which are filopodial (Cdc42, 
RhoD, Rif, Wrch-1, Chp) or lamellipodial (Rac1, Rac2, Rac3, RhoG) (Aspenstrom et 
al, 2004). Moreover, RhoGTPases can control the switch been mesenchymal and 
amoeboid migration and have been found to determine the direction of cell migration, 
of which cdc42 plays a major role but other Rho proteins may also be involved (Yang 
et al, 2006).
The use of RAC inhibitors, including NSC23766 has delivered important results 
especially in CML cells, as proliferation both in vitro and in vivo can be inhibited 
following treatment (Thomas et al, 2007). Furthermore, in mouse models in which 
Rac1 was over expressed, tumour progression was promoted in orthotopicaly 
injected adenocarcinoma cells. Conversely, following knockdown of R a d  in the
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same model, there was evidence of decreased tumour development (Espina et al,
2008). This finding has been recapitulated in other studies including mouse models 
of lung tumour formation in which reduced tumour formation and prolonged survival 
can be demonstrated (Kissil et al, 2007). It is clear from previous studies and the 
assays performed here, that specifically targeting RAC1 results in a reduction in 
aberrant cellular behaviour. Inhibition of RAC1 can reduce motility and invasiveness, 
most likely through a reduction in the RhoGTPase driven lamellipodial migration 
which is upregulated in MPNST cells. RAC1 inhibition is therefore likely to be 
therapeutically beneficial to solid tumours such as MPNSTs which harbour activated 
RAC.
6.5.2.2.2 Targeting ROCK2 
The role of ROCKs encompasses regulation of cell growth, migration, metabolism, 
and apoptosis (Liao et al, 2007). There are numerous downstream targets of ROCKs 
which regulate cellular responses involving actin cytoskeletal assembly and cell 
contraction (Riento and Ridley, 2003; Liao et al, 2007). These processes are 
achieved by phosphorylation of proteins including myosin light chain (MLC) 
phosphatase, LIM kinases, adducin, and ezrin-radixin-moesin (ERM) proteins, 
although it is expected that many other as yet undiscovered targets may also exist 
(Liao et al, 2007).
Upregulation of ROCK2 has been identified as a key factor in the process of tumour 
metastasis, contributing to promotion of invasion of tumour cells (Bourguignon et al, 
1999). This property has been demonstrated experimentally, including the inhibition 
of invasion in rat hepatoma cells and migration in metastatic breast cancer cells with 
dominant-negative forms of ROCK and treatment with small molecular inhibitors 
such as Y-27632 or fasudil. Such non-isoform specific inhibitors target ATP- 
dependent kinase domains and lead to the loss of stress fibres and focal adhesion 
complexes. Whilst at higher concentrations they may target other serine threonine 
kinases, their efficacy indicates that such methods may be appropriate therapeutic 
options, although little remains known about the underlying molecular mechanisms 
of ROCK activity (Ishizaki et al, 1996; Itoh et al, 1999; Kataoka et al, 2002).
As with inhibition of RAC1 signalling, previous studies on other tumours and the 
results presented here on MPNST cell lines, suggests that knockdown of ROCK2 
may also offer a reduction in the malignant and metastatic potential of MPNST cells.
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Whilst individual knockdown of RAC1 and ROCK2 resulted in a reduction in 
migratory and invasive behaviour and an increase in adhesion, the cells still 
demonstrated some metastatic behaviour indicating that there may be some 
redundancy in the RhoGTPase pathway. Indeed, keratinocyte cell-cell contact for 
example, is sensitive to inhibition of Rho and Rac but individual mouse knockouts do 
not affect keratinocyte cell junctions (Benitah and Watt, 2007). This may be as a 
result of activation of pathways which regulate the Rho GTPase signalling pathway 
or from the presence of lower or higher levels of molecules which regulate 
RhoGTPases. Some breast tumours for example, have been found to harbour 
upregulation of RhoGEFs such as Vav, Trio and Tiaml. It would therefore be 
important to determine whether double knockouts of genes in the RhoGTPase 
pathway would be required to completely inhibit tumour growth and metastasis.
6.5.2.3 RNAi vs. small molecular inhibitors
Some gene targets are not easily drugable, and the search for an appropriate 
inhibitor can be time consuming and laborious. There are instances of the use of 
RAC1 or ROCK2 inhibitors in cancer studies in the literature, namely in breast 
cancer (Hernandez et al, 2010), but often these inhibitors are novel and thus not 
commercially available. cM ET  inhibitors have been previously investigated in many 
cancers and many are currently commercially available (Crosswell et al, 2009). 
shRNA instead of inhibitors were therefore used to determine the affect of RAC1 and 
ROCK2 upregulation in MPNST cell lines. shRNA were chosen over other RNAi 
methods, such as siRNA due to the specificity and long term affects which it affords. 
Furthermore, shRNA clones with varying levels of knockdown can be selected to 
identify the affect of both partial and full knockdown. Overall, the two methods 
(inhibition and shRNA) are relatively comparable. Both shRNA and small molecular 
inhibitors were equally successful in either specifically reducing the gene expression 
of target genes without any off target effects or inhibiting receptor activation. shRNA 
and inhibition assays also took the same amount of time to complete and each 
produced the same end-result of a reduction in gene expression. Five clones were, 
however, required for each shRNA to give a range of knockdown efficiencies which 
increased the time and cost of producing the desired knockdown effect. Clearly small 
molecule inhibitors are also more readily transferable to in vivo assays and are
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more applicable to potential downstream clinical trials. However, it should be noted 
that molecular heterogeneity as demonstrated in this study, has implications for 
therapy of large malignant tumours. It should be recognised that different molecular 
signatures may exist in separate portions of a tumour and therefore targeted 
inhibition or knockdown of specific genes may only affect a section of a large tumour.
6.5.3 Conclusion
Although MPNSTs only develop in ~15% of NF1 patients, they represent a frequent 
cause of lethal progression of the NF1 phenotype. The prognosis for individuals 
diagnosed with an MPNST is usually very poor especially as treatment options for 
MPNSTs are currently rather limited and complete surgical excision with clear 
margins is the commonly recommended therapy for MPNSTs.
This study demonstrated that in addition to cellular heterogeneity, molecular 
heterogeneity is a prominent aspect of NF1 -associated MPNSTs, a finding which has 
important connotations for analysis of somatic alterations in MPNSTs in addition to 
the design and administration of targeted therapies. Pathway analysis based on data 
derived from Affymetrix microarray analysis (Upadhyaya et al, unpublished data) and 
relative quantification demonstrated MPNST specific amplification of genes mapping 
to the cMET and RhoGTPase pathways. In knockdown experiments involving short 
hairpin RNA for RAC1 and ROCK2, cell adhesion of MPNST cell lines was 
significantly increased whereas wound healing, cell migration and invasion were 
reduced. This is consistent with a role for RAC1 and ROCK2 in MPNST development 
and metastasis. Furthermore, cMET  inhibition with two small molecule inhibitors 
generated a reduction in gene expression and migratory behaviour in MPNST cell 
lines. This study has identified several new potential targets for therapeutic 
intervention in MPNST development.
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CHAPTER 7: General discussion
Following the identification of the NF1 gene on chromosome 17q11.2 by positional 
cloning experiments in 1990 (Cawthon et at, 1990; Wallace et al, 1990; Viskochil et 
al, 1990), it has become clear that analysis of germline and somatic NF1 mutations 
in the context of evaluating mechanisms for disease manifestation and genotype- 
phenotype correlations, would be a significant challenge. To date, over 1273 
different NF1 germline mutations have been identified (HGMD; Fahsold et al, 2000; 
Messiaen et al, 2000; Han et al, 2001; Ars et al, 2003). In comparison, only about 
215 different somatic NF1 mutations have so far been characterised. Furthermore, 
whilst reported germline mutation detection rates can be as high as 90% (Messiaen 
et al, 2000; Ars et al, 2000), even using the most up to date mutational analysis 
techniques, the somatic mutation detection rate has been recently reported to vary 
from 12% to 64% (John et al, 2000; Serra et al, 2001b; Upadhyaya et al, 2004; 
Spurlock et al, 2007). Much has been learned over the past 20 years on how a 
constitutional germline NF1 mutation might result in the plethora of manifestations 
associated with NF1 as a disease. Nevertheless, there is still a significant paucity in 
knowledge in NF1 research, particularly relating to the mechanisms and pathways 
involved in tumour development and malignancy. This thesis has therefore focused 
on some of the areas of NF1 tumour biology for which we currently have little depth 
of knowledge.
7.1 Mutation detection
The size and complexity of the NF1 gene, the lack of mutational hotspots, the 
diversity of disease-causing mutations, and the presence of NF1 pseudogene-like 
sequences, contribute to problems related to successful NF1 mutation detection. It is 
also increasingly recognised that the cellular and molecular heterogeneity of NF1- 
associated benign and malignant tumours is a contributory factor to poor mutation 
detection rates. Furthermore, comprehensive NF1 mutational analysis is costly and 
labour intensive as at least three different screening methods (LOH, MLPA and 
direct sequencing) are usually required to ensure detection of the complete spectrum 
of somatic NF1 mutations. Even when using patient-derived lymphocyte DNA, 
screening for NF1 constitutional mutations may require the use of both DNA and
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cDNA sequencing, in addition to MLPA analysis, to detect most point mutations, as 
well as genomic deletions and insertions that affect the gene. Due to the complexity 
of NF1 mutational types, no single standardised mutation detection platform is 
capable of detecting the range of NF1 mutations. Indeed, even some of these 
methods fail to provide complete coverage of the NF1 gene and so many mutations 
may remain unidentified. While this is not such a major issue for germline NF1 
mutation detection, with a reported 70-90% success rate (Fahsold et al, 2000; 
Messiaen et al, 2000; Han et al, 2001; Ars et al, 2003; Valero et al, 2011), for 
somatic NF1 mutation detection, significant improvements clearly are required. Such 
improvements may occur prior to the mutation analysis stage, such as by Schwann 
cell enrichment to significantly increase the cell population that exclusively harbours 
the NF1 somatic mutation, or it may await future advancements in mutation detection 
methodologies.
Cutaneous neurofibromas are usually small benign tumours, with an extracellular 
matrix and are populated with Schwann cells, the only tumour cells that harbour the 
somatic NF1 mutations. Unfortunately, neurofibromas demonstrate high cellular 
heterogeneity and whilst Schwann cells represent the predominant cell type, they 
only comprise 40%-80% of cells (Peltonen et al, 1988; Wallace et al, 2000), along 
with heterozygous fibroblasts, mast cells and perineural cells (Kimura et al, 1974; Le 
and parade, 2007). As a result, reported somatic mutation detection rates in 
neurofibromas show great variation (John et al, 2000; Serra et al, 2001b; Upadhyaya 
et al 2004; Spurlock et al, 2007). Thus, the focus for the initial part of the present 
research was to identify and validate new methods for improving mutation detection 
in such heterogeneous tumours, and involved Schwann cell enrichment both by 
Schwann cell culture and by Laser Capture Microdissection (LCM) of solid tumours. 
LCM was subsequently used in conjunction with standard NF1 mutation detection 
techniques, to identify the somatic NF1 mutations present in multiple benign 
cutaneous neurofibromas derived from NF1 patients with a high tumour burden 
(>500 cutaneous neurofibromas).
Validation of these two strategies involving Schwann cell enrichment revealed the 
pros and cons of both techniques, as outlined in chapter 3. For example, Schwann 
cell culture, is both time consuming; requiring some 4-6 weeks for one cell line and 
expensive as Schwann cells do not proliferate in standard culture conditions,
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requiring additional cell culture reagents and the necessary expertise to culture 
them. Thus, Schwann cell culture is not really suitable for the routine identification of 
NF1 somatic mutations. While the use of LCM was rapid and cost effective, it was 
found to be less sensitive in the context of mutation detection compared to Schwann 
cell culture.
Perhaps the most important consideration when comparing these two techniques is 
that Schwann cell culture is very much a prospective technique, requiring fresh 
tumour tissue, it cannot be applied retrospectively. Thus, if the somatic mutation is 
not identified by analysis of the whole tumour DNA, it is not possible to go back and 
analyse the same tumour by Schwann cell culture. Conversely, LCM whilst exhibiting 
a lesser Schwann cell enrichment and thus a lower somatic mutation detection rate 
of the two techniques, it can be applied both prospectively and retrospectively to 
older samples which are preserved by fixation and paraffin embedding. DNA from 
tumours fixed in this manner are viable for long periods of time. Indeed, some of the 
samples analysed in this study were over 10 years old. Thus, a combination of LCM 
and culture methods may represent the best Schwann cell enrichment strategy, 
encompassing both the sensitivity of Schwann cell culture with the flexibility of LCM 
for retrospective and prospective tumour studies.
Other enrichment techniques, such as COLD-PCR, have also been reported to be 
useful for detecting a variety of mutations, including those in KRAS. COLD-PCR is 
able to detect the mutant alleles even when restricted to a small region of the clinical 
samples, such as colorectal samples (Song et al, 2011). Aptamer-modified 
microfluidic devices have also been reported which rapidly capture target cells with 
over 97% purity and above 80% efficiency (Phillips et al, 2009). Such techniques 
might also be useful for enrichment of Schwann cell populations containing NF1 
somatic mutations from NF1 associated tumours, although validation would be 
required.
Comprehensive genome wide mutation analyses of many common non-NF1- 
associated malignant tumours have increasingly identified somatic mutations of the 
NF1 gene. Indeed, significant involvement of NF1 inactivation has been found in 
glioblastoma (Parsons et al, 2008), lung adenocarcinomas (Ding et al, 2008), ovarian 
serous carcinomas (Sangha et al, 2008), colorectal carcinomas (Ahlquist et al, 2008) 
and leukaemia (Haferlach et al, 2010). Several sporadic NF1-associated tumours
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including neurofibromas and MPNSTs have also been reported in individuals without 
a known constitutional NF1 mutation (Bottillo et al, 2009; Pearl and O'Toole, 2010). 
NF1 somatic mutations are therefore not restricted to tumours found in NF1 patients 
and thus the NF1 gene clearly has a much broader role in the pathogenesis of 
multiple tumour types. Hence, the enrichment processes validated in this study may 
have wider implications for analysis of somatic mutations in other tumour types. 
Clearly Schwann cell culture is only applicable to tumours in which Schwann cells 
harbour the NF1 somatic mutations. Enrichment cultures for other tumour cells may 
be valid for the overall identification of NF1 somatic mutations, in addition to finding 
genome-wide alterations in other heterogeneous cell types. Indeed, cell culture of 
leukaemic cell populations is common practice (Walsby et al, 2011), and mutation 
harbouring breast cancer cells have also been enriched by culture followed by 
immunomagnetic enrichment (Hu et al, 2003). LCM is routinely applied to many solid 
tumour types provided that molecular markers or a pathologist are available to 
determine the cells of interest to be dissected. Homogeneous lung adenocarcinoma 
cells have been purified by LCM with high specificity allowing the detection of a wide 
range of genetic alterations including TP53 (Nan et al, 2010). Djalilvand et al (2004) 
have also employed LCM in the detection of TP53 mutations in esophageal 
carcinomas, Keohavong et al (2004) employed LCM in breast ductal carcinomas and 
Wang et al (2006) have completed a similar study to that employed in this project, 
involving LCM followed by LOH analysis of advanced oral squamous cell carcinoma. 
The overall effectiveness of LCM for mutation analysis in the context of these solid 
tumours proved to be similar to the results ascertained in the present study. Thus, 
LCM is a readily applicable technique for both prospective and retrospective 
mutation analysis of the NF1 gene and other tumour suppressor loci, in a range of 
tumour types.
Even with these Schwann cell enrichment steps prior to mutation analysis in NF1- 
associated tumours, it was apparent that there were still problems with the methods 
employed to detect somatic mutations. Although there were no major issues with 
speed or sensitivity in the present analysis, the problems were more inherent and 
mainly arose from the use of techniques which cannot detect the whole spectrum of 
mutations, in addition to the tumour heterogeneity.
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Recent NF1 studies have confirmed that LOH is a common somatic mutational 
mechanism in NF1, especially in MPNSTs, where LOH is reported to account for 
85%-90% of the identified mutations (Upadhyaya et al, 2008; Laycock-VanSpyk et 
al, 2011). Even in benign cutaneous neurofibromas and plexiform neurofibromas, 
NF1 LOH is detected in about 49% and 79% of tumours respectively. Hence, 
somatic mutation detection is heavily reliant on the use of LOH analysis using a 
standard panel of chromosome 17 specific microsatellite and RFLP markers. While, 
the LOH PCR-based technique proved to be very efficient in detecting LOH, several 
technical problems arose during the validation process in this study. For example, 
the cellular heterogeneity of the tumours was found to mask the somatic mutations 
detected in several samples and this was significantly improved by the use of LCM 
and Schwann cell culture. However, many somatic mutations were still undetectable; 
thus the true extent of somatic NF1 LOH is probably underestimated. Whilst PCR 
based methods do permit multiplexing, allowing multiple markers to be screened 
concordantly, expansion of the technique to screen for LOH across an entire 
chromosome becomes expensive and thus FISH may be used instead. 
Constitutional DNA is also required for comparison in such LOH studies. In the 
present study, as some samples were obtained at post mortem, no normal tissue 
was available.
MLPA analysis was used in this study to screen for microdeletions or duplications. 
There are also several drawbacks with this technique, again MLPA is affected by the 
cellular heterogeneity, and also the presence of variant SNPs in the probe or primer 
regions may result in false positive and false negative results. A major issue with this 
current study was that FISH analysis could not be used to confirm any MLPA results 
as the relevant fresh tumour samples were often not available. Repeat analysis 
therefore had to be relied upon to confirm the MLPA results but this is clearly not a 
suitable method for confirmation.
The direct DNA and cDNA sequencing used in this study detected a wide range of 
different NF1 point mutations, including nonsense, missense and splice site 
mutations, as well as small deletions and insertions ranging in size from 1-114 bp. 
The major disadvantage to this technique relates to the size and complexity of the 
NF1 gene as well as the lack of any obvious mutational hotspots. Indeed, it is quite 
laborious and time consuming to amplify and sequence all 61 exons of the NF1 gene 
and it is quite likely that many somatic mutations were missed during sequence
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analysis in this study. Moreover, any deep intronic mutations would also be missed 
due to the location of the primers used in this study and the limitations on the 
sequencing read length (approximately 500-1 OOObp), which is restricted by the 
capillary length (Pros et al, 2009).
The use of cDNA sequencing of tumour RNA in this study helped to overcome 
several of these problems. Firstly, for cDNA sequencing of the entire coding region 
of the NF1 gene only 24 primer sets are required instead of 61, thus sequencing is 
far more efficient. Secondly, any deep intronic mutations that may affect the correct 
reading of the frame, and splice site mutations which disrupt correct splicing, are 
much more easily identified. Mutation detection rates may also be increased by 
cDNA sequencing and, in the present study; several mutations were identified by 
cDNA that were not immediately obvious from DNA. These somatic mutations were 
only later confirmed in tumour DNA following the identification of the location of the 
mutation. Similarly, cDNA has been employed in the analysis of other tumour 
suppressor genes such as TP53, in which cDNA analysis improved somatic mutation 
detection (Szybka et al 2009). The use of RNA from frozen tumour tissue should, 
however, be treated with some caution as several aberrant NF1 transcripts have 
been reported following analysis of stored tissue (Ars et al, 2000; Wimmer et al, 
2000; Serra et al, 2001; Vandenbroucke et al, 2001, 2002).
The panel of techniques used in this study were found to be no more efficient than 
other mutation detection methods such as DHPLC. DHPLC is reported to provide 
NF1 mutation detection rates of some 66% (DeLuca et al, 2004) which is 
comparable to the analysis of several other key tumour-related genes, such as VHL, 
in other malignant tumour types, including phaeochromocytomas (Meyer-Rochow et 
al, 2009). DHPLC can, however, only effectively detect point mutations and so really 
only represents a screening tool. The more comprehensive approach presented 
here, whilst relatively labour intensive, does analyse the entire NF1 mutational 
spectrum. Furthermore the identification of false positive results is a recurring 
problem with DHPLC, due to the detection of non-specific fragments. Whilst false 
positives can occur by direct sequencing, this is often circumvented by bidirectional 
sequencing of both strands at the same time.
The somatic mutational analysis techniques employed here (LOH, MLPA and direct 
sequencing) are all relevant mutational detection methods that are routinely
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employed in both the diagnostic and research setting for NF1 mutational analysis. 
This study represents the most effective analysis of somatic NF1 mutations in NF1- 
associated benign and malignant tumours with the highest mutational detection rate 
reported to date using Schwann cell culture (85%). These techniques are not specific 
to the analysis of NF1-associated tumours and are sensitive enough to be translated 
to the analysis of NF1 mutations in other tumour types. Indeed, LOH analysis and 
direct sequencing are the most common methods of mutational detection used for 
the analysis of somatic mutations at many other genomic loci in different tumour 
types, including colorectal carcinomas (Cawkwell et al, 1994; Ahlquist et al, 2008), 
lung adenocarcinomas (Ding et al, 2008) and ovarian serous carcinomas (Sangha et 
al, 2008). Microsatellite markers are available for other tumour suppressor genes 
and such markers were employed in this study to screen for TP53 mutations.
MLPA has proved advantageous in several NF1 mutation detection studies, not only 
in the identification but also in the complete characterisation of both intragenic 
deletions and duplications (Valero et al, 2011; Messiaen et al, 2011). Kits are also 
available for a range of other tumour suppressors including TP53, PTEN  and RB1 
(MRC Holland). Indeed, MLPA has been successfully applied in the testing and 
identification of genomic mutations in numerous genes, including BRCA1 and TSC2 
(Kozlowski et al, 2008).
Direct sequencing is a common technique used for detection of mutations at genetic 
loci throughout the genome. KRAS (c.61) and BRAF (V600E) mutations in particular, 
are frequently screened for in colorectal cancer using this method as it is a simple 
method for identifying the most common somatic alterations in this tumour type 
(Bennani et al, 2010). The advent of more rapid and sensitive techniques, such as 
pyrosequencing have recently replaced direct sequencing for the characterisation of 
specific mutations which frequently occur in some tumour types, especially KRAS 
mutations in colorectal cancer (Macedo et al, 2011). The application of a 
pyrosequencing-based mutational analysis for NF1 mutation detection would not be 
as advantageous as the methods described here, mainly due to the underlying 
complexity and size of the NF1 gene and the lack of any mutational hotspots. It may, 
however, represent a less labour intensive approach in diagnostic situations, 
especially as the time involved in post PCR processing is greatly reduced.
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In conclusion, the present study has made use of the most reliable and efficient 
techniques available at the onset of the study. The techniques presented here have 
proved to be valid and applicable for the enrichment and analysis of the NF1 gene in 
NF1 -associated benign and malignant tumours, and possibly for the analysis of other 
common malignant tumour types. Moreover, the methodology described here has 
implications for the identification of somatic mutations at genome-wide loci in other 
clinically important cancer types. The emergence of ‘next generation’ sequencing 
techniques offers the advantages of being able to identify multiple mutations across 
the entire genome and so clearly has implications for NF1 gene analysis. However, 
such novel sequencing techniques are not necessarily a direct replacement of 
current sequencing methodologies. At present, the high empirical costs and 
increased time involved in next generation sequencing demonstrates that such 
technologies may be more than is required for basic mutation detection 
methodologies used in single gene disorders such as NF1.
7.2 Functional Analysis
While detection of mutations within the NF1 gene has proved challenging, the 
problem in interpreting the likely pathogenicity of identified sequence variants 
continues to confound the issue. Therefore, functional and bioinformatic analysis of 
the possible disease causing ability of missense mutations within the GRD was 
studied, as discussed in chapter 4. These mutations had been previously detected 
as potential germline mutations in NF1 patients in both the NHS diagnostic lab 
(University Hospital of Wales, Cardiff) and the NF1 research lab (Cardiff University). 
However, without the relevant familial analysis, or comparison against a large panel 
of normal controls, it is always difficult to determine whether such sequence variants 
are actually contributing to disease development. In this study, 16 missense 
mutations from within the GRD were successfully characterised as either neutral or 
disease-causing variants using a Ras ELISA. In addition, bioinformatic analysis, 
completed by Matthew Mort (Cardiff University) helped to further dissect these 
missense mutations to determine the potential underlying molecular mechanisms 
that resulted in loss of NF1GAP-RAS binding in 11 of the 16 mutations.
Such functional analyses have previously been completed on fewer than 5 GRD 
mutations and so this present study represents the largest analysis to date.
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Moreover, the functional and bioinformatic data showed perfect correlation, signifying 
that both methods are likely to be reliable for pathogenic analysis. As discussed in 
chapter 4, this technique represents an improvement on previous NF1 functional 
analysis being simple, rapid and cost effective, and moreover, does not require 
either radio-labelled nucleotides (Li et al, 1992; Upadhyaya et al, 1997), or the 
construction of extensive libraries of vector constructs (Morcos et al, 1996).
Relatively few functional studies have been completed on missense mutations in 
other tumour suppressor genes. Gutmann et al (2001) undertook a very labour 
intensive approach to analyse eight missense mutations throughout the NF2 gene 
which were inducibly overexpressed in rat schwannoma cell lines. In comparison to 
the method presented here, inducible expression may not be suitable for analysis of 
mutations in a large gene such as NF1. Recently, missense mutations in the NF2 
gene were analysed by relative quantification and transfection of mutant constructs 
into cell lines (Yang et al, 2011). This study was very similar to the methodologies 
employed in the present project, although it was only based on a few NF2 variants. A 
study on PTEN missense mutations by Han et al (2000) also employed analogous 
methods to those utilised in this study in a comprehensive analysis of 42 missense 
mutations generated by site directed mutagenesis. Although this was a more 
extensive study, it did require the use of radio-labelled nucleotides to determine 
PTEN phosphatase activity, something which was avoided in the current study with 
the use of an ELISA. Finally, BRCA1 missense mutations have also been analysed 
in a study by Vallon-Cristersson et al (2001). Only 2 mutations were analysed in 
mammalian vectors and the remaining 11 variants used yeast constructs. 
Furthermore, the assay used by Vallon-Cristersson et al (2001) was semi- 
quantitative. ELISA assays can be fully quantitative and so represent a more useful 
strategy for determining protein function.
Overall, the present study represents a significant improvement on previous 
functional analyses of NF1 missense mutations and is comparable to, or even an 
advancement on the functional analyses of other tumour suppressor genes. In most 
of the studies outlined above, the analysis was not confined to the known functional 
domains of the gene under investigation, however, the present study analysed only 
the functional GRD of the NF1 gene. Whilst the GRD represents the majority of the 
known functionality of neurofibromin, several other regions such as the CSRD and 
C-terminal domains, may also have functional significance (section 1.3.4). While
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analysis of the GRD should take predominance over the other regions in 
neurofibromin, it is important to assess the likely pathogenicity of mutations within 
other NF1 gene regions, such as the CSRD, which is thought to modulate the activity 
of the GRD (Mangoura et al, 2006). It would also be interesting to apply the 
techniques established in this study to include analysis of all synonymous mutations, 
as opposed to non synonymous changes currently studied, as these may act as 
modifiers of drug efficacy and toxicity (Loktionov et al, 2004).
Many of the functional studies previously undertaken on other tumour suppressor 
missense mutations were purely cell based and no concurrent bioinformatic analysis 
was undertaken. It was therefore only possible to comment on in vitro activities of 
mutant cell lines and to speculate on the mechanisms responsible for mutant cell 
behaviour. Bioinformatic analysis proved to be a crucial tool for determining protein 
function in the absence of either functional or familial analysis, or the availability of a 
large cohort of controls. The addition of bioinformatic analysis to any functional 
assay clearly aids in the determination of the function of a mutant protein compared 
to the wild type protein. Furthermore, bioinformatic analysis in this study revealed 
important insights into the underlying mechanisms of pathogenicity associated with 
three of the mutations studied, although, for several missense mutations 
bioinformatic analysis was unable to provide any further information. It is therefore 
still unclear for the majority of missense mutations whether they resulted in (i) a loss 
of affinity for Ras, (ii) an inability to interact with Ras due to conformational changes 
or (iii) an, as yet unidentified mechanism that could account for loss of NF1-Ras 
signalling? Additional bioinformatic tools should also be employed in future studies to 
look at the complex molecular interactions of these NF1 mutants with Ras.
The bioinformatic tools used in this study are not the only computational methods 
and information databases available for prediction of protein function. The majority of 
such programs rely on conservation information and three-dimensional structural 
information. Such tools have recently been used to profile PTEN missense mutations 
and include: SWISSPROT used to determine whether the substitution is located in a 
binding site, active site, or site involved in a disulphide bond. The evolutionary 
conservation of amino acids normally implies an important functional or structural 
roles for the residue (Nassiri et al, 2009), so the use of programmes such as 
BLASTP can establish whether the position of an amino acid substitution is
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conserved in a family of homologous proteins. The PolyPhen program classifies 
missense mutations as likely to have a benign effect on the protein, to have a 
possibly damaging effect, or to have a probably damaging effect (Ramensky et al, 
2002; Sunyaev et al, 2001). SWISSPROT, BLASTP and PolyPhen serve a similar 
function to SIFT, PhyloP and MutPred which were used in the present study, 
indicating that the current bioinformatic analyses were appropriate for this study. 
Additional prediction programs are becoming available for similar analysis, including 
the SNAP program which may prove useful in future studies of this type (Li et al, 
2007).
Overall, the bioinformatic tools employed in this study are comparable to the other 
programmes available. However, this study would have benefitted from the use of 
molecular modelling tools, such as Panther, MODELLER and VERIFY-3D that have 
been used to investigate p53 mutations (Thomas et al, 2003; Pirolli et al, 2011). 
Molecular modelling can be used to determine if the amino acid substitution 
interrupts nearby atoms or changes the accessibility of side chains. Such techniques 
may prove to be important for future investigation to provide a prediction of how NF1 
mutations may affect molecular interactions between NF1 and Ras proteins.
7.3 Methylation
This present study represents the first comprehensive use of pyrosequencing to 
analyse the methylation status across the entire NF1 gene as well as the RASSF1A 
and MGMT  promoters, in DNA from a large cohort of NF1-associated tumours. The 
results from this study confirmed that methylation of the NF1 gene is unlikely to 
contribute to tumorigenesis, although hypermethylation of the RASSF1A promoter, 
but not the MGMT promoter, may play a role in the early stages of tumour 
development. A problem in the analysis of CpG methylation in the NF1 gene was 
determining what actually constitutes a recognised CpG island. In the NF1 gene, by 
the most stringent of definitions (Gardiner-Garden and Frommer, 1987; Takai and 
Jones, 2002), only 2 CpG islands; one identified in the promoter region and a second 
in intron 39 that is associated with an adenylate kinase 3 (AK3L1) pseudogene 
sequence. However, studies on other cancers have found that methylation of CpG 
rich regions downstream of the promoter are capable of affecting gene expression 
(Li et al, 2003; Ortmann et al, 2008). It was therefore postulated that this may also
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occur in the NF1 gene, so CpG rich regions that are not strictly CpG islands were 
also included in this methylation analysis. Inclusion of these additional regions 
should allow the methylation pattern across the entire NF1 gene to be determined. 
While this was achieved, and the largest number of CpG dinucleotides to date were 
analysed, there are at least 2000 additional CpG dinucleotides in the NF1 gene that 
were not profiled. As discussed in chapter 4, the majority of these dinucleotides were 
discrete and scattered throughout the large 283kb NF1 gene. With few sites 
conforming to the definitions of a  CpG island and none known to be clustered in any 
recognised functional regions, it is unlikely that methylation of these sites will play a 
role in NF1 gene inactivation. Only a few previous studies have focused on 
methylation analysis of discrete CpG  dinucleotides. No evidence for a contribution of 
methylation at these sites to gene inactivation has been reported (Bauer et al, 1999; 
Zhu et al, 2005).
As outlined in table 1.8 many other tumour suppressor loci are known to be 
methylated in a range of tumour types, with similar pyrosequencing methylation 
analyses, applied to such genes. While most of these studies have a comparable 
efficacy to the present study, in comparison to the NF1 gene, methylation of other 
tumour suppressors, such as CDKN2A, appear to have a much more important role 
in tumour development and are also often associated with a poor clinical outcome 
(Mirchev et al, 2010). For example, Muggerud et al (2010) assessed the level of 
PTEN  methylation in breast ductal carcinomas where it was not found to be 
significantly methylated. Conversely, PTEN methylation in non small cell lung cancer 
appears to have a prognostic effect and is also associated with the clinical outcome 
in surgically treated stage I and II non small cell lung cancer patients (Buckingham et 
al, 2010). Both the RASSF1A  and APC  promoters are hypermethylated in 
parathyroid tumours as well as several instances of CDKN2A methylation which 
have also been reported with pyrosequencing-based analysis. In such studies, the 
RASSF1A gene demonstrated similar levels of methylation in tumour samples (90%) 
to that seen in the current study (80%), indicating that high levels of 
hypermethylation of several Ras pathway effectors is involved in the development of 
multiple tumour types (Joplin et al, 2010). Recently, Kullar et al (2010) profiled CpG 
island hypermethylation of the N F2  gene in 40 vestibular schwannomas by 
pyrosequencing and similar to the results in this study, they found that NF2
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methylation is unlikely to contribute to development of vestibular schwannomas 
although only the NF2  promoter region was screened. This is often the situation in 
methylation studies with only the gene promoter region being analysed.
In the present study, pyrosequencing methylation analysis proved to be rapid, 
sensitive quantitative and a cost effective technique, with the methylation of the NF1 
gene comparable to previous studies using pyrosequencing. This study does, 
however, have an advantage in that additional functional analysis with the 
methylation inhibitor 5aza2dc was undertaken. Most previous studies have analysed 
methylation levels and gene expression levels, although methylation studies 
involving pyrosequencing are rarely translated from genetic findings into meaningful 
in vitro or in vivo functional data. This study was therefore not only able to identify 
and characterise the NF1 methylation status of both NF1 benign and malignant 
tumour types, it also assessed the affect that such methylation had on gene 
expression. Indeed, without this functional aspect, it would be difficult to definitively 
determine whether the methylation identified is pathogenic. Unlike in this study, the 
major effect of methylation on other tumour suppressor genes in the majority of 
previous analysis is therefore unclear.
As discussed in chapter 5, pyrosequencing offers unique advantages over previously 
used methylation detection techniques such as Methylation specific PCR (Herman et 
al, 1996), quantitative methylation PCR (Q-MSP) and quantitative multiplex- 
methylation-specific PCR (QM-MSP) (Herman et al, 1996; Eads et al, 2000; Cohen 
et al, 2003; Jeronimo et al, 2004). Since the commencement of this study, however, 
new high-throughput ‘next generation’ DNA sequencing techniques have emerged, 
although few screening-based studies have employed these techniques due to the 
cost and technical skills required for this type of analysis. Next generation DNA 
sequencing has, however, simplified whole-genome DNA methylation profiling, 
permitting production of whole genome-wide methylation profiles at single-base 
resolution. MethylCap-seq, for example, involves the capture of methylated DNA 
using the methyl-DNA binding protein domain (MBD) of MeCP2 (Brinkman et al, 
2010). While pyrosequencing is relatively high-throughput it is still restricted to a 96 
well format. The application of new sequencing techniques able to analyse the entire 
methylome in multiple samples concurrently would clearly provide an advantage for 
future analysis of genome wide methylated loci which may be associated with NF1 
tumorigenesis.
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7.4 MPNST tumorigenesis
There were several aspects to the studies discussed in chapter 6. Firstly, the overall 
molecular heterogeneity in MPNSTs was determined and the effect of upregulation 
of three genes (cMET, RAC1 and ROCK2) was also assessed. From many previous 
array studies it is clear that MPNST tumorigenesis is a complex, multistep 
processes, involving a range of genetic abnormalities to promote malignant 
transformation from a benign tumour to an MPNST (Lothe et al, 1996; Bridge et al, 
2004; Watson et al, 2004; Holtkamp et al, 2004; Storlazzi et al, 2006; Thomas et al, 
2007; Levy et al, 2007; Shen et al, 2007; Kresse et al, 2008; Mantripragada et al, 
2008; Mantripragada et al, 2009; Fang et al, 2009; Brekke et al, 2009; Miller et al, 
2009; Pemov et al, 2010; Brekke et al, 2010; Miller et al, 2010; Subramanian et al, 
2010; Chai et al, 2010). This study successfully determined that overexpression of 
cMET, RAQ1 and ROCK2 in these tumours resulted in an increase in both the 
migratory and invasive behaviour of MPNST cells that is likely to contribute to the 
malignant progression of these tumours. These three genes may therefore represent 
biomarkers and may be considered as probable targets for future therapies.
In the current study, inhibitors and RNAi both proved to be valuable tools for 
dissecting the mechanisms of NF1 tumorigenesis. RNAi for RAC1 and ROCK2 have 
also been studied using adhesion, migration, invasion and wound healing assays in 
cell lines derived from other tumours including epithelial cells, keratinocytes and 
glioma-derived cells (Valster et al, 2005; Kimura et al, 2006; Lock and Hotchin, 
2009). These studies used similar methods to those employed here and gave 
comparable results. Although the advantage of the present study was the use of 
shRNA instead of siRNA which provides a more sustained knockdown. Furthermore, 
few of the previous studies utilised all four of the assays employed here and these 
studies are therefore not as comprehensive as the present study.
Animal models of RAC1 and ROCK2 have been generated with Samuel et al, (2011) 
targeting Rac1 in a mouse model of epidermal papillomas which was able to 
demonstrate that K-ftas-mediated murine epidermal tumorigenesis is associated 
with elevated R a d  activity. Furthermore, Bosco et al (2010) determined the impact 
of inhibition of R a d  on p53-deficient B- and T-lymphoma cells in mice. Such 
inhibition resulted in increased apoptosis of B- and T-lymphoma cells. Only a single
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ROCK2 animal model has so far been reported, with Ying et al, (2006) reporting that 
the ROCK2 inhibitor fasudil inhibited tumor progression in rat models of lung 
metastasis. This ROCK2 inhibitor also showed promise in human studies where it 
appeared to be well tolerated (Ying et al, 2006). Based on the present findings and 
those of the RAC1 and ROCK2 mouse models it is likely that targeting the RAC1 and 
ROCK2 genes in animal models of NF1 may be an important aspect for future 
experimentation.
The cMET pathway has also been targeted in assays of several other tumours 
including neuroblastoma (Crosswell et al, 2009), with antibodies used to block 
HGF/c-Met function in cells derived from MPNSTs (Su et al, 2004). While this study 
obtained similar results to those demonstrated in the current study, a critical 
difference is that the cMET  inhibitors validated here are much more applicable to 
pre-clinical and clinical trials than antibodies. Indeed, an orally available cMET 
kinase inhibitor has been trialled in a human tumour xenograft mouse model of 
gastric carcinoma and glioblastoma, tumours that are both associated with NF1 
patients (Yamazaki et al, 2008). Near-complete inhibition of cMET phosphorylation 
was achieved (>90%) and tumour growth was significantly inhibited (>50%) 
indicating that such inhibitors may also prove effective in NF1 mouse models.
It is clear from several previous studies on other tumour-derived cell types that both 
the cMET and RhoGTPase pathway genes are important, not just to MPNST 
development but also to the growth of several other common malignant tumour 
types. The present study successfully dissected the roles of the cMET, RAC1 and 
ROCK2 genes in MPNST development and has also outlined important biological 
pathways that may represent future biomarkers and therapeutic options. Several 
improvements could, however, be made for similar future studies, with an important 
shortfall of this project being that only single gene knockouts were assessed in 
MPNST cells. As there is evidence for redundancy in many signalling pathways as 
well as feedback mechanisms, future studies might consider applying knockdown of 
both RAC1 and ROCK2, in addition to various other downstream signalling partners, 
for example, the ROCK effector LIMK1. Such studies should indicate whether 
knockdown of both genes is required to facilitate decreases in the malignant and 
metastatic activity of these tumours or whether a single gene knockdown is 
sufficient. Similarly, only cM ET  was targeted for inhibition and whilst there was a
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significant reduction in tumour cell migration, a high level of migratory activity was 
still present. This suggests that feedback mechanisms may also be functioning in 
this pathway. Indeed, a pilot study with rapamycin indicated that the mTOR pathway, 
and probably other effectors, such as STAT3 or AKT should also be targeted.
An improvement for the present study would be the use of adenoviral shRNA knock­
down libraries involving high-throughput assays to identify novel genes involved in 
cell migration. Indeed, when validated on prostate cancer cells, overexpression of 
CXCR4, PIK3CA, ROCK2 and PGF  were found to inhibit wound healing (Pril et al,
2009). Finally, producing sustainable delivery of gene therapy is a major problem. As 
was demonstrated in chapter 5, inhibition of methylation using 5aza2dc was found to 
be only a temporary effect with both methylation and gene expression returning to 
the levels prior to treatment following drug withdrawal. This suggests that while the 
use of such inhibitors is more applicable to animal and human trials, the application 
of RNAi such as the shRNA, used here instead of global agents, may prove more 
effective in future in vitro investigations.
This study also revealed that 70% of MPNSTs studied are highly heterogeneous, not 
only in their cellular and architectural composition but also in the underlying 
molecular aberrations. This indicates that improvements in the method of 
heterogeneity analysis should be sought, especially as LOH analysis lacks sensitivity 
and is also not a very quantitative method. More accurate methods, such as AQUA 
(Camp et a/,.2002; McCabe et al, 2005), and tissue analysis with multiplex quantum 
dots (QD) (Liu et al, 2010) have been used in other studies of molecular 
heterogeneity and these may represent suitable future alternatives for use in NF1 
tumour analysis.
Furthermore, heterogeneity analysis did indicate that multiple sections from the 
same tumour should be analysed in array and relative quantification assays due to 
the high levels of heterogeneity. Unfortunately, MPNSTs are rare tumours and 
although the NF1 lab has a panel of more than 40 MPNST derived DNA samples, 
frozen tissue was often not available and so limited samples were accessible for 
relative quantification analysis. Indeed, in many cases only small sections of the 
original whole tumour remained. As a result, only single sections could be used for 
the analysis in this study and so it is possible that the contribution of the genes 
studied to MPNST development could have been under-estimated. However, it
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should be mentioned that the use of multiple tumour sections for microarray analysis 
of many other tumour types is not common practice mainly due to the implications for 
time and cost of analysis. Furthermore, RNA quality from stored tumour material can 
often be a problem leading to inefficient cDNA conversion and thus poor 
amplification for relative quantification. The standard methods for analysis of cDNA 
are RIN/RQI analysis. This was not possible in our study but the quality and quantity 
of RNA was determined by spectrometry and gel analysis and this was not 
considered to represent a problem in this analysis.
7.5 Conclusions
This study is the first to assess the technique of LCM in the context of NF1 mutation 
analysis and to further employ it to successfully identify somatic mutations in benign 
and malignant NF1-related tumours. The use of enrichment strategies for improving 
mutation detection is critically important in these highly heterogeneous tumours 
associated with NF1, and this study should hopefully aid in the characterisation of 
new mechanisms of gene inactivation. The novel identification of LOH of the TP53 
and RB1 genes in benign cutaneous neurofibromas is a significant finding and is a 
mutational feature which has only previously been linked with plexiform 
neurofibromas and MPNSTs. It is therefore postulated that tumours from these 
severely affected patients may harbour an alternative molecular mechanism of 
tumour development to that present in patients with classical NF1.
One of the major aspects missing from the NF1 mutational analysis repertoire is the 
appropriate functional analysis of sequence variants with unknown pathological 
consequences, such as the synonymous and non-synonymous mutations. This study 
has remedied this issue through the establishment of a reliable technique to 
characterise such sequence variation as neutral or disease-causing. This 
methodology demonstrated that 11 of 16 previously detected potential germline 
mutations were very likely to be pathogenic. Indeed, the functional analysis was in 
concordance with the bioinformatic analysis. Therefore, this assay may be important 
not only for NF1 research but more importantly, for future diagnosis of NF1.
This report is also the first to apply pyrosequencing methylation analysis to the NF1 
gene to confirm that NF1 methylation is unlikely to be an underlying cause of 
tumorigenesis in NF1. Methylation of the RASSF1A promoter in NF1 tumours is,
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however, a novel finding that may represent an important event in the early stages of 
NF1 tumorigenesis. The functional dissection of biological pathways involved in 
malignancy in NF1 is crucial for the development of any treatment for NF1 
tumorigenesis. This study has shown that methylation inhibitors such as 5aza2dc 
may be important for therapy of tumours harbouring aberrant methylation patterns. 
Moreover, the cMET  and RhoGTPase pathways were specifically targeted with both 
RNAi and small molecule inhibitors. Such methods demonstrated a reduction in the 
malignant and metastatic potential of MPNST derived cell lines but the efficacy of 
these methods should be considered within the heterogeneous molecular and 
cellular background of the tumours studied. It is indicated from the current study that 
the cMET and RhoGTPase pathways may represent important biomarkers for 
MPNSTs and that of other malignant tumours. Thus, targeting the genes in these 
pathways may be an important therapeutic option.
The results of this project have successfully addressed all of the major aims of the 
study, providing a more comprehensive overview of the mutational mechanisms in 
NF1 tumorigenesis. By building on the results provided here, future studies may 
pave the way towards the development of efficient, cost effective mutation detection 
strategies, in addition to targeted therapies of NF1-associated tumours.
7.6 Future directions
7.6.1 Mutation detection
There are still many potentially fruitful areas for NF1 research. In terms of tumour 
development and potential treatment, there is a clear need for the development of 
sensitive, rapid, cost-effective genetic analysis for molecular NF1 diagnosis, and this 
study represents a first step in this process, in providing a validation for the 
application of Schwann cell enrichment techniques. Improved mutational analysis 
strategies are especially important for the identification of underlying mutations in 
atypical patients and young individuals who often have yet to develop the hallmark 
features of NF1. Conventional analysis methods are likely to become augmented by 
various microarray-based technologies as well as cell enrichment strategies, 
followed by application of high-throughput next generation sequencing 
methodologies (Mardis et al, 2008).
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Furthermore, crucial ‘driver’ and ‘passenger’ mutations in addition to genotype- 
phenotype correlations are hard to identify in NF1. Next generation technologies in 
conjunction with functional analysis such as the RasGAP assay undertaken in the 
current study may therefore help to better define genotype and phenotype 
interactions and also identify just which mutations are driving the development of 
NF1 associated manifestations from those that are neutral changes. Low level 
mosaicism is also very difficult to detect with the majority of methodologies routinely 
employed in NF1 analysis. It is clearly important to improve our ability to detect such 
mosaicism, as the developmental stage at which the mutations occur in patients with 
mosaicism (segmental NF1), determines the cell type(s) which are likely to be 
affected. Thus, this may provide important insights into the underlying mechanisms 
responsible for specific NF1-associated manifestations (Maertens et al, 2007)
Apart from NF1-associated tumour studies, it may be important to examine the 
extent of genome wide alterations in NF1 patients who are mildly affected, such as 
those with 3bp deletions or SPRED1 mutations. Making molecular comparisons of 
these patients to patients with classical NF1 or those who are severely affected, may 
help identify potential cancer susceptibility loci.
7.6.2 Therapeutic options and biomarkers
Few therapies aimed at targeting NF1 tumour development have even made it to the 
clinical trials stage (supplementary table 1) and indeed even those that have, do not 
have proven efficacy. Improvements and indeed development of novel therapeutics 
to specifically target highly aggressive MPNSTs is clearly required and as shown 
here, pathway analysis is likely to prove crucial to determining the underlying 
mechanisms responsible for tumour development. Many genes found in MPNSTs 
map to the same signalling pathways indicating that their deregulation may be crucial 
in providing a selective advantage to tumour cells during the process of malignant 
transformation. Identification of specific biomarkers to assess the probability of 
malignant progression in NF1 patients would allow prediction of the progression of 
an individual’s manifestations. At present, there is extreme variability in the 
expression of NF1 even between individuals with the same mutation. It is suggested 
and indeed demonstrated within this study that modifying loci are likely to underlie 
the extreme variability in disease presentation. Array studies have already identified
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many genes which are specifically altered in MPNSTs in comparison to benign 
neurofibromas, however, no single gene has been identified that represents a 
biomarker of tumour development and malignancy in NF1. Next generation 
sequencing techniques applied to a complete exome may therefore represent an 
important platform to discover genes which may modify the NF1 phenotype.
The cMETIRho GTPase analysis undertaken here is a promising start to such 
studies, although expansion to other cancer models is clearly warranted. The 
translation of in vitro analysis into effective in vivo results is usually quite difficult. 
Gene targeting in mouse models will be important to determine whether inhibition of 
signalling pathways such as those investigated here may be able to inhibit the 
development of NF1-associated tumours, or even reduce the volume of tumours. An 
important consideration for any prospective future study is whether it is more 
important to totally prevent tumour growth or just to attempt to reduce overall tumour 
load? The plethora of genes reported to be altered in MPNSTs suggests that it is 
unlikely that a single drug will provide suitable efficacy for the reduction in 
angiogenic, metastatic and malignant potential of NF1 -associated malignancies.
Approximately one third of somatic and germline NF1 mutations result from splicing 
alterations which can create new splice sites which results in the inclusion of intronic 
sequences in the final NF1 transcript (Messiaen et al, 2008). A number of 
bioinformatic and functional analysis methods have been employed to confidently 
predict the effect of splicing mutations on the NF1 transcript produced (Raponi et al, 
2006; Bottillo et al, 2007; Raponi et al, 2009). The development of antisense 
therapies for NF1 is already underway. Indeed, antisense morpholino oligomers 
have been employed in the treatment of fibroblasts and lymphocyte cell lines 
harbouring deep intronic NF1 mutations which prevented the inclusion of cryptic 
exons (Pros et al, 2009). At present, there are limited applications of splicing 
treatments and further development may allow them to become important 
therapeutic options in the near future.
7.6.3 Candidate genes
The RasMAPK pathway is a well defined biological signalling pathway although 
many novel protein partners and interactions are still being discovered. For example,
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it was only recently recognised that SHOC2 mutations can cause a variant form of 
Noonan syndrome (Cordeddu et al, 2009). For some patients suspected of having 
NF1, an NF1 germline mutation has yet to be identified, perhaps indicating that 
germline mutations in another gene within the RasMAPK pathway may be involved 
which is capable of eliciting an overlapping phenotype. Another prime example is the 
SPRED1 mutations in some patients with an NF1-like syndrome, now called Legius 
syndrome. Investigation of the RasMAPK genes including scaffold proteins such as 
14- 3- 3 is an important starting point, but may be aided with targeted array for the 
RasMAPK pathway and by the advent of second and third generation technologies.
An important prospective study may also involve the identification of other genes and 
consequently proteins which physically interact with Neurofibromin and may 
therefore modify its activity in a disease context. The 5’ and 3’ UTRs of NF1, for 
example, have functionally defined roles but it is still not clear whether they have 
other functions. The poly-A binding protein (PABP) interaction with the NF1 3’UTR in 
particular has not been studied (Hoshino et al, 1999). As the 3’UTR may represent a 
target of inactivating mutations, it is imperative that protein interactions with other 
NF1 regions are considered. The nature of signalling pathways indicates that 
complex feedback mechanisms and crosstalk between pathways both occur. It is 
postulated that the pathogenesis of primary tumours may therefore not be as simple 
as constitutive activation of the RasMAPK pathway following NF1 inactivation. 
Multiple downstream signalling pathways and the interactions of proteins in these 
pathways such as mTOR may therefore be of importance.
7.6.4 MicroRNA
Gene regulation is an extremely complex and multi-factorial process. MicroRNAs 
(miRNAs) are small noncoding RNAs that regulate gene expression and have 
recently been implicated in the pathogenesis of cancer. As identified in array studies 
on MPNSTs, several miRNA, including miRNA10b and miR-34a may be important to 
NF1 tumorigenesis (Chai et al, 2010; Subramanian et al, 2010). Furthermore, miRNA 
alterations in primary human cancers such as acute myeloid leukaemia have been 
shown to generate miRNA binding sites in the UTR regions of genes and may 
therefore represent another potential mechanism by which somatic mutations can
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affect gene expression (Ramsingh et al, 2010). Therefore, analysis of the 
‘miRNAome’ by next generation sequencing techniques will allow a comprehensive 
assessment of miRNA expression to identify genetic variants of miRNA genes in 
addition to miRNA biomarkers. Furthermore, alterations in miRNA binding sites in 
tumours and patient constitutional DNA may be revealed.
7.7 Concluding remarks
NF1 as a disease model has greatly benefitted from the experience and research of 
both clinicians and scientists ever since the identification of the NF1 gene in 1990. 
The research undertaken in this project has significantly improved our understanding 
of the molecular pathology underlying NF1-associated tumorigenesis, both in benign 
and malignant peripheral nerve sheath tumours. This study combined a variety of 
approaches to determine important genetic and epigenetic modifying loci, and also 
highlighted potential tumour biomarkers for future exploration. Furthermore, 
validation of two somatic mutation enrichment techniques may prove invaluable in 
facilitating future investigations of the NF1 gene, in addition to other tumour 
suppressor loci. In conclusion, while much still remains to be investigated, this 
project has provided a firm basis for further genetic, epigenetic and functional studies 
into the underlying mechanisms responsible for NF1 tumorigenesis, and also raises 
important questions to be addressed in the near future. It is also expected that with 
the expansion of current in vitro studies such as those presented here, into effective 
in vivo models and potential clinical trials, important and exciting developments in 
this field will arise.
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A P P E N D I X
Supplementary Table 1. NF1-associated tumours and chemotherapeutic treatments
Tumour Type/ 
Manifestation Treatment Target Study Outcome Reference
Imatinib mesylate 
(Gleevec, 
Novartis 
international)
Inhibitor of c-kit, PDGFjB and 
the bcr/abl receptor tyrosine 
kinases
Nf 1 flox/-; Krox20cre 
mouse models and a 
3 year old NF1 
patient
Reduces the volume of 
plexiform neurofibromas by 
70%. Cessation of symptoms 
associated with the site of 
tumour formation
Yang et al, 2008; 
Staser et al, 2010
Carboplatin Platinum based, formation of bulky adducts
Treatment of a stage 
I testicular seminoma 
in one patient
54% decrease in neurofibroma 
volume Hummel et al, 2011
Plexiform
Neurofibroma
Thalidomide Anti-angiongenic agent Open-label phase I study of 20 patients
Tolerated in doses up to 200 
mg/day. 4/12 patients 
demonstrated a response in 
tumor size (all <25%)
Gupta et al, 2003
Oral pirfenidone
Anti-fibrotic agent -modulates 
fibroblast growth factor and 
epidermal growth factor
Open-label phase II 
trial of 24 patients
4/24 had a minor decrease in 
tumour volume (15%), stable 
disease in 17/24 patients
Babovic-Vuksanovic 
et al, 2007
Pirfenidone Antifibrotic Agent Pediatric phase I trial Pirfenidone was well tolerated
Babovic-Vuksanovic 
etal, 2007
Tipifarnib (FTI 
Family)
Ras famesyltransferase 
inhibitor pediatric phase I trial
Tipifarnib was well tolerated
Widemann et al, 
2006
Interferon alpha Stimulation of immune 
response
12 month treatment 
in 1 patient
No observable change in 
tumour size
Citak et al, 2008
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Tumour Type/ 
Manifestation Treatment Target Study Outcome
Plexiform
Neurofibroma
pegylated
interferon-alpha-
2b
Phase 1 trial of 30 
patients
Improvement in 11/1C 
Decrease in tumoui 
13/14 patients.3A 
documented radioc 
progression sho 
stabilization or shri
Deep
Neurofibromas Sirolimus mTOR Pathway Inhibitor
2 Trials 
(NCT00652990, 
NCT00634270)
Trial Ongoing
MPNST
Lovastatin + 
famesyl protein 
transferase 
inhibitor
Inhibition of HMG-CoA 
reductase involved in 
cholesterol synthesis, affects 
the synthesis of famesyl 
pyrophosphate + Inhibition of 
Ras prenylation
Preclinical Studies
Low concentrations a 
inhibit prenylation ( 
Reduction of Ras pre 
increased cell cylcle < 
and apoptosis. Inci 
caspase activity in MF 
lines. Negligible toxi<
tipifarnib (FTI 
Family) 
(NCT00029354)
Inhibition of Ras prenylation Phase II trial Trial concludir
Tipifarnib + 
Eriotinib 
(NCT00085553) 
or Sorafenib 
(NCT00244972)
Inhibition of Ras prenylation Preclinical Studies and Phase 1 trials Not yet clinically de
neo-adjuvant
chemotherapy
Multicentre, 
multimodality 
therapeutic strategy
Major response in 
patients
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Tumour Type/ 
Manifestation Treatment Target Study Outcome
PCI-24781
(Pharmacyclics)
Histone deacetylase inhibitor 
(HDACi) Preclinical Studies
MPNST cell lines we 
sensitive to the ini 
Proapoptotic effect 
noted in vitro and
MPNST
Tamoxifen Antiestrogen Preclinical Studies
1-5 mM 4-hydroxy-fc 
induced MPNST ce 
0.01-0.1 mM 4-hy 
tamoxifen inhibi 
mitogenesis. Potent < 
activity in mice ortho 
xenografted with h 
MPNST cells, inhibits 
cell proliferation and 
via an ER-indepei 
mechanism.
BAY 43-9006 
(sorafenib)
tyrosine kinase inhibitor. 
Inhibitor of Raf-dependent 
MEK 
phosphorylation
Phase II clinical trial
Disappointing as a 
agent, inducin 
only minor respo
Sorafenib alone or 
in
combination with 
ifosfamide/dacarb 
azine
Tyrosine kinase inhibitor. 
Inhibitor of Raf-dependent 
MEK 
phosphorylation
Phase I/ll and Phase 
II trials 
(NCT00541840, 
NCT00837148).
Trial in progress. Sc 
efficacy might 
improved by combini 
other targetei 
drugs
U0126,
PD184352 (Cl- 
1040)and 
PD98059
MEK inhibitors Preclinical Studies
concentration-dep< 
suppression 
of proliferatio
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Tumour Type/ 
Manifestation Treatment Target Study Outcome
Rapamycin
and/or
rapamycin
derivative
RAD001
(everolimus)
mTOR Pathway Inhibitor Preclinical Studies
inhibit proliferation c 
cell lines 
derived from NF1-re 
sporadic MPNSTs. 
with xenograft g 
of ST26T cells. A 
transient, tumours re 
withdrawal of treatrr 
be tumouristatic ra1 
tumouricidal ag
Deforolimus mTOR Pathway Inhibitor Phase I/ll trials
more than 25% of 
achieved clinical 
(objective response 
disease for 16 \a
MPNST
PI-103 and 
LY294002
dual PI3K/AKT and mTOR 
inhibitory 
compounds
Preclinical Studies
showed a dosedepe 
growth inhibitory effe 
abrogated cell growt 
G1 cell cycle arre 
induction of auto
Erlotinib EGFR Inhibitor Preclinical Studies
Inhibition of grow 
invasion 
of MPNST cell
Erlotinib EGFR Inhibitor Preclinical Studies
Tumour antiangiogt 
antiproliferative resp 
xenog rafted m
Gefitinb EGFR Inhibitor Phase I trial Well Tolerate
Erlotinib EGFR Inhibitor Phase II trial No objective resp
Imatinib
mesylate PDGFR Inhibitor Preclinical Studies
Suppresses invasiv 
and cell growth of Ml 
lines
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Tumour Type/ 
Manifestation Treatment Target Study Outcome
Dasatinib
multi-TKR small-molecule 
inhibitor, blocks PDGFR in 
addition to SRC and KIT
Phase II and III 
studies 
(NCT00427583, 
NCT00464620)
Ongoing
MPNST
SU5416 VEGFR2 Inhibitor Preclinical Studies
No effect on MPNST 
in vitro. Growth of 
tumour explanted xc 
was reduced more tl 
Decreased turr 
angiogenesis an 
proliferation and in< 
apoptosis
Optic Gliomas
vincristine + 
carboplatin
Platinum based, formation of 
bulky adducts
Retrospective 
multicentre study
Long term visual ou 
uncertain
famesyl transferase inhibitors 
and MTOR pathway inhibitor
Too early to predicl 
Outcome
Astrocytomas
mTOR inhibitors 
and the 
LY294002 PI3- 
kinase (PI3-K) 
inhibitor
Pre-clinical suppressed cell gro level
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Supplementary Table 2. NF1 DNA sequencing PCR primers
EXON Sequence (5'-3')
Size
(bp)
1F CT CCACAGACCCT CTCCTT G
323
1R TCCCCTCACCTACTCTGTCC
2F AAACTGTTTACGTGTT'I I I I I I I IC
378
2R AAGAAAAGAAAGCAAATTCCCC
3F TTT CACTTTT CAGAT GT GT GTT G
245
3R T GGTCCACAT CT GTACTTT G
4aF TTAAATT CTAGGT GGT GT GT
517
4aR AAACT CATTT CT CT GGAG
4bF GATACCACACCTGTCCCCTAA 342
4bR CAT GATACTAGTTTTT GACCCAGIG
4cF TTTCCTAGCAGACAACTATCGA
308
4cR AGGAT GCTAACAACAGCAAAT
5F TGTTAGCATCCTGAATCAAAA 292
5R TCGTATCCTTACCAGCCATA
6F AATGCCAGGGATTTTGI ICC 294
6R AAGCCTAAAGTAATACACACCTTGA
7F GCTACATCT GGAATAGAAGAAACTTCA 391
7R CCATTTAGGCT GAT GAACACA
8F CAT GTTAGTAAAG AAATACT GC AT G G 273
8R TTTT GTTTATAAAGGATAACAGCAT CA
9F TT GAT GTTCGTTT CAAGACC 249
9R ACGCAAAGAAAAGAAAGAAAA
10aF ACGTAATTTTGTACITTTT C ITCC 222
10aR C AATAGAAAGGAGGT GAGATT C
10bF ATTATCCTGAGTCTTACGTC 506
10bR IAACI I AG IG IG A IA A T T  I I GAGA
10cF TCTTCCTCCTTCTAATCTCTCTCG 425
10cR AAG G AAC AT CAT G AAT GTAC ATAGTTA
11F CCAAAAAT GTTT GAGT GAGT CT 256
11R ACCATAAAACCTTTGGAAGTG
12aF T GCATTAGGTTATT GAT GAT GC 303
12aR T GAGAACATT GGGAGGAAGG
12bF CT CTT GGTT GT C AGT GCTT C 382
12bR CAGAAAACAAACAGAGCACAT
13F CACAGTTTATT GCATT GTTAGATTTT 385
13R CAGAT GCCAT GT GCTTT GAG
14F TTT GGGT GGAGCTTAT CAGG 562
15R ACTTTACT GAGCGACT CTT G AA
16F T G GATAAAGC ATAATTT GT C AAGT 549
16R TAGAGAAAGGTGAAAAATAAGAG
17F GGTACGAGTGTCTGCGTATATCTG 385
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EXON Sequence (5'-3')
Size
(bp)
17R CGAATTAAATGTAAGTTTGAAAACAA
18F AG AAGTT GT GTAC GTT CTTTT CT
367
18R CTCCTTT CTACCAATAACCGC
19aF TCATGTCACTTAGGTTATCTGG
268
19aR TAAAACCCACTAATACTTGAAGG
19bF T GAGGGGAAGT GAAAGAACT
275
19bR TCCTATCCTAGTCCTGTCATGG
20F CCACCCT GGCT GATTAT CG
340
20R GCTTCTCTTACATGCCAGTTC
21F TCAGCAAGGCCATGTTAGTA
381
21R CTTCCCCGCTTACT CTAAT C
22F TGCTACTCTTTAGCTTCCTAC
518
22R CCTTAAAAGAAGACAATCAGCC
23 .1F TTT GTAT CATT CATTTT GT GT GTA
327
23.2R ACTTTAGATTAATAATGGTAATCTC
24F T GACCTTT GAACT CTTT GTTTT CA 451
24R GAAAAGCT GAAAATTTAGTT GGAA
25F CCTGTTTTATTGTGTAGATACTTCA 338
25R TAAGTGGCAAGAAAATTACCT
26F GT GT GAACAAGCCCTCCATA 638
26R GAAGAT GCAAAGTAAAAAGCACT
27aF AT GATTAGCACATT CACGGG 298
27aR GCAAACT CTCCTT CT CAACC
27bF TTTATTGTTTATCCAATTATAGACTT 296
27bR TCCTGTTAAGTCAACTGGGAAAAAC
28F TTTCCTTAGGTTCAAAACTGG 561
28R CTAGGGAGGCCAGGATATAG
29F GGTT GGTTT CT GGAGCCTTT 473
29R AGCAAC AAACCCCAAAT CAA
30F C AACTT C ATTT GT GTTTT CT CCTAG 321
30R CTTTGAATTCTCTTAGAATAATTGTTA
31F T GAT GT GATTTT CATT GACCA 424
31R CAGATAAATAT GT GC AC AAAGGAGA
32F T G AATATACT CAT CCTTTCCT GG AT 352
32R CAT GGGACT CAAAGTTTTAGCA
33F TCCTGCTTCTTTACAGGTTATT 463
33R AAGTAAAATGGAGAAAGGAACTGG
34F TT C AAAAT GAAACATGGAACTTT 394
34R AAGTAC AAAATAGC AC AATAAACC AA
35F GCAT GGACT GT GTTATT GGTA 490
36R TGCTTTACAACTTGAGAACCATAAA
37F AATT CATTCCGAGATT CAGTTTAGGAG 240
37R AAGTAACATT CAACACT GATACCC
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EXON Sequence (5'-3')
Size
(bp)
38F AACT GCAGT GT GTTTT GAAAGAG
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38R GCAACAAGAAAAGATGGAAGAG
39F GAAAGCT ACT GT GT GAACCT CAT C AACC 289
39R GTAAGACATAAGGGCTAACTTACTTC
40F T CAGGGAAGAAGACCT CAGGAGAT GC
328
40R T G AACTTT CT GCT CT GCC ACGC AACC
41F GT GCACATTTAACAGGTACTAT 373
41 R CTTCCTAGGCCATCTCTAGAT
42 F CT CTATT GTTTT CAT CTTT C AGG 349
42R CAAAAACTTT GCTACACT GACAT GG
43F 1 ITTCTTTTTAGTGTATTCCCATT 399
43R GATT CTAAGAAATGGCT GGAA
44F CACGTTAATTCCCTATCTTGC 310
44R TGAGAAGTAGAAGACTGTATCC
45F CATGAATAGGATACAGTCTTCTAC 269
45R CACATTACTGGGTAAGCATTTAAC
46F GAAATGCCCCAGAAAGTAAA 358
46R GT CAGTGCATT CTACAACAGC
47F CTGTTACAATTAAAAGATACCTTGC 259
47R T GT GT GTT CTTAAAGC AGGC ATAC
48F TTTT GGCTT CAGA1GGGGATTTAC 447
48R AAGGGAATTCCTAATGTTGGTGTC
49F CTGGGAGAAACAGGCTATAC 377
49R AGCAAGCTTCACACGATCT
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Supplementary Table 3. NF1 cDNA primers
Primer Exons covered Sequence (5'-3')
Size
(bp)
1F 1,2,3 AACACTGGGAGCCTGCACT 3871R GTT GCCCAGCAAGAC ATTTT
2F
3, 4a, 4b AAGCGGCCT C ACTACTATTT 4012R TT GC ACAAT CC AC ATT GATA
3F
4b, 4c, 5, 6 C AGGAATT AACT GTTT GTT C AG A 3943R T 'lG I I I ICATCAACCACGIC
4F
6,7,8 CTGAAAGCACCAAACGTAAA 4124R AAGT GTT GGTT GTT GT G AGG
5F 8, 9, 10a, 10b TGATTGACTGCCTTGTTTCT 419
5R C C C C IG TTTTC I IGGA I I AC
6F 10b, 10c, 11, 12a, 
12b
TCTCTTGTCCATGGTGAAAC
493
6R GGCTCCAGGAGTACGTAGTAA
7F 12b, 13, 14, 15 GGAAATACCAGTCAAATGTCC 461
7R TTAGCTTTGTTGCTTGTTCC
8F 15, 16 CACT GAGGCTT GGGAAGATA 449
8R GACCCACCAGATCCTTAACA
9F 16, 17, 18, 19a GGCTGTTGTCCTTAATGGTG 462
9R CCATAACCCAGTCTGTCAGG
10F 19a, 19b, 20
GCC AAG AGAT G AAATTTAGG
395
10R GT GCATGAGACCACTGTCTA
11F 2 0 ,2 1 ,2 2 , 23.1
GGTCCTTGCAATGTCAAA
477
11R AAAGGAT CCAGGAGTTTTT GT
12F 23.1, 23.2, 24
AGACTCTCTTCCGAGGCAAC
392
12R TT CATACGGT GAGACAAT GG
13F 24, 25, 26, 27a
CAGTAGGAAGT GCC AT GTT C
402
13R TATCAAAAGGTCGTCTTCCA
14F 27a,27b,
C AAC AGGG AT CATAAAGCT G
394
14R TTTAAAGCGATTGCTAGGC
15F 27b, 28
AAAGCCATATTATGCAAAGC
396
15R TGGACAGCAGTAGAACCAAC
16F 28, 29, 30
GCT CT CAAGCT AGCT CACAA 454
16R AATCGAGGGCCAGTTACTAG
17F 30, 31, 32
TCTGTGTGCCTTAACTTGTACC
428
17R GAC AGTTT CAT CAAAACC AGT G
18F 32, 33
AAAAT AT GGGGAAGCCTT GG
376
18R AGGTCCGCTCTCCCTTAGAG
19F 33, 334, 35
T GAT GT GGC AGCT CAT CTT C
365
19R GTT GG AG AT CAT GG AGGCAT
20F 35, 36, 37, 38
T GAC ATCCTT GGAAAC AGT C
416
20R AAGT GCGGTACCTGCT GAAT
21F 38, 39, 40, 41
C IC I  I I rGGGTAGCTGTGG 416
21R CAGCGACTTCGAACTTCTT
22F 4 1 ,4 2 ,4 3
TGGCCTACTTAGCAGCTTTA
413
22R TGCTACTCTCCTCATTTTGG
23F 43, 44, 45, 46, 47
AAAAGGC AAG AAAT GGAAT C
515
23R TCTGGAATTTGTGTTTGCTT
24F 47, 48, 49
TTTGGTTTTAATGGCTTGTG 534
24R AACCGGAT GGGTT CATTAT
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Supplementary Table 4. Microsatellite and RFLP markers for chromosome 17
Marker Location Genomic Co-ordinates using Mar. 2006 (NCBI3G / hg18) 
Assembly using Fab. 2009 (GRCH37 / hg19) Assembly
Forward Primer Sequenee 6'-3' Reverse Primer Sequence 6'-3‘
Size
(bp)
Dye Reference
D17S831
(AFM058XF4) 17p13.3
1,857,446 > 1,857,467 {In R T N 4 R L 1  gene) 
1,910,400 > 1.910,767 CCCCTTTCCTCATACTCCAG
TAATTCAAGTCCCGTCTGGC 230 FAM Stewart ef a/ (2008)
D17S938
(AFM263W H5) 17p13.2
6,190,024 > 6,190,201 (Distal of AIPL1 gene) 
6,249,268  > 6,249,535 CCGGATTGCTACACCTAAAT
CTGCTCCAGAAGAGACTGTT 178 FAM
Legius ef a l (1994)
D17S796
(AFM177XH6) 17p13.2
6,192,318 »  6 ,192,477  (Distal of AIPL1 gene) 
6,251,522 > 6,251,775 CAATGGAACCAAATGTGGTC
CATCCTGGCATTATCGGACT 160 FAM
D17S804
(AFM225ZC1) 17p13.1
9,806,218 > 9 ,806,375 (In G A S 7 gene) 
9,865,376 > 9 ,865,697 GCCTGTGCTGCTGATAACC
GGAATGACATCTCATCACAGTG 158 FAM Stewart ef a/ (2008)
D17S1879
(AFMA070TC5) 17p13.1
10,053,182 > 10,053,494 (Proximal of MYH13gene) 
10,112,457 > 10,112,769 GAAGTTTACGAAAATTGCTGTC
AAGGGTAGTTCTGCGTGC 155 FAM
D17S520
(M FD144A) 17p13.1
10,209,846 > 10,209,987 (In M YH13 gene) 
10,269,009 > 10,269,266 GGAGAAAGTGATACAAGGGA
GGTGGGTATTAATCTAACTA 142 FAM
Stewart ef a l (2008)
D17S799
(AFM192YH2) 17p12
13,111,696 > 13,111,885 (Proximal of ELAC2 gene) 
13,170,956 » 13,171,304 ATTGCCAGCCGTCAGTT
GCTTGTCTATAATGATATGCTGGTC 190 FAM
D17S953
(AFM304xh5) 17p11.2
16,043,171 >16,043,481 (In N C O I gene) 
16,102,446 > 16,102,756
ACTATCCGCCCAATACA AAGGGCTTGCTTTGAC 123 FAM
Upadhyaya ef a l 
(2004)
« « « « « <  CENTROM ERE > » » » »
D17S33
(HHH202) 17q11.1
23,148,612 > 23,148,920 (In NOS2gene) 
26.124,485 > 26.124.793 ACTTGCCAAAGGTTACAGGGCTAC
AAGCCTGTCCCTTGACTTGTTCAT 309 RFLP Upadhyaya ef a l 
(2004)
5'NF1 17q11.2 26,334,358 > 26,334,879 (In RNF135 gene) 
29,310,232 > 29,310,753 ATTGGAACCCTCTGCACTGT
CATAAACTCATGCCCATAGC 522 HEX
Exon 5 17q11.2 26,532,689 > 26,532.941 Exon 5 N F 1  gene 
29.508,563 > 29,508,815
TGTTAGCATCCTGAATCAAAA TATGGCTGGTAAGGATACGA 253 RFLP
J1J2 Alu 17q11.2 26,641,851 > 26,642,254 IVS27b N F 1  gene
29,617,725 > 29,618,128 CAAGAAAAGCTAATATCGGC
CTAAGTGAACTTAAGGTTCC 404 FAM
IVS27 -28.4 17q11.2 26.668,420 > 26,668,626 IVS27b N F 1  gene 
29,644,294 > 29.644,500 GTTCTCAACTTAAATGTAAGT
GGTACTTGTTGTTAATGTTC 207 HEX
EV120 (D 17S1166) 17q11.2 26,673,142 > 26,673,342 IVS27b N F 1  gene29,649,016 > 29,649,216 CCCATACCTAGTTCTTAAAGT
AATAATTGCTGCAGTTCCACAATTGTTA 201 FAM
IVS38 17q11.2 26,692,798 > 26,692,821 IVS38 N F 1  gene 29,668,672 > 29,668,695 CAGAGCAAGACCCTGTCTCC
CTCCTAACATTTATTAACCTTA 172 FAM Upadhyaya ef a l (2004)
3NF1 17q11.2 26,943,468 > 26,943,712 (Distal of RAB11FIP4 gene) 29,919.355 > 29,919,599 CTTCCATGGCTGCTAACATC
TG7TGAACTACACCACAGGG 245 HEX
D17S798
(AFM179XG11) 17q11.2
28,314,080 > 28,314.299 (Distal of TM EM 98 gene) 
31.289,812 > 31,290 190 CCATGAGAAAGATGTfTAGTAGTCTCTGCT
CTGCACTCCCAAGAATATACCCATCAAA 220 FAM
E W 206 (D17S57) 17q11.2 28,495,054 > 28,495,402 (In ACCN1 gene) 31,470,941 > 31,471,289 TGCAGTGTGGTGCATCATTCAGTG
ATCAGGAATATGGCTGGCCCTGTC 349 RFLP
EW 207 17q11.2 28,812,190 > 28,812,774 (In ACCN1 gene) 31,788.077 > 31,788,661 AGGTATCAGTCAGGACCCTCTTAG
CACATTACAGAAACCAGAGTGTCAG 585 RFLP
D17S250
(Mfd15A) 17q12
34,405,618 > 34,405.641 (Distal of FBXD47 gene)
37,152,091 > 37,152,341 CATAAAAAGGAAGAATCAAATAGAC
GCTGGCCATATATATATTTAAACC 160 FAM
D17S789
(AFM107YB8) 17q24.2
64,140,110 > 64,140,423 (Distal of FAM 20A gene)
66,628,515 > 66,628,828 ACTCCAAATCAAGTTTGTACTGAGA
CTGCATACGAAGGGTAGGAC 156 FAM
Stewart ef a1 (2008)
D17S1822
(AFMA353YG1) 17q25.3
75,395,628 > 75,395,648 (Distal of CBXB gene) 
77,780.863 > 77,781,171 CAGGCATCTGTAATGGACCC
AACCGAGCCTAGGACTCC 127 FAM
D17S928  
(AFM217YD10 ) 17q25.3
77,846,296 > 77,846,316 (Distal of CSNK1D gene)
80,252,839 > 80,253 140 ATTTCCCCACTGGCTG
AAAACGGCTACAACACATACA 148 FAM
296
Supplementary Table 5. NF1 RFLP markers and conditions for restriction 
digest
Marker
Annealing
Temperature
(°C)
Enzyme Incubation
Product
Size
(bp)
Cut Size 
(bp)
HHH202 54 Rsal 2 Hours 37°C 310 190, 120
Exon5 54 Rsal 2 Hours 37°C 240 220
EW 207 54 Hindlll 16 hours 37°C 585
-585, 385, 
200
EW206 54 MsP1 17 hours 37°C 320 180
Supplementary Table 6. MSI microsatellite marker primer sequences
Marker Sequence (5'-3') Size(bp) Repeat Dye
Chromosomal
Location
mD13S153 F AAAGC ATT GTTT CAT GTT GG
230 [CA]25 FAM 13q14
mD13S153 R AAGGT CTAAGCCCT CGAGTT
mD5S406 F AACCT GCC AAT ACTT C AAG A
179 COMPLEX FAM 5p15
mD5S406 R GGATGCTAACTGCTGACTAT
mD5S107 F ATCCACTTTAACCCAAATACT
147 COMPLEX FAM 5q 11 -q 13
mD5S107 R AGGC AT C AACTT GAACAGCA
mBAT26 F T  G ACTACTTTT G ACTT C AGC 122 [A]26 FAM 2p16
mBAT26 R AAC C ATT C AAC ATTTTT AACC
m ACTCF C TT GACCT GAAT GCACT GT G 88 [TG]25 FAM 5q 11 -q 14
m ACTCR ATT CC ATACCT GGGAACGAG
D2S123 F AAACAGGAT GCCT GCCTTTA 211 COMPLEX HEX 2p16
D2S123 R GGACTTTCCACCTATGGGAC
BAT25 F TCG CCT CCAAGAAT GT AAGT 124 [A]25 HEX 4q12
BAT25R T CT GC ATTTT AACT AT GGCT C
BAT40F ACCAGTCCATTTTATATCCTCAA 183 [A]40 HEX 1 p13
BAT40R AAGAT CACACCTCTGCACTCT
D5S346 F ACT C ACT CT AGT GATAAAT CG 125 [T G] 15 TET 5q22
D5S346 R AGC AG ATAAG AC AGTATTACTAGT
D 17S250F CATAAAAAGG AAG AAT C AAATAG AC 160 COMPLEX FAM 17q12
D17S250 R GCT GGCCATAT AT AT ATTT AAACC
297
Supplementary table 7. TP53 CDKN2A, RB1 and PTEN LOH markers
Marker Location Gene Sense Primer Sequence (S'*?) Antisen9e Primer Sequence (5
TP53AIU 17p13.1 GCACTTTCCTCAACTCTACA CTGCCATTAAAGGAGCTGTI
D17S520 17p13.1 GGAGAAAGTGATACAAGGGA GGTGGGTATTAATCTAACTA
D17S804 17p13.1 TP53 GCCTGTGCTGCTGATAACC GGAATGACATCTCATCACAG1
TP53 c. 72 17p13.1 TP53 Codon 72 GCCAGAGGCTGCTCCCCC AAGTCTGTGACTTGCACG
TP53 Ex6 TP53 Exon 6 AGTTCTGGTTTGCAACTGGG CTGCTGCTTATTTGACCTC
D13S118 13q14.2 CCACAGACATCAGAGTCCTT GAAATAGTATTTGGACCTGG(
D13S153 13q14.2 AGCATTGTTTCATGTTGGTG CAGCAGTGAAGGTCTAAGCC
D13S917 13q14.2 RB1 ATTATCTCTGGGTAGAATGCTAACA CCCCAGGAGTCATTTTTAACCRB1.2 13q14.2 AAGIGiAAIGI IIIIC IAAG GAGGAAATTTACCTCTGCTA
RB1.26 13q14.2 ATTCAGTGAAGATATCTAAT TTCTTCAGTTGGCAGGTTTG
D13S119 13q21.1 AAGACTTTGAATGAAATTCCC TATTGCCTTTGTAGATCATTG
D9S304 9p21.1 GTGCACCTCTACACCCGGACTCCAGTCTTT ATAAGATAGATGTGTGTGGGCACA1
D9S1748 9p21.3 CDKN2A CACCTCAGAAGTCAGTGAGT GTGCTTGAAATACACCTTTCCD9S1751 9p21.3 TTGTTGATTCTGCCTTCAAAGTCTTTTAAC CGTTAAGTCCTCTATTACACAGi
D9S942 9p21.3 GCAAGATTCCAAACAGTA CTCATCCTGCGGAAACCAT7
D10S2491 10q23.2 PTEN TTATAAGGACTGAGTGAGGGA GTTAGATAGAGTACCTGCACTD10S251 10q23.2 TGGCATCATTCTGGGGA TTACGTTTCTTCACATGGT
Supplementary table 8. Primers for TP53 sequence analysis
Exon Primer Sequence (5'-3') Size (bp)
TP53 4F TCTGGTAAGGAC AAGGGTT GG
200
TP53 4R C AGG AAGCCTAAGGGT GAAG A
TP53 5_6F CT GCCGT GTTCC AGTT GCTTT
250
TP53 5_6R GTTT CACCGTTAGCCAGGAT
TP53 7F CCT CAT CTT GGGCCT GTGTT
256
TP53 7R GAG AGGTGG AT GGGTAGTAGT
TP53 8_9F AAAGG AC AAGGGTGG T T  GGG A
550
TP538_9R CC AGG AGCC ATT GT CTTT GAG
298
Supplementary Table 9. Primers for sequence analysis of MLH1, MSH2, MSH6 and PMS2
Gene/Exon Sequence (5'-3') Size Gene/Exon Sequen
MLH1-1F CACT GAGGT GATTGGCT GAA
295
MSH6-4.1F GGCTGCACG(
MLH1-1F ATGCGCTGTACATGCCTCT MSH6-4.1R GCTTTCGAGC
MLH1-2F TTGTTATCATTGCTTGGCTCA
246
MSH6-4.2R CTGTCATCAC
MLH1-2F CCAGAACAGAGAAAGGTC CTG MSH6-4.2F GAGTGACATT
MLH1-3F CACAGGAGGATATTTTACACAT
197
MSH6-4.3R TTTCCCCACC
MLH1-3F GAGATTT GGAAAAATGAGTAACA MSH6-4.3F GGTGACTGG/
MLH1-4F TTACTCTGAGACCTAGGCAAAAA
196
MSH6-4.4R CTTTCTACATI
MLH1-4F GGTGACCCAGCAGTGAGTTT MSH6-4.4F GGATTTCCTCAA
MLH1-5F TTTATAC AAACAAAGCTTCAACAA
196
MSH6-4.5R GGATAGTGTGCi
MLH1-5F GATTTTCTCTTTTCCCCTTGGG MSH6-4.5F TTTCCTGAAA
MLH1-6F GCCAGGACATCTTGGGTTT
249
MSH6-4.6R ACCCCAATGC
MLH1-6F GCTCAGCAACTGTTCAATGTATG MSH6-4.6F TTCTTCTGGC
MLH1-8F T GTGATGGAAT GATAAACCAA
416
MSH6-4.7F GTGGCACACT
MLH1-7F AAAAGGGGGCTCTGACATCT MSH6-4.7R TGTCACTGCA
MLH1-9F TGAI IC I I I IGIAAIGTTTGAGTT
242
MSH6-4.8F TTCCCTTGGA
MLH1-9F TCCCATAAAATTCCCTGTGG MSH6-4.8R TCAGGGGAG/
MLH1-10F ACCT GT GACCTCACCCCTCA
241
MSH6-4.9F TGATCGTCTAG
MLH1-10F TTAGCATGCT CAT CT CTTT CAA MSH6-4.9R CGAGCCTTTT
MLH1-11F AATCTGGGCTCTCACGTCTG
299
MSH6-4.10F CCCAGACAGC
MLH1-11F TACACCATA1GI GGGC'I T l I I MSH6-4.10R CAGCCCTTCTT
MLH1-12F TCTGTCTTATCCTCTGTGACAATG
317
MSH6-4.11R T GTATAT GC AT GT
MLH1-12F CTCCATTT GGGGACCT GTAT MSH6-4.11F TTGGGGGATI
MLH1-13F TTT CCAAAACCTTGGCAGTT
296
MSH6-5aF TTCCCTTGGC
MLH1-13F TGCTCCTCCAAAATGCAACC MSH6-5aR TAGGCTTTGC
299
Gene/Exon Sequence (5'-3') Size Gene/Exon Sequen
MLH1-14F rAGCTTT I G I GCC I G I GC I C
249
MSH6-5bF TAAAACCCCC
MLH1-14F GTCAATGAAGTGGGGTTGGT MSH6-5bR ATGACTGACC
MLH1-15F TTTT C AG AAACG AT C AGTT G AA
196
MSH6-6F CCATGTTAGC/*
MLH1-15F TTCTCCCATTTTGTCCCAAC MSH6-6R GGGCAACAA(
MLH1-16F CTTCATTTGGATGCTCCGTT
369
MSH6-7bF GCCAATAATTGC,
MLH1-16F A I GTTGGCCAGCI GG I I I I MSH6-7bR TT CAAATGAGAAG
MLH1-17F GGAAAGCACTGGAGAAAT GG
258
MSH6-7aR CTCCAACTATl
MLH1-17F TT CCAGAT CAAAGGGTGGT C MSH6-7aF CTCATGCAT
MLH1-18F TCTGTGATCTCCGTTTAGAATGA
245
MSH6-7R TCTGTGCCAC
MLH1-18F AAAGATTGTATGAGGTCCTGTCC MSH6-7F CTGACCTCAG(
MLH1-19F AAAGG AATACTAT C AG AAGGC AAG
380
MSH6-8V2F CCGATGTTGC
MLH1-19F GCCAGGACACCAGTGTATGTT MSH6-8v2R CCATGCATGC(
MSH2-1F GAGGCGGGAAACAGCTTAGT
356
MSH6-9R TCATAGTGCA1
MSH2-1R ACT CTCTG AGGCGGGAAAG MSH6-9F GCTGTGCGC
MSH2-2F TCCAGCTAATACAGTGCTTGA
297
MSH6-10R G AAAG AAAATGC
MSH2-2R AAAC AC AATTAAATT CTT CAC ATT MSH6-10F GGAAGGGATGi
MSH2-3F TTGGATT1 1 IC C I1 IT IG C I 1
400
PMS2-1F GTGGAGCACA
MSH2-3R GGCCTGGAATCTCCTCTATCA PMS2-1R ATTTCCAGGG
MSH2-4F CTTATTCCTI I ICICA1AGIAG
293
PMS2-2F TGTTGAGTCAT
MSH2-4R GAAATATCCTTCTAAAAAGTCAC PMS2-2R TGGCTTAAAAC
MSH2-5F T CTT GGTTT GGATT GGGAAG
371
PMS2-3F CTGATAGCATl
MSH2-5R TCTTCAGTATATGTCAATGAAAACAT PMS2-3R TTGCATTTCCC
MSH2-6R GGTATAATCATGTGGGTAACTG
242
PMS2-4F ACTGTCTTGGGA
MSH2-6F CTAATGAGCTTGCCATTCTTTC PMS2-4R AAGGGGTCAA
MSH2-7F ACTGCGCCCAGCAGATTC
374
PMS2-5F CCATGCCTGG
MSH2-7R TT GTAT GAGTT GAAGGAAAACA PMS2-5R CCAATACTCTTC
300
Gene/Exon Sequence (5'-3') Size Gene/Exon Sequer
MSH2-8F TCAGTCAAAATTTTATGATTTGTATTC
247
PMS2-6F GAGAACCTTC
MSH2-8R TCTTAAAGTGGCCTTTGCTTTT PMS2-6R GTTGAAGTA/
MSH2-9R ACAAAAGAATTATTCCAACCTC
210
PMS2-7F TTI I TGCGC
MSH2-9F T CTTT ACCG ATTATTTATAG GAT PMS2-7R TGTAGTTCTC1
MSH2-10R GTTAGAGCATTTAGGGAATTAA
259
PMS2-8F TCCCTTTCAC
MSH2-10F AATGGTAGTAGGTATTTATGG PMS2-8R TCCCGAGCTC
MSH2-11F CATTGCTTCTAGTACACATTTT
194
PMS2-9F GGCTGGGAA
MSH2-11R AGGTGACATTCAGAACATTAT PMS2-9R CTCATTCCAG1
MSH2-12F ATTATT C AGT ATT CCT GT GT AC
334
PMS2-10F CAAT GTTACTCC
MSH2-12R AAAACGTTACCCCCACAAAG PMS2-10R AAGCTTTAGAAG(
MSH2-13F AACAATCCATTTATTAGTAGCAG
317
PMS2-11.1F AGTCCCTGA<
MSH2-13R AGAGACATACATTTCTATCTTC PMS2-11.1R GACGCCTTTC
MSH2-14F CACATTTTATGT GAT GGGAAATT
337
PMS2-11.2F GGAGCCCTCT
MSH2-14R TCCC ATTACC AAGTTCT G AATT PMS2-11.2R GAGAGGCTGi
MSH2-15R AACACAGAGGAAAACAAACAACAA
362
PMS2-11.3F CTAATCTCGC
MSH2-15F CAAGGTGAGAAGGATAAATTCCA PMS2-11.3R CACTTCCGTC
MSH2-16R CCCATGGGCACTGACAGTTA
375
PMS2-12F ATGTCTGATAATT/
MSH2-16F T GTTTAG ATGG AAAT G AAAC AATTT PMS2-12R TCAATTTGAG
MSH6-1R CAAATGCTCCAGACTCGAC
668
PMS2-13F TTGTTTTCATT
MSH6-1F TACCCACCAGTGTGCCAG PMS2-13R CACACCCAG<
MSH6-2F TGCCAGAAGACTTGGAATTGT
440
PMS2-14F AAACGTGTTTG
MSH6-2R AAGCTTT C AC AACT GCCACC PMS2-14R ACAGCCAGG(
MSH6-3R TCCAGGGAACTACAGAAGTATGC
399
PMS2-15F CGTTGAACCA
MSH6-3F T GGT CTT GAACT GCT GGGA PMS2-15R GCGCATGCA)
301
Supplementary Table 10. Association of RAC1 alterations with cancer.
Rac1 Alteration Malignancy Refer<
Overexpression Progression and metastasis of breast tumors Schnelz<(20C
Overexpression Oral squamous cell carcinoma Liu et al
Hyperactivity Chronic myelogenous leukemia Thomas et
Overexpression Progression of gastric carcinoma Pan et al
Overexpression Progression of testicular cancer Kamai et c
Overexpression Breast cancer Fritz et al
Overexpression Progression of prostate cancer Engers et
Alternative splicing to 
Raclb Colorectal tumors Jordan et
302
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